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Abstract 
 The work presented herein details our efforts at characterizing and 
understanding the mechanisms that govern microglia homeostasis and activation in the 
central nervous system (CNS).  These studies have focused on the microglial response 
to aging and ischemic stroke, highlighting the importance of neuro-immune interactions 
and inflammatory signaling in the brain (Chapters 1 and 2).  We begin with our 
investigations into microglial activity following ischemic brain injury and how these 
responses differ from that of other bone marrow-derived monocyte populations (Chapter 
3).  Then we define the role of the CD200-CD200R1 immuno-inhibitory signaling axis in 
ischemic stroke (Chapter 4), highlighting the importance of neuronal-glial interactions in 
maintaining immune privilege and attenuating post-stroke inflammation.  Lastly, our 
work on the effects of aging on microglia function (Chapter 5) and immune surveillance 
(Chapter 6) in the CNS furthers our understanding of microglia senescence and the 
phenomenon of ‘inflamm-aging’.  
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Chapter 1: 
Introduction 
 
 
Stroke and inflammation 
 
Stroke affects 15 million people worldwide each year1.  Increasing life 
expectancy together with an expanding aging population will place a profound burden 
on the economy well beyond the current estimate of $69 billion annually1. In recent 
years, major advances in the area of ischemic injury have highlighted the importance of 
the inflammatory response to stroke.  This view is supported by growing evidence 
showing an association between inflammation, brain damage, and poor outcome in 
ischemic stroke patients2,3.  The sterile inflammatory response to stroke is robust and 
characterized by a stereotypic sequence of events involving the brain, its vasculature, 
and the peripheral immune system.  Oxidative stress and the release of pro-
inflammatory mediators induce expression of adhesion molecules (e.g., ICAM, VCAM-1, 
selectins) on brain endothelial cells, promoting leukocyte entry into the brain4.  
Infiltrating leukocytes amplify the immune response further by releasing a variety of 
cytotoxic agents including cytokines, reactive oxygen species (ROS), and extracellular 
proteases (e.g., MMP-9), ultimately leading to extensive neuronal death, blood brain 
barrier (BBB) breakdown, and further influx of leukocytes5.  Many investigators have 
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demonstrated experimentally that by antagonizing these features of the post-ischemic 
response, infarct damage can be salvaged, and survival outcomes improved6,7.  As key 
players in the initiation and maintenance of this response, microglia have become 
increasingly recognized as cellular targets for therapeutic drug development7,8. 
 
Role of microglia in stroke injury 
 
The hallmark of neuroinflammation is microglial activation.  Microglia express 
many pattern recognition receptors like toll-like receptors, that when activated, as in 
stroke, shift phenotype from a resting, ramified morphology to an activated, amoeboid 
state (Figure 1-1).  Activation is often accompanied by an increase in protein synthesis 
(e.g., production of cytokines), proliferation, migration, and MHCII/CD40 expression7.  
The release of chemokines, cytokines, and ROS further activate microglia and amplify 
the local inflammatory response.  Excessive activation can result in collateral damage 
(e.g., neuronal death), alter the neurovascular unit, and exacerbate tissue injury, 
potentially leading to a chronic inflammatory state9,10.  Indeed, severe ischemic insults 
are generally associated with increased numbers of microglia11.  However, when 
appropriately kept in check, microglia activation can be regarded as a beneficial host 
response to ischemic injury, responsible for resolving inflammation and restoring 
function by migrating to the site of injury, clearing apoptotic neutrophils, and releasing 
various growth factors (e.g., BDNF, VEGF) and anti-inflammatory mediators12-15.  Thus, 
the regulation of microglia following stroke is crucial in determining the extent of 
neuronal injury and disease progression.   
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Figure 1-1.  Microglia activation after ischemic stroke. 
Microglia can be visualized as Iba1-positive cells (A, green; and B, red) in the brain 
using immunohistochemistry.  Activation of microglia (green) can be observed as early 
as 6 hours in the ipsilateral (ischemic) cortex after MCAO (A).  After injury, microglia 
exhibit a morphological shift from a ramified (resting) state to an activated, amoeboid 
state (B).  Abbreviation:  Iba1 ionized calcium-binding adaptor molecule 1, MCAO 
middle cerebral artery occlusion 
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CD200 regulation of microglia 
 
The CNS also has several endogenous neuroprotective mechanisms that ensure 
inhibition of central immune responses, but these have been less studied.  These 
inhibitory signals are provided in the form of neuronal-glial interactions, which act to 
suppress microglial activation when neurons are healthy.  One such mechanism 
involves the immunosuppressant interaction between CD200 (OX-2), which is highly 
expressed on neurons and CD200 receptor 1 (CD200R1/OX-2R), a myeloid immune 
inhibitory receptor expressed at low levels on resting microglia.  Under normal 
conditions, activation of CD200R1 by its CD200 ligand prevents immune activation by 
inhibiting signaling pathways involved in the production of pro-inflammatory mediators16-
18.  Following CNS injury, this interaction is disrupted (Figure 1-2).  Reduced activation 
of CD200R1 allows a pro-inflammatory response to ensue.  The functional significance 
of this disruption is best evidenced in CD200-deficient mice, which have an enhanced 
susceptibility to autoimmune disease and worsened outcome in several models of 
neuroinflammation19-21.  CD200-deficient mice exhibit widespread microglial activation 
as indicated by increased aggregation, CD40/MHCII expression, and amoeboid 
morphology19,21,22.  To date, few studies have examined the role of the CD200-
CD200R1 axis as it relates to experimental stroke; the literature is limited to two studies 
which report an early decrease in CD200 gene expression in the infarct core and an 
increase in CD200R1-positive cells in the brain23,24.  What accounts for these changes 
in CD200/CD200R1 expression, and how they impact the central immune response is 
the focus of this thesis work. 
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Figure 1-2.  Neuronal-glial Interactions in the healthy and diseased brain. 
Immunostaining shows Iba1-positive microglia (pink) and NeuN-positive neurons (blue) 
in the healthy brain (A).  Microglial extensions can be observed in close contact with 
neuronal cell bodies in every region throughout the brain.  A schematic of CD200-
CD200R1 signaling in the healthy brain and after stroke (B).  Under normal conditions, 
neurons maintain contact-dependent inhibition of microglia by engagement of CD200R1 
by CD200.  The proposed model demonstrates how ischemic injury results in microglia 
activation.  Neuronal death and remodeling of the extracellular matrix disrupts CD200-
CD200R1 interactions, thereby releasing the brake on microglia activation resulting in 
the release of pro-inflammatory mediators. 
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CD200 is ubiquitously expressed throughout the body including the CNS, 
whereas CD200R1 is primarily expressed on leukocytes of the myeloid lineage (e.g., 
microglia, monocytes, macrophages, dendritic cells, neutrophils).  CD200 and CD200R1 
are structurally similar, type I transmembrane glycoprotein members of the 
immunoglobulin superfamily.  These genes are located on the same chromosome and 
are highly conserved in structure and function across rodents and humans25.  CD200 
lacks a cytoplasmic motif capable of recruiting adapter proteins, and thus imparts a 
unidirectional inhibitory signal to CD200R1-expressing cells.   Both in vivo and in vitro 
studies have demonstrated that CD200R1 activation suppresses TLR-4- , IL-17- , and 
IFN-γ-mediated inflammatory pathways, resulting in the downregulation of many 
important cytokines (e.g., TNF, IL-1β) and chemokines (e.g., CXCL8), and a biased shift 
towards a Th2 response (i.e., IL-4, IL-10)26-29.  Interestingly, many of these pathways 
have been shown to be detrimental in stroke, leading us to speculate (Aim 3), that 
targeting of CD200-CD200R1 signaling by a CD200R1 agonist will provide protection by 
reducing the microglial response to injury30-34.   
Given that inflammation can be detrimental to stroke outcome35,36, recent efforts 
have targeted the immune system to develop novel neuroprotective therapies.  
Inflammation is an attractive target for therapy due to its wide therapeutic window.  In 
many stroke survivors, elevated levels of acute-phase markers and circulating 
leukocytes persist for weeks, even months after a stroke event, increasing the risk of 
recurrent events37-39.  Indeed, higher CSF and serum levels of IL-6 and IL-1 have been 
shown to correlate with larger infarcts in humans40-42.  To date, several clinical trials 
have examined the effectiveness of blocking antibodies directed against adhesion 
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molecules (e.g., ICAM-1 and CD11b/CD18); however, these drugs have proven 
unsuccessful due to lack of efficacy and adverse side effects43,44.  Although it is unclear 
why these therapies failed to translate, one explanation is that post-ischemic 
inflammation acts through multiple redundant pathways that cannot be effectively 
treated by targeting a single adhesion molecule or cytokine45.  The therapeutic potential 
of CD200R1 manipulation offers a promising new approach, as its activation is known to 
suppress several important pro-inflammatory mediators involved in multiple signaling 
pathways 46. 
 
Inflammation in the aging brain 
 
Acute ischemic stroke is a disease that primarily affects the elderly 47.  Indeed, 
the strongest independent risk factor for stroke is age, as elderly patients have the 
highest mortality and morbidity.  With increasing life expectancy, the world is facing a 
rapid expansion in its elderly population.  In addition to the looming economic toll, the 
concurrent rise in age-related disease and disability will also put a burden on the 
healthcare system. Currently, there is no treatment beyond the four-hour window with 
which a patient must present to be eligible for TPA.  To date, most treatments that have 
been successful in experimental models have failed to translate in clinical trials.  The 
reason for this lack of efficacy is not understood, although may be associated with the 
design of commonly used models 48.  For instance, the vast majority of rodent stroke 
studies are performed using 2 month-old young mice, roughly equivalent to that of a 10-
year-old human child.  Like humans, aged mice are profoundly different from their 
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younger counterparts.   Aging is associated with the following changes: epigenetic 
modifications, mitochondrial and DNA damage, redox stress, endocrinosenescence, 
immunosenescence, replicative senescence, and diminished regeneration capacity 49.  
As a consequence, aging individuals display considerable variation in normal 
physiology, response to injury, and facilitative recovery.  At the molecular level, aging 
induces significant changes in the CNS transcriptome and proteome.  At the cellular 
level, blood-brain barrier integrity is compromised and immune privilege is broken 50,51.  
Microglia in aged mice display a higher basal activated state, altered responsivity, and 
dysregulated responses to stimuli 52 (Figure 1-3).  Microglia dystrophy is a hallmark of 
CNS aging 53,54.  The gradual increase in basal inflammatory processes that occurs with 
age is a phenomenon known as ‘inflamm-aging’ and is believed to contribute to the 
etiology of several neurodegenerative diseases 55,56. Thus, understanding how the aged 
CNS environment influences the response and subsequent recovery following stroke 
injury is critical to developing reliable targets and efficacious treatments.   
The present dearth of studies exploiting the use of aged mice may explain why 
past therapeutic targets have failed to translate in the clinic, where the majority of 
enrolled patients are elderly.  By utilizing aged mice with varying degrees of disease 
state researchers may better model the pathological setting in which this disease occurs 
in humans.  The identification of age-specific targets and treatment paradigms may 
eventually yield more effective treatments for older populations.  In this work, we 
examine the functional contributions of microglia and monocytes to ischemia and 
identify novel inflammatory mechanisms that may help explain why older individuals are  
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Figure 1-3.  Age-related changes in microglia. 
The effects of normal aging on microglia morphology is shown (A).  Aging is associated 
with an increase in activated microglia with enlarged somas and pronounced 
morphological heterogeneity in branching patterns. 
 
 
 
 
 
 
 
 
 
	   	   	  10	  
more prone to chronic inflammatory responses and worse outcomes following traumatic 
brain injury. 
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Chapter 2: 
Microglia and ischemic stroke:  a double-edged sword 
 
Anita R. Patel, Rodney M. Ritzel, Louise D. McCullough, and Fudong Liu 
 
This chapter was published as a literature review in International Journal of Physiology, 
Pathophysiology, and Pharmacology.  2013 May; 5(2): 73-90. 
 
 
 
Abstract 
 
Inflammatory processes have a fundamental role in the pathophysiology of stroke. A 
key initial event is the rapid activation of resident immune cells, primarily the microglia. 
This cell population is an important target for new therapeutic approaches to limit stroke 
damage.  Activation of microglia is normally held in check by strictly controlled 
mechanisms involving neuronal-glial communication. Ischemic stroke is a powerful 
stimulus that disables the endogenous inhibitory signaling and triggers microglial 
activation.  Once activated, microglia exhibit a spectrum of phenotypes, release both 
pro- and anti-inflammatory mediators, and function to either exacerbate ischemic injury 
or help repair depending on different molecular signals the microglial receptors receive. 
Various ligands and receptors have been identified for microglial activation. 
Experimental tools to detect these inflammatory signals are being increasingly 
	   	   	  12	  
developed in an effort to define the functional roles of microglia. Fine-tuning 
immunomodulatory interventions based on the heterogeneous profiles of microglia are 
urgently needed for ischemic stroke. 
 
Introduction 
 
Inflammation plays a critical role in mediating post-ischemic injury. The activation of 
microglia, the major resident immune cells in the brain, is a key element in triggering the 
innate immune response 30.  When ischemia occurs, cessation of cerebral blood flow 
leads to deprivation of oxygen and glucose to areas supplied by the occluded vessel.  
Resultantly, vulnerable neurons are subject to death and the endogenous signaling that 
inhibits inflammatory responses under physiological conditions compromises, leading to 
microglial activation.  Once activated, microglia develop macrophage-like capabilities 
including phagocytosis, cytokine production, antigen presentation and the release of 
matrix metalloproteinases (MMPs) that weaken the blood brain barrier (BBB) 57.  As a 
result, peripheral leukocytes infiltrate into the brain and the normally immune-privileged 
brain environment is exposed to systemic responses that further exacerbate 
inflammation and brain damage.  
           The inflammatory response has dual effects on ischemic injury 58.  Stroke-
induced microglial activation causes a release of variety of inflammatory mediators 
many of which are cytotoxic and/or cytoprotective 59.   Phagocytosis of cellular debris 
and harmful substances along with the release of anti-inflammatory cytokines by 
microglia occurs in an effort to defend against damaging substances and restore tissue 
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homeostasis by clearing pathogens or necrotic cells, and consequently attenuate the 
detrimental effects of inflammation and aid in tissue repair 60,61. Because of their critical 
roles in the immune response to stroke, microglia have become a recent target of 
interest for many stroke scientists. This review focuses on current findings, providing an 
update on microglial activation, phenotype identification, and the roles of microglia in the 
pathophysiology of cerebral ischemia.  
 
Origin and development of microglia
 
There has been much controversy over the characterization of the cell lineage of 
microglia. The most significant hypotheses of the development of microglia debate their 
embryonic neuroectodermal or mesodermal origin. Unlike the ectodermal development 
of macroglia (astrocytes and oligodendrocytes) and neurons, a consensus in favor of 
the mesodermal hematopoietic origin of microglia is currently held 62,63.  A subset of 
primitive myeloid precursors, localized in the extra-embryonic yolk sac (YS) at 
embryonic day 8 (E8) was shown to contribute to the rise of yolk sac microglia that 
persists into adulthood 64. This cellular subset of primitive hematopoiesis contributes 
little to blood leukocyte development, which is largely specific to definitive 
hematopoiesis of hematopoetic stem cells (HSCs) 64-66.  Microglia precursors originate 
in the embryonic yolk sac before the emergence of definitive HSCs from the aorto-
gonad-mesenephros (AGM). The direct precursors of microglia that travel to the neural 
tube at E8 are exclusively the CD45-cKit+ cells. This subpopulation of erythromyeloid 
cells eventually begins expressing CX3CR1 and CD45 and travels into the 
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neuroectoderm in a matrix metalloproteinase 8 (MMP 8) and MMP 9 dependent manner 
to develop into microglia 67,68. These precursor cells are seen seeding the brain 
rudiment by E10 in rodents 64 and have a full microglial morphology beginning at E1467. 
           The transcription factor Myb is essential for the development of HSCs 69,70 and 
can be found in the AGM during embryogenesis 63,71. By using Myb knockout (KO) 
mice, Schulz et al. 70found that yolk sac-derived CD45+CX3CR1hiF4/80hi macrophages 
and microglia still develop in normal numbers and remain independent of Myb into 
adulthood; however, CD45+CX3CR1+F4/80lowCD11bhi monocytic phagocytes continually 
replaced by bone marrow (BM) in an adult are unable to develop without Myb. The 
transcription factor PU.1, on the other hand, is necessary for myelopoiesis of the YS but 
dispensable for the development of definitive HSCs 66,70. This further suggests two 
separate myeloid lineages of peripheral macrophages and resident microglia. 
             Moreover, colony stimulating factor (CSF) and its receptor CSF-1R are 
necessary for the differentiation of most macrophages/microglia 72.  Recent studies 
showed that in CSF-1R KO mice, yolk sac-derived microglia do not develop and are 
deficient throughout life, but HSC-derived monocytes are able to differentiate and 
circulate without dependence on CSF-1R 63,64,73. Fate mapping analysis of Flt3-Cre x 
RosaLSL-YFP mice also shows that yolk sac-derived microglia are independent of Flt3, a 
chemokine present on multipotent hematopoetic progenitors in the blood and brain 70. 
Taken together, the separation between HSCs and yolk sac derivations is evident and 
allows insight into microglial ontogeny.  
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Markers and methods for Identification 
 
To date, no single microglial-specific marker has been identified, keeping the cell type 
indistinguishable from macrophages and various myeloid-derived cells that infiltrate the 
brain during pathological states 74. Changes in microglial activation in response to 
central nervous system (CNS) injury are illustrated by diverse phenotypes and unique 
expression of cell surface proteins. Microglial activation stages can be detected by 
characterizations of these changes, but the similarities with other cell types pose a 
major hurdle for their definitive characterization and detection.  
 
Ionized calcium binding adaptor molecule-1 (Iba-1) expression by 
immunohistochemistry (IHC)   
 
Iba-1 is amongst the most useful proteins for distinguishing microglia through IHC and 
immunocytochemistry (ICC) staining 75,76, especially for studies of cerebral ischemia 
where the expression of Iba-1 is upregulated 77 (Figure. 2-1) .  However, Iba-1 has also 
been shown to bind various cells of monocytic lineage 75, and thus its specificity for 
microglia staining is limited in injured brain tissue where peripheral macrophages may 
infiltrate.  Other markers, such as CD11b, Isolectin (IB4), and F4/80, have also been 
used for in vivo and in vitro microglial staining.  Although the benefits of IHC include the 
ability to create a spatiotemporal and morphological profile of microglia within the CNS, 
it lacks in specificity and may be inconsistent depending on the type of histological 
preparation. 
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Figure 2-1.  (Legend on following page) 
 
 
 
!
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Figure 2-1: Microglia activation and leukocyte infiltration in the ischemic brain.   
(A) Representative brain slice stained with Iba-1 (red), GFP (green) and DAPI (blue) 
from a chimeric mouse after stroke (10x magnification).  The chimeric mouse model 
was made by transferring GFP+ bone marrow of a donor mouse to an irradiated WT 
mouse.  Eight weeks after reconstitution, the chimeric mouse was subjected to 90 min 
MCAO. The mouse was reperfused for 72 hours before sacrifice. GFP+ cells represent 
bone marrow-derived peripheral leukocyte infiltrates. Green fluorescence is localized to 
the region of injured tissue in the striatum and cortex. (B) 20x magnification of the box 
area in (A).  The arrow indicates a cell co-labeled with IbA-1 and GFP. (C) Resting 
microglia morphology with thin, ramified processes in the non-injured brain hemisphere. 
63x. (D) Activated microglia with large, ameboid cell body in the ischemic cortex. 63x. 
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CD45/CD11b expression by flow cytometry  
 
Flow cytometry provides a sensitive means to detect various markers and create a 
multiparameter characterization of different cell types.  In 1991, Sedgewick et al 
78observed differences in the expression of the hematopoietic cell surface marker CD45 
on resident microglia and infiltrating peripheral leukocytes. To date, the most common 
characterization profile derived from flow cytometry sorting still holds that resident 
microglial cells are CD45 low CD11b+, while infiltrating hematogenous leukocytes are 
CD45highCD11b+ 79.  Experimental stroke studies with two photon imaging 80 and IHC 81 
also demonstrated that infiltrating leukocytes in the ischemic hemisphere showed a 
higher expression of CD45, which is consistent with our flow cytometry data (Figure. 2-
2).   Although CD11c high and CD14– have sometimes been used to label microglia in 
flow cytometry, their similarity in expression on other peripheral cell types makes it 
difficult to justify resident microglial specificity 79,82. 
         There are, however, limitations to using variable levels of CD45 expression to 
distinguish between microglia and other monocyte/macrophage populations. CD45 on 
microglia can be upregulated in mouse models of EAE in spinal cord towards a CD45 
high phenotype 83. Inflammation in the periphery of humans also may upregulate CD45 
in CNS resident microglia with no changes in CD11b expression 84 . The possible 
instability of this marker’s levels during pathological states reiterates the need for a 
better method of tracking resident microglia and peripheral monocyte/macrophages. 
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Figure 2-2:  Representative flow cytometry plots of resident microglia and 
peripheral leukocytes in the mouse brain.  
In the brains of sham mice (left), CD45lowCD11b+ (box 1) and CD45highCD11b+ (box 2) 
cells were identified as resident microglia and peripheral leukocytes respectively. 72 
hours after 90 min MCAO (right), both CD45lowCD11b+ and CD45highCD11b+ cells were 
increased in the brain. 
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KDGD IDLQWHU &' LPPXQRVWDLQLQJZKLFK LV
FRQVLVWHQWZLWKRXUÁRZF\WRPHWU\GDWDFigure 
2). Although CD11chigh and CD14– have some-
WLPHV EHHQ XVHG WR ODEHO PLFURJOLD LQ ÁRZ
cytometry, their similarity in expression on 
RWKHUSHULSKHUDOFHOOW\SHVPDNHVLWGLIÀFXOWWR
MXVWLI\UHVLGHQWPLFURJOLDOVSHFLÀFLW\>@
7KHUHDUHKRZHYHUOLPLWDWLRQVWRXVLQJYDULDEOH
OHYHOV RI &' H[SUHVVLRQ WR GLVWLQJXLVK
between microglia and other monocyte/macro-
phage populations. CD45 on microglia can be 
XSUHJXODWHGLQPRXVHPRGHOVRI($(LQVSLQDO
cord towards a CD45 high phenotype [28]. 
,QÁDPPDWLRQ LQ WKHSHULSKHU\RIKXPDQVPD\
also upregulate CD45 in CNS resident microglia 
ZLWKQRFKDQJHVLQ&'EH[SUHVVLRQ>@7KH
SRVVLEOH LQVWDELOLW\RI WKLVPDUNHU·V OHYHOVGXU-
LQJSDWKRORJLFDOVWDWHVUHLWHUDWHVWKHQHHGIRUD
EHWWHU PHWKRG RI WUDFNLQJ UHVLGHQW PLFURJOLD
and peripheral monocyte/macrophages.
Transgenic mice
$ PXOWLWXGH RI WUDQVJHQLF PLFH FDQ DOVR EH
used to label cell populations by attaching a 
ÁXRUHVFHQWUHSRUWHUWRDP\HORLGSURPRWHU)RU
H[DPSOH &'E*)3 FDQ ODEHO DOO FHOOV RI
myeloid origin including microglia in the mouse 
brain [30]. Similarly, Iba-1-EGFP transgenic 
PLFHKDYHVKRZQVXFFHVVIXOÁXRUHVFHQWODEHO-
LQJ RI &16 PLFURJOLDPDFURSKDJHV LQ WLVVXH
VDPSOHV >@ 0RUH UHFHQWO\ D ÁXRUHVFHQW
NQRFNLQ WUDQVJHQLF PLFH OLQH FUHDWHG XVLQJ
CX3CR1-GFP and CCR2-RFP has shown to be 
WKHPRVWXVHIXOWRWKHÀHOGWRGLIIHUHQWLDWHUHVL-
GHQWPLFURJOLDIURPSHULSKHUDOPRQRF\WHV,WLV
QRZ NQRZQ WKDW &&5 WKRXJK GLIIHUHQWLDOO\
H[SUHVVHGLVVSHFLÀFWRWKHSHULSKHU\LQQDwYH
DQG ($( PLFH >@ DQG XQOLNH &' LV QRW
XSUHJXODWHGVLJQLÀFDQWO\LQSDWKRORJLFDOVWDWHV
,Q DGGLWLRQ IUDFWDONLQH UHFHSWRU &;&5 LV
SUHVHQW RQ PLFURJOLDO SURJHQLWRUV LQ WKH \RON
VDFDQGLQWKH&16UHPDLQVVSHFLÀFWRPLFURJ-
lia into adulthood [13].
6WXGLHV XVLQJ V\VWHPLF DQG UHJLRQVSHFLÀF
GHSOHWLRQRIP\HORLGFHOOVRUPDFURSKDJHVFDQ
EH GRQH XVLQJ '75&'E WUDQVJHQLF PLFH
7KHVH PLFH KDYH GLSKWKHULD WR[LQ UHFHSWRUV
'75 OLQNHG WR WKH &'E SURPRWHU
$GPLQLVWUDWLRQ RI GLSKWKHULD WR[LQ ZLOO GHSOHWH
CD11b+ (myeloid) cells [30, 33]. Another com-
monly used technique to selectively ablate 
CD11b+ FHOOV LQYROYHV WUHDWLQJ&'E+697.
WUDQVJHQLF PLFH ZLWK LQMHFWLRQ RI JDQFLFORYLU
*&9>@,QGXFLEOHGHDWKRI&'E+ cells has 
Figure 2.5HSUHVHQWDWLYHÁRZF\WRPHWU\SORWVRIUHVLGHQWPLFURJOLDDQGSHULSKHUDOOHXNRF\WHVLQWKHPRXVHEUDLQ,Q
WKHEUDLQVRIVKDPPLFHOHIW&'lowCD11b+ (box 1) and CD45highCD11b+ER[FHOOVZHUHLGHQWLÀHGDVUHVLGHQW
PLFURJOLDDQGSHULSKHUDO OHXNRF\WHV UHVSHFWLYHO\KRXUVDIWHUPLQ0&$2 ULJKWERWK&'lowCD11b+ and 
CD45highCD11b+ cells were increased in the brain.
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Transgenic mice 
 
A multitude of transgenic mice can also be used to label cell populations by attaching a 
fluorescent reporter to a myeloid promoter. For example, CD11b-GFP can label all cells 
of myeloid origin including microglia in the mouse brain 85.  Similarly, Iba-1-EGFP 
transgenic mice have shown successful fluorescent labeling of CNS 
microglia/macrophages in tissue samples 86.  More recently, a fluorescent knock-in 
transgenic mice line created using CX3CR1-GFP and CCR2-RFP has shown to be the 
most useful to the field to differentiate resident microglia from peripheral monocytes.  It 
is now known that CCR2, though differentially expressed, is specific to the periphery in 
naïve and EAE mouse 87, and unlike CD45, is not upregulated significantly in 
pathological states. In addition, fractalkine receptor (CX3CR1) is present on microglial 
progenitors in the yolk sac and, in the CNS, remains specific to microglia into 
adulthood68.  
            Studies using systemic and region-specific depletion of myeloid cells or 
macrophages can be done using DTR-CD11b transgenic mice. These mice have 
diphtheria toxin receptors (DTR) linked to the CD11b promoter. Administration of 
diphtheria toxin will deplete CD11b+ (myeloid) cells 85,88. Another commonly used 
technique to selectively ablate CD11b+ cells involves treating CD11b-HSV TK 
transgenic mice with injection of ganciclovir (GCV) 89. Inducible death of CD11b+ cells 
has more recently become a useful technique in the field. 
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Chimeras 
 
Irradiation chimera models are a popular technique to differentiate microglia from 
peripheral myeloid cells since there is no exclusive antigenic marker 90. To generate a 
BM chimera (Figure. 2-1), BM cells of a mouse with ubiquitously expressing fluorescent 
(GFP+, YFP+, RFP+, etc) protein is extracted and injected into a mouse of interest 
whose own marrow is first irradiated and eliminated. After weeks to months of 
reconstitution of the new cell population, it is possible to track the origins of cells in CNS 
tissue, particularly after neurological diseases, where cells from the periphery that cross 
the BBB have been labeled with fluorescence. BM chimeras can be performed with 
transgenic knockout or knockin mice to selectively target cells of the CNS or of the 
periphery. Unfortunately, the effects of irradiation are confounding and have been 
implicated in physiological alterations such as weakening of the BBB, potential cell 
death and activation of microglia 91-95. Though microglia are mostly radio-resistant, their 
numbers in the CNS may also be altered in uninjured and ischemic chimeric mice 
compared to nonchimeric mice in the hippocampus and the cortex 96. Changes in gene 
regulation with higher expression of proinflammatory cytokine and CCL2 can also 
accompany irradiation 93,97. These undesireable effects of irradiation pose a caveat to 
the technique. However, preventive measures can be taken to study the brain using 
chimeras. For example, targeted, instead of whole body irradiation using lead shielding 
of mouse heads is now often used in an effort to prevent damage or brain 
environmental changes due to radiation exposure 91,98.  
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Resting Microglia  
 
Resting phenotype  
 
Resting microglia in a healthy brain, more representatively known as “surveying 
microglia,” are constantly extending and retracting their thin ramified processes in an 
effort to inspect the CNS microenvironment (Table. 2-1) 99,100.  As the central 
macrophages of the brain, microglia are implicated in controlling synapse number and 
remodeling in the developing brain, and function to prevent accumulation of debris in 
the healthy adult CNS. They are not present uniformly in the adult brain and express 
differences in location, protein expression, and morphology 101.  Heterogeneity of 
morphology and location of microglia translates to differences in microglial responses to 
injuries and in activation states 102. The majority of microglia are found in the gray 
matter and express more ramified structure with radial branches than those found in the 
white matter with longitudinal processes 101.  In the ischemic lesion induced by MCAO 
modeling, the penumbral area ( the border zone of dead and living tissue) showed 
highly ramified cells (resting), while the ischemic core housed amoeboid bodies with 
thick ramifications (activated) 80.  To conclude, resting microglia are not “sleeping”; 
instead they are poised to respond to stimuli resulting from disturbances in the CNS 
environment by drastically altering their phenotypes and functions. 
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Table 2-1: Phenotypes of microglia. 
Abbreviations:  MHC, major histocompatibility complex; Arg, arginase; TNFR, tumor 
necrosis factor receptor; Fizz1: resting-like molecule alpha; MR, mannose receptor.  
 
 
 
 
 
 
 
!
Phenotype Identification Markers References 
Resting State Iba-1 
CD45int CD11b+ 
F4/80 
Isolectin (IB4)  
76,103 
78,79 
101,104 
Classical 
Activation (M1) 
MHCII  
CD16 (FcγR III) 
CD 32 (FcγR II) 
CD80(B7-1) 
CD86 (B7-2) 
CD40 (TNFR) 
83,100,105 
106,107 
106 
108,109 
108,109 
110 
Alternative 
Activation (M2) 
Arg-1 
CD68 (ED1) 
Fizz1(Relmα) 
Ym-1 
CD206 (MR) 
Dectin-1  
111 
112 
111,113 
111,113 
114,115 
114 
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Inhibitory signaling of microglia 
 
In the healthy brain, microglia express numerous inhibitory proteins, and interact with 
neurons to form a “brake” on inflammation 103.  The endogenous mechanisms in the 
form of neuronal-glial interactions may prevent excess microglial activation in the CNS.  
Following injury, these interactions may be disrupted due to neuronal cell death and 
structural tissue damage.  Regulating these inhibitions to keep microglia from acquiring 
a proinflammatory phenotype has been shown to prevent uncontrolled damage in 
models of Alzheimers Disease (AD), multiple sclerosis (MS), and neurodegeneration 
19,104-107.  Similarly, regulation of these inhibitory proteins may also have beneficial 
effects on ischemic stroke.   
 
CD200/CD200R1 
 
CD200 is a transmembrane glycoprotein mainly expressed on neurons 108,109.  The cell-
cell contact between CD200  and its receptor (CD200R1), expressed on the surface of 
all myeloid origin cells, provides microglia with stability to remain in a resting state under 
normal CNS conditions 110,111.  Cleavage of this interaction and subsequent microglial 
activation leads to the upregulation of proinflammatory cytokines and an inflammatory 
profile 108. Increased tissue damage was related to a decrease of CD200 level in mouse 
models of EAE, suggesting a detrimental effect of the activated microglia unbound from 
CD200/CD200R1 interaction 112.  Aging is also associated with a reduced level of 
CD200 and long-term potentiation (LTP), as well as an increased microglial activation in 
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the brain; however, treatment of CD200R1 agonist (CD200Fc) can attenuate the LTP 
deficit and ameliorate microglial activation, even after Lipopolysaccharide (LPS) 
stimulation113.  Little is known about the role of CD200/ CD200R1 signaling in ischemic 
stroke, but a primarily descriptive study of CD200 on Iba+ cells showed a decrease in 
gene transcripts of CD200 in the ischemic hemisphere 23.  
 
Fractalkine (CX3CL1)/CX3CR1 
 
Much like the immunoglobulin superfamily member CD200R1, fractalkine receptor 
(CX3CR1) on microglia can bind the soluble and membrane bound forms of CX3CL1,   
to keep microglia quiescent 114. However, under injury, neurons significantly decrease 
CX3CL1 release thereby enabling microglial activation 115. Loss of this contact has been 
shown to be neurotoxic in many disease models including Parkinson’s disease and ALS 
by exacerbating neuronal loss 104. Similarly, LPS stimulation of microglia on CX3CR1 (-/-) 
mice led to greater IL1- β secretion compared to CX3CR1 (+/-) mice104.   
             However, the effect of CX3CL1/CX3CR1 signaling in neuroinflammation is 
controversial as deleterious roles for the CX3CL1/ CX3CR1pair were reported in rodent 
models of AD and cerebral ischemia 105,106.  Twenty four hours after a transient MCAO, 
CX3CR1 (gfp/gfp) mice (GFP is inserted into both alleles of the CX3CR1 locus) were 
noted to have less severe cerebral infarct volumes than WT mice, possibly associated 
with a coinciding decrease in IL-1β  and TNF-α gene transcripts 116, as in the case of 
fractalkine knockout mice 117. Similar results were seen in a recent study by Ciprani et al 
with a pMCAO model in CX3CL1 -/- and CX3CR1 (gfp/gfp) rodents, both of which showed 
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less severe ischemic damage than WT mice 106.   Furthermore, CX3CL1-/- animals have 
increased damage after ischemia with exogenous intracerebroventricular CX3CL1 
administration. Interestingly, WT rodents show less severe infarct volumes and better 
functional outcomes with the addition of CX3CL1 in a dose dependent manner 106. The 
disparity in the effect of exogenous CX3CL1between KO and WT animals suggests that 
CX3CL1may be protective only when microglia exhibited a normal constitutive 
CX3CR1-mediated signaling throughout development in the WT brain 106.  
 
SIRPα/CD47 
 
SIRPα (CD147, signal regulatory alpha, SHPS-1, P84), expressed on myeloid cells 
including microglia, binds integrin associated protein CD47 on neurons to activate an 
intracellular immunotyrosine inhibitory motif  118,119, keeping microglia silenced and 
thereby suppressing phagocytosis 120,121.  Human MS lesions have shown a decrease in 
CD47 expression 107,  though little is known to date about the role of CD47 and SIRPα 
in ischemia specifically.  A reduction of infarct was seen 24 and 72 hours after 90 min 
MCAO in CD47 knockout mice, potentially due to a decrease in peripheral inflammatory 
cell infiltration 122. Wang et al recently also reported a reduction of infarct and 
improvement of behavior deficit after transient MCAO in SIRPα mutant mice 123.  
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Triggering receptor expressed on myeloid cells 2 (TREM2) 
 
The neuronal-microglial connection of heat shock protein 60 (HSP60)-TREM2 is 
important for the clearance of apoptotic neurons by microglial phagocytosis 124. 
Microglia, via its intracellular adaptor protein DAP12, prevent the release of 
proinflammatory cytokines and maintain an anti-inflammatory microglial profile 125,126. In 
EAE, mice lacking TREM-2 by antibody blockage suffered worse pathology, but are 
rescued with greater recovery and tissue repair by injection of myeloid cells expressing 
TREM-2  126.  Contrarily, TREM -2 KO mice showed a decrease in amoeboid Iba1+ and 
CD68+ microglial activation and an overall decreased inflammatory response 7 days 
post-reperfusion after a 30 minute MCAO model that did not translate into a decreased 
infarct volume 127. The inhibitory effect of TREM-2 on microglial activation following 
stroke is still uncertain at this time.  
 
Activation of microglia  
 
A commonly held assertion is that distinct activation states (based on protein expression 
signatures) impart defined functional roles of microglia and may account for heterogenic 
responses to CNS injury. These activation states are generally described in terms of the 
class of activating signals and selectively induced expression of unique markers. 
Microglia can change patterns of migration, cell surface protein expression, and 
functions in response to tissue damage or dysfunction (Figure. 2-3). The rapid  
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Figure 2-3:  Schematic of Microglia Activation after Ischemic Brain Injury.   
In the ischemic brain, microglia display prominent changes in morphology associated 
with various functional states.  Activation results in upregulation of transcriptional 
machinery which serves to increase the production of inflammatory mediators.  In 
response to chemotaxic factors, microglia can migrate to sites of ischemic tissue injury 
to increase phagocytic uptake of cellular debris and cytotoxic substances. Depending 
on their activation state, microglia may promote a proinflammatory environment (via M1 
activation) or regenerative milieu (via M2 activation).  IL-10: interleukin 10; TGFβ: 
Transforming growth factor beta; IGF-1: Insulin like growth factor 1; IL-1β: interleukin 1 
beta; ROS: reactive oxidative species; IL-6: interleukin 6; TNFα : Tumor necrosis factor 
alpha. 
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Triggering receptor expressed on myeloid cells 
2 (TREM2):7KHQHXURQDOPLFURJOLDOFRQQHFWLRQ
RI KHDW VKRFN SURWHLQ  +6375(0 LV
LPSRUWDQW IRU WKH FOHDUDQFH RI DSRSWRWLF QHX-
rons by microglial phagocytosis [71]. Microglia, 
via its intracellular adaptor protein DAP12, pre-
YHQWWKHUHOHDVHRISURLQÁDPPDWRU\F\WRNLQHV
DQG PDLQWDLQ DQ DQWLLQÁDPPDWRU\ PLFURJOLDO
SURÀOH>@,Q($(PLFHODFNLQJ75(0E\
DQWLERG\ EORFNDJH VXIIHUHG ZRUVH SDWKRORJ\
but are rescued with gre ter recovery and tis-
VXHUHSDLUE\LQMHFWLRQRIP\HORLGFHOOVH[SUHVV-
LQJ 75(0 >@ &RQWUDULO\ 75(0 .2PLFH
showed a decrease in amoeboid Iba1+ and 
CD68+ microglial activation and an overall 
GHFUHDVHGLQÁDPPDWRU\UHVSRQVHGD\VSRVW
UHSHUIXVLRQ DIWHU D  PLQXWH 0&$2 PRGHO
WKDWGLGQRWWUDQVODWH LQWRDGHFUHDVHGLQIDUFW 
YROXPH>@7KHLQKLELWRU\HIIHFWRI75(0RQ
PLFURJOLDO DFWLYDWLRQ IROORZLQJ VWURNH LV VWLOO
uncertain at this time.
Activation of microglia
A commonly held assertion is that distinct acti-
vation states (based on protein expression sig-
QDWXUHV LPSDUW GHÀQHG IXQFWLRQDO UROHV RI
PLFURJOLD DQG PD\ DFFRXQW IRU KHWHURJHQLF
UHVSRQVHV WR &16 LQMXU\ 7KHVH DFWLYDWLRQ
VWDWHVDUHJHQHUDOO\GHVFULEHG LQWHUPVRIWKH
FODVV RI DFWLYDWLQJ VLJQDOV DQG VHOHFWLYHO\
LQGXFHG H[SUHVVLRQ RI XQLTXH PDUNHUV
0LFURJOLDFDQFKDQJHSDWWHUQVRIPLJUDWLRQFHOO
VXUIDFH SURWHLQ H[SUHVVLRQ DQG IXQFWLRQV LQ
UHVSRQVH WR WLVVXH GDPDJH RU G\VIXQFWLRQ
(Figure 3 7KH UDSLG UHVSRQVHV WR DOWHUHG
Figure 3. 6FKHPDWLF RI0LFURJOLD $FWLYDWLRQ DIWHU ,VFKHPLF%UDLQ ,QMXU\ ,Q WKH LVFKHPLF EUDLQPLFURJOLD GLVSOD\
SURPLQHQWFKDQJHVLQPRUSKRORJ\DVVRFLDWHGZLWKYDULRXVIXQFWLRQDOVWDWHV$FWLYDWLRQUHVXOWVLQXSUHJXODWLRQRI
WUDQVFULSWLRQDOPDFKLQHU\ZKLFKVHUYHVWRLQFUHDVHWKHSURGXFWLRQRILQÁDPPDWRU\PHGLDWRUV,QUHVSRQVHWRFKH-
PRWD[LFIDFWRUVHJ$73HWF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responses to altered homeostasis of the brain parenchyma can be visualized in two 
photon imaging to show immediate (within minutes) increase in the motility of microglial 
processes towards area of injury in a chemical gradient dependent manner, while the 
cell bodies remain stationary 99,100.  In vivo data suggest that ATP signaling of P2Y12 
receptors on the cell surface is responsible for such extensions and directional guidance 
99,128,129.  
 
Microglial activation phenotypes: M1 and M2 
 
Changes in microglial phenotype during activation may be analogous to that of 
peripheral macrophages, as the two cell types are indistinguishable without definitive 
surface markers for either. Microglial responses to stimuli from a changing brain 
environment are characterized as either M1, classical activation, or M2, alternative 
activation (Table. 2-1). M1 is a proinflammatory cellular state associated with an 
increase in protein synthesis of pro-inflammatory mediators (IFNγ, Il-1β, TNFα, Il-6, 
CXCL10, etc.), ROS and NO production, and proteolytic enzymes (MMP 9, MMP3) that 
act on the extracellular matrix leading to BBB breakdown 7,130.  M1 phenotype can lead 
to increased neuronal death compared to alternatively activated M2 microglia 131; 
therefore, there is a growing interest to pharmacologically interfere with the signaling 
mechanisms that give rise to the classical activation phenotype of microglia.   M2 
microglia release anti-inflammatory mediators (IL-10, TGF-β, IL-4, IL-13, IGF-1, CD206,  
etc.) 132, leading to enhanced expression of genes associated with inflammation 
resolution, scavenging, and homeostasis 130,133-135.  Levels of IL-10, TGF-β and CD206 
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mRNA increased as early as day 1 after ischemic injury and peaked at 4-6 days.  In 
addition, TGF-β released by microglia promotes an anti-inflammatory profile associated 
with increased proliferation and neuroprotection in the ischemic brain 136 . This may be 
therapeutically relevant because TGF-β1 is specifically found in the salvageable peri-
infarcted region of the cortex 24 hours after a 60 min MCAO and involved in distinct 
spatiotemporally regulated inflammatory and neuroprotective processes 137. 
              During disease progression and in normal ageing, microglial activation 
phenotypes can switch from M2 to M1 138.  One recent study suggested that microglia 
first alternatively activate early after MCAO and morph into a reactive M1 phenotype by 
7 days 131. The balance between the M1 and M2 states is dynamic in inflammatory 
responses and may be offset in chronic disease states such as stroke, representing a 
novel mechanistic target for therapy 130.  Several proteins have been identified as 
markers for M1 or M2. MHC II, implicated in antigen presentation as an immune 
reaction, is upregulated on classically activated microglia, and is commonly used as a 
marker for M1 83.  The alternatively activated M2 up-regulates presentation of several 
antigens. Ym-1 (Chitinase 3-like 3), for example, has been found to be associated with 
the protective, pre-phagocytic state of macrophages after ischemia 80.  Some of Ym-1+ 
cells co-express CD206 (mannose receptor), which is another marker for M2 activation 
known to be involved in antigen internalization and processing 80.  CD68 (macrosialin) 
glycoprotein is another accepted marker for phagocytotic cells and is often used to 
distinguish the M2 debris clearing state of microglia 80.  Stroke-induced changes in the 
expression of specific cell surface proteins probably reflect a continuum of the microglial 
activation spectrum.  There is a growing need to identify subpopulations of M1/M2 
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microglia versus those of peripheral myeloid cells and the relative percentages of each 
over time to determine the overall functional contribution to stroke injury.   
 
Migration  
 
Microglia, as the first immune responders in the CNS, migrate to areas of injury through 
detection of chemoattractant gradient, and phagocytize debris, damaged tissue, 
neutrophils, and apoptotic cells that have the potential to release damaging molecules 
99,139,140. CX3CL1 and ATP released from dying neurons can act on microglial receptors 
to induce chemotaxis.  In addition, monocyte attractant protein 1 (MCP-1, CCL2) is a 
chemokine expressed both in the brain and in some peripheral organs that can induce 
migration of leukocytes and macrophages/microglia to the ischemic area 141,142.  After 
MCAO, MCP-1 expression increases at injured region and peaks at 2-3 days 143 when 
monocytes/macrophages also start to peak in the ischemic brain 144.   Transgenic CCL2 
knockout mice show decreased ischemic injury 145, suggesting that the recruitment of 
monocytes/macrophages to the injured area may be detrimental and that therapies 
designed to block the migration of leukocytes may have translational value.   Microglia 
at the border region of the infarct, “penumbral” microglia, may be the major targets of 
therapy given their large numbers, and activated status after stroke 146. Unlike microglia 
of the ischemic core, which appear to be dying with increased disease severity, 
penumbral microglia are presumably living and highly activated 102.  This suggests a 
regional target of interest to deliver treatments. 
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Phagocytosis by microglia and macrophages 
 
As the primary phagocytes in the brain, activated microglia phagocytize and uptake 
damaging components in an effort to reestablish homeostasis after insults 60.  Microglial 
phagocytosis of neuronal cells begins early even before peripheral macrophages 
infiltrate into the brain after stroke 147.  These phagocytotic cells were seen interacting 
with neurons and show neuron engulfment in the ischemic brain.  CD68 is a commonly 
used marker of macrophage phagocytosis and expressed as early as 6h after pMCAO 
on ramified CD11b+ cells in the penumbra, and continues to increase later in the 
hypertrophic ameboid cells of the ischemic core 80.  However, the phgocytosis marker 
can be expressed on both the resident and infiltrating phagocytes, and therefore may 
not be exclusive to microglia 80.   
            Phagocytosis is able to attenuate inflammation but can also be implicated in 
neuronal damage. A recent study of primary microglial cultures assessed the sequence 
of events from microglial activation to the phagocytosis of neurons 148. Production of 
peroxynitrite during a microglial immune response to TLR4 and TLR2 activation leads 
neurons to externalize phosphatidylserine on the outer membrane to act as an “eat me” 
signal to elicit phagocytosis.  Interestingly, inhibition of this process at any stage not 
only leads to the decrease in phagocytosis of the neurons, as would be suspected, but 
also prevents 90% of neuronal cell death 148.  The potential for microglia to phagocytize 
viable neurons illustrates the importance of microglial modulation in ischemic stroke 148. 
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Purinergic receptors  
 
Purinergic receptors (P2X7, etc.) are upregulated on microglia in the periinfarct region of 
injury 149 and have been shown to interact with ATP that is accumulated extracellularly  
in the ischemic brain 150, subsequently leading to microglial activation 151.  Activation of 
these receptors leads to cell death 152and the prominent release of proinflammatory 
cytokine IL-1β through caspase-1 pathway 153.  ATP leaked from dying neuronal cells 
and released by astrocytes 99,154 can act as a chemoattractant on microglia by 
interacting with P2Y12 receptor 155; the microglia attracted to sites of ischemic injury can 
further amplify activation by autocrine signaling of ATP 156. This positive feedback loop 
leads to increased proliferation and secretion of IL-1β, TNF-α, and ROS 151, and 
exacerbate inflammatory responses.  Blocking P2X7 receptors was shown to improve 
behavior deficits in a model of transient global ischemia where decreases in microglial 
activation and proinflammatory cytokines (TNF-α, IL1-β, and IL-6) were noted 157.  A 
nonselective P2 blocker, Reactive Blue 2, was shown to reduce infarction in a focal 
pMCAO model; however, P2X7 receptors are also expressed on neurons and 
astrocytes, therefore the function may not be solely attributed to microglia 158. 
 
Toll like receptor (TLR) 
 
The stroke-induced innate immune response is also associated with the release of 
various damage associated molecular patterns (DAMPs), which can further activate 
pattern recognition receptors (PRRs), including members of the TLR family on microglia 
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159,160.  TLRs are important in innate immunity in both the central and peripheral 
systems. TLR4 is the prominent LPS receptor that can lead to activation of LPS-
responsive cells, such as monocytes and macrophages, and subsequently causes 
upregulation of proinflammatory genes via NFκB signaling 161.  The most prominent 
TLRs on microglia are TLR4 and TLR2, both of which are upregulated after ischemia 
160,162-165.  TLR4 deficient mice have smaller infarct sizes, better neurological scores and 
decreased downstream NFκB signaling in experimental stroke studies 164,166. Recent 
studies have shown that CNS preconditioning with TLR4 agonist can lead to tolerance, 
eliciting a diminished proinflammatory response with subsequent less ischemic injury 
167,168.  Although there has been controversy as to the role of TLR2 deficiency in 
cerebral ischemia, recent studies have shown an exacerbation of injury in TLR2 KO 
mice 160,163,169.   Some endogenous ligands of TLRs have recently been identified.  
Purines and peroxiredoxin (prx) released to the extracellular space from dying cells can 
bind TLRs on macrophages and produce proinflammatory cytokines IL-23 and IL-17 170.  
Heat shock proteins (HSP) and High mobility group box 1 (HMGB1) are other 
endogenous ligands for TLRs that result in upregulation of NOS and proinflammatory 
cytokines (TNF-α, IL-6, and IL-1β) 171,172.  
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Functional insights of resident microglia and peripheral macrophages 
 
Microglial proliferation and renewal 
 
There is evidence that activated microglia are proliferative in the ischemic brain. Using 
carboxyfluorescein diacetate succinimidyl ester (CSFE) to intracellularly label peripheral 
cells before a 30-60min MCAO, one study found higher amounts of BrdU+ Iba1+ CSFE- 
colabeling microglia after stroke indicating increased proliferation 140.   Interestingly 
accumulating data show microglial proliferation is beneficial after ischemia.  In vitro 
studies have shown that increased microglial proliferation by stimulation of CSF-1R, 
which is upregulated in ischemia, is neuroprotective 83,173.  An in vivo study also showed 
that defective microglial proliferation was associated with significant increase in the size 
of ischemic lesion and a 2-fold increase in the number of apoptotic neurons 174.    
             In addition to microglia, choroid plexus macrophages, perivascular 
macrophages, and meningeal macrophages inhabit various regions around the CNS 175. 
This heterogeneous population of tissue macrophages is continuously replenished by 
circulating and peripheral monocytes, unlike microglia that are largely thought to be 
resident in the adult CNS from early development 93,176,177. Theories of another wave of 
microglial establishment postembryonic from peripheral monocytic precursers that last 
into adulthood are part of an ongoing debate 93,178. It is uncertain whether these 
monocytic precursors become integrated into the microglial population or remain bone 
marrow-derived monocytes. Nevertheless, Varvel et al. 179 suggest yet another mode of 
microglial replacement apart from proliferation exists in the adult brain.  They ablated 
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microglia using intracerebroventricular ganciclovir treatment in Tk+ /Ccr2+/rfp mice and 
found abundant levels of CD45high monocytes in neocortical areas of microglial 
depletion before engraftment. In addition, there were increased levels of Ccr2 RFP 
expression which returned to normal levels after engraftment. These infiltrating cells of 
monocytic origin are morphologically similar to microglia and functionally active in 
surveying the microenvironment of the brain, without changes in number over time 179. 
It’s possible that a population of dying microglia in the ischemic brain could be 
replenished by peripheral monocyte/macrophages infiltrating into the injured region and 
downregulating CCR2 and CD45 to morph into microglia. The topic of microglial 
renewal and proliferation, however, is still controversial.  
 
MMPs 
 
Macrophages, including microglia, are major contributors to the release of MMPs 
(mainly MMP3 and MMP9) which are responsible for the breakdown of the extracellular 
matrix and the BBB after ischemia 140,180.  MMP-3 and MMP-9 knockout mice were 
shown to suffer less neuronal injury after an ischemic episode 181,182.  Since MMP-9 can 
be derived from both brain and peripheral immune cells, its origin after ischemia has 
been debated. Recently, chimeric studies showed that the increased damage from 
MMP-9 toxicity in the ischemic brain are attributed to bone marrow cells as opposed to 
resident microglia 182,183.  This suggests that infiltrating monocytes/macrophages can 
also release MMPs and modulate their own entry into the CNS by weakening BBB.  
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TNF 
 
TNF-α can be released from both microglia and peripheral leukocytes. TNF-α has been 
largely regarded as neurotoxic 184; however, chimeric studies have found that TNF-α 
produced locally by resident brain microglia (but not by peripheral macrophages and 
leukocytes) exerted neuroprotection in pMCAO model via TNF-p55 signaling 185. The 
disparity in implications may be attributed to different signaling mechanisms between 
the neuroprotective TNF-p55 and neurotoxic TNF-p75 pathways 186 . 
 
iNOS 
 
Local accumulation of nitric oxide (NO) is also involved in the inflammatory cascade 
after cerebral ischemia 187.  Equipped with inducible nitric oxide synthase (iNOS), M1 
microglia are partially responsible for the changes in expression level of NO. The role of 
iNOS in ischemia is inconsistent in literature as both protective and deleterious roles 
have been reported 188-190.  Pruss et al 191 found that in chimeric iNOS-deficient mice 
transplanted with WT bone marrow (BM) cells and wild-type mice transplanted with 
iNOS-deficient BM cells, no difference in cerebral iNOS expression or in infarct volumes 
can be seen between the chimeric animals after MCAO, suggesting iNOS from 
microglia and peripheral myeloid cells may not be a significant regulator of ischemic 
injury.  
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Peroxiredoxin  
 
The peroxiredoxin family of proteins (Prxs) are intracellular antioxidant enzymes that are 
needed for cell survival in the brain 192,193 . However, once released from necrotic brain 
cells, extracellular Prxs promote neural cell death in ischemia by inducing expression of 
inflammatory cytokines including IL-23 in macrophages 170.  This study also utilized 
chimeric mice models and further showed that the infiltrating bone marrow-derived 
macrophages but not the resident microglia, are responsible for increased ischemic 
volume and inflammatory response triggered by Prxs release 170.  In addition, they 
found that neutralization of the released extracellular Prxs with a prx antibody is 
protective. 
 
 
Summary 
 
Despite more than one century of research since they were first investigated by Rio Del 
Hortega 194, “the father of microglia,” the precise role of microglia is still shrouded in 
mystery due to a current lack of tools and fundamental understanding of the 
heterogeneity of their observed activation spectrum. The nature of the microglial 
response to stroke is multi-faceted and complicated by the aggregate immune 
response.  The significance of the local and systemic inflammatory response as well as 
the interplay between the two is widely argued.  While many studies suggested that 
anti-inflammatory agents confer neuroprotection following ischemic brain injury, others 
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pointed to a requirement for pro-inflammatory cytokines and leukocyte activation in 
orchestrating repair.  Enhancing repair may be possible by targeting distinct populations 
of microglia with special attention to temporal and spatial specific therapeutic 
intervention in ischemic stroke and other neurological disorders. There is room for 
improvements of methods for better identification and manipulation of microglia. The 
roles of microglia in stroke-induced inflammatory responses merit further investigation, 
in hope that fine-tuning immunomodulatory therapies could be available to avoid the 
deleterious effects of total immunosuppression and the possible detrimental effects of 
chronic microglial inhibition. 
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Abstract 
 
The brain’s initial innate response to stroke is primarily mediated by microglia, the 
resident macrophage of the CNS.  However, as early as four hours after stroke the 
blood-brain barrier is compromised and monocyte infiltration occurs.  The lack of 
discriminating markers between these two myeloid populations has led many studies to 
generate conclusions based on the grouping of these two populations.  A growing body 
of evidence now supports the distinct roles played by microglia and monocytes in many 
disease models.  Using a flow cytometry approach, combined with ex-vivo functional 
assays, we were able to distinguish microglia from monocytes using the relative 
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expression of CD45, and assess the function of each cell type following stroke over the 
course of 7 days.  We found that at 72hrs after a 90-minute middle cerebral artery 
occlusion (MCAO), microglia populations decrease whereas monocytes significantly 
increase in the stroke brain compared to sham.  After stroke, BRDU incorporation into 
monocytes in the bone marrow increased. After recruitment to the ischemic brain these 
monocytes accounted for nearly all BRDU-positive macrophages.  Inflammatory activity 
peaked at 72hrs.  Microglia produced relatively higher reactive oxygen species and 
TNF, whereas monocytes were the predominant IL-1β producer.  Although microglia 
showed enhanced phagocytic activity after stroke, monocytes had significantly higher 
phagocytic capacity at 72hrs.  Interestingly, we found a positive correlation between 
TNF expression levels and phagocytic activity of microglia after stroke.  In summary, the 
resident microglia population is vulnerable to the effects of severe ischemia, show 
compromised cell cycle progression, and adopt a largely pro-inflammatory phenotype 
after stroke. Infiltrating monocytes are primarily involved with early debris clearance of 
dying cells.  These findings suggest that the early wave of infiltrating monocytes may be 
beneficial to stroke repair and future therapies aimed first at mitigating microglia cell 
death may prove more effective than attempting to elicit targeted anti-inflammatory 
responses from damaged cells. 
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Introduction 
 
Inflammation is a key component of stroke-induced injury and elevated levels of 
inflammatory markers are associated with poor outcome in stroke patients 35,195-197.  
Inflammation in the brain is generally mediated by microglia, the resident macrophage 
of the CNS 198.  In the protected confines of the blood-brain barrier microglia maintain 
healthy brain function by clearing debris, pruning synapses, and producing 
growth/repair factors 199.  These cells stand poised to respond to injuries in the CNS 
such as ischemic stroke.  Numerous experimental studies have shown that microglia 
become activated following stroke, notably shifting their morphology from a thin, 
ramified state to a large, amoeboid structure 200.  This change is generally thought to be 
accompanied by an increase in proliferation and production of inflammatory mediators.  
Yet despite the evidence for widespread recruitment of bone marrow-derived 
monocytes (and their derivatives) to injured brain regions, and a lack of discriminate cell 
markers, little is known regarding the functional differences between these two myeloid 
populations in ischemic stroke.  Given the high degree of macrophage heterogeneity 
that comprises our innate immune system, the functional role of these populations is 
likely distinct and of translational importance 201-204.  CNS-resident microglia are the first 
responders to ischemia, these cells likely serve a unique role in injury repair relative to 
monocytes, which have a finite lifespan and are recruited in higher numbers during the 
post-reperfusion phase from the periphery.  These differences have been made evident 
in recent studies that utilize transgenic bone marrow chimeras to distinguish between 
local and circulating myeloid populations 205.  These potentially disparate roles suggest 
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that drugs designed to modulate microglia function may adversely impact that of the 
infiltrating monocyte population.   
In this study, we investigated functional differences between brain-resident 
microglia and infiltrating monocytes in acute ischemic injury to better understand the 
contribution of each population to the recovery phase of stroke.  Using flow cytometry to 
discriminate between these two populations, we applied ex-vivo functional assays to 
ascertain their functional roles during stroke and early recovery.  By identifying the 
distinct function of microglia and monocytes early after ischemic stroke, the potential for 
targeting these specific cell populations will allow for the development of more effective 
therapeutic interventions.   
 
 
Materials and Methods 
 
Mice/Animals:  Young adult C57BL/6J male mice (10-12 weeks) of age were pair-
housed on sawdust bedding in a pathogen free facility (light cycle 12/12 h light/dark). All 
animals had access to chow and water ad libitium.   All procedures were performed in 
accordance with NIH guidelines for the care and use of laboratory animals and 
approved by the Institutional Animal Care and Use Committee of the University of 
Connecticut Health Center.  All analysis was performed blinded to surgical conditions. 
 
Ischemic Stroke Model:  Cerebral ischemia was induced by 90 minutes of reversible 
middle cerebral artery occlusion (MCAO, 20–25 gm mice) under Isoflurane anesthesia 
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as previously described 206. Rectal temperatures were maintained at approximately 
37°C during surgery and ischemia with an automated temperature control feedback 
system. A midline ventral neck incision was made, and unilateral MCAO was performed 
by inserting a 6.0 Doccol monofilament (Doccol Corp, Redland, CA) into the right 
internal carotid artery 6 mm from the internal carotid/pterygopalatine artery bifurcation 
via an external carotid artery stump. Following reperfusion mice were sacrificed at 
24hrs, 72hrs, and 7 days.  Sham-operated animals underwent the same surgical 
procedure, but the suture was not advanced into the internal carotid artery. 
 
Tissue Harvesting:  Mice were euthanized, transcardially perfused with 60 mL cold, 
sterile PBS, and the brains were harvested.  The brainstem, cerebellum, and optic 
nerve were removed.  The brain was then divided along the interhemispheric fissure 
into two hemispheres and subsequently rinsed with PBS to remove contaminant cells.   
 
Flow Cytometry:  Brains were placed in complete RPMI 1640 (Lonza) medium and 
mechanically and enzymatically digested in collagenase/dispase (1 mg/mL) and DNAse 
(10mg/mL; both Roche Diagnostics) for 1hr at 37C.  The cell suspension was filtered 
through a 70um filter.  Leukocytes were harvested from the interphase of a 70%/30% 
Percoll gradient.  Cells were washed and blocked with mouse Fc Block (ebioscience) 
prior to staining with primary antibody-conjugated flourophores:  CD45-eF450, CD11b-
APCeF780, Ly6C-PerCP-Cy5.5, Ly6G-PE, and SIRPα-APC.  All antibodies were 
commercially purchased from eBioscience.  For live/dead discrimination, a fixable 
viability dye, carboxylic acid succinimidyl ester (CASE-AF350, Invitrogen), was diluted 
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at 1:300 from a working stock of 0.3mg/mL.  Cells were briefly fixed in 2% 
paraformaldehyde (PFA).  Data were acquired on a LSRII using FACsDiva 6.0 (BD 
Biosciences) and analyzed using FlowJo (Treestar Inc.).  No less than 100,000 events 
were recorded for each sample.  Resident microglia were identified as the CD45int 
CD11b+Ly6C- population, whereas bone marrow-derived leukocytes were identified as 
CD45hiCD11b+Ly6C+Ly6G-.  Cell type-matched fluorescence minus one (FMO) controls 
were used to determine the positivity of each antibody.  Prior to assessment on the 
cytometer, isolated cells were briefly probed to determine phagocytosis activity, 
oxidative stress level, cell proliferation status, and cytokine production as described 
below. 
 
Phagocytosis Bead Assay:  To study the phagocytic activity of microglia, fluorescent 
latex beads (Fluoresbrite Yellow Green (YG) carboxylate microspheres; 1um diameter; 
Polysciences) were added to sorted microglia in a final dilution of 1:100 as described 
207.  After 1-hour incubation at 37°C the cells were washed three times with FACS 
buffer, re-suspended in FACS buffer, stained for surface markers, and fixed in PFA 
(N=6/group).  Mean fluorescence was determined from the YG bead+ microglia 
population, and used to measure the amount of beads per phagocytosing cell 208. 
 
Reactive Oxygen Species Measurement:  For detection of reactive oxygen species, 
microglial cells were incubated with redox-sensitive DHR (5uM; Ex/Em: 495/520) 
fluorogenic cell-permeant dye (Life Technologies, Invitrogen).  Cells were incubated for 
20min at 37C, washed three times with FACS buffer (without NaAz), and then stained 
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for surface markers including CASE (N=5/group).  After loading cells with DHR, each 
sample was separated into two tubes, one kept on ice and one at 37ºC. 
 
BRDU Labeling and Analysis:  For cell proliferation studies, 50mg/kg of BRDU 
(Sigma) was injected interperitoneally starting at 12hrs after reperfusion and again at 
24hrs and 48hrs.  BRDU staining was assessed using a BRDU Flow Kit (BD 
Biosciences).  In brief, cells were permeabilized with detergent and treated with DNAse 
prior to the addition of both anti-BRDU-FITC antibody and Ki67-PE (eBioscience). 
 
Intracellular Cytokine Production:  For intracellular cytokine staining, an in vivo 
brefeldin A (BFA) protocol was followed.  Briefly, 10mL/kg of BFA (Sigma, 0.5mg/mL in 
DMSO) was injected via tail vein.  Ten hours later, animals were sacrificed and tissue 
was harvested as noted above.  Prior to staining, 1ul of GolgiPlug containing brefeldin A 
(BD Biosciences) was added to 800ul complete RPMI and cells were incubated for 2h at 
37C (5% CO2).  Afterward, cells were re-suspended in Fc Block, stained for surface 
antigens and washed in 100ul of fixation/permeabilization solution (BD Biosciences) for 
20 min.  Microglia were then washed twice in 300ul permeabilization/wash buffer (BD 
Biosciences) and re-suspended in an intracellular antibody cocktail containing TNF-PE-
Cy7 (eBioscience) and IL-1β-FITC (eBioscience), and subsequently fixed (N=5-
7/group). 
 
Bone Marrow Chimera Generation:  Wildtype C57BL/6J mice (8 weeks old) were 
lethally irradiated (two doses of 5-6 Gy) in a Gammacell 40 research irradiator and 5 x 
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105 nucleated GFP-expressing donor bone marrow cells were injected retro-orbitally 209.  
Chimeras were maintained on sulfamethoxazole/trimethoprim antibiotics in their drinking 
water one day prior- and two weeks following irradiation.  Chimeras were used for 
experiments 10 weeks following transplantation. 
 
Statistical Analyses:  Data from individual experiments are presented as mean ± SEM 
and assessed by Student t test or One-way ANOVA with Tukey post-hoc test for 
multiple comparisons (GraphPad Prism Software Inc, San Diego, CA, USA).  For Two-
way ANOVA, significant differences between paired comparisons were conducted with 
the Holm-Sidak test.  The Spearman’s rank correlation test was used to ascertain the 
correlation between cytokine production and phagocytic activity.  Significance was set at 
p < 0.05. 
 
 
Results 
 
Ischemic stroke induces microglial death, bone marrow production of monocytes, 
and recruitment of monocytes to the injured brain 
 
We confirmed the ability to reliably distinguish CD45int microglia from CD45hi monocyte 
populations in the ischemic brain by generating GFP bone marrow chimeras, in which 
all bone marrow-derived cells were GFP-positive (Supplementary Figure 3-1A).  We 
demonstrated that the two populations did not significantly overlap after stroke, 
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validating this approach.  Absolute leukocyte counts were obtained by flow cytometry at 
24 and 72 hours after MCAO in non-irradiated, intact wild type mice using the gating 
strategy shown in Figures 3-1A-B.  A significant reduction in the number of microglia 
(CD45intCD11b+Ly6C-) after stroke was found after 24hrs (p<0.05; Figure 3-1C).  
Conversely, we found a dramatic increase in monocyte (CD45hiCD11b+Ly6C+Ly6G-) 
counts in the stroke hemisphere compared to sham brain (Figure 3-1D).  At 72hrs, 
Microglia expressed increased levels of Ki67, a marker of actively cycling cells 
(p=0.017; Figures 3-2A-B).  DNA synthesis, an indicator of cell proliferation, was then 
measured by BRDU incorporation.  Following repeated BRDU injections starting at 
12hrs, microglia showed little BRDU incorporation by 72hrs, whereas ~90% of 
monocytes in the ischemic brain were BRDU-positive (Figures 3-2C-D). Stroke is 
known to stimulate bone marrow production of myeloid cells that are subsequently 
recruited to the brain 210.  We found a significant increase in the percentage of BRDU+ 
monocytes in the bone marrow following stroke (p=0.016; Figures 3-2E-F).  These data 
suggest that after 90-minute tMCAO, there is a significant loss of resident microglia, 
impaired cell cycle progression, and an increased number of newly produced, bone 
marrow-derived monocytes. 
 
Differential oxidative stress and cytokine production by microglia and monocytes 
after stroke 
 
Reactive oxygen species production drives the oxidative stress response to stroke and 
is critical to injury progression 211.  We examined free radical formation in microglia and  
	   	   	  49	  
 
 
 
Figure 3-1.  Number of microglia and monocytes in the ischemic hemisphere in 
the early period after stroke.   
A representative dot plot depicts the gating strategy used to identify both brain-resident 
microglia and Ly6C+ monocytes at 72hrs after 90-minute MCAO (A-B).  Absolute cell 
counts of microglia (C) and monocytes (D) were quantified at 0-, 24- and 72hrs after 
stroke.  For all experiments, N=9/group.  Error bars show mean SEM.  Abbreviation: 
SEM, standard error of the mean. 
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monocytes after stroke.  Resident microglia expressed significantly more ROS relative 
to the infiltrating monocytes (p<0.01), as evidenced by increased DHR123 staining 
intensity (Figures 3-3A-B).  Because oxidative stress precipitates cytokine production, 
we next evaluated pro-inflammatory cytokine levels in these cells. Newly recruited 
monocytes expressed higher levels of TNF at 24hrs; however, microglia expressed 
significantly greater levels by 72hrs (Figures 3-3C-D).  Infiltrating monocytes expressed 
relatively higher levels of IL-1β at all time-points (p<0.001; Figures 3-3E-F).  The 
number of microglia expressing TNF remained elevated above sham levels at 7 days, 
whereas those expressing IL-1β did not differ.  Neither microglia nor brain-recruited 
monocytes expressed detectable levels of the anti-inflammatory cytokines IL-4 and IL-
10 after stroke (data not shown).  These results suggest that microglia play a critical role 
in oxidative injury and that these two cell types may mediate cell death via distinct 
signaling pathways.   
 
Monocytes are the predominant phagocytes in the brain at 72hrs after stroke. 
 
Microglia in the ischemic hemisphere were significantly more activated based on side 
scatter (granularity) properties compared to sham, suggesting enhanced uptake of 
dying cells and debris (Figures 3-4A-B).  Phagocytosis is important in debris clearance 
and injury repair.  Using a bead assay, we measured phagocytic activity of microglia 
and monocytes (Figure 3-4C).  After stroke, the percentage of microglia that 
phagocytosed beads significantly increased at 24hrs (p<0.001) and peaked at a near 
four-fold increase by 72hrs (p<0.01; Figure 3-4D). The phagocytic activity of microglia is  
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Figure 3-2.  (Legend on following page) 
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Figure 3-2.  Assessment of microglia proliferation and monocyte production by 
72hrs after stroke.  
A representative dot plot shows Ki67 expression by microglia at 72hrs after stroke (A).  
The percentages of Ki67+ microglia were quantified (B). BRDU incorporation of myeloid 
cells was assessed in the brain using flow cytometry.  A representative dot plot 
illustrates that resident microglia had not undergone DNA synthesis by 72hrs in the 
ischemic brain (C).  Quantification of BRDU+ cells revealed that nearly all monocytes 
had entered S phase of proliferation (D).  Analysis of bone marrow revealed that stroke-
induced production of monocytes likely account for BRDU+ monocytes in the brain (E-
F).  For all experiments, N=5/group.  Cell-specific FMO controls were used to determine 
positive gating.  Error bars show mean SEM. Abbreviation: SEM, standard error of the 
mean; SH, sham; ST, stroke.   
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Figure 3-3.  Measurement of cytokine production by microglia and monocytes at 
24 hours, 72 hours, and 7 days following stroke. 
A representative histogram showing microglia (red) have relatively higher reactive 
oxygen species levels than monocytes (blue) at 72hrs after stroke as measured with 
dihydrorhodamine (DHR) 123 (A).  The mean fluorescence intensity of DHR123 was 
quantified (B).  Representative dot plots showing microglia and monocyte production of 
TNF (C) and IL-1β (E) at 72hrs reveals differential expression patterns after stroke.  The 
respective percentages of cells positive for these cytokines are quantified at 0hrs, 
24hrs, 72hrs, and 7 days (D and F).  For all experiments, N=5-7/group.  Cell-specific 
FMO controls were used to determine positive gating.  Error bars show mean SEM. 
Abbreviation: SEM, standard error of the mean; SH, sham; ST, stroke  
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Figure 3-4.  Phagocytic activity of microglia and monocytes at 24hrs, 72hrs, and 7 
days following stroke. 
Representative histogram showing a relative increase in side scatter (granularity) 
properties of microglia at 72hrs after stroke (red) compared to sham (blue; A).  Mean 
side scatter intensity of microglia was quantified at different time points after MCAO 
(N=5/group; B).  Phagocytic activity after stroke was measured by bead assay using 
flow cytometry (C).  The percentages and mean fluorescence intensity (MFI) of bead+ 
cells were quantified at 0hrs, 24hrs, 72hrs, and 7 days (N=6/group; D-E).  A 
representative histogram shows higher expression of the phagocytic marker SIRPα on 
monocytes (blue) compared to microglia (red) at 72hrs in the ischemic hemisphere (F).  
The MFI of SIRPα+ cells are quantified (N=5/group; G).  Cell-specific FMO controls were 
used to determine positive gating.  Error bars show mean SEM. Abbreviation: SEM, 
standard error of the mean; SH, sham; ST, stroke; SSC, side scatter; YG, yellow green 
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Figure 3-5.  Relationship between TNF production and phagocytic activity of 
microglia after stroke. 
A representative dot plot shows the relationship between microglial TNF production and 
phagocytic activity at 24hrs (A).  The percentage of TNF+ microglia is significantly higher 
in the phagocytic subset of microglia compared to the non-phagocytic subset 
(N=5/group; B).  A positive correlation was found between the MFI of TNF expression in 
microglia and number of beads they phagocytosed after stroke (C).  Cell-specific FMO 
controls were used to determine positive gating.  Error bars show mean SEM. 
Abbreviation: SEM, standard error of the mean; SSC, side scatter; MFI, mean 
fluorescence intensity; a.u.i., arbitrary units of intensity. 
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restored back to baseline levels by 7 days.  Compared to microglia, however, infiltrating 
monocytes exhibited far greater capacity for phagocytosis. Significantly more 
monocytes were bead-positive as were the number of beads phagocytosed per cell as 
evidenced by MFI (p<0.001; Figure 3-4E).  Monocytes at 72 hrs also expressed 
significantly higher levels of the phagocytic marker SIRPα than did microglia (p=0.005; 
Figures 3-4F-G).  Interestingly, phagocytic microglia were more likely to express TNF 
and at higher levels than non-phagocytic microglia, indicating that pro-inflammatory 
(M1) markers may overlap with anti-inflammatory (M2) function (Figures 3-5A-B).  
Moreover, a positive correlation was found between the level of TNF production and the 
number of beads phagocytosed by microglia after stroke (p=0.0167; Figure 3-5C).  
Taken together, these data imply that microglia do increase phagocytic activity following 
stroke stimulus, albeit at significantly lower levels than recruited monocytes. 
 
 
Discussion 
 
We demonstrate for the first time that the increase in macrophage proliferation in the 
brain following severe tMCAO is a result of stimulus-driven bone marrow production of 
migrant monocytes rather than proliferation of microglia.  Resident microglia, as 
bystanders to ischemia, are similarly vulnerable to its detrimental effects.  We found that 
after a 90-minute MCA occlusion, the number of microglia is significantly less than that 
seen in sham brain.  Traditionally, the use of standard immunohistochemistry could not 
make this distinction; possibly overestimating the microglial response leading to the  
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concept that microglia are highly proliferative, even after severe ischemic injuries.  
Indeed, the microglia population in general appears to be severely compromised after 
stroke.  It is not known whether the microglial population replenishes itself during 
recovery, or if invading monocytes establish permanent residence and take over the 
microglial niche 93,179. 
 Although microglia and monocytes exhibit several features of pro-
inflammatory activation after stroke, several studies suggest a supportive and even 
beneficial role for each in stroke outcome 12,14,212-216.  These outcomes are likely 
influenced by the degree of ischemic severity and the ischemic setting/conditions.  
Distinguishing brain-resident microglia from monocyte populations in ischemic brains 
that have high numbers of infiltrating leukocytes can be challenging.  Due to the lack of 
available microglia-specific markers, the absolute identification of microglia can be 
hampered by up-regulation of CD45 expression on activated microglia after injury, 
which can cause overlap with bone marrow-derived macrophage populations 83,102,217.  
Bone marrow chimeras allowed us to differentiate between all fluorescently tagged bone 
marrow-derived leukocytes from resident microglia, definitively confirming that microglial 
expression of CD45 is relatively stable after stroke.  However, to further ensure the 
purity of our microglial gating strategy, we selected out any contaminating monocytes 
using Ly6C antibody, which is not expressed on adult microglia. These findings enabled 
us to provide a reliable functional assessment of resident microglia and recruited 
monocyte populations by ex-vivo flow cytometry.  
Recent work from the Merad laboratory has elegantly demonstrated that there is 
little bone marrow or systemic contribution to the resident microglia pool under normal 
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conditions 64,218.  These observations were made using donor-tagged bone marrow 
chimeras and parabiotic mice.  Consistent with these findings, our group has also found 
that as far out as one year following radiation, uninjured chimeras had less than 5% 
‘microglia-like’ monocytes as evidenced by their CD45intCD11b+GFP+Ly6C+ phenotype, 
reminiscent of the resident CD45intCD11b+GFP- microglia population (data not shown).  
Although these findings imply there is a low frequency of monocyte mixing in the 
resident CD45int microglia population of irradiated chimeras, these bone marrow-derived 
GFP+ cells can still be distinguished by the expression of Ly6C.  Although useful, 
chimera development and parabiotic manipulation have limitations, including the 
potential for radiation injury and immune activation from the invasive surgical stress, 
respectively.  Importantly, other studies have found that following an injury to the CNS, 
recruited monocytes can down-regulate Ly6C expression and establish permanent 
residence, thereby replenishing the attenuated microglia pool 179,219.  The acute time 
points described in our study are unlikely to be affected by the down-regulation of Ly6C 
on monocytes as earlier studies have shown this does not occur until after 7 days post-
injury.  While the genotoxic elimination of the microglia in mice appears to be non-
deleterious in the short-term, the long-term consequences of microglia removal are 
likely detrimental to CNS homeostasis as evidenced in several neurodegenerative 
models 220-223.  The long-term consequences of microglia elimination in necrotic regions 
following ischemic stroke warrants further investigation. 
We show that microglia numbers are decreased at 72hrs after a 90-minute 
tMCAO, and noted an inverse correlation between microglia and infiltrating monocyte 
counts.  This is in contrast to several reports that have shown significant increases in 
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microglia proliferation 61,163,224. However it is likely the severity of the ischemic injury 
plays a major role in the microglial response as other work has shown reduced 
microglial populations with more severe injury (e.g., longer occlusion times) 
140.  Previous work has shown that the morphological changes that accompany glial cell 
activation after stroke are not dependent on or coincident with neuronal death, but 
rather the duration of ischemia 225. Microglia are more ischemia-resistant than neurons 
and oligodendrocytes, but clearly they are also vulnerable to severe ischemia 226-
228.  The inability to distinguish microglia from infiltrating monocytes, which increase in 
number with injury severity using histological methods may further obfuscate 
this issue.  Flow cytometry may provide a more sensitive means of identification of cell 
type based on the well-accepted relative surface expression of CD45.  Depending on 
the compensation setup, overlapping of these cell populations may also occur with flow 
cytometry.  However, we have shown that it is extremely useful to use Ly6C as a 
monocyte marker to achieve maximal separation of these two populations, as infiltrating 
monocytes may down-regulate CD45 and MHCII levels over time, adopting a microglia-
like phenotype (CD45intCD11b+) 219.    
Increased production of bone marrow derived myeloid cells after stroke has been 
described 210.  We found that BRDU is incorporated into many newly 
produced monocytes in the bone marrow, which are subsequently recruited into the 
brain.  This is consistent with recent work showing ischemic stroke activates 
hematopoietic stem cells in the bone marrow, resulting in a myeloid bias and greater 
output of monocytes 229.  The number of BRDU-positive myeloid cells in the brain 
reaches its peak by 72hrs 140,163.  This parallels the time course of leukocyte infiltration 
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into the brain, which also peaks at 72hrs.  Although microglia did not enter S-phase in 
our study, many were Ki67+, indicating that they were actively cycling at 72hrs.  Ki67 
expression in activated microglia after stroke has also been documented 230.  The failure 
of most cells to progress through later stages of the cell cycle may also be due to 
altered length of G1 and/or cellular stress 231.  Based on this earlier work and given the 
differential effects of ischemia of microglia populations located throughout the 
hemisphere, we hypothesized that some of these cells would enter the S-phase of cell 
cycle to begin dividing prior to 72hrs.  Surprisingly, we did not observe this trend.  An 
earlier study using GFP bone marrow chimeras revealed that the vast majority of 
macrophages in the infarct area after 30min tMCAO were derived from local microglia 
232.  Despite the smaller injuries and altered leukocyte kinetics that result from shorter 
occlusion times, the ability to assess microglia numbers after stroke in an unbiased 
fashion using immunohistochemistry can be challenging due to the subtle difficulty of 
identifying microglia in their ramified state relative to those with amoeboid morphology, 
and given the rapid migration of activated microglia into the penumbral region often 
present in the field of view.  As such, shifts in population densities due to migration 
towards injury sites could be misinterpreted as local microglia proliferation.  It should be 
noted, however, that our data do not exclude the possibility that microglia proliferation 
occurs beyond 72hrs in the 90-minute tMCAO model. 
 A recent study of microglia proliferation after stroke was elegantly approached by 
implementing the parabiosis model using wild type and CX3CR1GFP/- mice 233.  The 
authors concluded that microglia proliferation accounted for the majority of microgliosis 
observed after stroke, rather than monocyte infiltration.  However, there are several 
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possible explanations for the disparate results.  The CX3CR1-GFP signal in these 
reporter mice is not specific only to microglia, especially following an injury stimulus, as 
it has been shown that Ly6Clo monocytes also express GFP 217,234,235.  As histological 
analyses would not be able to distinguish GFP+ microglia from GFP+ monocytes (or vice 
versa in non-GFP WT mice), these cells largely go undetected as they typically begin 
migrating to the brain within 12-24 hours of injury.  In addition, this study used a smaller, 
more localized injury induced photothrombosis, resulting in a milder inflammatory 
response.  The stimulus-driven production of monocytes in bone marrow in this milder 
injury would likely be less and further diluted following egress into the blood due to the 
~50% equilibrium of circulating cells in parabiotic (GFP-WT) mice.  These studies 
provide valuable information in the context of both the specific model of stroke being 
employed, the severity of ischemia, and the time points being investigated.  Taken 
together, these authors nicely demonstrate that microglia proliferation occurs early after 
stroke under mild or modest ischemic conditions, whereas our data implies this function 
is likely compromised after severe ischemic injury. 
 Oxidative stress and cytokine-induced cell death are key components of ischemic 
injury.  Reperfusion after ischemia produces a burst in ROS formation 236.  Oxidative 
stress increases within the first hour after reperfusion and delivers signals that promote 
necrosis and apoptosis.  The generation of ROS burst activity results from impaired 
mitochondrial respiratory chain function and activation of cytoplasmic oxidases. As a 
result, oxidative stress contributes directly to necrosis and apoptosis through a number 
of pathways in ischemic tissue.  Although neurons and endothelial cells are important 
sources of ROS, all cells subject to ischemic injury are vulnerable to ROS-mediated cell 
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death signaling 237.  The massive influx of ROS-producing infiltrating leukocytes adds 
considerably to the overall ROS levels in the brain after stroke.  Using bone marrow 
chimeras, a recent study demonstrated that NADPH oxidase (NOX2)-mediated ROS 
production in circulating leukocytes contributed to exacerbated infarct volumes 
compared to that produced by resident microglia after stroke 238.  Although we found 
ROS levels were higher in microglia after stroke, we did not evaluate the other subsets 
of infiltrating myeloid cells, namely neutrophils.  Instead, we show that on cell-to-cell 
basis, monocytes produce significantly less ROS after stroke than resident microglia.  
This may reflect the severely compromised state of microglia following ischemic 
reperfusion. 
 Injury-driven production of ROS can further amplify the inflammatory response by 
driving cytokine production. TNF and IL-1β are produced by both microglia and 
monocytes after stroke.  Numerous studies using transgenic mice and pharmacological 
agents have demonstrated a neurotoxic role for each of these pro-inflammatory 
cytokines in ischemic injury 185,239.  Our finding that microglia produced higher levels of 
ROS and TNF after stroke than monocytes suggest that the resident cells may be the 
more detrimental macrophage early after injury.  Excessive insult to resident microglia 
may impair their primary function to maintain brain homeostasis during recovery.  These 
findings build on previous work which described the expression of these cytokines in 
different subsets of microglia and macrophages 24hrs after permanent MCAO using a 
bone marrow chimera approach combined with immunohistochemistry and flow 
cytometry 240.  The authors reported that a greater number of CD11b+ CD45hi 
macrophages/granulocytes expressed TNF and IL-1β at 24hrs compared to CD11b+ 
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CD45dim microglia.  While innovative in its design, the use of GR-1 to distinguish 
between and identify monocytes/macrophages and neutrophils is not as accurate as 
Ly6C/Ly6G markers 234.  Despite this discrepancy, we found similar expression profiles 
in these two populations at 24hrs, whereas microglia became the predominant TNF 
producers by peak leukocyte infiltration at 72hrs.  The importance of TNF signaling to 
ischemic injury was recently evaluated 170.  Using bone marrow chimeras it was found 
that TLR2- and TLR4-mediated injury is primarily driven by infiltrating leukocytes rather 
than resident microglia.  However, TNF is also produced by microglia early after 
ischemia prior to monocyte infiltration, and TNF-directed therapies at these early time 
points are neuroprotective 31,241.  However, it must also be noted that infiltrating 
monocytes expressed higher levels of IL-1β, a cytokine associated with inflammasome-
signaling 242,243.  This implies that inflammatory signaling in macrophage populations is 
incredibly robust and complex.  Further understanding of these differences between 
these two cell subtypes and their inflammatory function after stroke may provide better 
insight on the targeted effects of known drug treatments, allowing for the development 
of more effective, cell-specific drugs. 
 Following ischemia, injured areas of the brain undergo apoptosis.  Dead and 
dying cells generate a vast amount of debris that requires clearance for regenerative 
processes to ensue.  As the ischemic/reperfusion injury core evolves after 24hrs, 
amoeboid microglia migrate from the core to the transition zone of the penumbral area 
following reperfusion and adopt an M1 phenotype 131,244.  The importance of debris 
clearance by phagocytes is evident in rodents and humans lacking the scavenger 
receptor gene CD36, resulting in exacerbated injury and hematoma absorption in 
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models of ICH 245,246. MRI imaging has demonstrated that USPIO particles can be 
tracked and localized to ED1+ microglia/macrophages with the highest signal intensities 
found in striatal and cortical penumbral regions at day 2 after 30min tMCAO in rats 247.  
Using GFP bone marrow chimeras, an earlier study had shown that activated microglia 
phagocytose neuronal material as early as 24hrs and are the predominant phagocyte by 
day 7 147.  While an early preponderance of phagocytic microglia would be expected 
given the delayed recruitment of monocytes, their use of a less severe, 30 min tMCA 
occlusion resulted in attenuated numbers of infiltrating monocytes.  In another study, 
rats that had underwent 3hr tMCAO exhibited poor microglial phagocytosis of caspase-
3-expressing neurons at 24hrs 14.  Moreover, the number of apoptotic neurons was not 
increased following liposome-mediated ablation of microglia, indicating a limited 
contribution to debris clearance in environments that are significantly impacted by 
ischemia.  Injury-related defects in migration and increased cytokine repulsion signals 
may halt microglia phagocytic activity under increasing ischemic stress.  
We provide the first functional evidence that microglia increase capacity for 
phagocytosis in acute ischemic stroke.  The number of phagocytic microglia initially 
increased at 24hrs, peaked at 72hrs, and returned to baseline by 7 days.  These data 
paralleled the increase in microglia side scatter properties (granularity) in separate 
experiments, further indication of phagocytic uptake.  Interestingly, however, infiltrating 
monocytes were significantly more efficient at phagocytosing material during the peak 
response at 72hrs.  Following tissue entry, monocytes may further mature into 
macrophage or dendritic cell subsets with tissue-specialized functions.  Monocyte-
derivatives retain the expression of lineage markers and have enhanced phagocytic 
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ability 248.  Our findings indicate that while these tissue phagocytes exhibit many 
classical pro-inflammatory features deemed destructive, they appear to play a critical 
role in debris clearance and post-stroke recovery. It may be that in addition to being 
injured, many resident microglia had already exhausted their capacity to phagocytize 
surplus debris prior to ex-vivo phagocytosis assessment.  However, by 7 days after 
stroke when monocytes diminish in the ischemic brain, resident microglia again become 
the predominant phagocyte, highlighting the importance of microglia in the long-term 
recovery and repair process.  Unpublished results from our laboratory suggest that 
circulating phagocyte populations are generally more efficient than microglia at 
phagocytizing material under non-stimulated conditions.  Recent work demonstrating 
the importance of monocytes to hemorrhage clearance in a model of intracerebral 
hemorrhage highlights their ability to significantly improve long-term outcomes through 
phagocytic function early after stroke 249.  This may relate in part to the degree of 
adaptive functionality associated with their different lifespans, as monocyte function may 
be more robust given their ‘boom and bust’ half-life, whereas the phagocytic activity of 
microglia likely endures at a steady rate throughout life. It is important to note that 
monocyte-targeted therapies aimed at inhibiting the function of these cells may 
inadvertently affect their phagocytic activity.  Moreover, strategies to exploit this 
capacity should be considered, especially during the early stages of injury when the 
blood-brain barrier is susceptible to monocyte entry. 
 Finally, we showed a positive correlation between TNF expression levels and the 
level of phagocytic activity of microglia after injury.  ROS and pro-inflammatory cytokine 
signaling is thought to hamper phagocytic activity and debris clearance 250,251.  Our 
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finding suggests that dichotomizing function into M1/M2 polarization, in which cells are 
polarized to become either pro-inflammatory/detrimental (M1) or anti-inflammatory/injury 
resolving (M2) may be too simplistic 252.  This concept more aptly applies to microglia in 
vitro and is polarization may be better appreciated as a continuum of activation in vivo 
due the combination of factors and diverse cell types present in intact tissue.  Indeed, 
the polarization dynamics of microglia and monocytes during stroke appear to be mixed 
and complex.  As mentioned, anti-inflammatory markers such as IL-4 and IL-10 were 
not expressed by either myeloid cell at any timepoint in this study.  However, we 
acknowledge that transitioning between M1 and M2 phases may occur weeks after 
injury as has been reported by others 131,198.  Whether there is a requirement for pro-
inflammatory signaling to induce or enhance phagocytic activity and debris clearance is 
currently not known.  These findings point to a possible side effect of 
microglia/macrophage inhibition that could hamper the removal of dead cells and slow 
recovery. 
 In conclusion, we have identified distinct functional roles for brain-resident and 
infiltrating macrophages after stroke.  To better both the interpretation of failed clinical 
trials and the development of more efficacious drugs to treat sterile inflammation in the 
CNS requires a better understanding of potential cellular targets.  We believe that 
functional assessment of immune cells after stroke ex-vivo could be a powerful tool in 
screening and validating the targeted cellular effects of drugs and various therapeutic 
interventions. 
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Supplemental Figure 3-1.  Relative stability of CD45 expression by microglia at 
72hrs after stroke. 
Bone marrow chimeras were generated using GFP+ donors and wildtype recipient mice.  
Microglial CD45 expression level was evaluated to determine if their CD45-intermediate 
expression level is increased after stroke, potentially overlapping with the CD45-high 
expressing bone marrow-derived myeloid population.  A representative dot plot of the 
ischemic brain at 72hrs illustrates that GFP- (wildtype) microglia do not substantially 
increase CD45 expression to CD45-high levels associated with GFP+ bone marrow-
derived populations (98% GFP reconstitution in this wildtype host; A).  Cell-specific 
FMO controls were used to determine positive gating.   
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Chapter 4: 
CD200R1 immune inhibitory signaling attenuates brain 
inflammation and promotes behavioral recovery after stroke 
 
Rodney M. Ritzel1, Joshua Crapser, Rajkumar Verma, Anita R. Patel, Brittany Knight, 
Jeremy M. Grenier, Brett Freidler, and Louise D. McCullough 
 
 
 
Abstract 
 
In ischemic stroke injury homeostatic pathways are dysregulated in the CNS, which 
leads to a sterile inflammatory response, subsequent cell death, and impaired survival.  
The CD200-CD200R1 pathway is a key regulator of inflammation and CNS 
homeostasis, and is perturbed in the brain following injury.  Given the immune-inhibitory 
properties of CD200, we investigated the role of CD200R1-mediated signaling in post-
acute brain inflammation and recovery following transient middle cerebral artery 
occlusion (tMCAO) using CD200R1-deficient mice.  At baseline, CD200R1 knockout 
mice had significantly more T cells with an activated, effector memory phenotype 
present in the brain compared to wild type littermates.   No changes in the microglial 
compartment were found, however CNS-specific T cells from CD200R1 knockout mice 
showed altered cytokine production.  Following ischemia, CD200R1 knockout mice had 
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significantly greater mortality by day 7.  These mice also displayed severe body weight 
loss, impaired motor recovery and decreased nesting activity compared to wild type 
mice.  Nearly thrice as many infiltrating leukocytes were found in the ischemic brain of 
CD200R1 knockout mice, with subtle differences in leukocyte composition.  Taken 
together, these data suggest that the immune-inhibitory effects of CD200R1 signaling in 
the CNS serve to attenuate the level of immune-surveillance by T cells, while having a 
negligible effect on microglia under normal conditions. More importantly, CD200R1 is 
up-regulated on the surface of activated leukocytes after stroke, where it serves an 
important compensatory function required to quell immune cell activation and 
transmigration, and thus, the amplitude of the overall inflammatory response.  The 
cellular basis for the observed protective effects of CD200-CD200R1 signaling on stroke 
recovery warrants further investigation. 
 
 
Introduction 
 
Inflammation plays a key role in the pathophysiology of stroke, the fourth leading cause 
of mortality and primary cause of disability in the United States 253. Mounting evidence 
suggests that stroke-induced inflammation significantly contributes to neuronal injury, 
disease progression, and clinical outcome 57. The innate immune system plays a pivotal 
role in the brain’s response to injury, including activation of microglia and macrophages.  
Microglia are of myeloid origin and represent the resident immune cells of the CNS, 
where their primary function is to maintain tissue homeostasis 254. As constant 
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surveyors of the environment, microglia are uniquely predisposed to both effectively 
initiate and subsequently quell inflammatory signaling in an effort to restore tissue 
structure and function back to steady state. Thus, microglial activation is a tightly 
regulated process. However, in a pathological setting signaling may become overactive 
or dysregulated leading to neuronal cell death and loss of function 198.  
Among the homeostatic mechanisms that regulate the activation state of 
microglia/macrophages, are a select group of membrane-associated glycoproteins 
collectively known as immune inhibitory receptors that regulate inflammation via 
neuronal-glial interactions. One known example involves the interaction between 
CD200R1 (expressed on myeloid cells) and CD200 ligand (expressed on neurons). In 
this paradigm, CD200R1 is activated upon binding to CD200 ligand resulting in 
downstream inhibition of pro-inflammatory pathways, thereby maintaining microglia in 
an inactive, resting state 19,27.  CD200-CD200R1 interactions depend upon a NPXY 
motif, leading to phosphorylation of Dok1 and Dok2 proteins, binding of RasGAP and 
SHIP, and subsequent downstream inhibition of the RasMAPK pathways 46,255-257.  
Following tissue injury, these interactions between neurons and microglia are disrupted, 
thus lifting the ‘brake’ on inflammation and enabling a pro-inflammatory response. 
Recent studies investigating the imbalance of CD200-CD200R1 signaling in models of 
neurodegenerative disease support the hypothesis that this interaction may also be 
disrupted after stroke 23,112,258-260.  To date, the functional role of the CD200-CD200R1 
signaling axis in sterile brain injuries such as stroke is not known. 
We therein proposed to investigate the role of CD200-CD200R1 signaling in 
experimental stroke.  CD200R1 knockout and littermate control mice were subject to 60-
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minute tMCAO and evaluated at day 7 for post-acute changes in neuroinflammation and 
behavioral recovery.  We report a novel role for the CD200-CD200R1 pathway in 
regulating the homeostatic control of T cell immunosurveillance in the CNS under 
normal conditions.  Moreover, we demonstrate that following an ischemic insult, 
CD200R1 inhibitory signaling functions as a critical regulator of inflammation.  Lack of 
CD200R1-mediated immunoregulation resulted in poor survival and worse outcomes 
following stroke.  Given the immunoregulatory role of the CD200R1 signaling pathway, 
its relevance to ischemic stroke is of great interest, as it serves as a potential 
therapeutic target for suppressing the deleterious effects of leukocyte activation. 
 
 
Materials and Methods 
 
Mice/Animals:  CD200R1+/− mice (bred on a C57BL/6J background) were generously 
provided by Professor R. Gorczynski (Toronto, Canada) 261.  Heterozygous CD200R1+/- 
mice were bred to obtain CD200R1-/- mutants and CD200R1+/+ wildtype littermates.  
Young adult male mice (12-14 weeks) of age were pair-housed on sawdust bedding in a 
pathogen free facility (light cycle 12/12 h light/dark).  C57BL/6J male mice 10-12 weeks 
(young adult; 24.5 ± 0.8 grams) and 18-20 months (aged; 33.1 ± 1.5 grams,) of age 
were obtained from Charles River Laboratories (Wilmington, MA) and the NIA breeding 
colony, respectively.  All animals had access to chow and water ad libitium.   All 
procedures were performed in accordance with NIH guidelines for the care and use of 
laboratory animals and approved by the Institutional Animal Care and Use Committee of 
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the University of Connecticut Health Center.  All analysis was performed blinded to 
surgical conditions. 
 
Ischemic Stroke Model:  Cerebral ischemia was induced by 60 minutes of reversible 
middle cerebral artery occlusion (MCAO, 25–32 gm mice) under Isoflurane anesthesia 
as previously described 206. Rectal temperatures were maintained at approximately 
37°C during surgery and ischemia with an automated temperature control feedback 
system. A midline ventral neck incision was made, and unilateral MCAO was performed 
by inserting a 6.0 Doccol monofilament (Doccol Corp, Redland, CA) into the right 
internal carotid artery 6 mm from the internal carotid/pterygopalatine artery bifurcation 
via an external carotid artery stump. Following reperfusion mice were sacrificed at 7 
days.  In a separate cohort, young and aged wildtype mice were subject to 90 minutes 
of MCAO and 72 hours of reperfusion prior to sacrifice.  0.21 mm and 0.23 mm silicone 
coated sutures were utilized in young and aged mice respectively to achieve occlusion.  
Sham-operated animals underwent the same surgical procedure, but the suture was not 
advanced into the internal carotid artery. 
 
Clinical assessment:  Before and after ischemia body weight was monitored daily.  
Rectal temperatures were recorded during ischemia and immediately prior to sacrifice.  
Neurological deficits were assessed by Bederson-score from 0 (no deficit) to 4 (severe 
deficit) with minor modifications 262. 
Behavioral Testing:  All the animals were tested on each behavioral task twice, three 
days prior to surgery to establish a baseline reference and again on the day of sacrifice. 
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The mice enrolled for surgeries did not demonstrate any behavioral deficits in any test 
(prior to surgery).  The testing was done at a fixed time in the morning.  All behavioral 
testing equipment and surfaces were cleaned with 70% ethanol before and after testing 
for each animal.  Mice were tested in the following order:  nesting activity (overnight), 
neurological scoring, open field, Y maze, static rod, rotarod, and wirehang. 
Hanging Wire:  The hanging wire tests both limb strength and balance after stroke 
263,264. This test was performed as described by 265, with slight modification. A wire cage 
top, dimensions, 18 inch × 9 inch with its edges taped off was used for this experiment. 
The mouse was placed on the center of the wire lid and the lid was slowly inverted and 
placed on top of cage. The wire lid was 9 inch above the cage bedding. Latency to fall 
from the wire was recorded.  The average time of three trials was taken.  Mice with a 
latency of less than 3 seconds were excluded from the study, whereas a maximum cut-
off of 120 seconds was assigned this value.  Mice were alternately tested to allow for a 
rest period of at least 5 minutes between trials. 
Open Field:  Open Field measures spontaneous locomoter activity in a novel 
environment and has been used in stroke models 266. In this task, the total ambulatory 
activity of the mouse was assessed. The mouse was placed in the open field chamber 
(15′′ × 15′′) in a dark room in Scoville Neurobehavioral Suite at UCHC. Locomotor 
activity was quantified as the total number of beam breaks by a computer operated PAS 
Open Field system (San Diego Instruments, San Diego, CA). Each testing session was 
20 minutes long and the data was collected in 60 second intervals.  All the mice were 
acclimatized to the dark testing room for 1 hour before the beginning of the test and the 
activity was recorded immediately after the mice were placed in the open field 
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apparatus. 
Y maze spontaneous alternation:  The Y maze test was used to evaluate cognitive 
function, especially working memory in a new environment 266.  All the mice were 
acclimatized to the testing room for 60 minutes prior to the beginning of the test and the 
activity was recorded immediately after the mice were placed in the maze.  The number 
of entries, spontaneous alteration and percentage of alteration were recorded for one 
5 min trial per test day. Entry is defined as a complete placement of hind paws within 
the arm of the maze. Spontaneous alteration is considered when a subject visits a new 
arm and does not return to one of previously-visited two arms.  The percentage of 
alteration was calculated as follows: [number of spontaneous alteration/(number of 
entry − 2)] × 100.  No difference in the number of arm entries was found between 
groups either before or after stroke. 
 
Static rod:  Balance and coordination of movement were assessed using a wooden rod 
of 60 cm in length and 2.8 cm in diameter as described by 267 with minor modification.  
Briefly, the rod was fixed by a G-clamp to a laboratory table such that the rod 
horizontally protruded into space 60 cm above a cotton-padded floor.  Mice were placed 
at the free end of the rod facing away from the home table (nose tip one head's length 
from the edge) and were allowed a maximum period of 180 seconds to turn 180 
degrees.  The time taken to achieve this orientation was scored for each mouse and 
taken as average of three trials.  The number of falls and successful turns was also 
tallied for each trial and the percentage was calculated.  Subjects that turned upside 
down or fell off were arbitrarily assigned (for statistical purposes) the maximum 
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orientation score of 180 seconds.  If it fell off in less than 3 seconds it was presumed to 
be due to faulty placement by the experimenter and allowed another attempt.  This test 
has been validated for the assessment of motor balance in models of Down syndrome 
and Huntington’s disease 268,269. 
 
Rotarod:  Mice were placed on a rotating cylindrical rod accelerating from 2 rotations 
per minute (rpm) to 20 rpm, over a span of 5 min 270,271. Subjects were given 4 trials on 
the rotarod on day -3 and 7 of testing.  A 5-minute break was given between the trials.  
The latency of the subject to fall from the rotating rod was recorded for each trial (in 
seconds), and the average latency was used for further analysis.  No differences were 
found between groups at baseline. 
 
Nesting activity:  Two hours prior to the onset of the dark phase, mice were separated 
into individual cages and supplied with a ~5 × 5 cm pressed cotton squared piece.  
Nesting activity was assessed as described by 272,273 with minor modifications.  In brief, 
each cotton pad was weighed prior to placing into cages for reference.  After mice had 
habituated for 15 min in a novel empty cage, the cotton pad was placed in a random 
cage corner.  The next morning (approximately 12 hours later) cages were inspected for 
nest construction.  Any loose, shredded material was gently brushed off the intact 
nesting pad.  Nesting activity was calculated as follows:  [1 – (post-pad wt. (g) / pre-pad 
wt. (g))] x 100 = % nested material. 
 
Terminal histopathology:  All animals were sacrificed at 7 days after stroke with 
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avertin overdose (i.p). A separate cohort of animals (n=7-9/group) was sacrificed at for 
immunohistochemistry.  Transcardial perfusion was performed with cold PBS followed 
by 4% paraformaldehyde; the brain was fixed for 24 hours and placed in cyroprotectant 
(30% sucrose). The brains were cut into 40-µm free-floating sections on a freezing 
microtome and every eighth slice was stained by cresyl violet staining to evaluate 
ischemic cell damage. The images were digitalized and cerebral atrophy was analyzed 
using computer software (Sigma scan Pro5) as previously described 264,274. 
Immunohistochemistry (IHC):  Immunohistochemical staining of fixed-frozen sections 
(40µm-thickness) was performed as described previously 275.  Briefly, brain slices were 
mounted onto gelatin-coated slides, allowed to air dry, and then blocked in 0.1 M 
phosphate buffer (PB) with 0.3% Triton X-100 (sigma) and 10% donkey serum (PBTDS) 
for an hour. Primary antibody (CD200, R&D Systems, 1:500; NeuN, Abcam, 1:200; 
GFAP, Dako, 1:200) was added overnight. After washes, the sections were incubated 
with secondary antibody (1:1000) and 4′,6-diamidino-2-phenylindole, dihydrochloride 
(DAPI, 1:1000, Invitrogen, Carlsbad, CA). Secondary antibody (1:1000, goat anti-mouse 
IgG conjugated to Alexa-488 or -594) was removed with three consecutive washes in 
PBTDS, 0.1 M PB, and 0.05 M PB respectively.  Images were acquired with a Zeiss 
Axiovert 200M microscope (Carl Zeiss, Oberkochen, Germany) using a X-Cite 120Q 
fluorescence illumination system (Lumen Dynamics Group Inc., Mississauga, ON, 
Canada) and Zeiss image acquisition software (Zeiss LSM 510). 
 
Enzyme-linked immunoabsorbant assay (ELISA):  Plasma cytokine concentrations 
were determined by ELISA (Bio-Plex Pro Mouse Cytokine Assay, Bio-Rad 
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Laboratories).  In brief, mice were euthanized by avertin injection and blood was 
collected by cardiac puncture into heparin-coated syringes.  Samples were centrifuged 
(13,000g for 10min at 4C) and plasma was collected and stored frozen (-80C) until 
assaying.  Samples were assayed according to the manufacturer’s instructions using a 
Luminex 200 (Luminex Corporation, Austin, TX, USA) magnetic bead array platform.  
Inter-and intra-assay coefficients of variation were than less than 10%.  CD200 protein 
concentrations were assayed using a mouse CD200 PicoKine ELISA kit (Boster Bio, 
Pleasanton, CA).  Brain hemispheres were collected and homogenized in ice-cold lysis 
buffer containing a protease inhibitor cocktail (Roche Diagnositics).  Homogenates were 
sonicated and centrifuged at 4C for 15 min at 14,000 rpm, and supernatants were 
assayed for total protein using a BCA protein assay kit (Pierce, Thermo scientific).  
Plasma and brain protein was assayed according to the manufacturer’s instructions 
using a microplate reader (EnSpire 2300 Multilabel Reader, Perkin Elmer).  Briefly, 50ul 
of plasma and 100ug of whole cell lysate brain protein were plated in triplicate for each 
sample.  CD200 protein concentration was quantitatively determined by measuring the 
optical density absorbance at 450 nm. 
 
Tissue processing for flow cytometry:  Mice were euthanized, transcardially perfused 
with 60 mL cold, sterile PBS, and the brains were harvested.  Blood was drawn by 
cardiac puncture with heparinized needles.  Red blood cell lysis was achieved by three 
consecutive 10-minute incubations with Tris-ammonium chloride (Stem Cell 
Technologies).  The brainstem and cerebellum were removed.  The brain was then 
divided along the interhemispheric fissure to isolate the ipsilateral hemisphere and 
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subsequently rinsed with PBS to remove contaminant cells.  Brains were placed in 
complete RPMI 1640 (Lonza) medium and mechanically and enzymatically digested in 
collagenase/dispase (1 mg/mL) and DNAse (10mg/mL; both Roche Diagnostics) for 1hr 
at 37C.  The cell suspension was filtered through a 70um filter.  Leukocytes were 
harvested from the interphase of a 70%/30% Percoll gradient.  Cells were washed and 
blocked with mouse Fc Block (CD16/CD32, ebioscience) prior to staining with primary 
antibody-conjugated flourophores:  CD45-eF450, CD11b-APCeF780, CD3e-APC, 
Ly6C-PerCP-Cy5.5, and Ly6G-PE.  All antibodies were commercially purchased from 
eBioscience.  For live/dead discrimination, a fixable viability dye, carboxylic acid 
succinimidyl ester (CASE-AF350, Invitrogen), was diluted at 1:300 from a working stock 
of 0.3mg/mL.  Cells were briefly fixed in 2% paraformaldehyde (PFA).  Data were 
acquired on a LSRII using FACsDiva 6.0 (BD Biosciences) and analyzed using FlowJo 
(Treestar Inc.).  No less than 100,000 events were recorded for each sample.  A gating 
strategy was designed as described in 276.  Resident microglia were identified as the 
CD45int CD11b+Ly6C- population, whereas bone marrow-derived leukocytes were 
identified as CD45hi.  Cell type-matched fluorescence minus one (FMO) controls were 
used to determine the positive gating for each antibody.  The following antibodies were 
used in this study:  CD69-APC (eBioscience), CD4-PE-Cy7 (eBioscience), CD8-Bv510 
(Biolegend), CD44-FITC (Biolegend), CD62L-PE (eBioscience), CD200R1-FITC 
(Biolegend), CD19-AF700 (eBioscience), MHCII-Bv510 (Biolegend), NKp46-
PerCPeF710 (eBioscience), and DX5-PE (Biolegend). 
To determine TCRvβ usage, we used a mouse vβ TCR screening panel (BD 
Pharmingen) according to the manufacturers instructions.  Briefly, after collecting blood 
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leukocytes each sample was divided into 15 separate FACS tubes and stained for the 
antibody cocktail including one of 15 respective TCRvβ FITC-conjugated monoclonal 
antibodies. 
 
Intracellular cytokine production:  For intracellular cytokine staining, a stock solution 
of brefeldin A (Sigma) was prepared at 20mg/mL in DMSO, and diluted with PBS to 
obtain a working solution of 0.5mg/mL.  Mice were euthanized 12 hours after 
intravenous injection of brefeldin A (250ul).  Leukocytes were collected as described 
above, and 1ul of GolgiPlug containing brefeldin A (BD Biosciences) was added to 
800ul complete RPMI.  To assess T cell cytokine production, cells were subsequently 
stimulated with Cell Stimulation Cocktail (eBioscience) containing PMA/ionomycin and 
incubated for 4 hours at 37C (5% CO2).  Cells were resuspended in Fc Block, stained 
for surface antigens and washed in 100ul of fixation/permeabilization solution (BD 
Biosciences) for 20 minutes.  Cells were then washed twice in 300ul 
Permeabilization/Wash buffer (BD Biosciences) and resuspended in an intracellular 
antibody cocktail containing TNF-PE-Cy7 (eBioscience), IL-1β –FITC (eBioscience), 
MMP-9-PE (StressMarq Biosciences), and IFNγ-PerCP-Cy5.5 (Biolegend) and then 
fixed. 
 
Statistical analyses:  Data from individual experiments are presented as mean ± SEM 
and assessed by Student t test or One-way ANOVA with Tukey post-hoc test for 
multiple comparisons (GraphPad Prism Software Inc, San Diego, CA, USA).  For Two-
way ANOVA, significant differences between paired comparisons were conducted with 
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the Holm-Sidak test.  Kaplan-Meier survival curves were compared using Cox-Mantel 
analysis to determine statistical significance between groups.  The neurological deficit 
scores, being ordinal in nature, were analyzed using the Mann-Whitney U test.  The 
Spearman’s rank correlation test was used to ascertain the correlation between 
leukocyte infiltration and neurological deficit score.  Significance was set at p ≤ 0.05. 
 
Results 
 
Characterization of CD200- and CD200R1-expressing cells in the healthy adult 
brain 
 
To begin our investigation into the functional role of CD200-CD200R1 immune inhibitory 
signaling in the brain we first characterized the cells that express CD200 or CD200R1 
protein in the wildtype brain using immunohistochemistry and flow cytometry. CD200 
protein was ubiquitously expressed throughout the central nervous system (Figure 4-
1A). The staining pattern in the cerebral cortex was diffuse, largely confined to gray 
matter regions, and mostly localized to the cell membrane of neurons (Figure 4-1B).  
Using flow cytometry, we assessed CD200R1 expression on leukocytes present in the 
healthy wildtype adult brain. We identified the presence of resident CD45intCD11b+ 
microglia, a small population of CD45hiCD11b+ peripheral myeloid cells, and a 
population of CD45hiCD11b- putative lymphocytes (Figure 4-2A), of which the majority 
were CD3+ T cells (Figure 4-2B).  Surprisingly, very few resident microglia expressed 
CD200R1 (Figure 4-2C).  However, 20-30% of brain-specific CD3+ T cells were 
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Figure 4-1.  CD200 protein expression in the normal adult cerebral cortex. 
Representative 40um-thick brain tissue sections illustrating the diffuse, ubiquitous 
expression of CD200 (red) surrounding DAPI-positive (blue) neurons (green) in the grey 
matter of the healthy, wildtype adult cortex (A; N=3).  Higher magnification shows 
CD200 is expressed on the cell membrane of neurons and secreted in the extracellular 
space (B).  Abbreviation:  DAPI 4’,6-diamidino-2-phenylindole, NeuN neuronal nuclei. 
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Figure 4-2.  Surface expression of CD200R1 by tissue-resident T cells with 
effector memory phenotype. 
A representative dot plot shows the identification of CD45intCD11b+ resident microglia, 
CD45hiCD11b+ peripheral myeloid cells, and CD45hiCD11b- peripheral lymphocytes in 
the PBS-perfused brain of healthy adult wildtype mice (A).  A representative dot plot 
shows that CD3+ T cells compose the majority of the CD45hiCD11b- peripheral 
lymphocyte population in the brain (B). A representative histogram illustrates the lack of 
CD200R1 protein expression on the cell surface of wildtype microglia in the adult brain 
(C).  A histogram depicts the presence of CD200R1 on the surface of CNS-resident T 
cells (D).  The percentage of CD200R1-positive T cells was quantified in lymphoid and 
tertiary tissues (E).  A representative dot plot depicts the CD200R1 expression on 
circulating blood T cells (F).  An overlay dot plot reveals that the majority of CD200R1-
positive CD3+ T cells (blue) in the blood have an effector memory phenotype 
(CD44hiCD62Llo) compared to CD200R1-negative (red) T cells (G).  For all experiments, 
N= 5-8/group.  Cell-specific FMO controls and genotype-confirmed CD200R1-/- controls 
were used to determine positive gating (shaded gray).  Error bars show mean SEM.   
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positive for CD200R1 (Figure 4-2D).  Interestingly, CD200R1 was expressed largely on 
CD3+ T cells present in tertiary tissues rather than lymphoid tissues (Figure 4-2E).  
CD200R1-positive CD3+ T cells in the blood were identified as those with an effector 
memory (CD44hiCD62Llo) phenotype indicating that they are antigen-experienced and 
activated (Figures 4-2F-G).  These data suggest that the migration and/or activation of 
CNS-resident (or circulating) T cells in the healthy brain are potentially regulated by 
CD200-mediated inhibition either through direct interactions with neurons or by soluble 
CD200 present in the extracellular environment. 
 
CD200R1 mediates T cell entry into the un-injured brain and regulates basal 
cytokine production in CNS-specific T cells but not microglia 
 
To determine the functional role of CD200R1 signaling in CNS-specific T cells we 
assessed changes in T cell migration and activation in CD200R1 (global) knockout mice 
and control wildtype littermates.  We observed no changes in the absolute number of 
resident microglia between groups, however CD200R1 knockout mice had a 
significantly greater number of CD45hi peripheral leukocytes per brain hemisphere 
compared to wildtype (Figures 4-3A and 4-4A-B, p=0.040).  Although no changes in 
peripheral myeloid cell counts were found, CD200R1 knockout mice showed a 
significant increase in the number of CD3+ T cells present in the brain (p=0.0004), of 
which the majority were identified as CD8+ subset of T cells (Figures 4-3B and 4-4C-F).  
Both CD4 and CD8 subsets of CNS-specific CD3+ T cells had an effector memory  
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Figure 4-3.  Characterization of brain leukocytes in naive CD200R1 wildtype and 
knockout mice by flow cytometry. 
Representative dot plots illustrate the differences in resident microglia (CD45intCD11b+) 
and peripheral leukocytes (CD45hi) in the normal brain of CD200R1 wildtype and 
knockout mice (A).  A representative dot plot shows that the CD45hiCD11b- lymphocyte 
population is largely composed of CD4 and CD8 subsets of CD3+ T cells (B).  Brain-
specific CD3+ T cells have an effector memory (CD44hiCD62Llo) phenotype (C). For all 
experiments, N= 5-12/group.  Cell-specific FMO controls were used to determine 
positive gating. Abbreviation:  WT wildtype, KO knockout. 
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Figure 4-4. Effect of CD200R1 deletion on microglia and peripheral leukocyte 
counts in the normal brain. 
The absolute number of microglia (A) and peripheral leukocytes (B) per brain 
hemisphere was quantified in CD200R1 wildtype and knockout mice (N=7/group).  The 
relative cellular composition of CD45hi peripheral leukocytes in the CD200R1 wildtype 
(C) and knockout (D) brain are shown.  The absolute number of CD45hiCD11b+ 
peripheral myeloid cells (E) and CD45hiCD11b- lymphocytes (F) are quantified.  Error 
bars show mean SEM.  Abbreviation:  SEM standard error of mean, WT wildtype, KO 
knockout, n.s. not significant.  *p≤0.05; **p≤0.01; ***p≤0.001 
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Figure 4-5.  Effect of CD200R1 deletion on basal production of pro-inflammatory 
cytokines by microglia. 
Representative dot plots show basal production of TNF (A), IL-1β (B), and MMP-9 (C) 
by microglia in the healthy adult brain of CD200R1 wildtype (red) and knockout (blue) 
mice.  The respective mean fluorescence intensities of these cytokines (D, E, and F) 
were quantified (arbitrary units of intensity, N=5-10/group).  Microglia-specific FMO 
controls were used to determine positive gating.  Error bars show mean SEM.  
Abbreviation:  SEM standard error of mean, MFI mean fluorescence intensity, WT 
wildtype, KO knockout, TNF tumor necrosis factor, IL-1β interleukin-1 beta, MMP-9 
matrix metalloproteinase-9, Max maximum, n.s. not significant.  *p≤0.05; **p≤0.01; 
***p≤0.001 
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Figure 4-6.  Effect of CD200R1 deletion on cytokine production by brain-resident 
T cells. 
Representative dot plots show PMA/ionomycin-induced CD8 T cell expression of TNF 
(A) and IFNγ (B) from the healthy adult brain of CD200R1 wildtype and knockout mice.  
The respective percentages (C and D) were quantified (N=6/group).  Cell-specific FMO 
controls were used to determine positive gating.  Error bars show mean SEM.  
Abbreviation:  SEM standard error of mean, SSC side scatter, WT wildtype, KO 
knockout, TNF tumor necrosis factor, IFNγ interferon gamma, Stim stimulation.  
*p≤0.05; **p≤0.01; ***p≤0.001 
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phenotype (Figure 4-3C).  No differences in the gross vasculature of the circle of Willis 
were found between groups (Supplemental Figure 4-1A).  Intracellular cytokine 
staining revealed that the basal production level of several pro-inflammatory mediators 
(TNF, IL-1β, and MMP-9) expressed by resident microglia in un-injured brains did not 
significantly differ between groups (Figures 4-5A-F).  However, CNS-specific CD8 T 
cells from CD200R1 knockout mice exhibited a significant increase in the number of 
cells expressing TNF following PMA/ionomycin stimulation (Figures 4-6A and 4-6C).  
Interestingly, IFNγ production was significantly diminished after stimulation of CNS-
specific CD8 T cells lacking CD200R1 compared to wildtype controls (Figures 4-6B and 
4-6D).  Taken together, our results suggest that the effects of CD200R1 immune-
inhibitory signaling are largely confined to the T cell population in the un-injured brain, 
rather than the resident microglia.  These data indicate that CD200R1 immune-inhibitory 
signaling regulates both T cell migration into the brain and effector cytokine production. 
 
CD200R1 immune-inhibitory signaling promotes better outcomes after ischemic 
stroke 
 
Next we investigated the functional role of CD200R1-mediated immune regulation 
following sterile brain injury using the middle cerebral artery occlusion (MCAO) model of 
ischemic stroke.  Given that our earlier findings showed an increase in CNS-specific T 
cell numbers in the brain of otherwise healthy mice lacking CD200R1, we designed our 
study to extend out to 7 days after stroke due to the well-accepted delayed-recruitment 
of T cells into the ischemic brain 61,277-279.   Following 60 minutes of MCAO, we 
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observed a 52.4% survival rate for CD200R1 knockout mice by day 7, significantly lower 
than was seen for wildtype (83.3%, Figure 4-7A, p=0.049).  CD200R1 knockout mice 
had significantly worse neurological deficit scores at day 7 compared to controls, as 
measured using the Bederson scoring system (Figure 4-7B, p=0.003).  In addition to 
exacerbated hemiparesis, CD200R1 knockout mice exhibited a dramatic increase in 
body weight loss following stroke, nearly twice as much as wildtype controls (Figure 4-
7C, p=0.003).  This depletion of fat stores was accompanied by a significant decrease in 
body temperature (Figure 4-7D).  CD200R1 knockout mice had a significant increase in 
thymic atrophy at day 7 (p=0.05); however, no differences in splenic atrophy were found 
between groups (Figures 4-7E-F).  In sum, these results indicate that CD200R1-
mediated inhibition of immune cells is required for survival and better neurological and 
physiological outcomes following ischemic stroke. 
 
Loss of CD200R1-mediated immune inhibition worsens behavioral recovery 
following stroke 
 
To see whether these outcomes were associated with changes in behavioral recovery, 
we ran a battery of behavioral tests to measure cognitive and sensorimotor deficits after 
stroke.  We found no difference in short-term spatial memory function between groups 
using a Y-maze spontaneous alternation test (Figure 4-8A).  Using one-way ANOVA 
analysis, spontaneous locomotor activity was significantly decreased in CD200R1 
knockout mice, albeit modestly in comparison to the change in wildtype after stroke 
(Figure 4-8B).  Motor coordination and endurance were measured using a rotarod  
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Figure 4-7.  (Legend on following page) 
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Figure 4-7.  Effect of CD200R1 deletion on stroke outcome at 7 days. 
The survival rate for CD200R1 wildtype and knockout mice was quantified after stroke 
(A).  Neurological deficit scores at day 7 are shown (B).  The percentage of body weight 
loss was measured at sacrifice (from baseline) and quantified (C).  Changes in rectal 
temperature were monitored at day 0 (Pre-ST) and day 7 (Post-ST) and quantified (D).  
Spleen (E) and thymus (F) weights were measured at day 7 and normalized to body 
weight.  For all experiments, N=16-24/group. Error bars show mean SEM.  Abbreviation:  
SEM standard error of mean, WT wildtype, KO knockout, ST stroke, BW body weight.  
*p≤0.05; **p≤0.01; ***p≤0.001 
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Figure 4-8.  (Legend on following page) 
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Figure 4-8.  CD200R1-mediated changes in behavioral recovery after stroke. 
The percentage of correct alternations/5 min in a Y-maze apparatus on day -3 and day 
7 after stroke (A; N=6/group). The total number of beam breaks/20 min were measured 
in an open field test (B; N=12/group). The total time spent on a rotarod device (2-20 
rpm) at day 7 was quantified (C; N=14-15/group) and the percentage of mice that fell off 
a horizontal cylinder rod during a 180-degree turning test are shown (D; N=7/group).  
The percentage of used nested material over an 8 hour period was determined on day 7 
(E; N=12/group).  The total time spent hanging on cage wire at day 7 was quantified (F; 
N=12/group).  Error bars show mean SEM.  Abbreviation:  SEM standard error of mean, 
WT wildtype, KO knockout, ST stroke, n.s. not significant.  *p≤0.05; **p≤0.01; 
***p≤0.001 
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performance test.  CD200R1 knockout mice showed significant impairment in remaining 
stable on an accelerating cylinder rod over time, having shorter durations before falling 
(Figure 4-8C, p=0.022).  Because the rotarod test measures several parameters of 
motor coordination and stroke may differentially affect motor functions, we assessed 
motor skills in more detail.  Using a static bar to measure the time it takes for a mouse 
to orient itself 180 degrees, we found that CD200R1 knockout mice failed to 
successfully orient themselves without falling in approximately half of the trials (Figure 
4-8D, p=0.008).  We next assessed for deficits in the ability to perform activities of daily 
living such as nest construction.  CD200R1 knockout mice showed a significant 
reduction in nesting activity after stroke compared to wildtype controls (Figure 4-8E, 
p=0.027).  This deficit did not appear to be associated with forelimb or grip strength as 
no difference was found in the length of time that each group of mice could hang from 
an elevated wire cage top before falling (Figure 4-8F).  Collectively this data implies 
that immune-inhibitory interactions between neurons and leukocytes are important for 
the recovery of motor processes involved with balance and coordination as well as an 
impaired ability to perform normal daily tasks such as nesting. 
 
CD200-CD200R1 signaling attenuates leukocyte infiltration into the ischemic 
brain 
 
To determine whether the behavioral deficits found in CD200R1 knockout mice were 
associated with an increased inflammatory response in the brain following stroke we 
assessed leukocyte infiltration via flow cytometry.  We first demonstrated that infiltrating 
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(and resident) lymphocyte populations were the predominant CD200R1-expressing cells 
in the ischemic brain at this time (Figure 4-9A).  CD200R1-positive T cells in the 
ischemic brain expressed significantly higher levels of the early activation marker CD69 
than CD200R1-negative T cells (Figure 4-9B-C, p=0.02).  An analysis of total CD45hi 
peripheral leukocyte counts found that CD200R1 knockout mice had approximately 
almost three times the number of infiltrating cells as wildtype controls at 7 days 
(Figures 4-10A-B, p=0.009).  Despite these changes, no differences in tissue atrophy 
were observed (Supplemental Figure 4-1B).  Further analysis revealed that 
CD11b+Ly6C+Ly6G- monocytes made up the majority of infiltrating myeloid cells 
whereas CD3+ T cells accounted for the majority of infiltrating lymphocytes in CD200R1 
knockout mice (Figures 4-10C-D).  The total number of all leukocyte subsets in the 
brain was higher in CD200R1 knockout mice.  The ratio of infiltrating lymphocytes-to-
peripheral myeloid cells was lower in the ischemic brain of CD200R1 knockout mice 
(Figures 4-10E-F).  The number of peripheral myeloid cells present in the ischemic 
brain at day 7 positively correlated with neurological deficit score (Figure 4-10G).  
Interestingly, although CD200R1 knockout mice showed a significant increase in 
CD45intCD11b+ microglia counts one week after stroke (Figure 4-11A, p=0.039), there 
were no differences in either cell size (Figure 4-11B) or cellular granularity (Figure 4-
11C), two characteristic features of microglia activation.  These findings suggest that 
CD200R1 signaling regulates the entry of leukocytes into the ischemic brain, 
potentiating the delayed recruitment of peripheral myeloid cells.  While the prolonged 
presence of these cells is associated with worse neurological function, the contribution 
of resident microglia to these outcomes appears to be minimal.   
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Figure 4-9.  Surface expression of CD200R1 on leukocyte subsets in the ischemic 
brain at 7 days. 
The percentage of CD200R1-positive leukocyte populations in the ischemic brain was 
determined (A).  A representative histogram shows the relative expression level of 
CD200R1-positive (red) and CD200R1-negative (blue) T cells (B).  The percentage of 
CD69-positive T cells for each subset was subsequently quantified (C). Cell-specific 
FMO controls were used to determine positive gating (shaded gray).  For all 
experiments, N=4-7/group.  Error bars show mean SEM.  Abbreviation:  SEM standard 
error of mean, p peripheral, Max maximum.  *p≤0.05; **p≤0.01; ***p≤0.001 
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Figure 4-10.  (Legend on following page) 
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Figure 4-10.  Effect of CD200R1 deletion on post-acute inflammatory response in 
ischemic brain. 
A representative dot plot depicts the infiltrating leukocytes in the ischemic hemisphere 
of CD200R1 wildtype and knockout mice at 7 days (A).  The overall number of CD45hi 
peripheral leukocytes was quantified (B).  The absolute counts of infiltrating myeloid (C) 
and lymphocyte (D) subsets were quantified. The relative composition of the brain 
infiltrate was determined for CD200R1 wildtype (E) and knockout (F) mice 
(N=12/group).  Correlation analysis between lymphocyte (or myeloid) cell count in the 
ischemic brain and neurological deficit score (G).  For all experiments, N=12/group.  
Cell-specific FMO controls were used to determine positive gating.  Error bars show 
mean SEM.  Abbreviation:  SEM standard error of mean, WT wildtype, KO knockout.  
*p≤0.05; **p≤0.01; ***p≤0.001 
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Figure 4-11.  CD200R1-mediated changes in post-acute activation of microglia 
after stroke. 
The absolute number of microglia in the ischemic hemisphere at 7 days after stroke was 
quantified (A).  To determine changes in cell size and granularity, the mean intensity of 
forward (B) and side (C) scatter intensity was quantified (N=12/group).  Error bars show 
mean SEM.  Abbreviation:  SEM standard error of mean, FSC forward scatter, SSC side 
scatter, WT wildtype, KO knockout, n.s. not significant.  *p≤0.05; **p≤0.01; ***p≤0.001 
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Lack of CD200R1-mediated inhibition results in exacerbated peripheral immune 
dysfunction at 7 days after stroke 
 
The peripheral immune response to stroke was first assessed using multiplex ELISA.  
Out of a panel of 24 targets, we found the plasma concentrations of six cytokines to be 
altered in CD200R1 knockout mice following stroke.  The concentration of TNF was 
significantly increased in CD200R1 knockout mice at 7 days (Figure 4-12A, p=0.05), 
whereas the concentrations of the anti-inflammatory molecules IL-10 and IL-13 were 
decreased (Figure 4-12C, p=0.002 and Figure 4-12D, p=0.02, respectively).  CD200R1 
knockout mice had significantly lower levels of circulating vascular endothelial growth 
factor (Figure 4-12F, p=0.03), and attenuated levels of IFNγ and IL-17A (Figure 4-12B, 
p=0.05 and Figure 4-12E, p=0.002, respectively).  To determine whether these 
alterations in plasma cytokine concentrations were associated with changes in the 
adaptive immune compartment after stroke we performed a phenotypic analysis of T 
cells in the blood.  A significant increase in lymphopenia was found in CD200R1 
knockout mice at 7 days (Figure 4-13A, p=0.05).  The percentage of circulating CD4+ T 
cells with effector memory phenotype was dramatically increased in CD200R1 knockout 
mice compared to wildtype controls (Figure 4-13B-C, p=0.05).  We performed an 
analysis of TCR vβ usage using monoclonal antibodies specific to 15 vβ families and 
found that CD4+ T cells from CD200R1 knockout mice exhibited greater shrinkage in 
their TCR vβ repertoire after stroke (Figure 4-13D).  Expression of the early TCR 
activation marker CD69 was also significantly increased on CD4+ T cells from CD200R1  
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Figure 4-12.  Plasma cytokine concentrations in CD200R1 wildtype and knockout 
mice after stroke. 
Plasma concentrations of TNF (A), IFNγ (B), IL-10 (C), IL-13 (D), IL-17A (E), and VEGF 
(F) are quantified in CD200R1 wildtype and knockout mice at 7 days after stroke 
(N=9/group).  Error bars show mean SEM.  Abbreviation:  SEM standard error of mean, 
WT wildtype, KO knockout, ST stroke, TNF tumor necrosis factor, IFNγ interferon 
gamma, IL-10 interleukin-10, IL-13 interleukin-13, IL-17A interleukin-17A, VEGF 
vascular endothelial growth factor.  *p≤0.05; **p≤0.01; ***p≤0.001 
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Figure 4-13.  Altered peripheral T cell compartment in CD200R1 knockout mice 
after stroke. 
The percentage of lymphocytes (versus myeloid cells) in the blood was quantified at 7 
days after stroke.  A representative smoothened dot plot shows the percentage of CD4+ 
T cells with CD44hiCD62Llo effector memory phenotype in the blood (B) and the 
quantification is shown (C).  A representative heat map analysis of 15 TCR vβ families 
was performed highlighting the narrowing in TCR vβ repertoire of CD4+ T cells in the 
blood at 7 days after stroke in CD200R1 knockout mice (D).  A representative dot plot is 
shown of CD69-expressing CD4+ T cells in the blood at 7 days (E).  The percentage of 
CD69-positiive CD4+ T cells in the blood was quantified (F). For all experiments, N=5-
7/group.  Cell-specific FMO controls were used to determine positive gating.  Error bars 
show mean SEM.  Abbreviation:  SEM standard error of mean, WT wildtype, KO 
knockout, SSC side scatter, TEM T cell effector memory, TCRvβ T cell receptor variable 
beta chain region.  *p≤0.05; **p≤0.01; ***p≤0.001 
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knockout mice after stroke (Figure 4-13F, p=0.032).  These results imply that the 
peripheral immune environment of mice lacking CD200R1-mediated inhibitory function 
is generally more pro-inflammatory and likely less capable of mounting an effective 
response to novel antigenic stimuli, such as a post-stroke infection. 
 
CD200 protein expression is exaggerated after stroke with advanced age 
 
The finding that neuroinflammation was augmented in mice lacking CD200R1 led us to 
speculate that changes in CD200 expression in the brain may be associated with the 
gradual increase in CNS inflammation with age, as well as with the exacerbated 
inflammatory responses found in age-related injuries.  We found that there is a 
significant reduction in CD200 protein expression in normal aged brains compared to 
their young counterparts (Figure 4-14A, p=0.002).  Following 90 minutes of MCAO and 
72 hours post-reperfusion, a significant decrease in brain CD200 protein levels was 
seen in aged, but not young mice (Figure 4-14B).  Although overall levels did not 
change in the young brain after stroke, increased astrocytic expression of CD200 was 
observed using immunohistochemistry (Figure 4-14C).  The decrease in aged brain 
expression of CD200 following stroke, was accompanied by a dramatic increase in 
soluble CD200 protein circulating in the plasma (Figure 4-14D).  These data indicate a 
potential role for CD200R1 immune-inhibitory signaling in mediating both chronic pro-
inflammatory responses in the brain and aggravated peripheral immunosuppression 
more commonly associated with older mice after stroke. 
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Figure 4-14.  CD200 protein concentrations in the brain and plasma of young and 
aged wildtype mice at 72 hours after stroke. 
The concentration of CD200 protein in the brain of naïve young and aged wildtype mice 
was measured by ELISA (A; N=12/group).  CD200 levels in the brain were determined 
for young and aged, sham and stroke mice at 72 hours after stroke (B; N=5-9/group).  A 
representative 40um-thick brain tissue section depicting areas of enhanced CD200 
expression (red) surrounding DAPI-positive (blue) GFAP+ astrocytes (green) in the grey 
matter of the young ischemic cortex at 72 hours (C; N=3-4/group).  Plasma 
concentrations of soluble CD200 in young and aged, sham and stroke mice are shown 
(D; N=9-14/group).  Error bars show mean SEM.  Abbreviation:  SEM standard error of 
mean, DAPI 4’,6-diamidino-2-phenylindole, GFAP glial fibrillary acidic protein, SH sham, 
ST stroke.  *p≤0.05; **p≤0.01; ***p≤0.001 
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Discussion 
 
In this study, we provide several pieces of evidence to support the hypothesis 
that (1) CD200-CD200R1 interactions regulate T cell entry and activation in the brain; 
(2) function to attenuate brain inflammation and peripheral immune dysfunction 
following experimental stroke; and (3) are critical for survival and behavioral recovery 
after stroke.  Previous work identified the CD200-CD200R1 signaling axis a major 
regulator of microglial homeostasis in the healthy and diseased CNS 19,280.  Neuronal-
microglial interactions are believed to impart a unidirectional immune-inhibitory signal 
that suppresses microglia activation and contributes to the immune-privileged status of 
the CNS 109.  Our work identifies a novel role for CD200R1 in regulating the homeostatic 
entry of immune-surveillant, effector memory T cells into tertiary tissues, including the 
CNS.  We show for the first time that CD200R1 inhibitory signaling is critical for 
attenuating brain inflammation and peripheral immune dysfunction after ischemic stroke, 
as well as promoting survival and behavioral recovery.  These findings implicate 
CD200-CD200R1 immunoregulatory pathway as a novel target for protection from CNS 
damage in experimental stroke.   
The working theory that neuronal-glial interactions function to suppress microglia 
activation and maintain CNS homeostasis via a constitutively active inhibitory 
mechanism provides an intriguing explanation for the brain’s unique immune privileged 
status.  Moreover, several studies support the notion that after injury these interactions 
are disrupted, releasing the brake on inflammation.  This concept is of translational 
interest because it implies that chronic inflammation is potentially amenable to 
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intervention in such a manner that restores homeostasis by enhancing neuronal-glial 
interactions.  Given that this theory is well established in the scientific literature, it is 
noteworthy that we did not detect surface expression of CD200R1 protein on adult 
microglia.  Despite this surprising finding, it is entirely consistent with the primary 
literature.  Several studies have reported that CD200R1 protein expression in the 
healthy brain is too weak to detect with western blot and can only be visualized via 
immunohistochemistry using a signal amplification kit 281.  CD200R1 protein expression 
is virtually absent in rodent and human microglia 22,84,109,259,282.  Low expression of 
CD200R1 on microglia has been attributed to receptor down-regulation in response to 
high levels of neuronal CD200 in the CNS 283.  Although little CD200R1 protein is 
present on the microglial surface, FACS sorted microglia confirmed the presence of 
CD200R1 transcript in these cells 109.  Others have reported that CD200R1 gene 
expression is significantly lower in human microglia than in human blood macrophages 
259.  Localization patterns of CD200R1 staining were very distinct, showing high 
expression on perivascular macrophages in both grey and white matter.  Microglial 
CD200R1 immunoreactivity was not detected in human CNS tissue.  These findings are 
consistent with a recent study by Shrivastava et al (2012) 281 which found no CD200R1-
expressing microglia in nervous tissue except in periventricular white matter regions.  
Instead, they had shown that CD200R1 expression was prominent on perivascular 
macrophages located in the pial meninges, the ventral lining of lateral ventricles, and 
surrounding blood vessels in the cortex and hippocampus.  In line with this finding, 
Melief and colleagues (2012) 84 showed that CD200R1 protein expression was highly 
expressed in choroid plexus macrophages, but virtually absent on human white matter 
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microglia.  We also noted higher expression of CD200R1 on CD45hiLy6C+ perivascular 
macrophages in the un-injured brain; however, unlike Denieffe S and colleagues (2013) 
280 we did not find that these cells were increased in number in CD200R1-deficient 
brains.  Taken together, the lack of surface CD200R1 expression on microglia likely 
explains our finding that CD200R1-deletion had minimal impact on the microglia 
compartment.  Our work is supported by previous studies that have reported no 
differences in the number of microglia in the normal brain of CD200 knockout mice 
22,280.  Moreover, previous work demonstrated that CD200-deletion had no effect on the 
secretion of TNF, IL-1b, and IL-6 in un-stimulated glia cultures 21.  After stimulation, 
however, several studies have noted increased microglia proliferation and exaggerated 
cytokine production 21,22.  We also observed a similar increase in microglia proliferation 
after stroke in mice lacking CD200R1, although this could not be attributed to any 
change in the physical properties of these cells with respect to wildtype controls.  In 
sum, the absence of functional CD200R1 protein in microglia is consistent with the null 
phenotype found in CD200- and CD200R1-knockout mice.  These findings suggest that 
CD200R1-mediated inhibition of microglia is dispensible for keeping them in a quiescent 
state, at least under normal conditions.   
Expression of CD200R is mainly restricted to cells of the myeloid lineage, 
however several studies have reported CD200R1 expression on lymphocytes 255,284-286.  
CD200R1 is expressed on T cells after TCR activation and upon chronic activation 
284,286.  The progressive acquisition of CD200R1 expression coincides with effector 
cytokine secretion and is found in both Th1 and Th2 subsets.  Our finding that 
CD200R1 expression is confined to the effector memory population is consistent with 
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these earlier studies.  Moreover, our finding that CD200R1-deficient brains have 
substantially increased numbers of T cells with effector memory phenotype suggest that 
these cells are in activated state.  Thus, it is of potential importance that CD200R1 is 
expressed on T cells in the healthy brain, and therefore conceivable that the interaction 
between CD200-positive neurons (and endothelial cells) functions to prevent the 
activation and extravasation of these cells into the CNS parenchyma.  This event would 
contribute to the maintenance of the immune privileged status of the CNS, in a 
microglia-independent manner, by limiting the number of T cells surveying the brain at 
the level of the blood-brain barrier.   
Immune-surveillant T cells in the CNS are believed to be tolerized to self-antigen, 
however it is not known whether the CNS-specific T cells in CD200R1-deficient mice 
are similarly tolerant.  Previous work has shown that CNS-irrelevant (OVA-specific) T 
cells may enter the brain, cause blood-brain barrier leakiness, but no glial pathology 287.  
Indeed, the lack of overt microglia activation or behavioral deficits under normal 
conditions suggests that these cells may not be deleterious under normal conditions.  In 
the absence of CD200 engagement, T cells are likely more resistant to inhibition at the 
level of the endothelium and to become chronically activated upon entering the CNS.  
We demonstrated that immune-surveillant CD8 T cells in CD200R1-deficient mice had 
significantly higher TNF expression, but greatly diminished IFNγ expression.  These 
findings are consistent with other work showing that CD200-CD200R1 interactions are 
critical for preventing pathological T cell responses during influenza infection 288,289.  
Another study demonstrated that TNF production was increased in splenocytes from 
CD200R1-deficient mice and that CD200-mediated suppression of graft rejection 
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requires CD200R1+ responder T cells 261.  These data indicate that inhibitory signaling 
is required to abrogate T cell activation and prevent dysregulated responses to injury 
and infection.  Further studies will be needed to determine the functional role of immune 
surveillant T cells in the healthy CNS and if they represent a viable therapeutic target.  
While there is continuous surveillance of CNS antigens in peripheral lymphoid 
tissue, antigen-specific T cells do not generally accumulate in CNS tissue in the 
absence of neuroinflammation 290.  Our finding that there is a higher accumulation of T 
cells in the normal brain of CD200R1-deficient mice implies there is underlying 
inflammation.  Indeed, blood-brain barrier permeability was found to be increased in 
naïve CD200-deficient mice 280.  Our findings do not exclude this as a potential 
explanation for the accumulation of lymphocytes in the CD200R1-deficient CNS, 
however, leukocyte extravasation is not a passive process, but rather an active one and 
our results indicate that entry is limited specifically to T cells.  In support of this view, the 
same study showed that CCL2 and IP-10 expression is up-regulated in the brain of 
CD200-deficient mice.  These chemokine signals may facilitate the recruitment of 
circulating T cells.  Moreover, CD200-CD200R1 interactions are involved in T cell 
adhesion to the endothelium but not macrophages 291. A recent study found that 
CD200R1 inhibitory signaling is important in regulating local T cell influx into the 
ischemic limb, but had no effect on macrophage transmigration 292.  Taken together, 
CD200-CD200R1 interactions between T cells and the endothelium may function to 
suppress transmigration and maintain immune privilege in the healthy CNS.  In this 
scenario, any disturbance (e.g., aging, injury) to the CD200-CD200R1 signaling axis 
would cause immune privilege to be broken.  At this time it is not known whether 
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heightened CNS immune surveillance is predictive of CNS integrity and brain function or 
if it represents an epiphenomenon.  However, our study would suggest that T cell 
accumulation in the CD200-deficient brain predisposes these mice to have worsened 
outcomes following injury. 
We demonstrated that the CD200-CD200R1 inhibitory signaling pathway is 
critical for quelling immune cell activation and mitigating transmigration into the brain 
after stroke.  Inflammation plays an important role in the pathogenesis of stroke and 
other forms of ischemic brain injury 293.  The restoration of brain function after stroke is 
dependent on the attenuation of inflammatory processes that trigger cell death.  
Mounting evidence highlights the detrimental impact of chronic inflammation on 
neuroplasticity and long-term recovery following stroke 2.  We hypothesized that 
neuroinflammation would be sustained in the absence of inhibitory signals.  Although 
our results unequivocally implicate CD200R1 as a master regulator responsible for 
slowing the progression of inflammation in the brain after stroke, the cellular basis for 
this action is not clear.  We reported that lymphocytes were the predominant CD200R1-
expressors in the ischemic brain at day 7 and that CD200R1+ T cells exhibited a higher 
level of activation than their CD200R1-negative counterparts.  Interestingly, however, 
similar fold-increases in infiltrating monocyte number were also found in knockout mice 
and those with higher myeloid-to-lymphocyte ratios had worse outcomes.  Previous 
work has shown that CD200R1 activation suppresses macrophage migration in part by 
down-regulating expression of the adhesion molecules LFA-1 and VLA-4 258.  This is 
consistent with other studies that have reported increased macrophage numbers in both 
sterile and autoimmune models of brain injury 19,112.  To this end, our observation that 
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microglia proliferation is increased in CD200R1-deficient mice may reflect accelerated 
glial scarring.  Together, these data imply that CD200R1 signaling may be more 
powerful in myeloid cells under inflammatory conditions.  However, we cannot exclude 
the possibility that activated T cells potentiate the recruitment and polarization of 
macrophages. 
The results presented in this study bare a striking resemblance to that reported 
for another immune inhibitory receptor, programmed death-1.  Ren X et al (2011) 294 
found that PD-1 was up-regulated on macrophages and lymphocytes in the CNS at 96-
hours after MCAO.  Moreover, deletion of PD-1 resulted in increased infiltration of 
inflammatory cells into the ischemic brain and augmented cytokine production by 
peripheral T cells.  Ischemic stroke is increasingly recognized as a systemic disease 
rather than being confined only to a brain lesion 295-298.  Indeed, while acute stroke 
patients may survive the initial brain insult, infections are the most common cause of 
morbidity and mortality in the stroke survivor299-302.  We demonstrated that CD200-
CD200R1-mediated regulation of immunity is essential for survival and improved 
behavioral recovery following stroke.  Nearly half of all mice lacking CD200R1 inhibitory 
signaling did not survive.  Although the exact cause of death is not clear, CD200R1-
deficient mice exhibited severe weight loss and exacerbated peripheral immune 
dysfunction.  These changes were accompanied by deficits in thermoregulation, 
neurological function, and impaired motor balance and coordination.  Our findings are 
consistent with other studies that have found CD200-CD200R1 interactions to be 
essential for attenuating disease progression in the CNS 19,258,283.  CD200R1-deficient 
mice were found to have an increase in the level of circulating pro-inflammatory factors 
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and a reduction in anti-inflammatory mediators.  Interestingly, we found that CD200R1-
deficient mice experience more severe lymphopenia after stroke.  A large proportion of 
CD200R1-defecient T cells acquired an effector memory phenotype, which likely 
occurred via lymphopenia-induced homeostatic proliferation of existing memory 
populations or by antigen-driven conversion 303.  Coincident with these changes, we 
demonstrated that T cells in the blood of CD200R1-deficient mice had a narrowing of 
the TCR repertoire after stroke.  A recent spectratype analysis has shown that clonal 
expansions of T cells are present in the brain at 7 days after stroke, and to a lesser 
extent in spleens and lymph nodes 278.  Given that lymphopenia is a prominent feature 
of stroke and that the majority of infiltrating T cells in the ischemic brain have an effector 
memory phenotype, it is conceivable that the purported clonal enrichment of T cells in 
the brain after stroke is a result of the stochastic entry of memory populations that arise 
from antigen-independent, cytokine-driven homeostatic proliferation rather than a 
directed autoimmune response to CNS antigen.  Although infarct volume is a major 
determiner of post-stroke immune cell function and susceptibility to infection 304, it is 
interesting to note that despite having significant T cell dysfunction, CD200R1-deficient 
brains did not have greater tissue damage, suggesting an important role for inhibitory 
signaling in regulating the amplitude of peripheral immune responses to stroke.  
Whether CD200R1-deficient mice display a heightened susceptibility to spontaneous 
infection following stroke is not clear.  It is important to note that the immunosuppressive 
effects of CD200 are critical to the long-term tolerance and survival of tissue allografts, 
and is associated with successful outcome of pregnancy 305,306.  Surprisingly, CD200 
ablation did not appear to ameliorate post-stroke immune suppression.  The paradoxical 
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role of CD200R1 inhibitory signaling in regulating the peripheral immune environment 
after stroke is an area that requires further exploration. 
 Our data show that the regulation of CD200 expression is sensitive to the effects 
of brain aging.  These results are supported by previous work showing CD200 gene 
expression is decreased in the hippocampus of older mice 307,308.  The age-related 
reduction in brain CD200 levels may underlie the steady increase in basal inflammatory 
responses that occurs with age 55. Although the spatial distribution of CD200 in the 
aging brain was not assessed, it is possible that the reduction in gray matter volume 
associated with aging accounts for this decrease 309,310.  Indeed, CD200 expression is 
diminished in the hippocampus and inferior temporal gyrus of Alzheimer’s patients 259.  
Moreover, CD200-fusion protein attenuates age-related decreases in LTP, whereas 
LPS-induced deficits in LTP are exacerbated in CD200-deficient mice 21,113.  CD200-Fc 
was also shown to attenuate the age-related increase in brain expression of CCL2 and 
IP-10, implicating CD200R1 as a potential regulator of leukocyte entry in the normal 
aging CNS 113.  As the integrity of the CD200-CD200R1 signaling axis becomes 
compromised with age, a concurrent loss of immune privilege and increase in 
inflammatory mediators may contribute to age-related deficits in brain function.  Our 
finding that CD200 brain protein is significantly decreased at day 3 in the brain of aged 
mice after stroke, but not young, further strengthens this concept.  Our laboratory has 
previously shown that glial scar formation is exacerbated in older mice after stroke 275.  
Thus, it is interesting to note that CD200R1-deficient mice showed a significant increase 
in microglia proliferation by day 7.  This injury-related loss of neuronal CD200 likely 
contributes to chronic inflammatory responses observed in aged mice 311.  Although 
	   	   	  115	  
young mice did not exhibit a significant reduction in total brain levels of CD200 at 72 
hours, physical disruption of CD200-CD200R1 interactions resulting from neuronal 
injury presumably account for any loss in immunoregulation.  A related study 
demonstrated that CD200 gene expression is decreased in the ischemic core beginning 
at 24 hours and returned to baseline after day 7 23.  While this study did not assess 
changes in CD200 protein expression, we would predict that due to the increased level 
of necrosis in the ischemic core, the loss of neurons would likely precipitate a decrease 
in CD200.  Furthermore, we showed that CD200 was up-regulated on reactive 
astrocytes in young ischemic brain, potentially offsetting any change in overall 
expression.  These findings are consistent with other work showing regional induction of 
CD200 in astrocytes found in chronic active plaques centers of multiple sclerosis 
patients and point to a potentially important role for astrocytes in ramping down chronic 
inflammatory responses 107,109.   
Perhaps most strikingly, aged mice exhibited a dramatic increase in circulating 
soluble CD200 levels following stroke.  These results point to a novel mechanism of 
peripheral immune suppression in which circulating CD200 down-regulates the normal 
adaptive function of lymphocytes and dendritic cells.  More importantly, if this increase 
in soluble CD200 emanates from dying neurons in the ischemic brain, it would establish 
a critical link between brain injury and peripheral immune suppression.  Indeed, infarct 
volumes positively correlate with immunosuppression status after stroke 304.  Aged mice 
also have higher mortality following traumatic CNS injury and are more 
immunosuppressed than young mice who sustain comparable injuries 312.  The 
suppressive effects of soluble CD200 are evidenced by its ability to enhance 
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engraftment of skin and cardiac allografts 313.  It remains to be seen whether soluble 
CD200 would serve as a useful prognostic marker for brain injury, or if anti-CD200 
blockade is a viable approach to attenuating post-stroke immune suppression in older 
subjects. 
To our knowledge, this is the first study to investigate the functional effect of 
ablating CD200R1 immune-inhibitory signaling in the CNS.  Given that the CD200 
receptor family has several isoforms, in which all (CD200R2-4) but one (CD200R1) are 
activating receptors that lack inhibitory motif-bearing proteins, the advantage of using 
transgenic mice containing a genetic deletion of CD200R1 rather than CD200 is that 
any observed effect is a result of the absence of inhibitory signaling rather than a 
combination of activating and inhibitory functions 25,314.  For example, CD200R3 is 
expressed in basophils and mast cells and cross-linking of CD200R3 induces 
degranulation and production of IL-4, respectively 315.  The phenotypic similarities in the 
neuroinflammatory state between CD200- and CD200R1-deficient mice imply that the 
functional role of the activating CD200R family members may be negligible 25,280.  We 
did not observe CD200R3 staining of adult microglia, however its expression after 
stroke and that of the other activating family members (CD200R2 and CD200R4) 
deserves further study before a complete interpretation can be made. 
In conclusion, our observations provide new insights into the contribution of the 
CD200-CD200R1 inhibitory pathway to immune privilege and the progression of chronic 
and systemic inflammation following stroke.  We propose a revision to the current 
framework of the CD200 hypothesis to include interactions involving T cells and 
inflammatory monocytes.  It is believed that inhibitory receptors such as CD200R1 
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evolved as a general strategy to prevent autoimmunity while closely homologous 
activating receptors are busy combating pathogens 316.  The compensatory increase in 
inhibitory receptor expression on the surface of chronically activated immune cells 
implies that this system can be exploited to ameliorate inflammation and restore 
homeostasis.  To this end, our findings suggest that agents that can target the CD200-
CD200R1 signaling axis may hold therapeutic potential for the treatment of chronic 
brain inflammation and peripheral immune depression following stroke. 
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Supplemental Figure 4-1.  CD200R1 deletion does not alter gross vasculature of 
normal brain or post-stroke atrophy. 
A representative photograph of a healthy brain perfused with India ink shows no 
apparent difference in the gross vasculature of adult CD200R1 wildtype and knockout 
mice (A; N=4/group).  Another representative image depicts no difference in cortical 
atrophy at 7 days after stroke as examined by cresyl violet staining (B; N=8-9/group).  
Abbreviation:  WT wildtype, KO knockout. 
 
 
 
 
WT# KO#
KO#WT#
A
B
	   	   	  119	  
Authors’ Contributions 
RMR and LDM conceived the project.  RMR performed most of the experiments and JC, 
ARP, JG, BK, BF assisted with the flow cytometry preparations.  RMR, JC and BK 
performed the behavioral experiments.  RV assisted with the surgeries and statistical 
analyses.  RMR and LDM wrote the paper.  All authors read and made comments on 
the manuscript draft and approved the final manuscript. 
 
Acknowledgements 
This work was supported by National Institutes of Health grants R21 NS082906-02 
(Louise D. McCullough), R21 NS076293-01A1 (Louise D. McCullough), and F31 
NS083244-01A1 (Rodney M. Ritzel). 
 
 
 
 
 
 
 
 
 
 
	   	   	  120	  
Chapter 5: 
Age- and location-related changes in microglia function 
 
Rodney M. Ritzel1, Anita R. Patel, Sarah Pan, Joshua Crapser, Matthew D. Hammond, 
Evan R. Jellison & Louise D. McCullough 
 
This chapter was published in its present form in Neurobiology of Aging; 
2015 Jun; 36(6): 2153-106. 
 
 
 
Abstract 
 
Inflammation in the central nervous system (CNS) is primarily regulated by microglia.  
No longer considered a homogenous population, microglia display a high degree of 
heterogeneity, immunological diversity and regional variability in function.  Given their 
low rate of self-renewal, the microenvironment in which microglia reside may play an 
important role in microglial senescence.  This study examines age-related changes in 
microglia in the brain and spinal cord.  Using ex-vivo flow cytometry analyses, functional 
assays were performed to assess changes in microglial morphology, oxidative stress, 
cytokine production, and phagocytic activity with age in both the brain and spinal cord.  
The regional CNS environment had a significant effect on microglial activity with age.  
Blood-CNS barrier permeability was greater in the aging spinal cord compared to aging 
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brain; this was associated with increased tissue cytokine levels.  Aged microglia had 
deficits in phagocytosis at baseline and following stimulus-induced activation. The 
identification of age-specific, high scatter microglia together with the use of ex-vivo 
functional analyses provides the first functional characterization of senescent microglia.  
Age and regional-specificity of CNS disease should be taken into consideration when 
developing immune-modulatory treatments. 
 
 
 
Introduction 
 
Microglia, the resident macrophages of the CNS, actively survey the environment and 
rapidly respond to homeostatic disturbances.  Although microglial responses have been 
widely studied in the context of injury, changes in microglial phenotype or activation 
status may also occur under normal conditions.  These responses may also vary 
depending on cues from the local microenvironment 317.   Microglial can have both pro-
inflammatory (M1) and wound healing roles (M2) and their phenotype can vary in 
response to local cues (regional effects) and across the lifespan (aging effects) 318-320.  
The brain and spinal cord are distinct CNS environments that serve very specialized 
functions 321.  However, the degree to which heterogeneity and immunological diversity 
is present in the microglial population in each area remains an understudied area of glial 
biology322.  
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Regional differences also occur in the response to injury throughout the 
neuroaxis, with the spinal cord showing a more robust inflammatory response and a 
greater vulnerability to the detrimental effects of activated microglia 323,324. For instance, 
spinal cord lesions produce greater microglia activation and more extensive leukocyte 
recruitment and blood-CNS barrier breakdown than comparable lesions to the cortex 
325,326.  Additionally, injury to white matter results in significantly more inflammation 
compared to an equivalent injury to gray matter, and caudal regions of the CNS respond 
with greater microglial activation than forebrain regions after focal cytokine injections 
323,327,328.  These findings suggest that the brain and spinal cord, because of their unique 
structural and functional organization, harbor microglial populations with distinct 
activation thresholds that are primed to respond differently to stimuli. As many CNS 
diseases are age-related and manifest in specific CNS regions (e.g., amyloid deposition 
in Alzheimer’s), furthering our knowledge of microglial diversity will increase our 
understanding of the role played by microglia in the pathogenesis of disease. 
Given that microglia have a low rate of self-renewal, the environment in which 
they reside likely shapes their identity over time.  In addition, aging itself has profound 
effects on cells of the myeloid lineage.  Earlier studies have shown microglia 
senescence is manifested by morphological changes and alterations in 
immunophenotypic expression and inflammatory profile 54,329-332.  A steady increase in 
the expression of markers that are up-regulated on young, activated microglia following 
acute CNS injury is seen at baseline in aged brain.  These observations lead to the 
hypothesis that age-induced microglial dystrophy results in chronic inflammation, a 
dysregulated or uncontrolled response to injury, and poorer recovery.  To better 
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understand the role played by microglia in age-related diseases, a clearer 
understanding of the effect aging on baseline microglia function is required.   Age-
related transitions from ramified to amoeboid morphology have been described 333, but 
much less is known regarding the functional importance of this phenotypic shift.  
The present study examined the effect of aging on mitochondrial activity, reactive 
oxygen species generation, and phagocytic potential of microglia within the two main 
CNS compartments, the brain and spinal cord.  We hypothesized that microglial identity 
and function is specified by the environment, and that aging impairs niche function.  Our 
findings indicate that microglia in the aging brain and spinal cord have distinct 
immunological profiles.  A significant enhancement of inflammatory cytokines and 
markers of oxidative stress, coupled with a loss of phagocytic function was seen, which 
was more profound in the aged spinal cord.  These changes may explain why microglial 
subsets can differentially contribute to the etiology and pathology of age-related 
neurodegenerative disease.  
 
 
Materials and Methods 
 
Mice/Animals:  C57BL/6J male mice 8-12 weeks (young adult; 31.5 ± 0.8 grams) and 
20-22 months (aged; 37.8 ± 1.0 grams,) of age were pair-housed on sawdust bedding in 
a pathogen free facility (light cycle 12/12 h light/dark) with free access to chow and 
water. Animal procedures were performed in accordance with NIH guidelines for the 
	   	   	  124	  
care and use of laboratory animals and approved by the Animal Care Committee of the 
University of Connecticut Health Center.  All studies were performed blinded to age. 
 
Tissue Harvesting:  Mice were euthanized, transcardially perfused with 60 mL cold, 
sterile PBS, and the brains and spinal cords were harvested.  The brainstem, 
cerebellum, and optic nerve were removed.  The brain was then divided along the 
interhemispheric fissure into two hemispheres.  Spinal cords were removed by flushing 
the spinal column with sterile PBS by hydrostatic pressure and subsequent rinsing with 
PBS to remove contaminant cells.  Samples were then processed in a blinded fashion.   
 
Flow Cytometry:  Brains and spinal were placed in complete RPMI 1640 (Lonza) 
medium and mechanically and enzymatically digested in collagenase/dispase (1 
mg/mL) and DNAse (10mg/mL; both Roche Diagnostics) for 1hr at 37C.  The cell 
suspension was filtered through a 70um filter.  Leukocytes were harvested from the 
interphase of a 70%/30% Percoll gradient.  Cells were washed and blocked with mouse 
Fc Block (ebioscience) prior to staining with primary antibody-conjugated flourophores:  
CD45-eF450, CD11b-APCeF780, Ly6C-PerCP-Cy5.5, and SIRPα-PE.  All primary-
conjugated antibodies were purchased from eBioscience.  For live/dead discrimination, 
a fixable viability dye, carboxylic acid succinimidyl ester (CASE-AF350, Invitrogen), was 
diluted at 1:300 from a working stock of 0.3mg/mL.  Cells were briefly fixed in 2% 
paraformaldehyde (PFA).  Data were acquired on a LSRII using FACsDiva 6.0 (BD 
Biosciences) and analyzed using FlowJo (Treestar Inc.).  No less than 100,000 events 
were recorded for each sample.  Fluorescence minus one (FMO) controls were used to 
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determine the positivity of each antibody.  Microglia were identified as CD45intCD11b+.  
Subsequently, to ensure that the microglia population was pure, we excluded all Ly6C+ 
bone marrow-derived myeloid populations with overlapping CD45 expression.  
To study the phagocytic activity of microglia, fluorescent latex beads 
(Fluoresbrite Yellow Green (YG) carboxylate microspheres; 1um diameter; 
Polysciences) were added to freshly isolated microglia in a final dilution of 1:100 as 
described 207.  After 1-hour at 37°C in an air incubator, the cells were washed three 
times with FACS buffer, re-suspended in FACS buffer, stained for surface markers, and 
fixed in PFA (N=7/group).  For beta-amyloid peptide and cell stimulation experiments, 
cells were incubated for 1hr in 37C water bath.  Lyophilized fluorescein-labeled 
(synthetic human) beta-amyloid (1-42) was dissolved in DMSO to a final stock 
concentration of 500ug/mL (rPeptide, Bogart, GA, USA).  This was further diluted 1:1 in 
PBS to obtain a working stock from which 1ul was added to every 100ul of sample and 
vortexed to mix.  Cell Stimulation Cocktail containing phorbol 12-myristate 13-acetate 
(PMA) and ionomycin was purchased from eBioscience.  Cells were treated with 
stimulation cocktail (500X) following the addition of phagocytic substrate and 
subsequently incubated (N=6/group). 
To determine mitochondrial activity, MitoTracker Red CM-H2XRos (Life 
Technologies, Invitrogen; Ex/Em: 579/599), a reduced, nonfluorescent dye that 
fluoresces upon oxidation was used to stain mitochondria in live cells.  Its accumulation 
is dependent upon membrane potential.  Mitotracker was diluted in DMSO to a working 
concentration of 500nM, at a final volume of 300ul.  Cells were incubated for 20 min at 
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37˚ C and subsequently washed three times with FACS buffer (without NaAz) to remove 
residual dye (N=6/group).   
For detection of reactive oxygen species, microglial cells were incubated with 
redox-sensitive CM-H2DCFDA (5uM; Ex/Em: 495/520) fluorogenic cell-permeant dye 
(Life Technologies, Invitrogen).  Cells were incubated for 20min at 37C, washed three 
times with FACS buffer (without NaAz), and then stained for surface markers including 
CASE (N=5-7/group).   
For intracellular cytokine staining, an in vivo brefeldin A (BFA) protocol was 
followed.  Briefly, 10mL/kg of BFA (Sigma, 0.5mg/mL in DMSO) was injected via tail 
vein.  Ten hours later, animals were sacrificed and tissue was harvested as noted 
above.  Prior to staining, 1ul of GolgiPlug containing brefeldin A (BD Biosciences) was 
added to 800ul complete RPMI and cells were incubated for 2h at 37C (5% CO2).  
Afterward, cells were re-suspended in Fc Block, stained for surface antigens and 
washed in 100ul of fixation/permeabilization solution (BD Biosciences) for 20 min.  
Microglia were then washed twice in 300ul permeabilization/wash buffer (BD 
Biosciences) and resuspended in an intracellular antibody cocktail containing TNF-PE-
Cy7 (eBioscience), IL-1β-FITC (eBioscience) and MMP-9-PE (StressMarq Biosciences, 
Inc.) and subsequently fixed (N=5/group). 
ImageStream data were acquired using the Amnis ImageStream Analyzer 
(Amnis Corporation, WA) equipped with the Amnis INSPIRE software. 
 
Assessment of blood-brain barrier permeability:  Two hours before the animals 
were euthanized, Evans blue (Sigma, 2% in isotonic saline, 4mL/kg) was injected 
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intraperitoneally.  The animals were anesthetized and perfused with 60mL of cold sterile 
PBS.  Spinal cords were syringe-flushed and brain hemispheres were harvested, rinsed 
with PBS and weighed.  Samples were homogenized in 1 ml of PBS using a tissue 
homogenizer.  An equal volume of 100% trichloroacetic acid (TCA) solution was added 
to each sample and incubated at 37⁰C for 1 hr.  Samples were then centrifuged at 
24,000g for 20 minutes at 4⁰C.  The supernatant was plated 100ul per well in triplicate 
and colormetric absorbance was measured at 608nm (EnSpire 2300 Multilabel Reader, 
Perkin Elmer).  For quantitative measurement of Evans blue leakage, the data was 
normalized to tissue weight and measured as a concentration (ug/mg tissue weight) of 
Evan’s blue using a standard curve (Evan’s blue in 50% TCA).  Data were normalized to 
young brain and expressed as fold change. 
Thirty minutes before the animals were euthanized 2ml/kg of a 10% sodium 
fluorescein (NaF) solution (Sigma) was injected and processed as above.  For each 
sample, 100ul of supernatant was measured in triplicate at ex. 400nm/ em. 516nm.  
Values obtained from 30% TCA were subtracted from each sample to remove 
background. 
 
ELISA cytokine measurement:  Brain and spinal cord cytokine levels were determined 
by ELISA (Milliplex Cytokine Assay, EMD Millipore).  Brains and spinal cords 
(n=5/group) were homogenized in ice-cold lysis buffer containing a protease inhibitor 
cocktail (Roche Diagnostics).  Homogenates were sonicated and centrifuged at 4C for 
15 min at 14,000 rpm, and supernatants were assayed for total protein using a BCA kit 
(Pierce, Thermo scientific).  100ug of each sample was loaded into each well in 
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duplicate.  Samples were assayed according to the manufacturer’s instructions using a 
Luminex 200 (Luminex Corporation, Austin, TX, USA) magnetic bead array platform.  
Inter-and intra-assay coefficients of variation were than less than 10%. 
 
RNA isolation and qPCR:  Brain hemispheres and spinal cords were harvested and 
RNA was extracted using TRIzol Reagent (Invitrogen, Carlsbad, CA).  Gene expression 
was normalized relative to GAPDH expression. Primer sequences were as follows: 
GAPDH, forward: 5'-ACCACCATGGAGAAGGC -3', reverse: 5'-
GGCATGGACTGTGGTCATGA -3'; CD47, forward: 5’-
TGCGGTTCAGCTCAACTACTG-3’, reverse: 5’-ACGATGCAAGGGATGACCAC-3’; 
TNFα, forward:  5’–GACCCTCACACTCAGATCATCTTCT-3’, reverse:  5’-
CCTCCACTTGGTGGTTTGCT-3’.  PCR conditions were as follows: 95⁰C for 10 min, 
followed by 40 cycles of 95⁰C for 15 sec and 60⁰C for 60 sec. Amplification reactions 
were performed in triplicate; relative expression levels were calculated from average 
threshold cycle number using the delta-delta Ct method.  The absolute levels of the 
housekeeping gene GAPDH did not vary significantly with age, consistent with previous 
findings by Chen, et al. 334 and others 335. 
 
Statistical Analyses:  Data from individual experiments are presented as mean ± SEM 
and age- and region-matched CNS samples were assessed by 2-way ANOVA or one-
way ANOVA with Bonferroni corrections for multiple comparisons (GraphPad Prism 
Software Inc, San Diego, CA, USA).  Groups were compared with Student's t-test where 
appropriate. Significance was set at p < 0.05. 
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Results 
 
Age- and location-related changes were seen in the physical properties and 
CD45/CD11b expression of microglia 
 
To ensure that all microglia populations under investigation were living and pure, 
samples were examined by flow cytometry.  We identified resident CD45int 
CD11b+Ly6C- microglia as the predominant myeloid cell population in young and aged 
C57Bl/6 mouse brain and spinal cord (Figure 5-1A) using a defined gating strategy 
(Supplemental Figure 5-1A).  We quantified the mean fluorescence intensity (MFI) for 
each marker. A significant interaction between age and location was seen for CD45 
(F(1,24)=P<0.05)) and CD11b (F(1,24)=P<0.01), resulting in an age- and location-
dependent increase in expression, with spinal microglia showing highest levels (Figures 
5-1B and 5-1C).  Next we examined the physical properties of microglia using the mean 
forward scatter (FSC-area) and side scatter (SSC-area) values as relative measures of 
cell size and granularity, respectively.  Spinal cord microglia were larger in size 
compared to brain microglia (F(1,24)=P<0.05)), although both  increased in size with 
age (Figure 5-1E).  Side scatter values were significantly increased with age in both 
groups, showing a nearly ~50% increase in overall cellular granularity (Figure 5-1F; 
F(1,24)=P<0.001)).  Aged dystrophic microglia were identified as high side scatter 
populations relative to young microglia, a characteristic that was also observed by  
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Figure 5-1.  Identification of microglial by CD45 and CD11b expression and light 
scatter properties.   
A representative zebra plot showing CD45intCD11b+ microglia in young and aged brains 
(A).  The relative expression of microglial CD45 and CD11b were quantified for brain 
and spinal cord with age (B and C).  Physical properties of microglia were measured by 
flow cytometry.  Figure 1D shows a representative zebra plot of microglia in young and 
aged brains illustrating the increased side scatter properties of aging microglia.  
Forward scatter area (FSC-A) and side scatter area (SSC-A) mean intensities were 
quantified revealing a significant interaction between aging and region with regard to 
cell size (E) and an effect of age on cellular granularity (F) according to 2-way ANOVA 
statistical analysis. For all experiments N=7/group. Error bars show mean SEM. 
Abbreviation: SEM, standard error of the mean. 
 
 
Br
ain
Sp
ina
l C
or
d
0
500
1000
1500
2000
2500
M
F
I o
f C
D
45
 (a
.u
.i) Young
Aged
Br
ain
Sp
ina
l C
or
d
60000
70000
80000
90000
M
I o
f F
SC
-A
 (a
.u
.i) Young
Aged
A"
D"
B" C"
E" F"
G"
Br
ain
Sp
ina
l C
or
d
0
1000
2000
3000
4000
5000
M
F
I o
f C
D
11
b
 (a
.u
.i) Young
Aged
Br
ain
Sp
ina
l C
or
d
0
20000
40000
60000
M
I o
f S
SC
-A
 (a
.u
.i) Young
Aged
Br
ain
Sp
ina
l C
or
d
2
3
4
5
Two-way ANOVA , not RM
M
FI
 o
f C
M
-H
2D
C
FD
A
+ 
(a
.u
.i 
x 
10
4 )
Young
Aged
Br
ain
Sp
ina
l C
or
d
2
3
4
5
Two-way ANOVA , not RM
M
FI
 o
f C
M
-H
2D
C
FD
A
+ 
(a
.u
.i 
x 
10
4 )
Young
Aged
CD45%
CD
11
b%
Gated%on%CD45intCD11b+%
CD45%
SS
C'
A
%
	   	   	  131	  
single cell fluorescent microscopy (Figure 5-1D and 5-1G).  These results suggest that 
aging is associated with general features of microglia activation, albeit to a greater 
extent in the spinal cord. 
 
Age- and location-related increases in mitochondrial activity, reactive oxygen 
species (ROS) production, and expression of the pro-inflammatory cytokines 
 
Aging is associated with altered mitochondrial dynamics 336,337.  Using two commercial 
dyes, Mitotracker Green and CM-H2XRos, the effects of aging on total mitochondrial 
content and membrane potential respectively were investigated.  Two-way ANOVA 
revealed a significant interaction between age and region on both mitochondrial content 
(Mitotracker, F(1,17)=P<0.0078) and membrane potential (CM-H2XRos, 
F(1,20)=P<0.0055), primarily driven by relatively large increases in mitochondrial 
activity of aged spinal cord microglia (Figure 5-2A-D).  Because both aging and 
changes in mitochondrial activity have been linked to elevated ROS generation we next 
measured ROS levels (Finkel T and Holbrook NJ, 2000).  A significant age-related 
increase in the basal production of microglial ROS after incubation with CM-H2DCFDA, 
was seen, indicating an increase in oxidative stress with age (Figure 5-2E-F; 
F(1,19)=P<0.0396). 
Increased production of ROS in aging cells is generally associated with 
increased expression of pro-inflammatory cytokines 338,339.  We measured basal 
production of M1-associated pro-inflammatory cytokines tumor necrosis factor-alpha 
(TNF-α) and interleukin 1-beta (IL-1β) in unstimulated microglia by intracellular staining  
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Figure 5-2.  Mitochondrial activity and reactive oxygen species production in 
microglia. 
Representative histograms of Mitotracker and CM-H2XRos dye staining of microglia, 
indicating overall mitochondrial content and mitochondrial membrane potential, 
respectively (A and B).  Quantification of mean fluorescence intensities reveal an effect 
of aging on mitochondrial mass and activity (C and D).  A representative dot plot of the 
ROS-indicator CM-H2DCFDA, used to assess ROS levels in unstimulated microglia (E).  
The relative fluorescent intensities of CM-H2DCFDA were significantly altered with age 
(F). The histogram color key is as follows: gray = microglia FMO dye control, red = 
brain, blue = spinal cord, light shade = young, dark shade = aged. For all experiments, 
N=5-7/group. Error bars show mean SEM. Abbreviation: SEM, standard error of the 
mean. 
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(Figure 5-3A and 5-3D).  Significant age- and regional effects were found in the both 
the percentage and mean intensity of TNF-α- and IL-1β-positive microglia; with aged 
spinal cord microglia showing relatively greater expression (F(1,16)=P<0001).  
Intracellular production of TNF-α protein was consistent with gene expression levels of 
TNF-α at the tissue level (Supplemental Figure 5-1B; F(1,9)=P<0.0021).  Together, 
these findings suggest that microglia adopt a M1 status with age, a transition that is also 
influenced by the CNS environment. 
 
Age- and location-related changes in phagocytic potential of microglia are 
associated with changes in the expression of immunoregulatory molecules 
 
The phagocytic potential of microglia was evaluated by phagocytosis substrate assays 
and microglial expression of signal regulatory protein α (SIRPα). SIRPα serves as a 
“don’t eat me” signal that negatively controls phagocytosis. The percentage of YG bead-
positive microglia was significantly higher in the brain compared to the spinal cord 
(Figure 5-4A-B; F(1,20)=P<0.01).  In addition, a decrease in the percent of bead-
positive microglia was seen in aged brain compared to the young.  We also observed an 
age-related decrease in the mean fluorescence intensity of YG bead-positive microglia 
(Figure 5-4C; F(1,20)=P<0.01), indicating a decrease in overall phagocytic activity of all 
bead-positive microglia.  The uptake of multiple beads by aged microglia was 
associated with increased side scatter properties as depicted in Figure 5-4G, indicating 
that side scatter intensity may be a useful indirect measure of phagocytic activity in 
some situations.  Next, to validate these findings using a substrate more reminiscent of 
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physiological cargo, we assessed phagocytosis of beta-amyloid peptide.  Similar effects 
of age (F(1,18)=P<0.001) and region (F(1,18)=P<0.001) on the number of phagocytic 
microglia were observed using beta-amyloid peptide as the substrate (Figure 5-4D-E).  
A significant age-related decrease in the overall amount of beta-amyloid uptake per cell 
was also found (Figure 5-4F; F(1,18)=P<0.01).  A similar regional effect was found in 
the expression of SIRPα, with spinal cord showing lower levels compared to brain 
(Figure 5-5A-B; F(1,24)=P=0.001).  The receptor ligand for SIRPα, CD47, was then 
evaluated.  Gene expression studies showed that endogenous CD47 transcription 
increases in an age- and region-dependent manner (Figure 5-5C; p<0.05).  
Interestingly, PMA/ionomycin stimulation increased phagocytic activity in young and 
aged microglia for both substrates, albeit to a lesser extent in aged microglia (beads, 
P=0.039; beta-amyloid, P=0.003; Figures 5-5D-F).  These results show that microglial 
phagocytic activity changes with age both at baseline and after stimulation in a region-
specific manner.  This may be regulated by the expression of immunoregulatory 
molecules known to keep microglia in a quiescent state.  
 
The blood-spinal cord barrier exhibits a relatively high degree of vascular leakage  
 
One possible mechanism for age- and location-related differences in microglia 
activation is increased exposure to systemic factors.  We assessed vascular 
permeability in brain and spinal cord tissue in young and aged mice.  Large (Evan’s 
blue, 961Da; bound to albumin, 70kDa) and small (NaF, 400Da) tracers were injected 
and subsequently analyzed by spectrophotometry (Figures 5-6A-B).  While vascular  
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Figure 5-3.  Basal cytokine production by microglia is altered with age and region. 
Representative dot plots illustrate intracellular production of pro-inflammatory cytokines 
IL-1β and TNF by unstimulated microglia (A and D, respectively).  Quantification of 
these plots show elevated microglial cytokine production with age, which is particularly 
higher in spinal cord microglia compared to brain microglia (B-C and E-F).  Age-specific 
microglial FMO cytokine controls were used to determine positive gating.  For all 
experiments, N=6/group. Error bars show mean SEM. Abbreviation: SEM, standard 
error of the mean. 
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Figure 5-4.  Microglia phagocytic activity impairment with age. 
A representative dot plot depicting the results of an ex-vivo bead assay to assess 
phagocytosis (A).  Quantification shows that the number of phagocytic microglia (B) and 
the rate of phagocytosis (C) decreased with age.  A representative dot plot depicting the 
results of an ex-vivo beta-amyloid peptide assay to assess phagocytosis (D).  The 
percent (E) and mean fluorescence intensity (F) of beta-amyloid uptake is quantified 
(N=6/group).  Representative ImageStream cytometer microphotographs of aged 
microglia that have phagocytized beads (G).  Age-specific microglial FMO bead and 
peptide controls were used to determine positive gating.  For bead assay experiment, 
N=7/group. Error bars show mean SEM. Abbreviation: SEM, standard error of the 
mean. 
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Figure 5-5.  Expression of phagocytic-regulatory molecules SIRPα/CD47 and the 
effects of acute stimulation on uptake. 
A representative histogram of the phagocytic regulator SIRP-alpha receptor on 
microglia (A) illustrates a relative decrease in spinal cord microglial SIRP-alpha 
expression compared to brain microglia (B).  Whole tissue gene expression of its 
cognate ligand, CD47, a suppressor of phagocytosis, was significantly increased in 
spinal cord (C; N=5/group).  A representative dot plot showing age-related changes in 
brain microglia after PMA/ionomycin stimulation (D).  The percent increase in the 
number of microglia that phagocytize beads (E) and beta-amyloid peptide (F) after 
stimulation is quantified (N=6/group).  The histogram color key is as follows: gray = age-
specific microglia FMO control, red = brain, blue = spinal cord, light shade = young, dark 
shade = aged. Stars indicate the significance by student T-test (*P≤0.05; **P≤0.01). 
Error bars show mean SEM. Abbreviation: SEM, standard error of the mean. 
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Figure 5-6.  Increased blood-CNS barrier permeability in the spinal cord. 
The concentrations of small (sodium fluorescein (400Da)) and large (Evan’s blue 
(70kDa)) tracers depict enhanced vascular permeability in normal spinal cord tissue 
compared to brain (A and B, respectively).  For each tracer experiment, N=9-13/group. 
A representative histogram of intracellular MMP-9 production by microglia (C).  The 
color key is as follows:  black = unstained control, gray = microglial FMO MMP-9 
control, red = brain, blue = spinal cord, light shade = young, dark shade = aged.  
Quantification of mean fluorescence intensity of MMP-9+ microglia shows higher 
expression in the spinal cord (D). Error bars show mean SEM. Abbreviation: SEM, 
standard error of the mean. 
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integrity was largely preserved with age in both regions, spinal cord tissue exhibited 
significantly higher permeability to both tracer molecules (F(1,40)=P<0.0001 and 
F(1,41)=P=0.013, respectively).  Intracellular cytokine staining revealed that spinal cord 
microglia expressed significantly higher levels of the enzyme matrix metalloproteinase-
9, a key player in extracellular matrix remodeling (Figures 5-6C-D, F(1,19)=P=0.005).  
These data suggest that factors originating from microglia are associated with changes 
in CNS vascular integrity and may underlie regional differences in blood-CNS barriers. 
 
Tissue cytokine production in the CNS is profoundly affected by the regional 
environment 
 
Increased exposure to systemic factors in spinal cord may lead to an enhanced 
inflammatory state of cord microglia via enhanced cytokine signaling.  Total cytokine 
protein levels in the young and aged brain and spinal cord were measured using 
multiplex ELISA.  Regional differences were found; many pro-inflammatory cytokines 
were elevated in the spinal cord compared to brain, and remained elevated with age 
(Figure 5-7A).  Total tissue levels of TNF, GM-CSF, IL-12p70 and IL-15 were 
significantly increased (F(1,14)=P<0.01) in the spinal cord, while the concentration of 
two anti-inflammatory cytokines, IL-9 and IL-13, were significantly lower in the  cord 
compared to the brain independent of age (F(1,14)=P<0.01).  Few age differences in 
baseline tissue cytokine levels were observed; however, increased expression of the 
macrophage  
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Figure 5-7.  (Legend on following page) 
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Figure 5-7.  Tissue-level cytokine production in aging brain and spinal cord. 
The concentration of several pro-inflammatory cytokines is elevated in the spinal cord 
compared to the brain.  Conversely, the levels of anti-inflammatory cytokines IL-13 and 
IL-9 are relatively lower in the spinal cord than brain.  A significant interaction between 
aging and region was observed for M-CSF and IL-9. For all experiments, N=5/group.  
Error bars show mean SEM. Abbreviation: SEM, standard error of the mean. 
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survival factor M-CSF and IL-12p40 were found in aged samples compared to young 
(F(1,14)=P<0.05).   
 
 
Discussion 
 
Emerging data suggests the CNS has a unique and significant immunological 
component. As the resident macrophages of the CNS, microglia perform many 
important functions required to maintain CNS homeostasis.  At the core of microglia 
function is the ability to sense changes in the microenvironment via expression of a 
complex functional repertoire of immunological proteins that enable them to react and 
respond to specific environmental stimuli.  Our findings suggest that microglia function 
is highly influenced by both the microenvironment in which they reside and the 
cumulative effects of aging.  At the tissue level, we found that inflammatory cytokines 
are present in significant concentrations throughout the CNS, and differ in their 
expression profile in the brain and spinal cord. Interestingly, pro-inflammatory cytokine 
concentrations were higher in the spinal cord compared to the brain in both young and 
aged animals.  The elevated basal cytokine level in the spinal cord may contribute to the 
higher activated state observed in these microglial populations, especially with age, 
leading to a pro-inflammatory feedback loop that disrupts normal maintenance 
functions.  Despite these findings, age-related diseases of the spinal cord are relatively 
rare compared to those that manifest in the brain, implying that cytokine concentrations 
may not accurately reflect cellular function or pathology.  Reasons for these regional 
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differences may reflect increased cytokine transport, or more broadly, altered blood-
CNS barrier integrity, exposing vulnerable areas to systemic factors.   Importantly, with 
age, microglia in both CNS regions exhibit a marked increase in cell size, granularity, 
mitochondrial activity, ROS and cytokine production, as well as defects in phagocytic 
activity.   
 A growing body of evidence supports the notion that like neurons, 
microglia are highly heterogeneous in form and function.  In a study examining 
heterogeneity in the postnatal maturation of microglia, Scheffel, et al. 340 showed that 
not only do microglia differentially respond to TLR4 and non-TLR challenges, these 
reactive phenotypes differ with time and within circumscribed CNS regions.  Butovsky, 
et al. 217 have provided further evidence of a unique microglia ‘signature’ using array 
profiling at the mRNA and miRNA level, highlighting many differences between 
microglia isolated from various regions of the adult CNS.  We have found that microglia 
from brain and spinal cord can be distinguished by their physical properties (size, 
granularity) and their activation status.  Spinal cord microglia were larger, more 
granular, and expressed higher levels of CD45 and CD11b than brain microglia.  
Regional differences in gene expression of these markers have been previously 
observed in young mice 341.  Although the functional relevance of these proteins on 
microglia is currently not known, it likely reflects enhanced translational efforts indicative 
of a heightened activation state, as evidenced by increased cytokine production 102,342.  
Although standard identification of microglia using flow cytometry relies on CD45int and 
CD11b+, our studies indicate that for spinal and aging microglia in particular, the Ly6C 
antibody may be a useful addition to delineate cell populations when the relative CD45 
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expression levels of peripheral monocytes overlap with that of resident microglia.  
Taken together, these data are consistent with previous work showing region-specific 
increases in oxidative activity and activation markers in white matter and more caudal, 
adult microglia 332,343.  
  Our finding that vascular permeability is greater in the spinal cord than brain may 
help explain regional differences in microglial reactivity and slower recovery after cord 
lesions 325. The structure of the blood-spinal cord barrier (BSCB) is different than the 
blood-brain barrier in that the BSCB has fewer tight- and adherence junction proteins 
317,326.  Earlier studies have shown increased transport of TNF and interferons in the 
spinal cords of healthy mice, compared to brain 344,345.  Schnell et al 325 found that 
mechanical lesions induced substantially greater and more durable barrier breakdown in 
the spinal cord compared to brain. This may result from differing entry dynamics of 
peripheral leukocytes important for repair following injury.  However, our observation 
that MMP-9 production was greater in spinal cord microglia at baseline than in brain 
suggests that active remodeling of the extracellular matrix may also contribute to 
increased leakage 346.  Whether these differences are due to the inherent structural 
features of this barrier or are a detrimental effect of increased microglial activation is not 
known, but likely involve a combination of both.  In a previous study, our laboratory 
failed to find any difference in cerebral blood flow flux or staining intensity of FITC-
dextran and CD31-labeled microvasculature in histological sections of young and aged 
cohorts 347.  However, we cannot rule out that insults that accrue with aging may 
increase the potential for temporary opening of the blood-CNS barrier at selective tissue 
sites.  Taken together, our findings provide clear evidence of regional heterogeneity in 
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microglia activation and highlight the relative leakiness of the blood-spinal cord barrier 
as a potential mechanism.  
 Microglia share many functional and phenotypic similarities to peripheral 
macrophages and have similar surface molecules 78.  Microglia are identified by an 
intermediate level of CD45 expression and CD11b positivity, but our work suggests that 
CD45 levels increase with age, further complicating differentiation of microglial from 
myeloid cells 102.  For example, the relative expression of CD45 and CD11b were 
significantly higher in the spinal cord compared to the brain and spinal cord microglia 
also showed comparably higher up-regulation with age.  These findings suggest that the 
inclusion of Ly6C antibody as a peripheral myeloid cell marker may safeguard against 
mixed populations due to overlapping CD45 expression.  
 Dystrophic microglia in the aging CNS are defined by altered morphology 
including enlarged cell bodies, retraction of fine branches, and cytoplasmic processes 
that appear beady or fragmented 54.  Many of these cellular inclusions contain lipofuscin 
granules with autofluorescent properties.  Similar profiles have been observed in aged 
rodent microglia, and are reminiscent of young healthy microglia activated after injury 
348,349.  We found that aging significantly increased microglial cell size and granularity in 
both the brain and cord.  Importantly, we found that dystrophic (high scatter) and 
ramified (low scatter) populations of microglia coexisted in a similar ratio as was 
reported by Streit et al 54 (data not shown).  These findings demonstrate that flow 
cytometry allows for the simple identification of dystrophic microglia based on their 
physical properties. 
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 Because the CNS has a high-energy demand relative to other tissues, changes 
in mitochondrial function, ATP production, and oxidative stress may contribute to energy 
failure and neurodegenerative disease.  The increase in mitochondrial content/activity 
may reflect deficits in mitophagy secondary to the cellular stress induced by aging. Age-
associated alterations in mitochondrial activity are also associated with increased 
production of reactive oxygen species (ROS) by the mitochondrial respiratory chain 
leading to oxidation of unsaturated fatty acids, proteins, and nucleic acids 350,351.  
Increased intracellular ROS may in turn activate microglia, leading to enhanced 
production of inflammatory mediators and lead to autophagic and lysosomal impairment 
352.  The long lifespan of microglia makes them especially vulnerable to the aggregate 
effects of oxidative stress. We found that microglial ROS and cytokine production 
increased with age.  While the augmented mitochondrial activity found in aged spinal 
cord did not necessarily translate into similar fold-change increases in ROS production, 
other factors such as cell volume or tissue-specific demands may account for this 
discrepancy.  Recent work by Youm YH et al 353 has identified Nlrp3 inflammasome-
mediated production of IL-1β as a critical link between systemic low-grade inflammation, 
innate immune activation, and functional decline in the aging CNS.  Our studies 
demonstrating that the blood-brain barrier remains relatively intact with age suggests 
that the detrimental effects of aging may be intrinsic to the cell and its environment 
rather than a direct result of systemic modulation. 
Deficits in phagocytosis with aging were evident as demonstrated by the reduced 
number of aged microglia that contained physiological (beta-amyloid peptide) and non-
physiological (beads) cargo.  This is consistent with prior studies 354,355. These deficits in 
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clearance have been implicated in the pathogenesis of age-related diseases such as 
Alzheimer’s 356,357.  Aging is associated with reductions in substrate uptake, proteolytic 
capacity, and decreased degradation efficiency of beta-amyloid 358.  Beta-amyloid can 
also trigger microglial production of pro-inflammatory mediators that inhibit phagocytosis 
136,359,360. In this study, we examined basal phagocytic potential of “unstimulated” 
microglia in an effort to understand the normal homeostatic changes that occur with 
age.  To our knowledge, this is the first study to demonstrate phagocytic deficits in aged 
microglia. The increased generation of debris and inflammatory mediators in the aging 
CNS may inhibit mechanisms of microglial phagocytosis. These defects in debris 
clearance could have several consequences including increased glial activation, as 
evidenced by the deposition of amyloid plaques in Alzheimer’s disease 361, increased 
cytokine activation, impaired lysosomal function, and disruption of autophagy 362,363.  
One limitation pertaining to ex-vivo assays is the possibility that the isolation process 
itself may ‘activate’ the cells, and lead to changes in their functional capabilities.  
Interestingly, we found that ex-vivo stimulation by PMA/ionomycin enhanced the rate of 
phagocytic activity in all microglia, albeit to a significantly lesser extent in aged 
microglia.  These results suggest that aged microglia may be less responsive to 
inductive cues and/or more prone to become exhausted from high levels of cellular and 
inflammatory stress 364.  There are several endogenous mechanisms that also control 
phagocytosis.  SIRPα, a receptor found primarily on myeloid cells, binds to its ligand 
CD47 and functions as a regulator of phagocytosis 365,366.  This was consistently down-
regulated with age.  Our results also show that tissue expression of CD47 increased 
with age, which may account for the age-related inhibition of phagocytosis.  Previous 
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studies have shown that down-regulation of CD47 promotes phagocytosis of compact 
myelin by microglia in vitro 365.    It is possible that age-associated increases in CD47 
may serve a compensatory function to prevent unwanted phagocytic removal of 
myelinated axons by dysregulated microglia. Further studies are required to determine 
the therapeutic efficacy of targeting phagocytic pathways in aged microglia. 
In summary, the normal homeostatic functional status of unstimulated microglia 
can be assessed using ex-vivo functional assays.  We found profound regional 
differences in microglia function, demonstrating the importance of the local 
microenvironment to microglial function.  M1-like activation status increased with age in 
nearly all microglial populations, although regional differences were preserved.  Striking 
differences were seen in vascular permeability and cytokine levels in the brain versus 
the spinal cord, with greater potential exposure of spinal cord tissue to systemic factors, 
mirroring the overall increased activation status of microglia in this region.  This work 
provides the first evidence at the cellular level of a functional decline in microglia 
homeostasis with age. 
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Supplemental Figure 5-1.  Gating strategy used for identification of microglia 
using flow cytometry. 
SA1 illustrates the gating strategy used for the definitive identification of microglia (A).  
Using unstained spleen samples for reference, leukocyte gating was determined by 
relative scatter (area) identification.  To eliminate biased protein expression due to 
increased event size (doublet or cell clumping) single cells were gated on based on 
forward scatter (width x height) identification.  Living cells were gated on based on the 
relative exclusion of the viability dye CASE (as determined by FMO).  Microglia were 
subsequently identified based on CD45int CD11b expression.  Lastly, to exclude bone 
marrow-derived macrophage populations, Ly6C+ cells were excluded. 
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Supplemental Figure 5-2.  Age- and region-specific gene expression of TNF. 
SA2 shows RT-PCR analysis of TNF-alpha mRNA in brain and spinal cord tissue with 
age. N=4/group. Error bars show mean SEM. Abbreviation: SEM, standard error of the 
mean. 
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Chapter 6: 
Opposing roles for immune surveillant CD8 T cells in the aging 
central nervous system 
 
Rodney M. Ritzel1, Anita R. Patel, Joshua Crapser, Evan R. Jellison, and Louise D. 
McCullough 
 
 
 
Abstract 
 
Aging is associated with an increase in basal inflammatory processes in the central 
nervous system (CNS) and an overall decline in cognitive function and recovery 
following injury.  Growing evidence suggests that leukocyte recruitment to the CNS is 
also increased with normal aging, but to date, no systematic evaluation of these “age-
associated” leukocytes have been performed.  In this work the effect of aging on CNS 
leukocyte recruitment was examined.  Despite no overt change in global blood-brain 
barrier permeability, aging was associated with an increased number of CD45hi 
leukocytes, primarily composed of conventional CD8+ T cells. These cells were CCR3, 
CCR5, and CXCR3-positive and coincided with age-related increases in the CNS 
production of chemokines known to be involved in T cell recruitment (CCL11, CXCL9, 
CCL5, CXCL10).  CD8 T cells in the aged brain expressed significantly higher levels of 
	   	   	  153	  
the adhesion molecules required for CNS entry, CD11a and CD49d, compared to those 
in the blood.  Intravascular labeling and immunohistology revealed the presence of 
parenchymal CD8+ T cells in several regions of the brain including the choroid plexus 
and meninges.  These cells had an effector/memory (CD44+CD62L-) phenotype and 
expressed markers associated T cell receptor (TCR) activation.  This population of 
CNS-specific CD8 T cells had a similar pattern of TCRvβ family repertoire usage 
suggesting that entry into the CNS is likely stochastic rather than antigen-driven.  
Correlational analyses revealed a positive association between CD8 T cell numbers and 
decreased pro-inflammatory function of microglia.  However, the effects of cerebral 
ischemia and ex-vivo stimulation of these cells dramatically increased production of 
tumor necrosis factor (TNF) and interferon gamma (IFNγ) as well as several 
chemokines associated with neutrophil chemotaxis.  Taken together, we identified a 
novel population of CNS-specific immunosurveillant CD8 T cells that appear to maintain 
microglia homeostasis under normal conditions, but are primed to potentiate 
inflammation and leukocyte recruitment following ischemic brain injury.  These cells 
serve as a hallmark feature of CNS aging and provide an alternative explanation for the 
noted differences in the neuroinflammatory response of young and aged animals. 
 
 
Introduction 
 
Aging is associated with cognitive decline, a heightened risk of neurodegenerative 
disease, and poorer recovery after injury.  As the average life expectancy continues to 
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increase the median age of the population has also increased. People aged 80 and over 
are the fastest growing segment of the population, projected to reach 19.4 million in 
2030 367.  These statistics highlight growing concerns over the burden to the health 
services industry as aging affects all of the organ systems in the body.  The aging 
process exerts profound changes on the nervous and immune systems, which extend 
into nearly all organ systems 368-370. Indeed, the relationship between these two systems 
is bidirectional, and the concept of the CNS as an immune privileged organ is evolving 
371. The brain is under constant immune surveillance by resident microglia and 
trafficking systemic T lymphocytes recruited by the choroid plexus under normal 
conditions 372-374.  These generally cells serve a protective role, as a rapid response 
system to detect damaging agents that disrupt homeostasis.  Although T lymphocytes 
transit the CNS at low numbers in healthy brains, the role of these cells and how it 
changes with age is not well understood 375.  Activated CD4 central memory (Tcm) cells 
reside within human cerebrospinal fluid and circulate in the subarachnoid space and 
ventricular system of the brain and spinal cord 376,377.  Moreover, CD4 effector memory 
(TEM) cells with a TCR repertoire specific to CNS antigen are constitutively present in 
the epithelial layers of the choroid plexus where, at this interface between brain and 
blood, they are poised to act as immunomodulators of aging and senescence 372,378.  
Like neurons, T cells are specified for many unique functions that serve important roles 
in immunity.  For example, Scid mice, which lack functional T cells, show deficits in 
cognitive abilities compared to WT matched mice, implying that T cell functions can 
influence CNS functions whether they reside in the CNS itself or outside in the periphery 
379-381.  Given the functional importance of T cell subsets implicated in several 
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neurological diseases, little is known regarding the role and identity of the lymphocytes 
that traffic throughout the CNS under normal conditions such as aging. 
Surveillance is the process whereby the immune system identifies and eliminates 
cancerous or pre-cancerous cells before they cause harm 382.  Although little is known 
concerning the role of aging on immune surveillance in the CNS, the increase in basal 
inflammatory levels indicative of the phenomenon known as “inflammaging” support the 
notion that the necessity for surveillance may be heightened 55. The low-grade 
inflammatory status of the aged CNS may favor their recruitment, but the critical 
mediators of this phenomenon and the functional role of the immune cell subtypes 
entering the aged brain in steady state remain to be established.  Few studies have 
provided a comprehensive analysis of the peripheral leukocytes present within the aged 
CNS. Stichel and Luebbert (2002)383 showed a significant increase in both CD11c+ 
dendritic cells and CD3+ T cells with wide distribution throughout the brain beginning at 
middle age and increasing with advanced age.  Although CD4 effector memory cells 
have been reported in the choroid plexus of aged mice it is not clear whether these 
populations are confined only to this region.  Studies assessing donor human brain 
tissue have identified the presence of resident CD8+ T cells enriched in white matter 
and regions of blood-brain barrier leakiness 50,384.  These findings indicate that the 
observed changes in leukocyte recruitment in the aging mouse brain likely have 
translational relevance as immune surveillance also occurs in the human CNS, 
however, our current understanding of these cells is still lacking. 
In the present study, we examined for the presence of peripheral leukocytes in the 
aging CNS to further understand the functional relevance of these cells with regard to 
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age-related inflammatory signaling in the normal CNS.  In order to assess this 
possibility, we examined blood brain barrier permeability, evaluated the potential for 
lymphocyte recruitment guidance and response cues, and performed a comprehensive 
phenotypic analysis of cell subsets found in normal CNS.  Lastly, to determine if there 
was a functional consequence of these CNS-specific leukocytes we assessed 
production of inflammatory mediators after ex-vivo stimulation and in an age-relevant 
model of ischemic brain injury. 
 
 
Materials and Methods 
 
Mice/Animals:  C57BL/6J mice of 8-12 wks (young adult) and 18-22 months (aged) of 
age were pair-housed on sawdust bedding in a specific pathogen free facility (light cycle 
12/12 h light/dark). The average weight of the naïve, young mice was 29.6 ± 2.3 grams 
and that of aging mice was 35.7 ± 3.2 grams before sacrifice. All animals had access to 
chow and water ad libitium.   Animal procedures were performed in accordance with 
NIH guidelines for the care and use of laboratory animals and approved by the Animal 
Care Committee of the University of Connecticut Health Center.  Ex-vivo studies were 
performed by an investigator blinded to age. 
 
Tissue Harvesting:  Mice were euthanized, transcardially perfused with 60mL cold, 
sterile PBS, and the brains were harvested.  The olfactory bulb, brainstem, and 
cerebellum were removed.  The brain was then divided along the interhemispheric 
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fissure into two hemispheres and then subsequently rinsed with PBS to remove 
contaminant cells.   
 
Flow cytometry:  Blood was drawn by cardiac puncture with heparinized needles.  Red 
blood cell lysis was achieved by three consecutive 10-minute incubations with Tris-
ammonium chloride (Stem Cell Technologies).  CNS tissue to be analyzed by flow 
cytometry was placed in complete Roswell park memorial institute (RPMI) 1640 (Lonza) 
medium and mechanically and enzymatically digested in collagenase/dispase (1 
mg/mL) and DNAse (10mg/mL; both Roche Diagnostics).  The cell suspension was 
filtered through a 70um filter.  Leukocytes were harvested from the interphase of a 
70%/30% Percoll gradient.  Blood and brain leukocytes were washed and blocked with 
mouse Fc Block (ebioscience) prior to staining with primary antibody-conjugated 
flourophores (see Supplementary Materials Table 1).  For live/dead discrimination, a 
fixable viability dye, CASE-AF350 (Invitrogen), was diluted at 1:300 from a working 
stock of 0.3mg/mL.  Data were acquired on a LSRII using FACsDiva 6.0 (BD 
Biosciences) and analyzed using FlowJo (Treestar Inc.).  No less than 100,000 events 
were recorded for each sample.  Resident microglia were identified as the CD45int 
CD11b+ population, whereas bone marrow-derived leukocytes were identified as 
CD45hi.  Cell-specific fluorescence minus one (FMO) controls were used to determine 
the positivity of each antibody. 
For intracellular cytokine staining, a stock solution of brefeldin A (Sigma) was 
prepared at 20mg/mL in DMSO, and diluted with PBS to obtain a working solution of 
0.5mg/mL.  Mice were euthanized 8 hours after intravenous injection of brefeldin A 
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(250ul).  Leukocytes were collected as described above, and 1ul of GolgiPlug 
containing brefeldin A (BD Biosciences) was added to 800ul complete RPMI.  Cells 
were subsequently stimulated with PBS or Cell Stimulation Cocktail (eBioscience) 
containing PMA/ionomycin and incubated for 4 hours at 37C (5% CO2).  Afterward, 
cells were resuspended in Fc Block, stained for surface antigens and washed in 100ul 
of fixation/permeabilization solution (BD Biosciences) for 20 minutes.  Cells were then 
washed twice in 300ul Permeabilization/Wash buffer (BD Biosciences) and 
resuspended in an intracellular antibody cocktail containing TNF-PE-Cy7, IL-17A-FITC, 
IL-17F-PerCP-eF710, CCL2-PE, CCL5-PE, Granzyme B-Bv510, and IFNγ-PerCP-
Cy5.5 and fixed. 
For detection of reactive oxygen species, leukocytes were incubated with redox-
sensitive CM-H2DCFDA (5uM; Ex/Em: 495/520) fluorogenic cell-permeant dye (Life 
Technologies, Invitrogen).  Cells were incubated for 20min at 37C, washed three times 
with FACS buffer (without NaAz), and then stained for surface markers including CASE.   
To determine TCRvβ usage, we used a mouse vβ TCR screening panel (BD 
Pharmingen) according to the manufacturers instructions.  Briefly, after collecting blood 
and tissue leukocytes each sample was divided into 15 separate FACS tubes and 
stained for the antibody cocktail including one of 15 respective TCRvβ FITC-conjugated 
monoclonal antibodies.  Liver, epididymal adipose, and lung tissue was processed as 
above using percol gradient. 
Phagocytic activity of microglia was performed as described by Ritzel et al 
(2015).  Briefly, fluorescent latex beads (Fluoresbrite Yellow Green (YG) carboxylate 
microspheres; 1um diameter; Polysciences) were added to sorted microglia in a final 
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dilution of 1:100 as described 385. After 1-h incubation at 37 °C, the cells were washed 
three times with FACS buffer, re-suspended in FACS buffer, stained for surface 
markers, and fixed in PFA. 
 
ELISA cytokine measurement:  Plasma and whole tissue brain chemokine levels were 
determined by ELISA (Milliplex Cytokine/Chemokine Assay, EMD Millipore).  In brief, 
mice were euthanized by avertin injection and blood was collected by cardiac puncture 
into heparin-coated syringes.  Samples were centrifuged (13,000g for 10min at 4C) and 
plasma was collected and stored frozen (-80C) until assaying.  Brain hemispheres were 
collected and homogenized in ice-cold lysis buffer containing a protease inhibitor 
cocktail (Roche Diagnositics).  Homogenates were sonicated and centrifuged at 4C for 
15 min at 14,000 rpm, and supernatants were assayed for total protein using a BCA 
protein assay kit (Pierce, Thermo scientific).  Using a standard curve, protein 
concentration was determined and 100ug of each sample was loaded into each well in 
duplicate.  Samples were assayed according to the manufacturer’s instructions using a 
Luminex 200 (Luminex Corporation, Austin, TX, USA) magnetic bead array platform.  
Inter-and intra-assay coefficients of variation were than less than 10%. 
 
Intravascular staining and cell isolation:  A total of 7ug anti-CD3e-PE was injected 
i.v.  At 4 minutes after injection, the animals were sacrificed, and perfused with 40mL 
PBS.  Blood was taken by cardiac puncture prior to perfusion to confirm injection 
efficiency.  The brain hemispheres were harvested within 3 minutes, washed with PBS 
to remove free antibody, and leukocytes were isolated as described above.  Leukocytes 
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were then stained with CD45-eF450, CD11b-AF700, CD3e-APCeF780, CD4-APC, 
CD8-PerCPCy5.5 and CASE.  Co-labeling was used determine the percentage of peri-
vascular/parenchymal (CD3e-PE-/CD3e-APCeF780+) versus intravascular cells (CD3e-
PE+/CD3e-APCeF780+). 
 
Immunohistochemistry:  Following PBS perfusion brains were harvested and 
embedded in an optimal cutting temperature (OCT) embedding solution and 
subsequently frozen on dry ice and stored at -80ºC. Brains were sectioned on a 
77200187 Issue 5 Thermo cryostat at a thickness of 10 µm at a temperature of 17ºC. 
These sections were mounted on charged slides and stored at -20ºC until use.  After 
being brought to room temperature the sections were fixed with 4% paraformaldehyde 
(PFA) for 10 minutes, washed and then blocked in 0.1 mol/L phosphate buffer with 0.3% 
Triton X-100 (Sigma) and 10% donkey serum for one hour. Primary antibodies rat anti-
CD8 (Abcam, 1:200), rabbit anti-myelin basic protein (Abcam, 1:200), mouse anti-NeuN 
(Millipore, 1:200) and rabbit anti-CD3 (Abcam, 1:100) were added and incubated 
overnight at 4ºC. These sections were washed and secondary antibodies Alexa Flour 
488 anti-rat (Invitrogen, 1:1000), Alexa Flour 594 anti-rabbit (Life Technologies, 1:1000), 
and Alexa Flour 594 anti-mouse (Invitrogen, 1:1000) as well as conjugated antibodies 
Texas Red Lycopersicon Esculentum (Tomato) Lectin (Vector, 1:200), mouse anti-glial 
fibrillary acidic protein (GFAP)-Cy3 (Sigma, 1:200) and 4′,6-diamidino-2-phenylindole, 
dihydrochloride (DAPI, Invitrogen, 1:1000) were added and incubated at room 
temperature for one hour, washed and coverslipped for viewing. Images were acquired 
with a Zeiss Axiovert microscope (Carl Zeiss, Oberkochen, Germany) using a X-Cite 
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120Q fluorescence illumination system (Lumen Dynamics Group Inc, Mississauga, ON, 
Canada) and Zeiss image acquisition software (Zeiss LSM 510). 
 
Middle Cerebral Artery Occlusion (MCAO) model of ischemic stroke:  Cerebral 
ischemia was induced by 90 min of reversible middle cerebral artery occlusion under 
isoflurane anesthesia as previously described 206. Rectal temperatures were maintained 
at approximately 37 °C during surgery and ischemia with an automated temperature 
control feedback system. A midline ventral neck incision was made, and unilateral 
MCAO was performed by inserting a 0.23mm silicone-coated suture (Doccol Corp, 
Redlands, CA, USA) into the right internal carotid artery 6 mm from the internal 
carotid/pterygopalatine artery bifurcation via an external carotid artery stump. Following 
reperfusion mice were sacrificed at 4 hours after reperfusion. Sham-operated animals 
underwent the same surgical procedure, but the suture was not advanced into the 
internal carotid artery. 
 
Statistical Analyses:  Data from individual experiments are presented as mean ± SEM 
and compared with Student's t-test (GraphPad Prism Software Inc, San Diego, CA, 
USA).  Multiple comparisons were assessed by one-way or two-way ANOVA analysis 
with Tukey post-hoc correction.  Correlation analyses were performed using Pearson’s 
correlation.  p < 0.05 was considered statistically significant.   
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Results 
 
Aging increases the number of peripheral leukocytes in the CNS 
 
To confirm that aging increases leukocyte trafficking in the CNS we quantified the 
absolute number of bone marrow-derived cells present in each tissue using the gating 
strategy shown in Supplemental Figure 6-1A.  The number of CD45hi leukocytes was 
significantly increased in the aged brain (Figure 6-1A).  Absolute cell counts revealed a 
nearly three-fold increase in peripheral cells in aged brain (Figure 6-1B, p<0.0001).  
Similar increases were also observed in the aged spinal cord (Supplemental Figure 6-
2A).  T cells composed the majority of these age-associated leukocytes, wherein the 
CD8 subset was more numerous than the CD4 subset (Figure 6-1C-E, p<0.001).  
These were identified as conventional TCR α/β, CD8 α/β T cells (data not shown). The 
results show that T lymphocyte trafficking into the CNS is more permissive with age.   
 
Age-related chemokine production is associated with active recruitment of CD8 T 
cells into the aging brain  
 
To determine whether CD8 T cell recruitment to the aging brain could result from a 
directed, homeostatic process rather than an indirect result of injury, we examined 
protein expression of known T cell chemokines.  RANTES (CCL5), Eotaxin (CCL11), 
MIG (CXCL9), and IP-10 (CXCL10) concentrations were all significantly upregulated in  
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Figure 6-1.  CD8 T cell recruitment in the aging CNS. 
A representative dot plot depicts an increase in CD45hi peripheral leukocytes in one 
aged brain hemisphere compared to young (A).  The absolute number of CD45hi 
peripheral leukocytes is quantified (B).  A pie chart shows the composition of peripheral 
leukocytes in the aged brain (C).  A representative dot plot shows T cell subsets in the 
aged brain (D).  The percentage of T cell subsets is quantified (E).  Error bars show 
mean SEM.  Abbreviation:  SEM standard error of mean.  *p<0.05; **p<0.01; ***p<0.001 
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Figure 6-2.  T cell chemokine production in the brain with age. 
Brain concentrations of RANTES/CCL5 (A), Eotaxin/CCL11 (B), MIG/CXCL9 (C), IP-
10/CXCL10 (D) are quantified in young and aged mice.  Plasma concentrations of these 
respective chemokines (E, F, G, and H) are quantified.  Error bars show mean SEM.  
Abbreviation:  SEM standard error of mean.  *p<0.05; **p<0.01; ***p<0.001 
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the brain with age by ELISA (Figure 6-2A-D).  Levels of these chemokines were 
similarly increased in aged plasma (Figure 6-2E-H), suggesting that gradient levels are 
accessible to circulating T cells.  Surface expression of chemokine receptors to these 
respective chemokines was then assessed on both blood and brain CD8 T cells.  An 
increase in expression of these chemokine receptors was found on blood CD8 T cells 
with age (Figure 6-3A-H).  Interestingly, CD8 T cells in the aged brain expressed lower 
levels of these receptors relative to those in circulation, and levels were comparable to 
that found in young blood.  These results suggest that the aged brain is a source of 
chemokine cues required for active T cell recruitment, and after migrating to the CNS 
then down-regulate expression of their chemokine receptors in order to establish 
residence. 
 
CD8 T cells are present in perivascular and parenchymal regions throughout the 
aging CNS 
 
T cell extravasation across the endothelium involves a series of adhesion events that 
include attachment, rolling, and transmigration.  Because ICAM-1 expression is reported 
to be increased in aged brain vasculature 386,387, we examined CD8 T cell expression of 
CD11a (LFA1) and CD49d (VLA4), adhesion molecules required for T cell entry into 
peripheral tissues.  Figure 6-4A-B shows that CD11a and CD49d expression were 
dramatically increased on brain CD8 T cells compared to those in the blood (N=5, 
p<0.0001 and p<0.01, respectively).  Vessel capture of T cells implies subsequent 
extravasation into perivascular and parenchymal CNS tissue.  Using tomato-lectin  
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Figure 6-3.  CD8 T cell chemokine receptor expression with age. 
Representative histograms show higher expression of CCR5 (A), CCR3 (B), CCR6 (C), 
and CXCR3 (D) on circulating CD8 T cells with age, and down-regulation in the brain.  
Young blood (dotted red), aged blood (solid red), and aged brain (blue) CD8 T cells are 
depicted.  The mean fluorescence intensity for each of the respective chemokine 
receptors was quantified (E, F, G, and H; N=5/group).  Cell-specific FMO controls were 
used to determine positive gating (shaded gray).  Error bars show mean SEM.  
Abbreviation:  SEM standard error of mean, MFI mean fluorescence intensity.  *p<0.05; 
**p<0.01; ***p<0.001 
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Figure 6-4.  Extravasation of CD8 T cells into the aged brain. 
A representative histogram depicts higher expression of the adhesion molecules CD11a 
(A) and CD49d (B) on CD8 T cells in the aged brain (blue) relative to those in the blood 
(red; N=5/group). Immunohistochemistry shows the presence of CD8-positive cells 
(green) outside of lectin-positive (red) blood vessels (C).  A representative dot plot from 
the Intravascular labeling experiment  shows the absence of injected-CD3+ antibody on 
CD8 T cells in the aged brain (D).  The percentage of intravascular-labeled CD3+ CD8 
T cells was quantified in the aged brain and blood (for control).  For the intravascular 
labeling experiment, N= 8/group.  Cell-specific FMO controls were used to determine 
positive gating (shaded gray).  Error bars show mean SEM.  Abbreviation:  SEM 
standard error of mean.  *p<0.05; **p<0.01; ***p<0.001 
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immunohistochemistry, we identified the putative presence of CD8 T cells outside of 
lectin-positive lumen of vessels (Figure 6-4C).  To confirm that T cells resided in the 
parenchymal tissue, and were not adherent to the brain endothelium, we performed an 
injection labeling experiment as previously described 388,389.  All circulating and vessel-
associated cells bound to transcardially injected PE-conjugated CD3e antibody, 
processed for leukocyte collection, and subsequently stained with APCeF780-
conjugated CD3e antibody.  Compared to an injection labeling efficiency of ~98% for all 
blood CD3e-injected+CD8 T cells, only 7.7±5% of aged brain CD8 T cells were positive 
for CD3e-injected antibody, suggesting these cells are located outside of the vascular 
network and in the parenchyma or perivascular spaces (Figure 6-4D-E).  
Immunohistology revealed the presence of CD3+CD8+ T cells in circumventricular 
organs (choroid plexus and meninges) and most gray and white matter regions (cortex, 
striatum, corpus collosum) throughout the anterior-posterior axis of the brain (Figure 6-
5A-B).  Further, we found that these cells were often associated with astrocytes, 
although the precise nature of this association is unknown (Figure 6-5C).   
 
Age-related, CNS-specific CD8 T cells have memory/effector phenotype and 
expression markers of T cell-receptor activation  
 
The trafficking of T cells into CNS tissues is thought to occur following antigenic 
presentation in draining lymph nodes by professional antigen-presenting cells.  Antigen-
experienced memory T cell subsets are defined by CD44+CD62L+ (Central Memory, 
TCM) and CD44+CD62L- (Effector Memory, TEM) expression, whereas naïve T cells are  
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Figure 6-5.  Histological assessment of CD8 T cells in the aged brain. 
Representative 10um-thick brain tissue sections illustrating the presence of CD3+CD8+ 
T cells in the aged brain, meninges, and choroid plexus (A).  CD8+ T cells were found 
throughout the anterior-posterior axis of the brain, including the striatum, cortex, and 
corpus collosum (B) and in association with activated astrocytes (C). .  Abbreviation:  
DAPI 4’,6-diamidino-2-phenylindole, MBP myelin basic protein, NeuN neuronal nuclei, 
GFAP glial fibrillary acidic protein. 
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largely negative for the activation marker CD44 (Roberts AD et al 2004).  Applying this 
paradigm to CD8 T cells in the aging brain we found that the vast majority (87±4%) of all 
CNS-specific CD8 T cells have an effector memory phenotype (N=5), compared to just 
9±4% of blood CD8 T cells (Figure 6-6A-B).  A similar percentage of T cells with 
effector memory phenotype was observed in young brains, despite the fact that T cells 
were found in significantly lower abundance.  To determine the general activation state 
of CNS-specific CD8 TEM cells we probed these cells with known markers of T cell 
activation.  The early activation and tissue-retention marker, CD69, was highly 
upregulated on CNS-specific CD8 T cells compared to those in the blood (Figure 6-6C, 
N=5, p<0.001).  Expression of programmed death-1 (PD-1) receptor, which is 
upregulated on activated T cells, was also dramatically increased on nearly all CNS-
specific T cells compared CD8 T cells in aged blood (Figure 6-6D, p<0.0001), implying 
the presence of widespread T cell activation in the aged brain.  Expression of the 
resident memory marker alpha E integrin CD103 was also found on a significant fraction 
of these cells (Figure 6-6E).  The following data suggest that a pool of activated, 
antigen-experienced memory effector CD8 T cells are constitutively present throughout 
adult life in the CNS. 
 
Age-related recruitment of CNS-specific CD8 T cells is mostly stochastic 
 
To determine if CNS-specific CD8 T cells were responding to antigenic signals present 
in the aging CNS, CD8 T cells in the blood, CNS, liver, adipose, and lung were 
screened for TCRvβ usage to determine T cell clonality in tertiary tissues.  No  
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Figure 6-6.  CNS-specific CD8 T cells have resident and effector memory 
phenotypes. 
A representative dot plot shows effector memory phenotype of CD8 T cells in the aged 
brain and central memory phenotype of CD8 T cells in the aged blood (A).  The 
percentage of CD8 T cells with effector memory phenotype (CD44hiCD62lo) was 
quantified (B).  Representative histograms depict significant expression of the activation 
markers CD69 (C) and PD-1 (D) in the brain (blue) relative to blood (red), as well as the 
resident memory marker CD103 (E).  For all experiments, N= 5-6/group.  Cell-specific 
FMO controls were used to determine positive gating (shaded gray).  Error bars show 
mean SEM.  Abbreviation:  SEM standard error of mean.  *p<0.05; **p<0.01; ***p<0.001 
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Figure 6-7.  Characterization of CD8 T cell receptor v beta usage in the aged brain. 
A mouse vβ TCR screening panel containing 15 FITC-conjugated monoclonal 
antibodies was used to assess TCR vβ usage in the blood and brain of aged mice.  The 
mean percentage for each of the 15 subfamilies of T cell receptor vβ (A). No differences 
were found between groups (N= 11/group).  Cell-specific FMO controls were used to 
determine positive gating. Error bars show mean SEM.  Abbreviation:  SEM standard 
error of mean. 
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differences in TCRvβ usage between CNS-specific CD8 T cells and their blood 
counterparts was found for any of the 15 TCRvβ families (Figure 6-7A).  Based on the 
absence of major clonal expansions in the CNS, these results suggest that CD8 T cell 
entry into the aged brain is largely random, rather than antigen-driven.   
 
Increased immune surveillance by CD8 T cells in the aging brain is associated 
with healthier microglial function 
 
We investigated the functional role of CNS-specific CD8 T cells indirectly by correlating 
the absolute number in each brain with the activation status of microglia in that brain.  
Correlation analyses revealed that aged brains with greater numbers of CNS-specific 
CD8 T cells had significantly more microglia (Figure 6-8A, p<0.05), indicating that these 
cells may promote microglia survival or prevent microglial death.  Brains that contained 
large numbers of CNS-specific CD8 T cells were also associated with smaller sized 
microglia relative to brains with fewer CD8 T cells (Figure 6-8B, p<0.05), indicative of a 
more ramified, resting morphology.  Functionally, higher numbers of T cells were 
associated with increased microglia phagocytosis (Figure 6-8D, p<0.001) and 
decreased TNF production (Figure 6-8C, p<0.05).  These data imply that CNS-specific 
CD8 T cells promote an anti-inflammatory, injury-resolving microglia phenotype in the 
aged brain. 
 
Basal and stimulus-driven production of cytokines and chemokines associated 
with neutrophil chemotaxis following ischemic stroke 
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Figure 6-8.  Correlational analyses of CNS-specific CD8 T cell counts and 
microglia function in the aged brain. 
Correlation analysis between CD8 T cell count and microglia count (A, p=0.0125 and 
r=0.534), forward scatter/cell size (B, p=0.0421 and r=-0.5488), percentage TNF-
positive (C, p=0.0105 and r=-0.7616), and percentage bead-positive phagocytic (D, 
p=0.0003 and r=0.6945). For all experiments, N= 10-22/group.  Cell-specific FMO 
controls were used to determine positive gating. Abbreviation: TNF tumor necrosis 
factor. 
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T cells are polarized to effector memory cells following TCR reactivation to selected 
antigenic stimuli.  The effector function of these cells is largely specified by cytokine 
production.  An in vivo brefeldin protocol was used to measure cytokine production in 
CNS-specific CD8 T cells as in 390.  Cytokines commonly associated with CD8 T cell 
pro-inflammatory responses (TNF and IFNγ) were basally produced at significant levels 
(Figure 6-9A-C), whereas granzyme B was not expressed under any conditions 
(Supplemental Figure 6-3A).  Both the number and relative expression level of TNF 
and IFNγ were significantly increased after stimulation in CNS-specific CD8 T cells 
compared to those in blood (Figure 6-9D-F, p<0.001).  Interestingly, basal production of 
IL-17A and IL-17F was observed in CNS-specific CD8 T cells but not in blood or spleen 
(Figure 6-10D-I).  The mean fluorescence intensities of IL-17A and IL-17F were 
significantly increased in CNS-specific CD8 T cells after stimulation (Figure 6-10F and 
6-10I, p<0.05 and p<0.01, respectively). Given the prominent role of IL-17 in neutrophil 
chemotaxis we assessed these cells for the heightened production of other chemokines.  
CCL2 and CCL5 production by CNS-specific CD8 T cells was significantly higher at 
baseline and after stimulation compared to those in the blood (Figure 6-9C and 6-9F, 
p<0.001; and Figure 6-10A-C, p<0.001).  These data suggest that CNS-specific T cells 
in the aged CNS are a rich source of pro-inflammatory cytokines, likely contributing to 
the steady increase in overall levels that occurs with advanced age.  CNS-specific CD8 
T cells appear to be significantly more primed to produce higher levels of pro-
inflammatory cytokines and chemokines involved in neutrophil chemotaxis following 
activation.  Next we determined whether these cells were similarly responsive to brain 
injury.  We tested this in an experimental model of ischemic stroke, as this is a disease  
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Figure 9.  PMA/ionomycin-induced cytokine production of CD8 T cells in the aged 
brain. 
Representative histograms show CD8 T cell expression of TNF (A), IFNγ (B), and CCL2 
(C) in blood (solid blue) and brain (solid red) and after stimulation (dotted). The 
respective mean fluorescence intensities (D, E, F) were quantified.  For all experiments, 
N= 4-10/group.  Cell-specific FMO controls were used to determine positive gating 
(shaded gray).  Error bars show mean SEM.  Abbreviation:  SEM standard error of 
mean, MFI mean fluorescence intensity, a.u.i. arbitrary units of intensity, TNF tumor 
necrosis factor, IFNγ interferon gamma, CCL2 monocyte chemoattractant protein-1.  
*p<0.05; **p<0.01; ***p<0.001 
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Figure 6-10.  PMA/ionomycin-induced production of neutrophil chemokines by 
CD8 T cells in the aged brain. 
Representative histograms show CD8 T cell expression of CCL5 (A), IL-17A (D), and IL-
17F (G) in blood (solid blue) and brain (solid red) and after stimulation (dotted).  The 
respective percentages (B, E, H) and mean fluorescence intensities (C, F, I) were 
quantified.  For all experiments, N= 4-10/group.  Cell-specific FMO controls were used 
to determine positive gating (shaded gray).  Error bars show mean SEM.  Abbreviation:  
SEM standard error of mean, MFI mean fluorescence intensity, a.u.i. arbitrary units of 
intensity.  *p<0.05; **p<0.01; ***p<0.001 
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Figure 6-11.  (Legend on following page) 
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Figure 6-11.  Acute stimulation of CD8 T cells in an age-relevant model of cerebral 
ischemia. 
Aged mice were subject to 60 minutes of occlusion followed by 2 hours of reperfusion 
and 1 hour ex-vivo stimulation by PMA/ionomycin.  CD8 T cells from the ischemic 
hemisphere (ipsilateral) were compared to those in the contralateral hemisphere for 
internal control.  A representative zebra plot shows reactive oxygen species levels in 
CD8 T cells after stroke as measured by CM-H2DCFDA (A) and quantification of mean 
fluorescence intensity (B).  A representative dot plot shows intracellular production of 
TNF (C) and the percentages quantified (D).  A representative dot plot depicts a stroke-
induced increase in CCL2 production by CD8 T cells in the aged brain (E).  The 
percentages were quantified (F).  For all experiments, N= 4/group.  Cell-specific FMO 
controls were used to determine positive gating.  Error bars show mean SEM.  
Abbreviation:  SEM standard error of mean, SSC side scatter intensity, MFI mean 
fluorescence intensity, CM-H2DCFDA 5-(and-6)-chloromethyl-2’,7’-
dichlorodihydrofluorescein diacetate, acetyl ester, TNF tumor necrosis factor, CCL2 
monocyte chemoattractant protein-1.  *p<0.05; **p<0.01; ***p<0.001 
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that mainly affects the aging population.  Cytokine production was assessed at 2 hours 
post-reperfusion following 60 minutes of occlusion.  Reactive oxygen species 
generation was significantly increased in CD8 T cells subjected to ischemia compared 
to those in the control contralateral hemisphere, as evidenced by CM-H2DCFDA 
staining (Figure 6-11A-B, p<0.05).  The percentage of TNF- and CCL2-positive CD8 T 
cells was also increased in ischemic hemisphere compared to control (Figure 6-11C-F, 
p<0.05 and p<0.01, respectively).  These data suggest that activated CNS-specific CD8 
T cells contribute to the age-related exacerbation of acute ischemic brain injury by 
amplifying production of pro-inflammatory cytokines and promoting recruitment of 
peripheral leukocytes.   
 
 
Discussion 
 
This work has identified a novel population of immune surveillant CD8 T cells in the 
CNS that have opposing roles in health and disease.  The present study has added to 
previous findings confirming that immune privilege in the aging CNS is compromised 
and more permissive to T cell entry.  We base this observation on several criteria: 1) 
increased production of T cell chemokines, 2) expression of adhesion molecules, 3) 
extravasation into perivascular and parenchymal regions, 4) activated effector memory 
phenotype, 5) presence alters microglia function, and 6) primed to elicit strong cytokine 
and chemokine responses after brain injury.  These cells have a phenotype indicative of 
resident memory cells (CD44hi CD62L- CD11a+ CD69+ CD103+/-).  To our knowledge, 
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this is the first study to systematically characterize CD8 T cells in the normal aging CNS 
and identify a population of CNS-specific T cells with resident memory phenotype and 
the potential to influence the neuroimmunological landscape. 
We have shown that aging increases production of T cell chemokine signals 
originating from the brain, providing gradient cues for the directed migration of 
circulating T cells.  Moreover, our findings support other studies that have shown aging 
to increase chemokine receptor expression on T cells and the chemotactic response to 
these cues 391-394. The expression of chemokines is generally associated with increased 
microglia activation in aging mice, suggesting that chemokines may contribute to 
decreased brain function that occurs during normal aging.  Two of these chemokines, 
Eotaxin and IP-10, have been recently described as biomarkers for neurodegenerative 
disease and aging 395,396.  Systemic administration of eotaxin (CCL11) in young mice 
has been shown to decrease neurogenesis and induce defects in learning and behavior 
397. Chemokines may also play an important role in injury repair as several chemokines 
have been shown to be essential for the attraction, differentiation, survival, and cytokine 
production of stem cells 398.  It remains to be seen whether immune surveillance can be 
abolished using a chemokine blockade and what those effects would have on glial 
function and cognitive status. 
Recent evidence suggests that locoregional leakiness in the hippocampus 
increases with age 51.  Elahy M et al (2015) 399 have shown that blood-brain barrier tight 
junction proteins are down-regulated in the cortex and hippocampus with age resulting 
in regional neuroinflammation, but not leukocyte infiltration.  Because sites of leukocyte 
infiltration do not necessarily correlate with the areas showing the most leakage, it 
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appears more likely that leukocytes enter the CNS via a specified, active process of 
extravasation 400.  Indeed, we found that CNS-specific CD8 T cells expressed high 
levels of the integrins CD11a and CD49d, two adhesion molecules required for entry 
into tertiary tissues 401.  Because endothelial-ICAM expression has been shown to be 
enhanced with age 387, we evaluated the potential for these cells to be adherent to 
vessels.  We discovered that the majority of CNS-specific CD8 T cells were not 
associated with the vascular lumen.  In fact, CNS-specific CD8 T cells were largely 
found to have extravasated beyond the vascular lumen into many parenchymal regions 
across the CNS.  The presence of CNS-specific CD8 T cells in the CNS parenchyma 
underscores their potential importance to CNS function. 
The present study has demonstrated that the normal aging brain contains greater 
numbers of CD8 than CD4 T cells.  A recent study on post-mortem human tissue 
suggests that CD8 T cells are more enriched in the corpus collosum compared to 
peripheral blood 384. The authors noted the distribution of these cells to the perivascular 
space and parenchyma.  The ratio of nearly 3.5:1 of CD8-to-CD4 T cells in the normal 
aged CNS tissue is intriguing given that the reciprocal ratio is found in cerebrospinal 
fluid and in the choroid plexus 376,402,403.  The presence of CD8 T cells in the CNS 
parenchyma suggests they interact with neurons and glial to serve an effector role 
rather than as sentinels at the interface between the blood and the cerebrospinal fluid.  
CD8 T cells have received comparably less attention than their CD4 counterparts with 
regard to CNS disease and aging.  This is partly due to their narrowly defined role in 
anti-viral responses.  Yet, emerging data suggests that CD8 T cells may play more 
diverse roles in disease settings than previously considered. Mounting evidence 
	   	   	  183	  
supports a role for CD8-mediated immune surveillance in peripheral tissues as part of 
the body’s normal defense against cancer and viral infection 382.  The prevalence of 
pathogenic and oncogenic insults increases with age, triggering the induction of intrinsic 
defense mechanisms such as cell death signaling and senescence.  Naturally extrinsic 
mechanisms evolved that alert the immune system to eliminate these cells to prevent 
further bystander damage.  One mechanism through which this occurs is via immune 
surveillance of tissue-patrolling CD8 T cells.  These cells specify elimination of 
unhealthy cells that increase presentation of non-self peptide.  The role of immune 
surveillance in aging individuals and like-wise the effect of aging on the efficacy of 
immune surveillance is understudied and warrants further investigation given the 
relationship between aging and disease. 
CD8 T cell-astrocyte interactions have also received growing attention 404,405.  
Functional evidence that CD8 T cells are prime candidates for immune surveillance of 
the CNS is based on the exquisitely specific destruction of transgenic astrocytes 
expressing MHCI-restricted hemagglutinin 406.  In this study, CD8 T cell-mediated 
removal of antigen-containing astrocytes occurred in absence of leukocyte infiltration or 
bystander damage to oligodendrocytes and neurons.  Moreover, OVA-expressing 
oligodendrocytes elicit the proliferation and effector memory conversion of responding 
OT-1 T cells in healthy mice without infiltrating the CNS, indicating that antigen 
sampling is performed by CD8 T cells under steady state conditions 290.  Interestingly, 
the authors found that neuroinflammation augmented the level of antigen sampling and 
led to the accumulation of OT-1 T cells in the inflamed brain.  Thus, it is increasingly 
evident that CD8 T cells have the capacity to mediate responses against CNS antigens 
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407. While the age-related increase in neuroinflammation likely promotes the recruitment 
of immune surveillant CD8 T cells, how they impact CNS function is poorly understood.  
Tissue-resident memory CD8 T cells (TRM) provide superior protection against viral 
reactivation compared to the circulating memory T cell pool 408,409.  The increased 
presence of these cells in the aged CNS may reflect an evolutionary need to generate a 
rapid response to control senescent transformation of cells and/or prevent reactivation 
of latent neurotropic viruses.  
The role of immunosurveillance as a defense mechanism that safeguards the 
functional integrity of tissues implies that it is an adaptive response to an environment 
under constant insult.  Normal aging is associated with deficits in microglia phagocytosis 
and increased expression pro-inflammatory mediators 385.  We demonstrated that the 
increased presence of CNS-specific CD8 T cells in older brains was associated with an 
attenuation of TNF production and enhanced phagocytic activity by microglia.  Although 
causality cannot be proven, the effects of CD8 T cells on microglia need not occur via 
direction cell-cell interaction.  As well, while T cells are generally associated with CNS 
injury, several studies have that T cells can enter the brain and not cause glial 
pathology 287.  Furthermore, emerging data indicates that T cells may function to 
support learning and memory under normal physiological conditions 379.  It is possible 
that by eliminating nearby senescent cells CD8 T cells serve to attenuate age-related 
neuroinflammation, thereby indirectly preventing the chronic activation of microglia.   
Antigen-specific CD8 memory T cells remain at stable levels in peripheral tissues 
for prolonged periods of time in the complete absence of antigen by cytokine-driven 
homeostatic proliferation 410-412.  Such resident memory cells can enter peripheral 
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tissues and form the front line of defense against reinfection, but become dependent on 
the local milieu for function and survival 413.  Our findings indicate that CNS-specific 
CD8 T cells are not of central memory phenotype, but rather represent a unique subset 
of effector memory cells.   As TEM cells, CNS-specific CD8 T cells have remarkable 
effector function, but low proliferative potential compared to TCM 414.  Unpublished work 
from our laboratory also supports the notion that these cells are not mitotically active 
(data not shown).  These findings suggest that CNS-specific CD8 T cells are poised to 
provide immune surveillance in peripheral tissues. 
The question remains whether TCR activation precedes the migration of CD8 T 
cells into the CNS, or whether activation occurs in situ.  Our finding that CD69, an early 
activation marker, and PD-1 expression are induced in CNS-specific CD8 (and CD4) T 
cells and not circulating T cells, suggests that the putative TCR triggering event occurs 
primarily in situ.  However, it is possible CD8 T cells are primed and/or re-activated in 
the cervical lymph nodes, as some degree of prior activation likely occurs at the level of 
the blood-CNS barrier interface, enabling the expression of adhesion molecules 
required for entry. 
Given the lack of stereotypical anti-viral responses and recent evidence showing 
clonal expansion of CNS antigen-specific CD4 T cells in the choroid plexus of aged 
mice, we hypothesized that CNS-specific CD8 T cell activation is similarly induced by 
CNS antigen.  However, we reported relatively little clonal expansion of TCRvβ subsets 
in the aged CNS as evidenced by equilibrium in TCRvβ usage between those in the 
CNS and other non-lymphoid tissues.  Thus, our data argue that their migration into the 
CNS is stochastic and not antigen-driven. Consistent with our findings, studies using 
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OVA-specific T cells have shown that CNS-irrelevant T cells recognizing non-
mammalian antigen also have the capacity to enter the CNS 287.  Similarly, intracranial 
injection of dendritic cells loaded with OVA peptide resulted in T cell priming in 
peripheral lymphoid organs and the subsequent infiltration and persistence of OT-1 T 
cells into the brain for at least 30 days 413.  However, recent findings by Baruch et al 
(2014)415 have elegantly demonstrated that splenic CD4 T cells of mice immunized with 
spinal cord homogenate had a similar TCRβ repertoire composition as CD4 T cells in 
the aged choroid plexus. Because the age-related accumulation of CD8 memory cells 
described in our study represent a naturally occurring population of CNS-specific T 
cells, it may stand as a better model for understanding the biology of this subset of cells.  
Taken together, migration of effector memory CD8 T cells into the aged CNS does not 
require stimulation by CNS antigen, although deeper sequencing of the T cell receptor 
repertoire might be a useful approach in determining the antigenic specificity of these 
cells. 
Memory T cells traffic into inflamed tissues where they can exert effector 
functions permitting they receive the necessary antigenic signals.  Although not reported 
in this study, we believe it is important to note that CNS-specific CD4 T cells shared 
many of the same characteristics as CNS-specific CD8 T cells, including effector 
phenotype and IL-17A expression.  These findings illustrate that while there appears to 
be a select preference for CD8 T cells to migrate into the CNS, the cues and 
mechanisms underlying T cell recruitment are not exclusively CD8-mediated.  Although 
IL-17-expressing CD4 T cells have been well studied in the context of autoimmune 
disease, less is known regarding the role of their CD8 counterparts, or Tc17 cells.  
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Human Tc17 cells have recently been described in healthy individuals 416.  Increased 
numbers of Tc17 are detectable in cerebrospinal fluid (CSF) from patients with early-
stage MS, suggesting their potential contribution to disease progression in human 417-
419. Recent work has shown that the developmental pathways of Tc17 and CTL are 
mutually exclusive; with Tc17 cells displaying greatly suppressed cytotoxic function and 
low levels of CTL markers granzyme B and IFNγ 420.  Similarly, CD8 T cells found in the 
corpus collosum of older individuals exhibited low levels of cytolytic enzymes 384.  
Because CTL CD8 T cells have been shown to kill neurons via Fas Ligand and perforin 
cell death pathways in vitro, the lack of these effector molecules on CNS-specific CD8 T 
cells does not support a neurotoxic role 421.  Yet, at sites of inflammation IL-17 functions 
by inducing the expression of IL-1β, IL-6, and TNF by many cells and has an inhibitory 
effect on neurogenesis.  In addition, IL-17 promotes the induction of chemokines 
important for neutrophil recruitment.  The role of IL-17 in the aging CNS requires further 
investigation. 
We demonstrated that upon activation by either PMA/ionomycin stimulation or 
ischemic brain injury, CNS-specific CD8 T cells in aged brains are prone to highly 
volatile responses that include the enhanced production of reactive oxygen species, 
TNF, and IFNγ, as well several chemokines involved in granulocyte recruitment.  These 
cells may therefore predispose the aged brain to overreact to stimuli, further 
exaggerating the inflammatory response and altering the context of injury via the 
recruitment of injury-causing neutrophils.  This is in contrast to that of the infiltrating 
CD8 T cell population, which is involved in the delayed response to ischemia during the 
recovery period.  Indeed, the inflammatory milieu and leukocyte response in the 
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ischemic brain is dramatically different in older mice 422-426.  Furthermore, these 
exaggerated immune responses are tightly linked to worse outcomes in aged mice 
427,428.  For example, unpublished data from our laboratory found that neutrophils are the 
predominant leukocyte in the ischemic brain of aged mice, whereas monocytes largely 
comprise the infiltrating population in young mice.  Neutrophils contribute to neuronal 
injury and blood-brain barrier breakdown through the release of oxidative stress signals 
and matrix metalloproteinases, respectively 429,430.  Whether stroke-induced activation of 
CNS-specific CD8 T cells results in the biased recruitment of neutrophils in the aged 
brain by producing elevated levels of chemokines is not known, but would provide an 
alternative explanation for differences in the kinetics of leukocyte infiltration with age.  
Moreover, given their role in promoting leukocyte recruitment, CNS-specific CD8 T cells 
may represent important therapeutic targets in the acute period following stroke. 
In this study we have demonstrated that tissue-resident, memory effector CD8 T 
cells make up the majority of peripherally recruited cells in the aged CNS. To date, our 
efforts have been focused on resolving the phenotype of these cells in order to 
understand their role in the CNS; however, more work will be required to ascertain the 
importance of this population with regard to CNS function.  The absolute number of 
these cells obtained from the aged brain prohibits their utility in adoptive transfer 
experiments, which require on the order of 500,000 cells to achieve significant 
engraftment.  Nevertheless, our findings suggest that CNS-specific CD8 T cells are 
poised to influence CNS function by direct interaction with aged glial cells.  This data 
suggests that the working definition of ‘inflamm-aging’ in the CNS be revised to include 
the increased level of immune surveillance by CD8 T cells.  The discovery that resident 
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microglial function is influenced by the increased presence of these cells leads us to 
speculate whether this effect is direct or indirect and which mechanisms likely underlie 
these changes.  However, the beneficial role for CD8 T cells in suppressing the pro-
inflammatory activity of microglia while increasing phagocytosis is offset by their 
exaggerated response to stimuli resulting in significant production of pro-inflammatory 
cytokines and chemokine signals that favor recruitment of granulocytes.  As such, the 
functional role of these cells may be best described as a double-edged sword - 
advantageous under normal conditions, but prone to exacerbate injury when stimulated.  
This opposing role may likely account for the observed differences in brain inflammation 
found in older mice following traumatic injuries such as ischemic stroke.  Future studies 
are needed to determine whether these interactions can be experimentally manipulated 
to better understand their functional role in normal aging. 
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Supplementary Figure 6-1.  Flow cytometry gating strategy for identification of 
leukocytes. 
A representative series of dot plots illustrating the gating strategy used in this study (A).  
The initial leukocyte gate is based on the typical scatter properties for spenocytes.  
Subsequently, singlets were selected for to eliminate doublets and cell clumping.  CASE 
dye  exclusion is used to identify living cells.  CD45intCD11b+ microglia represent the 
resident macrophages, whereas the CD45hi leukocyte population is bone marrow-
derived and not native to the CNS.  CD45hiCD11b+ represent the peripheral myeloid 
population.  CD45hiCD11b-negative cells are putative lymphocyte populations.  The 
lymphocyte population is generally composed of CD19+MHCII+ B cells and CD3+CD4+ 
and CD3+CD8+ T cells. FMO controls were used to determine positive gating. 
Abbreviation:  SSC side scatter intensity, FSC forward side scatter, CASE carboxylic 
acid succinimidyl ester. 
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Supplementary Figure 6-2.  Peripheral leukocyte counts in the brain and spinal 
cord with age. 
The absolute number of CD45hi peripheral leukocytes in young and aged brain 
hemispheres and spinal cords normalized to tissue weight (A, N=10-15/group). Error 
bars show mean SEM.  Abbreviation:  SEM standard error of mean.  *p<0.05; **p<0.01; 
***p<0.001 
                                      
                                       
Supplementary Figure 6-3.  Lack of granzyme B expression by CD8 T cells in the 
aged brain. 
A representative histogram shows an absence of granzyme B production by CD8 T cells 
in aged blood (solid blue) and brain (solid red) and following stimulation (dotted, N=4-
10, A). 
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Chapter 7: 
Significance and Future Directions 
 
 
Significance: 
 
To date, the functional contribution of CD200R1 signaling to CNS homeostasis and 
disease pathogenesis has been mostly limited to expression studies and those 
examining its role in autoimmune disease models of multiple sclerosis and uveitis 
(Chapter 1).  However, the majority of brain injuries are sterile in nature.  This work 
examined the microglial response to normal aging and ischemic brain injury, with 
particular emphasis on the role of CD200R1 in regulating these responses.  Through 
our investigations we have made several novel findings, not the least of which is the 
revelation that CD200 is essential for survival following stroke (Chapter 4).  Although we 
have found a lack evidence of implicating CD200R1 as a major regulator of microglia, 
its role in the CNS is critical to maintaining the brain’s immune privileged status and in 
preventing chronic brain inflammation and peripheral immune suppression after stroke. 
 Despite sharing common myeloid origin and phenotypic similarities, our work 
found that the microglial response to ischemic stroke is unique among macrophages 
and other cells of this lineage (Chapter 2 and 3).  We demonstrated that microglia, likely 
a result of being resident, are highly vulnerable to the effects of ischemia.  These cells 
tended to become increasingly pro-inflammatory and apoptotic over time.  Conversely, 
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stimulus-driven production of monocytes in the bone marrow favored their recruitment to 
the ischemic brain where they displayed a remarkable capacity for phagocytosis.  These 
findings are the first to show differential changes in microglia- and monocyte-specific 
functions after stroke.  The sustained inflammatory activity of microglia after ischemia is 
consistent with the apparent lack of CD200R1 expression on these cells.  However, 
brain-infiltrating monocytes, of which a significant fraction does express this inhibitory 
receptor, are dramatically increased in CD200R1-deficient mice and are positively 
correlated with poor outcome (Chapter 4).  These data add to our understanding of 
immunoregulation in the injured brain and suggest that CD200R1 signaling may be 
more important for controlling peripheral myeloid responses rather than those of tissue-
resident microglia. 
 We demonstrated for the first time that microglia exhibit deficits in phagocytosis 
with age, which likely contribute to the build-up of fibrillar plaques and toxic by-products 
of metabolism (Chapter 5).  Aged microglia showed not only a poor ability to 
phagocytize amyloid and other material, but failed to increase this capacity when 
activated.  In comparison to young microglia, the increase in oxidative stress levels and 
pro-inflammatory cytokine production was reminiscent, albeit to a lesser extent, of what 
we have observed in younger microglia following stroke.  In addition to showing that 
microglia populations are highly heterogeneous in phenotype and function, we provide 
evidence for alterations in the blood-brain barrier and cytokine environment as possible 
explanation for these differences. 
In our studies we have discovered a newly identified role for CD200R1 in the 
regulation of T cell entry into the CNS under steady state conditions (Chapter 4).  Given 
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that effector/memory CD8 T cells made up a significant proportion of this population, we 
presumed the increase in knockout mice to reflect an increase in CNS immune 
surveillance.  Unlike microglia, CD200R1 was widely expressed on T cells in the 
wildtype brain, implicating endothelial-T cell interactions as a major determinant of 
immune privilege.  Moreover, we found that CD200 levels were decreased in the brain 
with age.  This was an interesting finding especially given the fact that effector/memory 
CD8 T cells are significantly increased in aged brains (Chapter 6).  Importantly, CNS T 
cells lacking CD200R1 exhibited increased production of pro-inflammatory mediators 
after stimulation.  This is consistent with our data showing that T cells in the aged brain 
are primed to produce dramatically elevated levels of pro-inflammatory cytokines and 
chemokines.  Given that a larger population of CD8 T cells expresses CD200R1 in the 
aged brain, the age-related decrease in CD200 levels likely contributes to this 
exaggerated response to stimuli.  Although the increased presence of CD8 T cells was 
associated with healthier microglia (M2) function in the naïve brain, we have shown that 
these cells are equally responsive to an ischemic brain stimulus, further highlighting 
their importance in the pathogenesis of age-related CNS disease. 
Lastly, we have shown that CD200-CD200R1 immune-inhibitory signaling is 
critical for attenuating brain inflammation after stroke (Chapter 4).  By limiting T cell and 
monocyte infiltration after ischemia, the CD200R1 pathway promoted neurological 
recovery.  CD200R1-deficient mice had severe impairment in motor coordination and 
balance at 7 days.  Moreover, mice lacking CD200R1 had defects in peripheral 
immunity resulting in severe lymphopenia, T cell receptor activation, and a narrowing of 
the TCR repertoire.  The role of CD200 in the peripheral immune response to stroke is 
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further highlighted and confounded by data showing aged mice have strikingly 
increased levels of soluble CD200 in the plasma after stroke.  Given that total CD200 
levels were significantly decreased in the ischemic brain of aged mice, but not young, 
we provide evidence for a novel link between brain injury and peripheral immune 
suppression.  Taken together, our data support the hypothesis that CD200-CD200R1 
signaling is important for maintaining CNS homeostasis under normal and injury 
conditions, but extend beyond neuronal-glial interactions in the brain to include 
monocyte and T cell interactions. 
 
 
Future directions: 
 
Our findings shine new light on the role of CD200-CD200R1 signaling in the CNS and 
call for a re-examination of the current model.  While this work advances our 
understanding of CNS regulation of microglia and T cell surveillance, many questions 
remain outstanding.  Specifically, our studies have raised three important questions that 
require further investigation.  These current gaps in knowledge and the strategies 
designed to fill them will be discussed below. 
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Is CD200 regulation of microglia an indirect consequence of its ability to control T cell 
entry and activation in the CNS? 
 
Our initial studies had set out to understand the immunoregulatory role of the CD200-
CD200R1 signaling and its ability to suppress microglia activation and maintain 
homeostasis in the healthy CNS.  As is often the case in science, our data pointed us in 
new directions.  Albeit repeatedly proven but rarely discussed in the literature, the lack 
of CD200R1 expression on microglia presented an early challenge to the notion that this 
pathway was important for microglia regulation.  We have since demonstrated that 
CD200R1 signaling is important for controlling the activation and entry of T cells in the 
brain under steady state conditions.  Although there were no ‘overt’ changes in 
microglia activation in healthy mice lacking CD200R1, we observed increased myeloid 
responses including microglia proliferation following stroke.  Thus, while CD200 may not 
be essential for keeping microglia in a quiescent state under normal conditions, it may 
be involved in later stages of injury which require a mechanism to de-escalate 
inflammatory responses.  Previous studies showing that T cells can disrupt the blood-
brain barrier while having negligible effects on glia 287 are interesting in light of recent 
work which suggests CD200-deficient mice have increased blood-brain barrier 
permeability and greater leukocyte infiltration 280.  To determine the precise role of 
CD200R1 signaling in microglia, we propose to exploit the use of conditional targeting 
approaches by generating transgenic mice with cell-specific, promoter-driven control of 
CD200R1 deletion.  Such studies will help to explain whether the effects of CD200 on 
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microglia are a direct result of CD200 receptor engagement or secondary to its effect on 
T cells (and other leukocytes). 
 
What is the functional significance of T cell immune surveillance in the CNS? 
 
Our data suggest that heightened immune surveillance has little effect on microglia 
activation, and may even be beneficial with age.  However, brains that have increased 
numbers of surveillant T cells tend to be predisposed to exacerbated inflammatory 
responses and worsened outcome after injury.  Experimental manipulation of these cells 
is difficult given their relatively low number.  To this end, we propose profiling these cells 
using RNA sequencing to obtain the transcriptome signature of T cells in healthy and 
injured brains.  These data might then be used to ascertain the signaling pathways that 
are highly up-regulated in these cells and allow us to further probe these functions using 
inducible, conditional transgenic mice. 
 
Is CD200 therapy an effective treatment for ischemic stroke and other age-related CNS 
diseases? 
 
We demonstrated that CD200R1 signaling is essential for limiting inflammation and 
promoting survival following stroke.  Mice that lacked CD200R1-mediated inhibition 
exhibited a greater severity of brain inflammation and peripheral immune dysfunction.  
This leads us to believe that given the previous findings in EAE mice, ischemic stroke 
may also be amenable to treatment with CD200-tailored therapies.  Our results suggest 
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that CD200 therapy may be effective in treating stroke at both acute and chronic 
timepoints after stroke.  Interestingly, CD200’s role as a negative regulator of immune 
cells also enables it to function as a powerful immunosuppressive agent.  Thus, while 
the deleterious effects of inflammation might be mitigated by CD200 therapy, the 
devastating effects of post-stroke immune suppression could be exacerbated.  These 
unintended side effects could lead to higher rates of infection and greater mortality.  
Importantly, we discovered that circulating levels of soluble CD200 were dramatically 
increased in aged mice following stroke.  This may also explain in part why aged mice 
experience greater immune suppression after traumatic brain injury.  Aside from 
establishing a potential link between brain injury and peripheral immune function, this 
paradoxical role for CD200 in stroke implies that caution is needed in developing its use 
for treating inflammation.  Based on our findings, efforts to target- and promote CD200 
signaling in the brain at acute stages may help spare further injury by attenuating 
inflammation, whereas targeting the peripheral system via CD200-blockade may be 
more effective at attenuating immune suppression.  
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Conclusion: 
 
Since it was first proposed by Wright 283 and Hoek 19 at the turn of the century, the 
hypothesis that neuronal-glial interactions involving the CD200-CD200R1 immune-
inhibitory pathway maintain tight control of microglia activation has provided a sound 
explanation for the brain’s unique immune privileged status.  The studies presented 
here have identified several novel roles for this pathway in the regulation of T cell 
surveillance in the healthy CNS, and in promoting survival following stroke by controlling 
central and peripheral inflammatory responses.  Additionally, its diminished expression 
with age in both the normal and stroke-injured brain indicate that CD200 serves as an 
important regulator of age-related changes in immune surveillance and 
microglia/macrophage activation.  As the focus of stroke treatment shifts away from 
targeting the underlying cause of disease in an effort to manage symptoms and promote 
rehabilitation, the prospect of a therapeutic candidate that can potentially ameliorate the 
devastating effects of chronic inflammation may hold great promise for the future. 
 
 
 
	   	   	  201	  
References 
 1	   Lloyd-­‐Jones,	  D.	  et	  al.	  Heart	  disease	  and	  stroke	  statistics-­‐-­‐2009	  update:	  a	  report	  from	  the	  American	  Heart	  Association	  Statistics	  Committee	  and	  Stroke	  Statistics	  Subcommittee.	  Circulation	  119,	  480-­‐486,	  doi:10.1161/CIRCULATIONAHA.108.191259	  (2009).	  2	   Kamel,	  H.	  &	  Iadecola,	  C.	  Brain-­‐immune	  interactions	  and	  ischemic	  stroke:	  clinical	  implications.	  Arch	  Neurol	  69,	  576-­‐581,	  doi:10.1001/archneurol.2011.3590	  (2012).	  3	   Worthmann,	  H.	  et	  al.	  Linking	  infection	  and	  inflammation	  in	  acute	  ischemic	  stroke.	  
Annals	  of	  the	  New	  York	  Academy	  of	  Sciences	  1207,	  116-­‐122,	  doi:10.1111/j.1749-­‐6632.2010.05738.x	  (2010).	  4	   Iadecola,	  C.	  &	  Alexander,	  M.	  Cerebral	  ischemia	  and	  inflammation.	  Current	  opinion	  in	  
neurology	  14,	  89-­‐94	  (2001).	  5	   Danton,	  G.	  H.	  &	  Dietrich,	  W.	  D.	  Inflammatory	  mechanisms	  after	  ischemia	  and	  stroke.	  
Journal	  of	  neuropathology	  and	  experimental	  neurology	  62,	  127-­‐136	  (2003).	  6	   Macrez,	  R.	  et	  al.	  Stroke	  and	  the	  immune	  system:	  from	  pathophysiology	  to	  new	  therapeutic	  strategies.	  Lancet	  neurology	  10,	  471-­‐480,	  doi:10.1016/S1474-­‐4422(11)70066-­‐7	  (2011).	  7	   Yenari,	  M.	  A.,	  Kauppinen,	  T.	  M.	  &	  Swanson,	  R.	  A.	  Microglial	  activation	  in	  stroke:	  therapeutic	  targets.	  Neurotherapeutics	  :	  the	  journal	  of	  the	  American	  Society	  for	  
Experimental	  NeuroTherapeutics	  7,	  378-­‐391,	  doi:10.1016/j.nurt.2010.07.005	  (2010).	  8	   Kaminska,	  B.,	  Gozdz,	  A.,	  Zawadzka,	  M.,	  Ellert-­‐Miklaszewska,	  A.	  &	  Lipko,	  M.	  MAPK	  signal	  transduction	  underlying	  brain	  inflammation	  and	  gliosis	  as	  therapeutic	  target.	  
Anat	  Rec	  (Hoboken)	  292,	  1902-­‐1913,	  doi:10.1002/ar.21047	  (2009).	  9	   Lull,	  M.	  E.	  &	  Block,	  M.	  L.	  Microglial	  activation	  and	  chronic	  neurodegeneration.	  
Neurotherapeutics	  :	  the	  journal	  of	  the	  American	  Society	  for	  Experimental	  
NeuroTherapeutics	  7,	  354-­‐365,	  doi:10.1016/j.nurt.2010.05.014	  (2010).	  10	   Dheen,	  S.	  T.,	  Kaur,	  C.	  &	  Ling,	  E.	  A.	  Microglial	  activation	  and	  its	  implications	  in	  the	  brain	  diseases.	  Current	  medicinal	  chemistry	  14,	  1189-­‐1197	  (2007).	  11	   Vexler,	  Z.	  S.,	  Tang,	  X.	  N.	  &	  Yenari,	  M.	  A.	  Inflammation	  in	  adult	  and	  neonatal	  stroke.	  
Clinical	  neuroscience	  research	  6,	  293-­‐313	  (2006).	  12	   Lalancette-­‐Hebert,	  M.,	  Gowing,	  G.,	  Simard,	  A.,	  Weng,	  Y.	  C.	  &	  Kriz,	  J.	  Selective	  ablation	  of	  proliferating	  microglial	  cells	  exacerbates	  ischemic	  injury	  in	  the	  brain.	  The	  Journal	  
of	  neuroscience	  :	  the	  official	  journal	  of	  the	  Society	  for	  Neuroscience	  27,	  2596-­‐2605,	  doi:10.1523/JNEUROSCI.5360-­‐06.2007	  (2007).	  13	   Watanabe,	  H.,	  Abe,	  H.,	  Takeuchi,	  S.	  &	  Tanaka,	  R.	  Protective	  effect	  of	  microglial	  conditioning	  medium	  on	  neuronal	  damage	  induced	  by	  glutamate.	  Neuroscience	  
letters	  289,	  53-­‐56	  (2000).	  14	   Faustino,	  J.	  V.	  et	  al.	  Microglial	  cells	  contribute	  to	  endogenous	  brain	  defenses	  after	  acute	  neonatal	  focal	  stroke.	  The	  Journal	  of	  neuroscience	  :	  the	  official	  journal	  of	  the	  
Society	  for	  Neuroscience	  31,	  12992-­‐13001,	  doi:10.1523/JNEUROSCI.2102-­‐11.2011	  (2011).	  
	   	   	  202	  
15	   Schroeter,	  M.,	  Jander,	  S.,	  Huitinga,	  I.,	  Witte,	  O.	  W.	  &	  Stoll,	  G.	  Phagocytic	  response	  in	  photochemically	  induced	  infarction	  of	  rat	  cerebral	  cortex.	  The	  role	  of	  resident	  microglia.	  Stroke;	  a	  journal	  of	  cerebral	  circulation	  28,	  382-­‐386	  (1997).	  16	   Nathan,	  C.	  &	  Muller,	  W.	  A.	  Putting	  the	  brakes	  on	  innate	  immunity:	  a	  regulatory	  role	  for	  CD200?	  Nature	  immunology	  2,	  17-­‐19,	  doi:10.1038/83124	  (2001).	  17	   Kawasaki,	  B.	  T.	  &	  Farrar,	  W.	  L.	  Cancer	  stem	  cells,	  CD200	  and	  immunoevasion.	  Trends	  
in	  immunology	  29,	  464-­‐468,	  doi:10.1016/j.it.2008.07.005	  (2008).	  18	   Rosenblum,	  M.	  D.,	  Yancey,	  K.	  B.,	  Olasz,	  E.	  B.	  &	  Truitt,	  R.	  L.	  CD200,	  a	  "no	  danger"	  signal	  for	  hair	  follicles.	  J	  Dermatol	  Sci	  41,	  165-­‐174,	  doi:10.1016/j.jdermsci.2005.11.003	  (2006).	  19	   Hoek,	  R.	  M.	  et	  al.	  Down-­‐regulation	  of	  the	  macrophage	  lineage	  through	  interaction	  with	  OX2	  (CD200).	  Science	  290,	  1768-­‐1771	  (2000).	  20	   Broderick,	  C.	  et	  al.	  Constitutive	  retinal	  CD200	  expression	  regulates	  resident	  microglia	  and	  activation	  state	  of	  inflammatory	  cells	  during	  experimental	  autoimmune	  uveoretinitis.	  The	  American	  journal	  of	  pathology	  161,	  1669-­‐1677,	  doi:10.1016/S0002-­‐9440(10)64444-­‐6	  (2002).	  21	   Costello,	  D.	  A.	  et	  al.	  Long	  term	  potentiation	  is	  impaired	  in	  membrane	  glycoprotein	  CD200-­‐deficient	  mice:	  a	  role	  for	  Toll-­‐like	  receptor	  activation.	  J	  Biol	  Chem	  286,	  34722-­‐34732,	  doi:10.1074/jbc.M111.280826	  (2011).	  22	   Deckert,	  M.,	  Sedgwick,	  J.	  D.,	  Fischer,	  E.	  &	  Schluter,	  D.	  Regulation	  of	  microglial	  cell	  responses	  in	  murine	  Toxoplasma	  encephalitis	  by	  CD200/CD200	  receptor	  interaction.	  Acta	  Neuropathol	  111,	  548-­‐558,	  doi:10.1007/s00401-­‐006-­‐0062-­‐z	  (2006).	  23	   Matsumoto,	  H.	  et	  al.	  Expression	  of	  CD200	  by	  macrophage-­‐like	  cells	  in	  ischemic	  core	  of	  rat	  brain	  after	  transient	  middle	  cerebral	  artery	  occlusion.	  Neurosci	  Lett	  418,	  44-­‐48,	  doi:10.1016/j.neulet.2007.03.027	  (2007).	  24	   K.	  Shrivastava,	  G.	  L.,	  P.	  Gonzalez,	  L.	  Acarin.	  in	  International	  Symposium	  on	  Cerebral	  
Blood	  Flow,	  Metabolism,	  and	  Function	  	  	  	  2	  (Brain,	  Barcelona,	  Spain,	  2011).	  25	   Wright,	  G.	  J.	  et	  al.	  Characterization	  of	  the	  CD200	  receptor	  family	  in	  mice	  and	  humans	  and	  their	  interactions	  with	  CD200.	  J	  Immunol	  171,	  3034-­‐3046	  (2003).	  26	   Gorczynski,	  R.	  M.	  Transplant	  tolerance	  modifying	  antibody	  to	  CD200	  receptor,	  but	  not	  CD200,	  alters	  cytokine	  production	  profile	  from	  stimulated	  macrophages.	  Eur	  J	  
Immunol	  31,	  2331-­‐2337,	  doi:10.1002/1521-­‐4141(200108)31:8&#60;2331::AID-­‐IMMU2331&#62;3.0.CO;2-­‐#	  (2001).	  27	   Jenmalm,	  M.	  C.,	  Cherwinski,	  H.,	  Bowman,	  E.	  P.,	  Phillips,	  J.	  H.	  &	  Sedgwick,	  J.	  D.	  Regulation	  of	  myeloid	  cell	  function	  through	  the	  CD200	  receptor.	  J	  Immunol	  176,	  191-­‐199	  (2006).	  28	   Carter,	  D.	  A.	  &	  Dick,	  A.	  D.	  CD200	  maintains	  microglial	  potential	  to	  migrate	  in	  adult	  human	  retinal	  explant	  model.	  Current	  eye	  research	  28,	  427-­‐436,	  doi:10.1080/02713680490503778	  (2004).	  29	   Simelyte,	  E.	  et	  al.	  CD200-­‐Fc,	  a	  novel	  antiarthritic	  biologic	  agent	  that	  targets	  proinflammatory	  cytokine	  expression	  in	  the	  joints	  of	  mice	  with	  collagen-­‐induced	  arthritis.	  Arthritis	  Rheum	  58,	  1038-­‐1043,	  doi:10.1002/art.23378	  (2008).	  30	   Wang,	  Q.,	  Tang,	  X.	  N.	  &	  Yenari,	  M.	  A.	  The	  inflammatory	  response	  in	  stroke.	  Journal	  of	  
neuroimmunology	  184,	  53-­‐68,	  doi:10.1016/j.jneuroim.2006.11.014	  (2007).	  
	   	   	  203	  
31	   Caso,	  J.	  R.	  et	  al.	  Toll-­‐like	  receptor	  4	  is	  involved	  in	  brain	  damage	  and	  inflammation	  after	  experimental	  stroke.	  Circulation	  115,	  1599-­‐1608,	  doi:10.1161/CIRCULATIONAHA.106.603431	  (2007).	  32	   Villa,	  P.	  et	  al.	  The	  interleukin-­‐8	  (IL-­‐8/CXCL8)	  receptor	  inhibitor	  reparixin	  improves	  neurological	  deficits	  and	  reduces	  long-­‐term	  inflammation	  in	  permanent	  and	  transient	  cerebral	  ischemia	  in	  rats.	  Mol	  Med	  13,	  125-­‐133,	  doi:10.2119/2007–00008.Villa	  (2007).	  33	   Spera,	  P.	  A.,	  Ellison,	  J.	  A.,	  Feuerstein,	  G.	  Z.	  &	  Barone,	  F.	  C.	  IL-­‐10	  reduces	  rat	  brain	  injury	  following	  focal	  stroke.	  Neuroscience	  letters	  251,	  189-­‐192	  (1998).	  34	   Yilmaz,	  G.,	  Arumugam,	  T.	  V.,	  Stokes,	  K.	  Y.	  &	  Granger,	  D.	  N.	  Role	  of	  T	  lymphocytes	  and	  interferon-­‐gamma	  in	  ischemic	  stroke.	  Circulation	  113,	  2105-­‐2112,	  doi:10.1161/CIRCULATIONAHA.105.593046	  (2006).	  35	   Vila,	  N.,	  Castillo,	  J.,	  Davalos,	  A.	  &	  Chamorro,	  A.	  Proinflammatory	  cytokines	  and	  early	  neurological	  worsening	  in	  ischemic	  stroke.	  Stroke;	  a	  journal	  of	  cerebral	  circulation	  
31,	  2325-­‐2329	  (2000).	  36	   Vila,	  N.	  et	  al.	  Cytokine-­‐induced	  inflammation	  and	  long-­‐term	  stroke	  functional	  outcome.	  Journal	  of	  the	  neurological	  sciences	  162,	  185-­‐188	  (1999).	  37	   Beamer,	  N.	  B.	  et	  al.	  Persistent	  inflammatory	  response	  in	  stroke	  survivors.	  Neurology	  
50,	  1722-­‐1728	  (1998).	  38	   Clark,	  W.	  M.,	  Beamer,	  N.	  B.,	  Wynn,	  M.	  &	  Coull,	  B.	  M.	  The	  initial	  acute	  phase	  response	  predicts	  long-­‐term	  stroke	  recovery.	  Journal	  of	  stroke	  and	  cerebrovascular	  diseases	  :	  
the	  official	  journal	  of	  National	  Stroke	  Association	  7,	  128-­‐131	  (1998).	  39	   Akopov,	  S.	  E.,	  Simonian,	  N.	  A.	  &	  Grigorian,	  G.	  S.	  Dynamics	  of	  polymorphonuclear	  leukocyte	  accumulation	  in	  acute	  cerebral	  infarction	  and	  their	  correlation	  with	  brain	  tissue	  damage.	  Stroke;	  a	  journal	  of	  cerebral	  circulation	  27,	  1739-­‐1743	  (1996).	  40	   Smith,	  C.	  J.	  et	  al.	  Peak	  plasma	  interleukin-­‐6	  and	  other	  peripheral	  markers	  of	  inflammation	  in	  the	  first	  week	  of	  ischaemic	  stroke	  correlate	  with	  brain	  infarct	  volume,	  stroke	  severity	  and	  long-­‐term	  outcome.	  BMC	  neurology	  4,	  2,	  doi:10.1186/1471-­‐2377-­‐4-­‐2	  (2004).	  41	   Emsley,	  H.	  C.	  et	  al.	  Correlation	  of	  systemic	  inflammatory	  response	  with	  infarct	  volume	  in	  acute	  ischemic	  stroke	  patients.	  Stroke;	  a	  journal	  of	  cerebral	  circulation	  36,	  228-­‐229;	  author	  reply	  228-­‐229,	  doi:10.1161/01.STR.0000155197.88944.ac	  (2005).	  42	   Rodriguez-­‐Yanez,	  M.	  &	  Castillo,	  J.	  Role	  of	  inflammatory	  markers	  in	  brain	  ischemia.	  
Current	  opinion	  in	  neurology	  21,	  353-­‐357,	  doi:10.1097/WCO.0b013e3282ffafbf	  (2008).	  43	   Chopp,	  M.,	  Li,	  Y.,	  Jiang,	  N.,	  Zhang,	  R.	  L.	  &	  Prostak,	  J.	  Antibodies	  against	  adhesion	  molecules	  reduce	  apoptosis	  after	  transient	  middle	  cerebral	  artery	  occlusion	  in	  rat	  brain.	  Journal	  of	  cerebral	  blood	  flow	  and	  metabolism	  :	  official	  journal	  of	  the	  
International	  Society	  of	  Cerebral	  Blood	  Flow	  and	  Metabolism	  16,	  578-­‐584,	  doi:10.1097/00004647-­‐199607000-­‐00007	  (1996).	  44	   Yilmaz,	  G.	  &	  Granger,	  D.	  N.	  Cell	  adhesion	  molecules	  and	  ischemic	  stroke.	  
Neurological	  research	  30,	  783-­‐793,	  doi:10.1179/174313208X341085	  (2008).	  45	   del	  Zoppo,	  G.	  J.,	  Becker,	  K.	  J.	  &	  Hallenbeck,	  J.	  M.	  Inflammation	  after	  stroke:	  is	  it	  harmful?	  Archives	  of	  neurology	  58,	  669-­‐672	  (2001).	  
	   	   	  204	  
46	   Holmannova,	  D.	  et	  al.	  CD200/CD200R	  paired	  potent	  inhibitory	  molecules	  regulating	  immune	  and	  inflammatory	  responses;	  Part	  I:	  CD200/CD200R	  structure,	  activation,	  and	  function.	  Acta	  Medica	  (Hradec	  Kralove)	  55,	  12-­‐17	  (2012).	  47	   Mozaffarian,	  D.	  et	  al.	  Heart	  disease	  and	  stroke	  statistics-­‐-­‐2015	  update:	  a	  report	  from	  the	  American	  Heart	  Association.	  Circulation	  131,	  e29-­‐322,	  doi:10.1161/CIR.0000000000000152	  (2015).	  48	   Lapchak,	  P.	  A.,	  Zhang,	  J.	  H.	  &	  Noble-­‐Haeusslein,	  L.	  J.	  RIGOR	  guidelines:	  escalating	  STAIR	  and	  STEPS	  for	  effective	  translational	  research.	  Transl	  Stroke	  Res	  4,	  279-­‐285,	  doi:10.1007/s12975-­‐012-­‐0209-­‐2	  (2013).	  49	   Jenny,	  N.	  S.	  Inflammation	  in	  aging:	  cause,	  effect,	  or	  both?	  Discov	  Med	  13,	  451-­‐460	  (2012).	  50	   Loeffler,	  C.	  et	  al.	  Immune	  surveillance	  of	  the	  normal	  human	  CNS	  takes	  place	  in	  dependence	  of	  the	  locoregional	  blood-­‐brain	  barrier	  configuration	  and	  is	  mainly	  performed	  by	  CD3(+)/CD8(+)	  lymphocytes.	  Neuropathology	  31,	  230-­‐238,	  doi:10.1111/j.1440-­‐1789.2010.01167.x	  (2011).	  51	   Montagne,	  A.	  et	  al.	  Blood-­‐brain	  barrier	  breakdown	  in	  the	  aging	  human	  hippocampus.	  Neuron	  85,	  296-­‐302,	  doi:10.1016/j.neuron.2014.12.032	  (2015).	  52	   Streit,	  W.	  J.	  &	  Xue,	  Q.	  S.	  Human	  CNS	  immune	  senescence	  and	  neurodegeneration.	  
Curr	  Opin	  Immunol	  29,	  93-­‐96,	  doi:10.1016/j.coi.2014.05.005	  (2014).	  53	   Conde,	  J.	  R.	  &	  Streit,	  W.	  J.	  Microglia	  in	  the	  aging	  brain.	  J	  Neuropathol	  Exp	  Neurol	  65,	  199-­‐203,	  doi:10.1097/01.jnen.0000202887.22082.63	  (2006).	  54	   Streit,	  W.	  J.,	  Sammons,	  N.	  W.,	  Kuhns,	  A.	  J.	  &	  Sparks,	  D.	  L.	  Dystrophic	  microglia	  in	  the	  aging	  human	  brain.	  Glia	  45,	  208-­‐212,	  doi:10.1002/glia.10319	  (2004).	  55	   Franceschi,	  C.	  et	  al.	  Inflamm-­‐aging.	  An	  evolutionary	  perspective	  on	  immunosenescence.	  Ann	  N	  Y	  Acad	  Sci	  908,	  244-­‐254	  (2000).	  56	   Deleidi,	  M.,	  Jaggle,	  M.	  &	  Rubino,	  G.	  Immune	  aging,	  dysmetabolism,	  and	  inflammation	  in	  neurological	  diseases.	  Front	  Neurosci	  9,	  172,	  doi:10.3389/fnins.2015.00172	  (2015).	  57	   Iadecola,	  C.	  &	  Anrather,	  J.	  The	  immunology	  of	  stroke:	  from	  mechanisms	  to	  translation.	  Nat	  Med	  17,	  796-­‐808,	  doi:10.1038/nm.2399	  (2011).	  58	   Wang,	  X.	  &	  Feuerstein,	  G.	  Z.	  The	  Janus	  face	  of	  inflammation	  in	  ischemic	  brain	  injury.	  
Acta	  neurochirurgica.	  Supplement	  89,	  49-­‐54	  (2004).	  59	   Wood,	  P.	  L.	  Microglia	  as	  a	  unique	  cellular	  target	  in	  the	  treatment	  of	  stroke:	  potential	  neurotoxic	  mediators	  produced	  by	  activated	  microglia.	  Neurological	  research	  17,	  242-­‐248	  (1995).	  60	   Neumann,	  H.,	  Kotter,	  M.	  R.	  &	  Franklin,	  R.	  J.	  Debris	  clearance	  by	  microglia:	  an	  essential	  link	  between	  degeneration	  and	  regeneration.	  Brain	  132,	  288-­‐295	  (2009).	  61	   Jin,	  R.,	  Yang,	  G.	  &	  Li,	  G.	  Inflammatory	  mechanisms	  in	  ischemic	  stroke:	  role	  of	  inflammatory	  cells.	  J	  Leukoc	  Biol	  87,	  779-­‐789,	  doi:10.1189/jlb.1109766	  (2010).	  62	   Chan,	  W.	  Y.,	  Kohsaka,	  S.	  &	  Rezaie,	  P.	  The	  origin	  and	  cell	  lineage	  of	  microglia:	  new	  concepts.	  Brain	  Res	  Rev	  53,	  344-­‐354	  (2007).	  63	   Gomez	  Perdiguero,	  E.,	  Schulz,	  C.	  &	  Geissmann,	  F.	  Development	  and	  homeostasis	  of	  "resident"	  myeloid	  cells:	  The	  case	  of	  the	  microglia.	  Glia	  61,	  112-­‐120	  (2013).	  64	   Ginhoux,	  F.	  et	  al.	  Fate	  mapping	  analysis	  reveals	  that	  adult	  microglia	  derive	  from	  primitive	  macrophages.	  Science	  330,	  841-­‐845	  (2010).	  
	   	   	  205	  
65	   Kissa,	  K.	  &	  Herbomel,	  P.	  Blood	  stem	  cells	  emerge	  from	  aortic	  endothelium	  by	  a	  novel	  type	  of	  cell	  transition.	  Nature	  464,	  112-­‐115	  (2010).	  66	   Lichanska,	  A.	  M.	  et	  al.	  Differentiation	  of	  the	  mononuclear	  phagocyte	  system	  during	  mouse	  embryogenesis:	  the	  role	  of	  transcription	  factor	  PU.1.	  Blood	  94,	  127-­‐138	  (1999).	  67	   Kierdorf,	  K.	  et	  al.	  Microglia	  emerge	  from	  erythromyeloid	  precursors	  via	  Pu.1-­‐	  and	  Irf8-­‐dependent	  pathways.	  Nat	  Neurosci	  (2009).	  68	   Mizutani,	  M.	  et	  al.	  The	  fractalkine	  receptor	  but	  not	  CCR2	  is	  present	  on	  microglia	  from	  embryonic	  development	  throughout	  adulthood.	  J	  Immunol	  188,	  29-­‐36	  (2012).	  69	   Mukouyama,	  Y.	  et	  al.	  Hematopoietic	  cells	  in	  cultures	  of	  the	  murine	  embryonic	  aorta-­‐gonad-­‐mesonephros	  region	  are	  induced	  by	  c-­‐Myb.	  Curr	  Biol	  9,	  833-­‐836	  (1999).	  70	   Schulz,	  C.	  et	  al.	  A	  lineage	  of	  myeloid	  cells	  independent	  of	  Myb	  and	  hematopoietic	  stem	  cells.	  Science	  336,	  86-­‐90	  (2012).	  71	   Labastie,	  M.	  C.,	  Cortes,	  F.,	  Romeo,	  P.	  H.,	  Dulac,	  C.	  &	  Peault,	  B.	  Molecular	  identity	  of	  hematopoietic	  precursor	  cells	  emerging	  in	  the	  human	  embryo.	  Blood	  92,	  3624-­‐3635	  (1998).	  72	   Erblich,	  B.,	  Zhu,	  L.,	  Etgen,	  A.	  M.,	  Dobrenis,	  K.	  &	  Pollard,	  J.	  W.	  Absence	  of	  colony	  stimulation	  factor-­‐1	  receptor	  results	  in	  loss	  of	  microglia,	  disrupted	  brain	  development	  and	  olfactory	  deficits.	  PLoS	  One	  6,	  e26317	  (2011).	  73	   Ovchinnikov,	  D.	  A.	  Macrophages	  in	  the	  embryo	  and	  beyond:	  much	  more	  than	  just	  giant	  phagocytes.	  Genesis	  46,	  447-­‐462	  (2008).	  74	   Tambuyzer,	  B.	  R.,	  Ponsaerts,	  P.	  &	  Nouwen,	  E.	  J.	  Microglia:	  gatekeepers	  of	  central	  nervous	  system	  immunology.	  J	  Leukoc	  Biol	  85,	  352-­‐370	  (2009).	  75	   Imai,	  Y.,	  Ibata,	  I.,	  Ito,	  D.,	  Ohsawa,	  K.	  &	  Kohsaka,	  S.	  A	  novel	  gene	  iba1	  in	  the	  major	  histocompatibility	  complex	  class	  III	  region	  encoding	  an	  EF	  hand	  protein	  expressed	  in	  a	  monocytic	  lineage.	  Biochemical	  and	  biophysical	  research	  communications	  224,	  855-­‐862	  (1996).	  76	   Ito,	  D.	  et	  al.	  Microglia-­‐specific	  localisation	  of	  a	  novel	  calcium	  binding	  protein,	  Iba1.	  
Brain	  Res	  Mol	  Brain	  Res	  57,	  1-­‐9	  (1998).	  77	   Ito,	  D.,	  Tanaka,	  K.,	  Suzuki,	  S.,	  Dembo,	  T.	  &	  Fukuuchi,	  Y.	  Enhanced	  expression	  of	  Iba1,	  ionized	  calcium-­‐binding	  adapter	  molecule	  1,	  after	  transient	  focal	  cerebral	  ischemia	  in	  rat	  brain.	  Stroke;	  a	  journal	  of	  cerebral	  circulation	  32,	  1208-­‐1215	  (2001).	  78	   Sedgwick,	  J.	  D.	  et	  al.	  Isolation	  and	  direct	  characterization	  of	  resident	  microglial	  cells	  from	  the	  normal	  and	  inflamed	  central	  nervous	  system.	  Proceedings	  of	  the	  National	  
Academy	  of	  Sciences	  of	  the	  United	  States	  of	  America	  88,	  7438-­‐7442	  (1991).	  79	   Ford,	  A.	  L.,	  Goodsall,	  A.	  L.,	  Hickey,	  W.	  F.	  &	  Sedgwick,	  J.	  D.	  Normal	  adult	  ramified	  microglia	  separated	  from	  other	  central	  nervous	  system	  macrophages	  by	  flow	  cytometric	  sorting.	  Phenotypic	  differences	  defined	  and	  direct	  ex	  vivo	  antigen	  presentation	  to	  myelin	  basic	  protein-­‐reactive	  CD4+	  T	  cells	  compared.	  J	  Immunol	  
154,	  4309-­‐4321	  (1995).	  80	   Perego,	  C.,	  Fumagalli,	  S.	  &	  De	  Simoni,	  M.	  G.	  Temporal	  pattern	  of	  expression	  and	  colocalization	  of	  microglia/macrophage	  phenotype	  markers	  following	  brain	  ischemic	  injury	  in	  mice.	  J	  Neuroinflammation	  8,	  174	  (2011).	  81	   Gesuete,	  R.	  et	  al.	  Recombinant	  C1	  inhibitor	  in	  brain	  ischemic	  injury.	  Ann	  Neurol	  66,	  332-­‐342,	  doi:10.1002/ana.21740	  (2009).	  
	   	   	  206	  
82	   Guillemin,	  G.	  J.	  &	  Brew,	  B.	  J.	  Microglia,	  macrophages,	  perivascular	  macrophages,	  and	  pericytes:	  a	  review	  of	  function	  and	  identification.	  J	  Leukoc	  Biol	  75,	  388-­‐397	  (2004).	  83	   Ponomarev,	  E.	  D.,	  Shriver,	  L.	  P.,	  Maresz,	  K.	  &	  Dittel,	  B.	  N.	  Microglial	  cell	  activation	  and	  proliferation	  precedes	  the	  onset	  of	  CNS	  autoimmunity.	  J	  Neurosci	  Res	  81,	  374-­‐389	  (2005).	  84	   Melief,	  J.	  et	  al.	  Phenotyping	  primary	  human	  microglia:	  tight	  regulation	  of	  LPS	  responsiveness.	  Glia	  60,	  1506-­‐1517,	  doi:10.1002/glia.22370	  (2012).	  85	   Hume,	  D.	  A.	  Applications	  of	  myeloid-­‐specific	  promoters	  in	  transgenic	  mice	  support	  in	  vivo	  imaging	  and	  functional	  genomics	  but	  do	  not	  support	  the	  concept	  of	  distinct	  macrophage	  and	  dendritic	  cell	  lineages	  or	  roles	  in	  immunity.	  J	  Leukoc	  Biol	  89,	  525-­‐538	  (2011).	  86	   Hirasawa,	  T.	  et	  al.	  Visualization	  of	  microglia	  in	  living	  tissues	  using	  Iba1-­‐EGFP	  transgenic	  mice.	  J	  Neurosci	  Res	  81,	  357-­‐362	  (2005).	  87	   Saederup,	  N.	  et	  al.	  Selective	  chemokine	  receptor	  usage	  by	  central	  nervous	  system	  myeloid	  cells	  in	  CCR2-­‐red	  fluorescent	  protein	  knock-­‐in	  mice.	  PLoS	  One	  5,	  e13693	  (2010).	  88	   Goren,	  I.	  et	  al.	  A	  transgenic	  mouse	  model	  of	  inducible	  macrophage	  depletion:	  effects	  of	  diphtheria	  toxin-­‐driven	  lysozyme	  M-­‐specific	  cell	  lineage	  ablation	  on	  wound	  inflammatory,	  angiogenic,	  and	  contractive	  processes.	  Am	  J	  Pathol	  175,	  132-­‐147,	  doi:10.2353/ajpath.2009.081002	  (2009).	  89	   Gowing,	  G.,	  Vallieres,	  L.	  &	  Julien,	  J.	  P.	  Mouse	  model	  for	  ablation	  of	  proliferating	  microglia	  in	  acute	  CNS	  injuries.	  Glia	  53,	  331-­‐337,	  doi:10.1002/glia.20288	  (2006).	  90	   Tang,	  X.,	  Zheng	  Z	  and	  Yenari,	  MA.	  Bone	  Marrow	  Chimeras	  in	  the	  Study	  of	  Experimental	  Stroke.	  Transl.	  Stroke	  Res	  3,	  341-­‐347	  (2012).	  91	   Monje,	  M.	  L.,	  Mizumatsu,	  S.,	  Fike,	  J.	  R.	  &	  Palmer,	  T.	  D.	  Irradiation	  induces	  neural	  precursor-­‐cell	  dysfunction.	  Nat	  Med	  8,	  955-­‐962	  (2002).	  92	   Davoust,	  N.,	  Vuaillat,	  C.,	  Androdias,	  G.	  &	  Nataf,	  S.	  From	  bone	  marrow	  to	  microglia:	  barriers	  and	  avenues.	  Trends	  Immunol	  29,	  227-­‐234	  (2008).	  93	   Mildner,	  A.	  et	  al.	  Microglia	  in	  the	  adult	  brain	  arise	  from	  Ly-­‐6ChiCCR2+	  monocytes	  only	  under	  defined	  host	  conditions.	  Nat	  Neurosci	  10,	  1544-­‐1553	  (2007).	  94	   Wirenfeldt,	  M.	  et	  al.	  Population	  control	  of	  resident	  and	  immigrant	  microglia	  by	  mitosis	  and	  apoptosis.	  Am	  J	  Pathol	  171,	  617-­‐631	  (2007).	  95	   Li,	  Y.	  Q.,	  Chen,	  P.,	  Jain,	  V.,	  Reilly,	  R.	  M.	  &	  Wong,	  C.	  S.	  Early	  radiation-­‐induced	  endothelial	  cell	  loss	  and	  blood-­‐spinal	  cord	  barrier	  breakdown	  in	  the	  rat	  spinal	  cord.	  
Radiat	  Res	  161,	  143-­‐152	  (2004).	  96	   Lambertsen,	  K.	  L.	  et	  al.	  Microglia	  protect	  neurons	  against	  ischemia	  by	  synthesis	  of	  tumor	  necrosis	  factor.	  J	  Neurosci	  29,	  1319-­‐1330,	  doi:10.1523/JNEUROSCI.5505-­‐08.2009	  (2009).	  97	   Linard,	  C.	  et	  al.	  Acute	  induction	  of	  inflammatory	  cytokine	  expression	  after	  gamma-­‐irradiation	  in	  the	  rat:	  effect	  of	  an	  NF-­‐kappaB	  inhibitor.	  Int	  J	  Radiat	  Oncol	  Biol	  Phys	  
58,	  427-­‐434	  (2004).	  98	   Mizumatsu,	  S.	  et	  al.	  Extreme	  sensitivity	  of	  adult	  neurogenesis	  to	  low	  doses	  of	  X-­‐irradiation.	  Cancer	  Res	  63,	  4021-­‐4027	  (2003).	  99	   Davalos,	  D.	  et	  al.	  ATP	  mediates	  rapid	  microglial	  response	  to	  local	  brain	  injury	  in	  vivo.	  Nat	  Neurosci	  8,	  752-­‐758	  (2005).	  
	   	   	  207	  
100	   Nimmerjahn,	  A.,	  Kirchhoff,	  F.	  &	  Helmchen,	  F.	  Resting	  microglial	  cells	  are	  highly	  dynamic	  surveillants	  of	  brain	  parenchyma	  in	  vivo.	  Science	  308,	  1314-­‐1318	  (2005).	  101	   Lawson,	  L.	  J.,	  Perry,	  V.	  H.,	  Dri,	  P.	  &	  Gordon,	  S.	  Heterogeneity	  in	  the	  distribution	  and	  morphology	  of	  microglia	  in	  the	  normal	  adult	  mouse	  brain.	  Neuroscience	  39,	  151-­‐170	  (1990).	  102	   Carson,	  M.	  J.	  et	  al.	  A	  rose	  by	  any	  other	  name?	  The	  potential	  consequences	  of	  microglial	  heterogeneity	  during	  CNS	  health	  and	  disease.	  Neurotherapeutics	  4,	  571-­‐579	  (2007).	  103	   Biber,	  K.,	  Neumann,	  H.,	  Inoue,	  K.	  &	  Boddeke,	  H.	  W.	  Neuronal	  'On'	  and	  'Off'	  signals	  control	  microglia.	  Trends	  Neurosci	  30,	  596-­‐602,	  doi:10.1016/j.tins.2007.08.007	  (2007).	  104	   Cardona,	  A.	  E.	  et	  al.	  Control	  of	  microglial	  neurotoxicity	  by	  the	  fractalkine	  receptor.	  
Nat	  Neurosci	  9,	  917-­‐924	  (2006).	  105	   Fuhrmann,	  M.	  et	  al.	  Microglial	  Cx3cr1	  knockout	  prevents	  neuron	  loss	  in	  a	  mouse	  model	  of	  Alzheimer's	  disease.	  Nat	  Neurosci	  13,	  411-­‐413	  (2010).	  106	   Cipriani,	  R.	  et	  al.	  CX3CL1	  is	  neuroprotective	  in	  permanent	  focal	  cerebral	  ischemia	  in	  rodents.	  J	  Neurosci	  31,	  16327-­‐16335	  (2011).	  107	   Koning,	  N.,	  Bo,	  L.,	  Hoek,	  R.	  M.	  &	  Huitinga,	  I.	  Downregulation	  of	  macrophage	  inhibitory	  molecules	  in	  multiple	  sclerosis	  lesions.	  Ann	  Neurol	  62,	  504-­‐514,	  doi:10.1002/ana.21220	  (2007).	  108	   Barclay,	  A.	  N.,	  Wright,	  G.	  J.,	  Brooke,	  G.	  &	  Brown,	  M.	  H.	  CD200	  and	  membrane	  protein	  interactions	  in	  the	  control	  of	  myeloid	  cells.	  Trends	  Immunol	  23,	  285-­‐290	  (2002).	  109	   Koning,	  N.,	  Swaab,	  D.	  F.,	  Hoek,	  R.	  M.	  &	  Huitinga,	  I.	  Distribution	  of	  the	  immune	  inhibitory	  molecules	  CD200	  and	  CD200R	  in	  the	  normal	  central	  nervous	  system	  and	  multiple	  sclerosis	  lesions	  suggests	  neuron-­‐glia	  and	  glia-­‐glia	  interactions.	  J	  
Neuropathol	  Exp	  Neurol	  68,	  159-­‐167,	  doi:10.1097/NEN.0b013e3181964113	  (2009).	  110	   Webb,	  M.	  &	  Barclay,	  A.	  N.	  Localisation	  of	  the	  MRC	  OX-­‐2	  glycoprotein	  on	  the	  surfaces	  of	  neurones.	  J	  Neurochem	  43,	  1061-­‐1067	  (1984).	  111	   Barclay,	  A.	  N.	  The	  localization	  of	  populations	  of	  lymphocytes	  defined	  by	  monoclonal	  antibodies	  in	  rat	  lymphoid	  tissues.	  Immunology	  42,	  593-­‐600	  (1981).	  112	   Chitnis,	  T.	  et	  al.	  Elevated	  neuronal	  expression	  of	  CD200	  protects	  Wlds	  mice	  from	  inflammation-­‐mediated	  neurodegeneration.	  Am	  J	  Pathol	  170,	  1695-­‐1712,	  doi:10.2353/ajpath.2007.060677	  (2007).	  113	   Cox,	  F.	  F.,	  Carney,	  D.,	  Miller,	  A.	  M.	  &	  Lynch,	  M.	  A.	  CD200	  fusion	  protein	  decreases	  microglial	  activation	  in	  the	  hippocampus	  of	  aged	  rats.	  Brain	  Behav	  Immun	  26,	  789-­‐796,	  doi:10.1016/j.bbi.2011.10.004	  (2012).	  114	   Ludwig,	  A.	  &	  Weber,	  C.	  Transmembrane	  chemokines:	  versatile	  'special	  agents'	  in	  vascular	  inflammation.	  Thromb	  Haemost	  97,	  694-­‐703	  (2007).	  115	   Fumagalli,	  S.,	  Perego,	  C.,	  Ortolano,	  F.	  &	  De	  Simoni,	  M.	  G.	  CX3CR1	  deficiency	  induces	  an	  early	  protective	  inflammatory	  environment	  in	  ischemic	  mice.	  Glia	  (2013).	  116	   Denes,	  A.,	  Ferenczi,	  S.,	  Halasz,	  J.,	  Kornyei,	  Z.	  &	  Kovacs,	  K.	  J.	  Role	  of	  CX3CR1	  (fractalkine	  receptor)	  in	  brain	  damage	  and	  inflammation	  induced	  by	  focal	  cerebral	  ischemia	  in	  mouse.	  J	  Cereb	  Blood	  Flow	  Metab	  28,	  1707-­‐1721	  (2008).	  117	   Soriano,	  S.	  G.	  et	  al.	  Mice	  deficient	  in	  fractalkine	  are	  less	  susceptible	  to	  cerebral	  ischemia-­‐reperfusion	  injury.	  Journal	  of	  neuroimmunology	  125,	  59-­‐65	  (2002).	  
	   	   	  208	  
118	   Jiang,	  P.,	  Lagenaur,	  C.	  F.	  &	  Narayanan,	  V.	  Integrin-­‐associated	  protein	  is	  a	  ligand	  for	  the	  P84	  neural	  adhesion	  molecule.	  J	  Biol	  Chem	  274,	  559-­‐562	  (1999).	  119	   Fujioka,	  Y.	  et	  al.	  A	  novel	  membrane	  glycoprotein,	  SHPS-­‐1,	  that	  binds	  the	  SH2-­‐domain-­‐containing	  protein	  tyrosine	  phosphatase	  SHP-­‐2	  in	  response	  to	  mitogens	  and	  cell	  adhesion.	  Mol	  Cell	  Biol	  16,	  6887-­‐6899	  (1996).	  120	   Okazawa,	  H.	  et	  al.	  Negative	  regulation	  of	  phagocytosis	  in	  macrophages	  by	  the	  CD47-­‐SHPS-­‐1	  system.	  J	  Immunol	  174,	  2004-­‐2011	  (2005).	  121	   Yamao,	  T.	  et	  al.	  Negative	  regulation	  of	  platelet	  clearance	  and	  of	  the	  macrophage	  phagocytic	  response	  by	  the	  transmembrane	  glycoprotein	  SHPS-­‐1.	  J	  Biol	  Chem	  277,	  39833-­‐39839	  (2002).	  122	   Jin,	  G.	  et	  al.	  CD47	  gene	  knockout	  protects	  against	  transient	  focal	  cerebral	  ischemia	  in	  mice.	  Exp	  Neurol	  217,	  165-­‐170	  (2009).	  123	   Wang,	  L.	  et	  al.	  SHPS-­‐1	  deficiency	  induces	  robust	  neuroprotection	  against	  experimental	  stroke	  by	  attenuating	  oxidative	  stress.	  J	  Neurochem	  122,	  834-­‐843	  (2012).	  124	   Stefano,	  L.	  et	  al.	  The	  surface-­‐exposed	  chaperone,	  Hsp60,	  is	  an	  agonist	  of	  the	  microglial	  TREM2	  receptor.	  J	  Neurochem	  110,	  284-­‐294	  (2009).	  125	   Piccio,	  L.	  et	  al.	  Blockade	  of	  TREM-­‐2	  exacerbates	  experimental	  autoimmune	  encephalomyelitis.	  Eur	  J	  Immunol	  37,	  1290-­‐1301	  (2007).	  126	   Takahashi,	  K.,	  Rochford,	  C.	  D.	  &	  Neumann,	  H.	  Clearance	  of	  apoptotic	  neurons	  without	  inflammation	  by	  microglial	  triggering	  receptor	  expressed	  on	  myeloid	  cells-­‐2.	  J	  Exp	  
Med	  201,	  647-­‐657	  (2005).	  127	   Sieber,	  M.	  W.	  et	  al.	  Attenuated	  inflammatory	  response	  in	  triggering	  receptor	  expressed	  on	  myeloid	  cells	  2	  (TREM2)	  knock-­‐out	  mice	  following	  stroke.	  PLoS	  One	  8,	  e52982	  (2013).	  128	   Ohsawa,	  K.	  et	  al.	  Involvement	  of	  P2X4	  and	  P2Y12	  receptors	  in	  ATP-­‐induced	  microglial	  chemotaxis.	  Glia	  55,	  604-­‐616	  (2007).	  129	   Haynes,	  S.	  E.	  et	  al.	  The	  P2Y12	  receptor	  regulates	  microglial	  activation	  by	  extracellular	  nucleotides.	  Nat	  Neurosci	  9,	  1512-­‐1519,	  doi:10.1038/nn1805	  (2006).	  130	   Varnum,	  M.	  M.	  &	  Ikezu,	  T.	  The	  classification	  of	  microglial	  activation	  phenotypes	  on	  neurodegeneration	  and	  regeneration	  in	  Alzheimer's	  disease	  brain.	  Arch	  Immunol	  
Ther	  Exp	  (Warsz)	  60,	  251-­‐266	  (2012).	  131	   Hu,	  X.	  et	  al.	  Microglia/macrophage	  polarization	  dynamics	  reveal	  novel	  mechanism	  of	  injury	  expansion	  after	  focal	  cerebral	  ischemia.	  Stroke;	  a	  journal	  of	  cerebral	  
circulation	  43,	  3063-­‐3070,	  doi:10.1161/STROKEAHA.112.659656	  (2012).	  132	   Ponomarev,	  E.	  D.,	  Veremeyko,	  T.	  &	  Weiner,	  H.	  L.	  MicroRNAs	  are	  universal	  regulators	  of	  differentiation,	  activation,	  and	  polarization	  of	  microglia	  and	  macrophages	  in	  normal	  and	  diseased	  CNS.	  Glia	  61,	  91-­‐103,	  doi:10.1002/glia.22363	  (2013).	  133	   Liu,	  H.	  C.	  et	  al.	  N9	  microglial	  cells	  polarized	  by	  LPS	  and	  IL4	  show	  differential	  responses	  to	  secondary	  environmental	  stimuli.	  Cell	  Immunol	  278,	  84-­‐90,	  doi:10.1016/j.cellimm.2012.06.001	  (2012).	  134	   Shin,	  W.	  H.	  et	  al.	  Microglia	  expressing	  interleukin-­‐13	  undergo	  cell	  death	  and	  contribute	  to	  neuronal	  survival	  in	  vivo.	  Glia	  46,	  142-­‐152,	  doi:10.1002/glia.10357	  (2004).	  
	   	   	  209	  
135	   Zhou,	  X.,	  Spittau,	  B.	  &	  Krieglstein,	  K.	  TGFbeta	  signalling	  plays	  an	  important	  role	  in	  IL4-­‐induced	  alternative	  activation	  of	  microglia.	  J	  Neuroinflammation	  9,	  210,	  doi:10.1186/1742-­‐2094-­‐9-­‐210	  (2012).	  136	   Hanisch,	  U.	  K.	  &	  Kettenmann,	  H.	  Microglia:	  active	  sensor	  and	  versatile	  effector	  cells	  in	  the	  normal	  and	  pathologic	  brain.	  Nature	  neuroscience	  10,	  1387-­‐1394,	  doi:10.1038/nn1997	  (2007).	  137	   Pal,	  G.	  et	  al.	  Time	  course,	  distribution	  and	  cell	  types	  of	  induction	  of	  transforming	  growth	  factor	  betas	  following	  middle	  cerebral	  artery	  occlusion	  in	  the	  rat	  brain.	  PLoS	  
One	  7,	  e46731	  (2012).	  138	   Jimenez,	  S.	  et	  al.	  Inflammatory	  response	  in	  the	  hippocampus	  of	  PS1M146L/APP751SL	  mouse	  model	  of	  Alzheimer's	  disease:	  age-­‐dependent	  switch	  in	  the	  microglial	  phenotype	  from	  alternative	  to	  classic.	  J	  Neurosci	  28,	  11650-­‐11661,	  doi:10.1523/JNEUROSCI.3024-­‐08.2008	  (2008).	  139	   Katayama,	  T.	  et	  al.	  Accumulating	  microglia	  phagocytose	  injured	  neurons	  in	  hippocampal	  slice	  cultures:	  involvement	  of	  p38	  MAP	  kinase.	  PLoS	  One	  7,	  e40813	  (2012).	  140	   Denes,	  A.	  et	  al.	  Proliferating	  resident	  microglia	  after	  focal	  cerebral	  ischaemia	  in	  mice.	  J	  Cereb	  Blood	  Flow	  Metab	  27,	  1941-­‐1953	  (2007).	  141	   Sakanashi,	  Y.	  et	  al.	  Kinetics	  of	  macrophage	  subpopulations	  and	  expression	  of	  monocyte	  chemoattractant	  protein-­‐1	  (MCP-­‐1)	  in	  bleomycin-­‐induced	  lung	  injury	  of	  rats	  studied	  by	  a	  novel	  monoclonal	  antibody	  against	  rat	  MCP-­‐1.	  J	  Leukoc	  Biol	  56,	  741-­‐750	  (1994).	  142	   Kumar,	  A.	  G.	  et	  al.	  Induction	  of	  monocyte	  chemoattractant	  protein-­‐1	  in	  the	  small	  veins	  of	  the	  ischemic	  and	  reperfused	  canine	  myocardium.	  Circulation	  95,	  693-­‐700	  (1997).	  143	   Che,	  X.,	  Ye,	  W.,	  Panga,	  L.,	  Wu,	  D.	  C.	  &	  Yang,	  G.	  Y.	  Monocyte	  chemoattractant	  protein-­‐1	  expressed	  in	  neurons	  and	  astrocytes	  during	  focal	  ischemia	  in	  mice.	  Brain	  Res	  902,	  171-­‐177	  (2001).	  144	   Ceulemans,	  A.	  G.	  et	  al.	  The	  dual	  role	  of	  the	  neuroinflammatory	  response	  after	  ischemic	  stroke:	  modulatory	  effects	  of	  hypothermia.	  J	  Neuroinflammation	  7,	  74	  (2010).	  145	   Dimitrijevic,	  J.	  et	  al.	  [10-­‐year	  analysis	  of	  cerebrovascular	  accidents	  at	  the	  Neurology	  Clinic	  in	  Sarajevo	  (before,	  during	  and	  after	  the	  war)].	  Medicinski	  arhiv	  56,	  151-­‐153	  (2002).	  146	   del	  Zoppo,	  G.	  J.,	  Sharp,	  F.	  R.,	  Heiss,	  W.	  D.	  &	  Albers,	  G.	  W.	  Heterogeneity	  in	  the	  penumbra.	  J	  Cereb	  Blood	  Flow	  Metab	  31,	  1836-­‐1851,	  doi:10.1038/jcbfm.2011.93	  (2011).	  147	   Schilling,	  M.	  et	  al.	  Predominant	  phagocytic	  activity	  of	  resident	  microglia	  over	  hematogenous	  macrophages	  following	  transient	  focal	  cerebral	  ischemia:	  an	  investigation	  using	  green	  fluorescent	  protein	  transgenic	  bone	  marrow	  chimeric	  mice.	  Experimental	  neurology	  196,	  290-­‐297,	  doi:10.1016/j.expneurol.2005.08.004	  (2005).	  148	   Neher,	  J.	  J.	  et	  al.	  Inhibition	  of	  microglial	  phagocytosis	  is	  sufficient	  to	  prevent	  inflammatory	  neuronal	  death.	  J	  Immunol	  186,	  4973-­‐4983	  (2011).	  149	   Franke,	  H.	  et	  al.	  P2X7	  receptor	  expression	  after	  ischemia	  in	  the	  cerebral	  cortex	  of	  rats.	  J	  Neuropathol	  Exp	  Neurol	  63,	  686-­‐699	  (2004).	  
	   	   	  210	  
150	   Melani,	  A.	  et	  al.	  ATP	  extracellular	  concentrations	  are	  increased	  in	  the	  rat	  striatum	  during	  in	  vivo	  ischemia.	  Neurochem	  Int	  47,	  442-­‐448,	  doi:10.1016/j.neuint.2005.05.014	  (2005).	  151	   Monif,	  M.,	  Reid,	  C.	  A.,	  Powell,	  K.	  L.,	  Smart,	  M.	  L.	  &	  Williams,	  D.	  A.	  The	  P2X7	  receptor	  drives	  microglial	  activation	  and	  proliferation:	  a	  trophic	  role	  for	  P2X7R	  pore.	  J	  
Neurosci	  29,	  3781-­‐3791	  (2009).	  152	   Brough,	  D.,	  Le	  Feuvre,	  R.	  A.,	  Iwakura,	  Y.	  &	  Rothwell,	  N.	  J.	  Purinergic	  (P2X7)	  receptor	  activation	  of	  microglia	  induces	  cell	  death	  via	  an	  interleukin-­‐1-­‐independent	  mechanism.	  Mol	  Cell	  Neurosci	  19,	  272-­‐280	  (2002).	  153	   Ferrari,	  D.	  et	  al.	  The	  P2X7	  receptor:	  a	  key	  player	  in	  IL-­‐1	  processing	  and	  release.	  J	  
Immunol	  176,	  3877-­‐3883	  (2006).	  154	   Verderio,	  C.	  &	  Matteoli,	  M.	  ATP	  mediates	  calcium	  signaling	  between	  astrocytes	  and	  microglial	  cells:	  modulation	  by	  IFN-­‐gamma.	  J	  Immunol	  166,	  6383-­‐6391	  (2001).	  155	   Honda,	  S.	  et	  al.	  Extracellular	  ATP	  or	  ADP	  induce	  chemotaxis	  of	  cultured	  microglia	  through	  Gi/o-­‐coupled	  P2Y	  receptors.	  J	  Neurosci	  21,	  1975-­‐1982	  (2001).	  156	   Pellegatti,	  P.,	  Falzoni,	  S.,	  Pinton,	  P.,	  Rizzuto,	  R.	  &	  Di	  Virgilio,	  F.	  A	  novel	  recombinant	  plasma	  membrane-­‐targeted	  luciferase	  reveals	  a	  new	  pathway	  for	  ATP	  secretion.	  Mol	  
Biol	  Cell	  16,	  3659-­‐3665,	  doi:10.1091/mbc.E05-­‐03-­‐0222	  (2005).	  157	   Chu,	  K.	  et	  al.	  Inhibition	  of	  P2X7	  receptor	  ameliorates	  transient	  global	  cerebral	  ischemia/reperfusion	  injury	  via	  modulating	  inflammatory	  responses	  in	  the	  rat	  hippocampus.	  J	  Neuroinflammation	  9,	  69	  (2012).	  158	   Melani,	  A.	  et	  al.	  P2X7	  receptor	  modulation	  on	  microglial	  cells	  and	  reduction	  of	  brain	  infarct	  caused	  by	  middle	  cerebral	  artery	  occlusion	  in	  rat.	  J	  Cereb	  Blood	  Flow	  Metab	  
26,	  974-­‐982,	  doi:10.1038/sj.jcbfm.9600250	  (2006).	  159	   Piccinini,	  A.	  M.	  &	  Midwood,	  K.	  S.	  DAMPening	  inflammation	  by	  modulating	  TLR	  signalling.	  Mediators	  Inflamm	  2010,	  doi:10.1155/2010/672395	  (2010).	  160	   Ziegler,	  G.	  et	  al.	  Mrp-­‐8	  and	  -­‐14	  mediate	  CNS	  injury	  in	  focal	  cerebral	  ischemia.	  
Biochim	  Biophys	  Acta	  1792,	  1198-­‐1204	  (2009).	  161	   Chow,	  J.	  C.,	  Young,	  D.	  W.,	  Golenbock,	  D.	  T.,	  Christ,	  W.	  J.	  &	  Gusovsky,	  F.	  Toll-­‐like	  receptor-­‐4	  mediates	  lipopolysaccharide-­‐induced	  signal	  transduction.	  J	  Biol	  Chem	  
274,	  10689-­‐10692	  (1999).	  162	   Lehnardt,	  S.	  et	  al.	  Toll-­‐like	  receptor	  2	  mediates	  CNS	  injury	  in	  focal	  cerebral	  ischemia.	  
Journal	  of	  neuroimmunology	  190,	  28-­‐33	  (2007).	  163	   Bohacek,	  I.	  et	  al.	  Toll-­‐like	  receptor	  2	  deficiency	  leads	  to	  delayed	  exacerbation	  of	  ischemic	  injury.	  J	  Neuroinflammation	  9,	  191	  (2012).	  164	   Hyakkoku,	  K.	  et	  al.	  Toll-­‐like	  receptor	  4	  (TLR4),	  but	  not	  TLR3	  or	  TLR9,	  knock-­‐out	  mice	  have	  neuroprotective	  effects	  against	  focal	  cerebral	  ischemia.	  Neuroscience	  171,	  258-­‐267,	  doi:10.1016/j.neuroscience.2010.08.054	  (2010).	  165	   Lalancette-­‐Hebert,	  M.,	  Phaneuf,	  D.,	  Soucy,	  G.,	  Weng,	  Y.	  C.	  &	  Kriz,	  J.	  Live	  imaging	  of	  Toll-­‐like	  receptor	  2	  response	  in	  cerebral	  ischaemia	  reveals	  a	  role	  of	  olfactory	  bulb	  microglia	  as	  modulators	  of	  inflammation.	  Brain	  132,	  940-­‐954,	  doi:10.1093/brain/awn345	  (2009).	  166	   Suzuki,	  Y.	  et	  al.	  Pharmacological	  inhibition	  of	  TLR4-­‐NOX4	  signal	  protects	  against	  neuronal	  death	  in	  transient	  focal	  ischemia.	  Sci	  Rep	  2,	  896,	  doi:10.1038/srep00896	  (2012).	  
	   	   	  211	  
167	   Chen,	  Z.	  et	  al.	  Lipopolysaccharide-­‐induced	  microglial	  activation	  and	  neuroprotection	  against	  experimental	  brain	  injury	  is	  independent	  of	  hematogenous	  TLR4.	  J	  Neurosci	  
32,	  11706-­‐11715	  (2012).	  168	   Vartanian,	  K.	  B.	  et	  al.	  LPS	  preconditioning	  redirects	  TLR	  signaling	  following	  stroke:	  TRIF-­‐IRF3	  plays	  a	  seminal	  role	  in	  mediating	  tolerance	  to	  ischemic	  injury.	  J	  
Neuroinflammation	  8,	  140,	  doi:10.1186/1742-­‐2094-­‐8-­‐140	  (2011).	  169	   Lu,	  C.	  et	  al.	  TLR2	  ligand	  induces	  protection	  against	  cerebral	  ischemia/reperfusion	  injury	  via	  activation	  of	  phosphoinositide	  3-­‐kinase/Akt	  signaling.	  J	  Immunol	  187,	  1458-­‐1466.	  170	   Shichita,	  T.	  et	  al.	  Peroxiredoxin	  family	  proteins	  are	  key	  initiators	  of	  post-­‐ischemic	  inflammation	  in	  the	  brain.	  Nat	  Med	  18,	  911-­‐917	  (2012).	  171	   Li,	  G.,	  Liang,	  X.	  &	  Lotze,	  M.	  T.	  HMGB1:	  The	  Central	  Cytokine	  for	  All	  Lymphoid	  Cells.	  
Front	  Immunol	  4,	  68,	  doi:10.3389/fimmu.2013.00068	  (2013).	  172	   Vabulas,	  R.	  M.	  et	  al.	  HSP70	  as	  endogenous	  stimulus	  of	  the	  Toll/interleukin-­‐1	  receptor	  signal	  pathway.	  J	  Biol	  Chem	  277,	  15107-­‐15112,	  doi:10.1074/jbc.M111204200	  (2002).	  173	   Mitrasinovic,	  O.	  M.	  et	  al.	  Microglia	  overexpressing	  the	  macrophage	  colony-­‐stimulating	  factor	  receptor	  are	  neuroprotective	  in	  a	  microglial-­‐hippocampal	  organotypic	  coculture	  system.	  J	  Neurosci	  25,	  4442-­‐4451	  (2005).	  174	   Lalancette-­‐Hebert,	  M.	  et	  al.	  Galectin-­‐3	  is	  required	  for	  resident	  microglia	  activation	  and	  proliferation	  in	  response	  to	  ischemic	  injury.	  J	  Neurosci	  32,	  10383-­‐10395	  (2012).	  175	   McMenamin,	  P.	  G.	  Distribution	  and	  phenotype	  of	  dendritic	  cells	  and	  resident	  tissue	  macrophages	  in	  the	  dura	  mater,	  leptomeninges,	  and	  choroid	  plexus	  of	  the	  rat	  brain	  as	  demonstrated	  in	  wholemount	  preparations.	  J	  Comp	  Neurol	  405,	  553-­‐562	  (1999).	  176	   Bechmann,	  I.	  et	  al.	  Immune	  surveillance	  of	  mouse	  brain	  perivascular	  spaces	  by	  blood-­‐borne	  macrophages.	  Eur	  J	  Neurosci	  14,	  1651-­‐1658	  (2001).	  177	   Lassmann,	  H.,	  Schmied,	  M.,	  Vass,	  K.	  &	  Hickey,	  W.	  F.	  Bone	  marrow	  derived	  elements	  and	  resident	  microglia	  in	  brain	  inflammation.	  Glia	  7,	  19-­‐24,	  doi:10.1002/glia.440070106	  (1993).	  178	   Geissmann,	  F.	  et	  al.	  Blood	  monocytes:	  distinct	  subsets,	  how	  they	  relate	  to	  dendritic	  cells,	  and	  their	  possible	  roles	  in	  the	  regulation	  of	  T-­‐cell	  responses.	  Immunol	  Cell	  Biol	  
86,	  398-­‐408	  (2008).	  179	   Varvel,	  N.	  H.	  et	  al.	  Microglial	  repopulation	  model	  reveals	  a	  robust	  homeostatic	  process	  for	  replacing	  CNS	  myeloid	  cells.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  109,	  18150-­‐18155	  (2012).	  180	   Candelario-­‐Jalil,	  E.,	  Yang,	  Y.	  &	  Rosenberg,	  G.	  A.	  Diverse	  roles	  of	  matrix	  metalloproteinases	  and	  tissue	  inhibitors	  of	  metalloproteinases	  in	  neuroinflammation	  and	  cerebral	  ischemia.	  Neuroscience	  158,	  983-­‐994,	  doi:10.1016/j.neuroscience.2008.06.025	  (2009).	  181	   Walker,	  E.	  J.	  &	  Rosenberg,	  G.	  A.	  TIMP-­‐3	  and	  MMP-­‐3	  contribute	  to	  delayed	  inflammation	  and	  hippocampal	  neuronal	  death	  following	  global	  ischemia.	  Exp	  
Neurol	  216,	  122-­‐131	  (2009).	  182	   Gidday,	  J.	  M.	  et	  al.	  Leukocyte-­‐derived	  matrix	  metalloproteinase-­‐9	  mediates	  blood-­‐brain	  barrier	  breakdown	  and	  is	  proinflammatory	  after	  transient	  focal	  cerebral	  ischemia.	  Am	  J	  Physiol	  Heart	  Circ	  Physiol	  289,	  H558-­‐568	  (2005).	  
	   	   	  212	  
183	   Wang,	  G.	  et	  al.	  Bone	  marrow-­‐derived	  cells	  are	  the	  major	  source	  of	  MMP-­‐9	  contributing	  to	  blood-­‐brain	  barrier	  dysfunction	  and	  infarct	  formation	  after	  ischemic	  stroke	  in	  mice.	  Brain	  Res	  1294,	  183-­‐192	  (2009).	  184	   Dawson,	  D.	  A.,	  Martin,	  D.	  &	  Hallenbeck,	  J.	  M.	  Inhibition	  of	  tumor	  necrosis	  factor-­‐alpha	  reduces	  focal	  cerebral	  ischemic	  injury	  in	  the	  spontaneously	  hypertensive	  rat.	  
Neurosci	  Lett	  218,	  41-­‐44	  (1996).	  185	   Lambertsen,	  K.	  L.,	  Biber,	  K.	  &	  Finsen,	  B.	  Inflammatory	  cytokines	  in	  experimental	  and	  human	  stroke.	  Journal	  of	  cerebral	  blood	  flow	  and	  metabolism	  :	  official	  journal	  of	  the	  
International	  Society	  of	  Cerebral	  Blood	  Flow	  and	  Metabolism	  32,	  1677-­‐1698,	  doi:10.1038/jcbfm.2012.88	  (2012).	  186	   Fontaine,	  V.	  et	  al.	  Neurodegenerative	  and	  neuroprotective	  effects	  of	  tumor	  Necrosis	  factor	  (TNF)	  in	  retinal	  ischemia:	  opposite	  roles	  of	  TNF	  receptor	  1	  and	  TNF	  receptor	  2.	  J	  Neurosci	  22,	  RC216	  (2002).	  187	   Iadecola,	  C.,	  Zhang,	  F.,	  Xu,	  S.,	  Casey,	  R.	  &	  Ross,	  M.	  E.	  Inducible	  nitric	  oxide	  synthase	  gene	  expression	  in	  brain	  following	  cerebral	  ischemia.	  J	  Cereb	  Blood	  Flow	  Metab	  15,	  378-­‐384,	  doi:10.1038/jcbfm.1995.47	  (1995).	  188	   Loihl,	  A.	  K.,	  Asensio,	  V.,	  Campbell,	  I.	  L.	  &	  Murphy,	  S.	  Expression	  of	  nitric	  oxide	  synthase	  (NOS)-­‐2	  following	  permanent	  focal	  ischemia	  and	  the	  role	  of	  nitric	  oxide	  in	  infarct	  generation	  in	  male,	  female	  and	  NOS-­‐2	  gene-­‐deficient	  mice.	  Brain	  Res	  830,	  155-­‐164	  (1999).	  189	   Iadecola,	  C.,	  Zhang,	  F.,	  Casey,	  R.,	  Nagayama,	  M.	  &	  Ross,	  M.	  E.	  Delayed	  reduction	  of	  ischemic	  brain	  injury	  and	  neurological	  deficits	  in	  mice	  lacking	  the	  inducible	  nitric	  oxide	  synthase	  gene.	  J	  Neurosci	  17,	  9157-­‐9164	  (1997).	  190	   Iadecola,	  C.,	  Zhang,	  F.	  &	  Xu,	  X.	  Inhibition	  of	  inducible	  nitric	  oxide	  synthase	  ameliorates	  cerebral	  ischemic	  damage.	  The	  American	  journal	  of	  physiology	  268,	  R286-­‐292	  (1995).	  191	   Pruss,	  H.	  et	  al.	  Inducible	  nitric	  oxide	  synthase	  does	  not	  mediate	  brain	  damage	  after	  transient	  focal	  cerebral	  ischemia	  in	  mice.	  J	  Cereb	  Blood	  Flow	  Metab	  28,	  526-­‐539	  (2008).	  192	   Hu,	  X.	  et	  al.	  Peroxiredoxin-­‐2	  protects	  against	  6-­‐hydroxydopamine-­‐induced	  dopaminergic	  neurodegeneration	  via	  attenuation	  of	  the	  apoptosis	  signal-­‐regulating	  kinase	  (ASK1)	  signaling	  cascade.	  J	  Neurosci	  31,	  247-­‐261,	  doi:10.1523/JNEUROSCI.4589-­‐10.2011	  (2011).	  193	   Rashidian,	  J.	  et	  al.	  Essential	  role	  of	  cytoplasmic	  cdk5	  and	  Prx2	  in	  multiple	  ischemic	  injury	  models,	  in	  vivo.	  J	  Neurosci	  29,	  12497-­‐12505,	  doi:10.1523/JNEUROSCI.3892-­‐09.2009	  (2009).	  194	   Del	  Rio	  Hortega,	  P.	  &	  Penfield,	  W.	  Cerebral	  Cicatrix:	  the	  reaction	  of	  neuroglia	  and	  microglia	  to	  brain	  wounds.	  Bulletin	  of	  the	  Johns	  Hopkins	  Hospital	  41,	  278-­‐303	  (1892).	  195	   Whiteley,	  W.	  et	  al.	  Inflammatory	  markers	  and	  poor	  outcome	  after	  stroke:	  a	  prospective	  cohort	  study	  and	  systematic	  review	  of	  interleukin-­‐6.	  PLoS	  medicine	  6,	  e1000145,	  doi:10.1371/journal.pmed.1000145	  (2009).	  196	   Di	  Napoli,	  M.,	  Papa,	  F.	  &	  Bocola,	  V.	  C-­‐reactive	  protein	  in	  ischemic	  stroke:	  an	  independent	  prognostic	  factor.	  Stroke;	  a	  journal	  of	  cerebral	  circulation	  32,	  917-­‐924	  (2001).	  
	   	   	  213	  
197	   Vila,	  N.	  et	  al.	  Levels	  of	  anti-­‐inflammatory	  cytokines	  and	  neurological	  worsening	  in	  acute	  ischemic	  stroke.	  Stroke;	  a	  journal	  of	  cerebral	  circulation	  34,	  671-­‐675,	  doi:10.1161/01.STR.0000057976.53301.69	  (2003).	  198	   Benakis,	  C.,	  Garcia-­‐Bonilla,	  L.,	  Iadecola,	  C.	  &	  Anrather,	  J.	  The	  role	  of	  microglia	  and	  myeloid	  immune	  cells	  in	  acute	  cerebral	  ischemia.	  Front	  Cell	  Neurosci	  8,	  461,	  doi:10.3389/fncel.2014.00461	  (2014).	  199	   Joseph,	  B.	  &	  Venero,	  J.	  L.	  A	  brief	  overview	  of	  multitalented	  microglia.	  Methods	  Mol	  
Biol	  1041,	  3-­‐8,	  doi:10.1007/978-­‐1-­‐62703-­‐520-­‐0_1	  (2013).	  200	   Patel,	  A.	  R.,	  Ritzel,	  R.,	  McCullough,	  L.	  D.	  &	  Liu,	  F.	  Microglia	  and	  ischemic	  stroke:	  a	  double-­‐edged	  sword.	  Int	  J	  Physiol	  Pathophysiol	  Pharmacol	  5,	  73-­‐90	  (2013).	  201	   London,	  A.,	  Cohen,	  M.	  &	  Schwartz,	  M.	  Microglia	  and	  monocyte-­‐derived	  macrophages:	  functionally	  distinct	  populations	  that	  act	  in	  concert	  in	  CNS	  plasticity	  and	  repair.	  
Frontiers	  in	  cellular	  neuroscience	  7,	  34,	  doi:10.3389/fncel.2013.00034	  (2013).	  202	   Prinz,	  M.,	  Priller,	  J.,	  Sisodia,	  S.	  S.	  &	  Ransohoff,	  R.	  M.	  Heterogeneity	  of	  CNS	  myeloid	  cells	  and	  their	  roles	  in	  neurodegeneration.	  Nat	  Neurosci	  14,	  1227-­‐1235,	  doi:10.1038/nn.2923	  (2011).	  203	   Mildner,	  A.	  et	  al.	  Distinct	  and	  non-­‐redundant	  roles	  of	  microglia	  and	  myeloid	  subsets	  in	  mouse	  models	  of	  Alzheimer's	  disease.	  The	  Journal	  of	  neuroscience	  :	  the	  official	  
journal	  of	  the	  Society	  for	  Neuroscience	  31,	  11159-­‐11171,	  doi:10.1523/JNEUROSCI.6209-­‐10.2011	  (2011).	  204	   Yamasaki,	  R.	  et	  al.	  Differential	  roles	  of	  microglia	  and	  monocytes	  in	  the	  inflamed	  central	  nervous	  system.	  The	  Journal	  of	  experimental	  medicine	  211,	  1533-­‐1549,	  doi:10.1084/jem.20132477	  (2014).	  205	   Tang,	  X.	  N.,	  Zheng,	  Z.	  &	  Yenari,	  M.	  A.	  Bone	  marrow	  chimeras	  in	  the	  study	  of	  experimental	  stroke.	  Translational	  stroke	  research	  3,	  341-­‐347,	  doi:10.1007/s12975-­‐012-­‐0169-­‐6	  (2012).	  206	   McCullough,	  L.	  D.,	  Zeng,	  Z.,	  Blizzard,	  K.	  K.,	  Debchoudhury,	  I.	  &	  Hurn,	  P.	  D.	  Ischemic	  nitric	  oxide	  and	  poly	  (ADP-­‐ribose)	  polymerase-­‐1	  in	  cerebral	  ischemia:	  male	  toxicity,	  female	  protection.	  Journal	  of	  cerebral	  blood	  flow	  and	  metabolism	  :	  official	  journal	  of	  
the	  International	  Society	  of	  Cerebral	  Blood	  Flow	  and	  Metabolism	  25,	  502-­‐512,	  doi:10.1038/sj.jcbfm.9600059	  (2005).	  207	   Voss,	  E.	  V.	  et	  al.	  Characterisation	  of	  microglia	  during	  de-­‐	  and	  remyelination:	  can	  they	  create	  a	  repair	  promoting	  environment?	  Neurobiology	  of	  disease	  45,	  519-­‐528,	  doi:10.1016/j.nbd.2011.09.008	  (2012).	  208	   Pul,	  R.,	  Chittappen,	  K.	  P.	  &	  Stangel,	  M.	  Quantification	  of	  microglial	  phagocytosis	  by	  a	  flow	  cytometer-­‐based	  assay.	  Methods	  Mol	  Biol	  1041,	  121-­‐127,	  doi:10.1007/978-­‐1-­‐62703-­‐520-­‐0_14	  (2013).	  209	   Schaefer,	  B.	  C.,	  Schaefer,	  M.	  L.,	  Kappler,	  J.	  W.,	  Marrack,	  P.	  &	  Kedl,	  R.	  M.	  Observation	  of	  antigen-­‐dependent	  CD8+	  T-­‐cell/	  dendritic	  cell	  interactions	  in	  vivo.	  Cellular	  
immunology	  214,	  110-­‐122,	  doi:10.1006/cimm.2001.1895	  (2001).	  210	   Denes,	  A.	  et	  al.	  Experimental	  stroke-­‐induced	  changes	  in	  the	  bone	  marrow	  reveal	  complex	  regulation	  of	  leukocyte	  responses.	  Journal	  of	  cerebral	  blood	  flow	  and	  
metabolism	  :	  official	  journal	  of	  the	  International	  Society	  of	  Cerebral	  Blood	  Flow	  and	  
Metabolism	  31,	  1036-­‐1050,	  doi:10.1038/jcbfm.2010.198	  (2011).	  211	   Chan,	  P.	  H.	  Reactive	  oxygen	  radicals	  in	  signaling	  and	  damage	  in	  the	  ischemic	  brain.	  
Journal	  of	  cerebral	  blood	  flow	  and	  metabolism	  :	  official	  journal	  of	  the	  International	  
	   	   	  214	  
Society	  of	  Cerebral	  Blood	  Flow	  and	  Metabolism	  21,	  2-­‐14,	  doi:10.1097/00004647-­‐200101000-­‐00002	  (2001).	  212	   Chiba,	  T.	  &	  Umegaki,	  K.	  Pivotal	  roles	  of	  monocytes/macrophages	  in	  stroke.	  
Mediators	  of	  inflammation	  2013,	  759103,	  doi:10.1155/2013/759103	  (2013).	  213	   Womble,	  T.	  A.	  et	  al.	  Monocytes	  are	  essential	  for	  the	  neuroprotective	  effect	  of	  human	  cord	  blood	  cells	  following	  middle	  cerebral	  artery	  occlusion	  in	  rat.	  Molecular	  and	  
cellular	  neurosciences	  59,	  76-­‐84,	  doi:10.1016/j.mcn.2014.01.004	  (2014).	  214	   Schilling,	  M.,	  Strecker,	  J.	  K.,	  Ringelstein,	  E.	  B.,	  Schabitz,	  W.	  R.	  &	  Kiefer,	  R.	  The	  role	  of	  CC	  chemokine	  receptor	  2	  on	  microglia	  activation	  and	  blood-­‐borne	  cell	  recruitment	  after	  transient	  focal	  cerebral	  ischemia	  in	  mice.	  Brain	  research	  1289,	  79-­‐84,	  doi:10.1016/j.brainres.2009.06.054	  (2009).	  215	   Schuette-­‐Nuetgen,	  K.,	  Strecker,	  J.	  K.,	  Minnerup,	  J.,	  Ringelstein,	  E.	  B.	  &	  Schilling,	  M.	  MCP-­‐1/CCR-­‐2-­‐double-­‐deficiency	  severely	  impairs	  the	  migration	  of	  hematogenous	  inflammatory	  cells	  following	  transient	  cerebral	  ischemia	  in	  mice.	  Experimental	  
neurology	  233,	  849-­‐858,	  doi:10.1016/j.expneurol.2011.12.011	  (2012).	  216	   Hughes,	  P.	  M.	  et	  al.	  Monocyte	  chemoattractant	  protein-­‐1	  deficiency	  is	  protective	  in	  a	  murine	  stroke	  model.	  Journal	  of	  cerebral	  blood	  flow	  and	  metabolism	  :	  official	  journal	  
of	  the	  International	  Society	  of	  Cerebral	  Blood	  Flow	  and	  Metabolism	  22,	  308-­‐317,	  doi:10.1097/00004647-­‐200203000-­‐00008	  (2002).	  217	   Butovsky,	  O.	  et	  al.	  Identification	  of	  a	  unique	  TGF-­‐beta-­‐dependent	  molecular	  and	  functional	  signature	  in	  microglia.	  Nature	  neuroscience	  17,	  131-­‐143,	  doi:10.1038/nn.3599	  (2014).	  218	   Hashimoto,	  D.	  et	  al.	  Tissue-­‐resident	  macrophages	  self-­‐maintain	  locally	  throughout	  adult	  life	  with	  minimal	  contribution	  from	  circulating	  monocytes.	  Immunity	  38,	  792-­‐804,	  doi:10.1016/j.immuni.2013.04.004	  (2013).	  219	   Getts,	  D.	  R.	  et	  al.	  Ly6c+	  "inflammatory	  monocytes"	  are	  microglial	  precursors	  recruited	  in	  a	  pathogenic	  manner	  in	  West	  Nile	  virus	  encephalitis.	  The	  Journal	  of	  
experimental	  medicine	  205,	  2319-­‐2337,	  doi:10.1084/jem.20080421	  (2008).	  220	   Grathwohl,	  S.	  A.	  et	  al.	  Formation	  and	  maintenance	  of	  Alzheimer's	  disease	  beta-­‐amyloid	  plaques	  in	  the	  absence	  of	  microglia.	  Nature	  neuroscience	  12,	  1361-­‐1363,	  doi:10.1038/nn.2432	  (2009).	  221	   Derecki,	  N.	  C.	  et	  al.	  Wild-­‐type	  microglia	  arrest	  pathology	  in	  a	  mouse	  model	  of	  Rett	  syndrome.	  Nature	  484,	  105-­‐109,	  doi:10.1038/nature10907	  (2012).	  222	   Chouery,	  E.	  et	  al.	  Mutations	  in	  TREM2	  lead	  to	  pure	  early-­‐onset	  dementia	  without	  bone	  cysts.	  Human	  mutation	  29,	  E194-­‐204,	  doi:10.1002/humu.20836	  (2008).	  223	   Neumann,	  H.	  &	  Takahashi,	  K.	  Essential	  role	  of	  the	  microglial	  triggering	  receptor	  expressed	  on	  myeloid	  cells-­‐2	  (TREM2)	  for	  central	  nervous	  tissue	  immune	  homeostasis.	  Journal	  of	  neuroimmunology	  184,	  92-­‐99,	  doi:10.1016/j.jneuroim.2006.11.032	  (2007).	  224	   Baba,	  T.	  et	  al.	  Electrical	  stimulation	  of	  the	  cerebral	  cortex	  exerts	  antiapoptotic,	  angiogenic,	  and	  anti-­‐inflammatory	  effects	  in	  ischemic	  stroke	  rats	  through	  phosphoinositide	  3-­‐kinase/Akt	  signaling	  pathway.	  Stroke;	  a	  journal	  of	  cerebral	  
circulation	  40,	  e598-­‐605,	  doi:10.1161/STROKEAHA.109.563627	  (2009).	  225	   Sugawara,	  T.,	  Lewen,	  A.,	  Noshita,	  N.,	  Gasche,	  Y.	  &	  Chan,	  P.	  H.	  Effects	  of	  global	  ischemia	  duration	  on	  neuronal,	  astroglial,	  oligodendroglial,	  and	  microglial	  reactions	  
	   	   	  215	  
in	  the	  vulnerable	  hippocampal	  CA1	  subregion	  in	  rats.	  Journal	  of	  neurotrauma	  19,	  85-­‐98,	  doi:10.1089/089771502753460268	  (2002).	  226	   Yenari,	  M.	  A.	  &	  Giffard,	  R.	  G.	  Ischemic	  vulnerability	  of	  primary	  murine	  microglial	  cultures.	  Neuroscience	  letters	  298,	  5-­‐8	  (2001).	  227	   Panickar,	  K.	  S.	  &	  Norenberg,	  M.	  D.	  Astrocytes	  in	  cerebral	  ischemic	  injury:	  morphological	  and	  general	  considerations.	  Glia	  50,	  287-­‐298,	  doi:10.1002/glia.20181	  (2005).	  228	   Dewar,	  D.,	  Underhill,	  S.	  M.	  &	  Goldberg,	  M.	  P.	  Oligodendrocytes	  and	  ischemic	  brain	  injury.	  Journal	  of	  cerebral	  blood	  flow	  and	  metabolism	  :	  official	  journal	  of	  the	  
International	  Society	  of	  Cerebral	  Blood	  Flow	  and	  Metabolism	  23,	  263-­‐274	  (2003).	  229	   Courties,	  G.	  et	  al.	  Ischemic	  stroke	  activates	  hematopoietic	  bone	  marrow	  stem	  cells.	  
Circulation	  research	  116,	  407-­‐417,	  doi:10.1161/CIRCRESAHA.116.305207	  (2015).	  230	   Zhang,	  Q.	  et	  al.	  Cell	  cycle	  inhibition	  attenuates	  microglial	  proliferation	  and	  production	  of	  IL-­‐1beta,	  MIP-­‐1alpha,	  and	  NO	  after	  focal	  cerebral	  ischemia	  in	  the	  rat.	  
Glia	  57,	  908-­‐920,	  doi:10.1002/glia.20816	  (2009).	  231	   Ishimura,	  R.,	  Martin,	  G.	  R.	  &	  Ackerman,	  S.	  L.	  Loss	  of	  apoptosis-­‐inducing	  factor	  results	  in	  cell-­‐type-­‐specific	  neurogenesis	  defects.	  The	  Journal	  of	  neuroscience	  :	  the	  official	  
journal	  of	  the	  Society	  for	  Neuroscience	  28,	  4938-­‐4948,	  doi:10.1523/JNEUROSCI.0229-­‐08.2008	  (2008).	  232	   Schilling,	  M.	  et	  al.	  Microglial	  activation	  precedes	  and	  predominates	  over	  macrophage	  infiltration	  in	  transient	  focal	  cerebral	  ischemia:	  a	  study	  in	  green	  fluorescent	  protein	  transgenic	  bone	  marrow	  chimeric	  mice.	  Experimental	  neurology	  
183,	  25-­‐33	  (2003).	  233	   Li,	  T.	  et	  al.	  Proliferation	  of	  parenchymal	  microglia	  is	  the	  main	  source	  of	  microgliosis	  after	  ischaemic	  stroke.	  Brain	  :	  a	  journal	  of	  neurology	  136,	  3578-­‐3588,	  doi:10.1093/brain/awt287	  (2013).	  234	   Rose,	  S.,	  Misharin,	  A.	  &	  Perlman,	  H.	  A	  novel	  Ly6C/Ly6G-­‐based	  strategy	  to	  analyze	  the	  mouse	  splenic	  myeloid	  compartment.	  Cytometry.	  Part	  A	  :	  the	  journal	  of	  the	  
International	  Society	  for	  Analytical	  Cytology	  81,	  343-­‐350,	  doi:10.1002/cyto.a.22012	  (2012).	  235	   Butovsky,	  O.	  et	  al.	  Modulating	  inflammatory	  monocytes	  with	  a	  unique	  microRNA	  gene	  signature	  ameliorates	  murine	  ALS.	  The	  Journal	  of	  clinical	  investigation	  122,	  3063-­‐3087,	  doi:10.1172/JCI62636	  (2012).	  236	   Peters,	  O.	  et	  al.	  Increased	  formation	  of	  reactive	  oxygen	  species	  after	  permanent	  and	  reversible	  middle	  cerebral	  artery	  occlusion	  in	  the	  rat.	  Journal	  of	  cerebral	  blood	  flow	  
and	  metabolism	  :	  official	  journal	  of	  the	  International	  Society	  of	  Cerebral	  Blood	  Flow	  
and	  Metabolism	  18,	  196-­‐205,	  doi:10.1097/00004647-­‐199802000-­‐00011	  (1998).	  237	   Manzanero,	  S.,	  Santro,	  T.	  &	  Arumugam,	  T.	  V.	  Neuronal	  oxidative	  stress	  in	  acute	  ischemic	  stroke:	  sources	  and	  contribution	  to	  cell	  injury.	  Neurochemistry	  
international	  62,	  712-­‐718,	  doi:10.1016/j.neuint.2012.11.009	  (2013).	  238	   Tang,	  X.	  N.,	  Zheng,	  Z.,	  Giffard,	  R.	  G.	  &	  Yenari,	  M.	  A.	  Significance	  of	  marrow-­‐derived	  nicotinamide	  adenine	  dinucleotide	  phosphate	  oxidase	  in	  experimental	  ischemic	  stroke.	  Annals	  of	  neurology	  70,	  606-­‐615,	  doi:10.1002/ana.22476	  (2011).	  239	   Moskowitz,	  M.	  A.,	  Lo,	  E.	  H.	  &	  Iadecola,	  C.	  The	  science	  of	  stroke:	  mechanisms	  in	  search	  of	  treatments.	  Neuron	  67,	  181-­‐198,	  doi:10.1016/j.neuron.2010.07.002	  (2010).	  
	   	   	  216	  
240	   Clausen,	  B.	  H.	  et	  al.	  Interleukin-­‐1beta	  and	  tumor	  necrosis	  factor-­‐alpha	  are	  expressed	  by	  different	  subsets	  of	  microglia	  and	  macrophages	  after	  ischemic	  stroke	  in	  mice.	  
Journal	  of	  neuroinflammation	  5,	  46,	  doi:10.1186/1742-­‐2094-­‐5-­‐46	  (2008).	  241	   Sumbria,	  R.	  K.,	  Boado,	  R.	  J.	  &	  Pardridge,	  W.	  M.	  Brain	  protection	  from	  stroke	  with	  intravenous	  TNFalpha	  decoy	  receptor-­‐Trojan	  horse	  fusion	  protein.	  Journal	  of	  
cerebral	  blood	  flow	  and	  metabolism	  :	  official	  journal	  of	  the	  International	  Society	  of	  
Cerebral	  Blood	  Flow	  and	  Metabolism	  32,	  1933-­‐1938,	  doi:10.1038/jcbfm.2012.97	  (2012).	  242	   Abulafia,	  D.	  P.	  et	  al.	  Inhibition	  of	  the	  inflammasome	  complex	  reduces	  the	  inflammatory	  response	  after	  thromboembolic	  stroke	  in	  mice.	  Journal	  of	  cerebral	  
blood	  flow	  and	  metabolism	  :	  official	  journal	  of	  the	  International	  Society	  of	  Cerebral	  
Blood	  Flow	  and	  Metabolism	  29,	  534-­‐544,	  doi:10.1038/jcbfm.2008.143	  (2009).	  243	   Zhang,	  N.	  et	  al.	  Chrysophanol	  inhibits	  NALP3	  inflammasome	  activation	  and	  ameliorates	  cerebral	  ischemia/reperfusion	  in	  mice.	  Mediators	  of	  inflammation	  2014,	  370530,	  doi:10.1155/2014/370530	  (2014).	  244	   Tanaka,	  R.	  et	  al.	  Migration	  of	  enhanced	  green	  fluorescent	  protein	  expressing	  bone	  marrow-­‐derived	  microglia/macrophage	  into	  the	  mouse	  brain	  following	  permanent	  focal	  ischemia.	  Neuroscience	  117,	  531-­‐539	  (2003).	  245	   Woo,	  M.	  S.	  et	  al.	  Genetic	  deletion	  of	  CD36	  enhances	  injury	  after	  acute	  neonatal	  stroke.	  Annals	  of	  neurology	  72,	  961-­‐970,	  doi:10.1002/ana.23727	  (2012).	  246	   Fang,	  H.	  et	  al.	  CD36-­‐mediated	  hematoma	  absorption	  following	  intracerebral	  hemorrhage:	  negative	  regulation	  by	  TLR4	  signaling.	  J	  Immunol	  192,	  5984-­‐5992,	  doi:10.4049/jimmunol.1400054	  (2014).	  247	   Rausch,	  M.	  et	  al.	  Dynamic	  patterns	  of	  USPIO	  enhancement	  can	  be	  observed	  in	  macrophages	  after	  ischemic	  brain	  damage.	  Magnetic	  resonance	  in	  medicine	  :	  official	  
journal	  of	  the	  Society	  of	  Magnetic	  Resonance	  in	  Medicine	  /	  Society	  of	  Magnetic	  
Resonance	  in	  Medicine	  46,	  1018-­‐1022	  (2001).	  248	   Geissmann,	  F.	  et	  al.	  Development	  of	  monocytes,	  macrophages,	  and	  dendritic	  cells.	  
Science	  327,	  656-­‐661,	  doi:10.1126/science.1178331	  (2010).	  249	   Hammond,	  M.	  D.	  et	  al.	  CCR2+	  Ly6C(hi)	  inflammatory	  monocyte	  recruitment	  exacerbates	  acute	  disability	  following	  intracerebral	  hemorrhage.	  The	  Journal	  of	  
neuroscience	  :	  the	  official	  journal	  of	  the	  Society	  for	  Neuroscience	  34,	  3901-­‐3909,	  doi:10.1523/JNEUROSCI.4070-­‐13.2014	  (2014).	  250	   Mallat,	  M.,	  Marin-­‐Teva,	  J.	  L.	  &	  Cheret,	  C.	  Phagocytosis	  in	  the	  developing	  CNS:	  more	  than	  clearing	  the	  corpses.	  Current	  opinion	  in	  neurobiology	  15,	  101-­‐107,	  doi:10.1016/j.conb.2005.01.006	  (2005).	  251	   Lauber,	  K.,	  Blumenthal,	  S.	  G.,	  Waibel,	  M.	  &	  Wesselborg,	  S.	  Clearance	  of	  apoptotic	  cells:	  getting	  rid	  of	  the	  corpses.	  Molecular	  cell	  14,	  277-­‐287	  (2004).	  252	   Murray,	  P.	  J.	  et	  al.	  Macrophage	  activation	  and	  polarization:	  nomenclature	  and	  experimental	  guidelines.	  Immunity	  41,	  14-­‐20,	  doi:10.1016/j.immuni.2014.06.008	  (2014).	  253	   Towfighi,	  A.	  &	  Saver,	  J.	  L.	  Stroke	  declines	  from	  third	  to	  fourth	  leading	  cause	  of	  death	  in	  the	  United	  States:	  historical	  perspective	  and	  challenges	  ahead.	  Stroke	  42,	  2351-­‐2355,	  doi:10.1161/STROKEAHA.111.621904	  (2011).	  254	   Ransohoff,	  R.	  M.	  &	  Cardona,	  A.	  E.	  The	  myeloid	  cells	  of	  the	  central	  nervous	  system	  parenchyma.	  Nature	  468,	  253-­‐262,	  doi:10.1038/nature09615	  (2010).	  
	   	   	  217	  
255	   Gorczynski,	  R.	  M.	  CD200	  and	  its	  receptors	  as	  targets	  for	  immunoregulation.	  Curr	  
Opin	  Investig	  Drugs	  6,	  483-­‐488	  (2005).	  256	   Mihrshahi,	  R.,	  Barclay,	  A.	  N.	  &	  Brown,	  M.	  H.	  Essential	  roles	  for	  Dok2	  and	  RasGAP	  in	  CD200	  receptor-­‐mediated	  regulation	  of	  human	  myeloid	  cells.	  J	  Immunol	  183,	  4879-­‐4886,	  doi:10.4049/jimmunol.0901531	  (2009).	  257	   Mihrshahi,	  R.	  &	  Brown,	  M.	  H.	  Downstream	  of	  tyrosine	  kinase	  1	  and	  2	  play	  opposing	  roles	  in	  CD200	  receptor	  signaling.	  J	  Immunol	  185,	  7216-­‐7222,	  doi:10.4049/jimmunol.1002858	  (2010).	  258	   Liu,	  Y.	  et	  al.	  CD200R1	  agonist	  attenuates	  mechanisms	  of	  chronic	  disease	  in	  a	  murine	  model	  of	  multiple	  sclerosis.	  J	  Neurosci	  30,	  2025-­‐2038,	  doi:10.1523/JNEUROSCI.4272-­‐09.2010	  (2010).	  259	   Walker,	  D.	  G.,	  Dalsing-­‐Hernandez,	  J.	  E.,	  Campbell,	  N.	  A.	  &	  Lue,	  L.	  F.	  Decreased	  expression	  of	  CD200	  and	  CD200	  receptor	  in	  Alzheimer's	  disease:	  a	  potential	  mechanism	  leading	  to	  chronic	  inflammation.	  Exp	  Neurol	  215,	  5-­‐19,	  doi:10.1016/j.expneurol.2008.09.003	  (2009).	  260	   Wang,	  X.	  J.,	  Ye,	  M.,	  Zhang,	  Y.	  H.	  &	  Chen,	  S.	  D.	  CD200-­‐CD200R	  regulation	  of	  microglia	  activation	  in	  the	  pathogenesis	  of	  Parkinson's	  disease.	  J	  Neuroimmune	  Pharmacol	  2,	  259-­‐264,	  doi:10.1007/s11481-­‐007-­‐9075-­‐1	  (2007).	  261	   Boudakov,	  I.	  et	  al.	  Mice	  lacking	  CD200R1	  show	  absence	  of	  suppression	  of	  lipopolysaccharide-­‐induced	  tumor	  necrosis	  factor-­‐alpha	  and	  mixed	  leukocyte	  culture	  responses	  by	  CD200.	  Transplantation	  84,	  251-­‐257,	  doi:10.1097/01.tp.0000269795.04592.cc	  (2007).	  262	   Bederson,	  J.	  B.	  et	  al.	  Rat	  middle	  cerebral	  artery	  occlusion:	  evaluation	  of	  the	  model	  and	  development	  of	  a	  neurologic	  examination.	  Stroke	  17,	  472-­‐476	  (1986).	  263	   Abe,	  T.	  et	  al.	  The	  neuroprotective	  effect	  of	  prostaglandin	  E2	  EP1	  receptor	  inhibition	  has	  a	  wide	  therapeutic	  window,	  is	  sustained	  in	  time	  and	  is	  not	  sexually	  dimorphic.	  J	  
Cereb	  Blood	  Flow	  Metab	  29,	  66-­‐72,	  doi:10.1038/jcbfm.2008.88	  (2009).	  264	   Li,	  X.	  et	  al.	  Chronic	  behavioral	  testing	  after	  focal	  ischemia	  in	  the	  mouse:	  functional	  recovery	  and	  the	  effects	  of	  gender.	  Exp	  Neurol	  187,	  94-­‐104,	  doi:10.1016/j.expneurol.2004.01.004	  (2004).	  265	   Hattori,	  K.	  et	  al.	  Cognitive	  deficits	  after	  focal	  cerebral	  ischemia	  in	  mice.	  Stroke	  31,	  1939-­‐1944	  (2000).	  266	   Wahl,	  F.,	  Allix,	  M.,	  Plotkine,	  M.	  &	  Boulu,	  R.	  G.	  Neurological	  and	  behavioral	  outcomes	  of	  focal	  cerebral	  ischemia	  in	  rats.	  Stroke	  23,	  267-­‐272	  (1992).	  267	   Deacon,	  R.	  M.	  Measuring	  motor	  coordination	  in	  mice.	  J	  Vis	  Exp,	  e2609,	  doi:10.3791/2609	  (2013).	  268	   van	  Dellen,	  A.,	  Blakemore,	  C.,	  Deacon,	  R.,	  York,	  D.	  &	  Hannan,	  A.	  J.	  Delaying	  the	  onset	  of	  Huntington's	  in	  mice.	  Nature	  404,	  721-­‐722,	  doi:10.1038/35008142	  (2000).	  269	   Galante,	  M.	  et	  al.	  Impairments	  in	  motor	  coordination	  without	  major	  changes	  in	  cerebellar	  plasticity	  in	  the	  Tc1	  mouse	  model	  of	  Down	  syndrome.	  Hum	  Mol	  Genet	  18,	  1449-­‐1463,	  doi:10.1093/hmg/ddp055	  (2009).	  270	   Bouet,	  V.	  et	  al.	  Sensorimotor	  and	  cognitive	  deficits	  after	  transient	  middle	  cerebral	  artery	  occlusion	  in	  the	  mouse.	  Exp	  Neurol	  203,	  555-­‐567,	  doi:10.1016/j.expneurol.2006.09.006	  (2007).	  271	   Truong,	  D.	  T.,	  Venna,	  V.	  R.,	  McCullough,	  L.	  D.	  &	  Fitch,	  R.	  H.	  Deficits	  in	  auditory,	  cognitive,	  and	  motor	  processing	  following	  reversible	  middle	  cerebral	  artery	  
	   	   	  218	  
occlusion	  in	  mice.	  Exp	  Neurol	  238,	  114-­‐121,	  doi:10.1016/j.expneurol.2012.08.011	  (2012).	  272	   Deacon,	  R.	  Assessing	  burrowing,	  nest	  construction,	  and	  hoarding	  in	  mice.	  J	  Vis	  Exp,	  e2607,	  doi:10.3791/2607	  (2012).	  273	   Deacon,	  R.	  M.	  Assessing	  nest	  building	  in	  mice.	  Nat	  Protoc	  1,	  1117-­‐1119,	  doi:10.1038/nprot.2006.170	  (2006).	  274	   Liu,	  F.,	  Schafer,	  D.	  P.	  &	  McCullough,	  L.	  D.	  TTC,	  fluoro-­‐Jade	  B	  and	  NeuN	  staining	  confirm	  evolving	  phases	  of	  infarction	  induced	  by	  middle	  cerebral	  artery	  occlusion.	  J	  
Neurosci	  Methods	  179,	  1-­‐8,	  doi:10.1016/j.jneumeth.2008.12.028	  (2009).	  275	   Manwani,	  B.	  et	  al.	  Functional	  recovery	  in	  aging	  mice	  after	  experimental	  stroke.	  Brain	  
Behav	  Immun	  25,	  1689-­‐1700,	  doi:10.1016/j.bbi.2011.06.015	  (2011).	  276	   Ritzel,	  R.	  M.	  et	  al.	  Functional	  differences	  between	  microglia	  and	  monocytes	  after	  ischemic	  stroke.	  J	  Neuroinflammation	  12,	  106,	  doi:10.1186/s12974-­‐015-­‐0329-­‐1	  (2015).	  277	   Liesz,	  A.,	  Hu,	  X.,	  Kleinschnitz,	  C.	  &	  Offner,	  H.	  Functional	  role	  of	  regulatory	  lymphocytes	  in	  stroke:	  facts	  and	  controversies.	  Stroke	  46,	  1422-­‐1430,	  doi:10.1161/STROKEAHA.114.008608	  (2015).	  278	   Liesz,	  A.,	  Karcher,	  S.	  &	  Veltkamp,	  R.	  Spectratype	  analysis	  of	  clonal	  T	  cell	  expansion	  in	  murine	  experimental	  stroke.	  J	  Neuroimmunol	  257,	  46-­‐52,	  doi:10.1016/j.jneuroim.2013.01.013	  (2013).	  279	   Shichita,	  T.	  et	  al.	  Pivotal	  role	  of	  cerebral	  interleukin-­‐17-­‐producing	  gammadeltaT	  cells	  in	  the	  delayed	  phase	  of	  ischemic	  brain	  injury.	  Nat	  Med	  15,	  946-­‐950,	  doi:10.1038/nm.1999	  (2009).	  280	   Denieffe,	  S.,	  Kelly,	  R.	  J.,	  McDonald,	  C.,	  Lyons,	  A.	  &	  Lynch,	  M.	  A.	  Classical	  activation	  of	  microglia	  in	  CD200-­‐deficient	  mice	  is	  a	  consequence	  of	  blood	  brain	  barrier	  permeability	  and	  infiltration	  of	  peripheral	  cells.	  Brain	  Behav	  Immun	  34,	  86-­‐97,	  doi:10.1016/j.bbi.2013.07.174	  (2013).	  281	   Shrivastava,	  K.,	  Gonzalez,	  P.	  &	  Acarin,	  L.	  The	  immune	  inhibitory	  complex	  CD200/CD200R	  is	  developmentally	  regulated	  in	  the	  mouse	  brain.	  J	  Comp	  Neurol	  
520,	  2657-­‐2675,	  doi:10.1002/cne.23062	  (2012).	  282	   Dentesano,	  G.	  et	  al.	  Inhibition	  of	  CD200R1	  expression	  by	  C/EBP	  beta	  in	  reactive	  microglial	  cells.	  J	  Neuroinflammation	  9,	  165,	  doi:10.1186/1742-­‐2094-­‐9-­‐165	  (2012).	  283	   Wright,	  G.	  J.	  et	  al.	  Lymphoid/neuronal	  cell	  surface	  OX2	  glycoprotein	  recognizes	  a	  novel	  receptor	  on	  macrophages	  implicated	  in	  the	  control	  of	  their	  function.	  Immunity	  
13,	  233-­‐242	  (2000).	  284	   Rijkers,	  E.	  S.	  et	  al.	  The	  inhibitory	  CD200R	  is	  differentially	  expressed	  on	  human	  and	  mouse	  T	  and	  B	  lymphocytes.	  Mol	  Immunol	  45,	  1126-­‐1135,	  doi:10.1016/j.molimm.2007.07.013	  (2008).	  285	   Minas,	  K.	  &	  Liversidge,	  J.	  Is	  the	  CD200/CD200	  receptor	  interaction	  more	  than	  just	  a	  myeloid	  cell	  inhibitory	  signal?	  Crit	  Rev	  Immunol	  26,	  213-­‐230	  (2006).	  286	   Caserta,	  S.	  et	  al.	  Chronic	  infection	  drives	  expression	  of	  the	  inhibitory	  receptor	  CD200R,	  and	  its	  ligand	  CD200,	  by	  mouse	  and	  human	  CD4	  T	  cells.	  PLoS	  One	  7,	  e35466,	  doi:10.1371/journal.pone.0035466	  (2012).	  287	   Smorodchenko,	  A.	  et	  al.	  CNS-­‐irrelevant	  T-­‐cells	  enter	  the	  brain,	  cause	  blood-­‐brain	  barrier	  disruption	  but	  no	  glial	  pathology.	  Eur	  J	  Neurosci	  26,	  1387-­‐1398,	  doi:10.1111/j.1460-­‐9568.2007.05792.x	  (2007).	  
	   	   	  219	  
288	   Rygiel,	  T.	  P.	  et	  al.	  Lack	  of	  CD200	  enhances	  pathological	  T	  cell	  responses	  during	  influenza	  infection.	  J	  Immunol	  183,	  1990-­‐1996,	  doi:10.4049/jimmunol.0900252	  (2009).	  289	   Snelgrove,	  R.	  J.	  et	  al.	  A	  critical	  function	  for	  CD200	  in	  lung	  immune	  homeostasis	  and	  the	  severity	  of	  influenza	  infection.	  Nat	  Immunol	  9,	  1074-­‐1083,	  doi:10.1038/ni.1637	  (2008).	  290	   Harris,	  M.	  G.	  et	  al.	  Immune	  privilege	  of	  the	  CNS	  is	  not	  the	  consequence	  of	  limited	  antigen	  sampling.	  Sci	  Rep	  4,	  4422,	  doi:10.1038/srep04422	  (2014).	  291	   Ko,	  Y.	  C.	  et	  al.	  Endothelial	  CD200	  is	  heterogeneously	  distributed,	  regulated	  and	  involved	  in	  immune	  cell-­‐endothelium	  interactions.	  J	  Anat	  214,	  183-­‐195,	  doi:10.1111/j.1469-­‐7580.2008.00986.x	  (2009).	  292	   van	  den	  Borne,	  P.	  et	  al.	  The	  CD200-­‐CD200	  receptor	  inhibitory	  axis	  controls	  arteriogenesis	  and	  local	  T	  lymphocyte	  influx.	  PLoS	  One	  9,	  e98820,	  doi:10.1371/journal.pone.0098820	  (2014).	  293	   Ahmad,	  M.	  et	  al.	  Inflammation	  in	  ischemic	  stroke:	  mechanisms,	  consequences	  and	  possible	  drug	  targets.	  CNS	  Neurol	  Disord	  Drug	  Targets	  13,	  1378-­‐1396	  (2014).	  294	   Ren,	  X.,	  Akiyoshi,	  K.,	  Vandenbark,	  A.	  A.,	  Hurn,	  P.	  D.	  &	  Offner,	  H.	  Programmed	  death-­‐1	  pathway	  limits	  central	  nervous	  system	  inflammation	  and	  neurologic	  deficits	  in	  murine	  experimental	  stroke.	  Stroke	  42,	  2578-­‐2583,	  doi:10.1161/STROKEAHA.111.613182	  (2011).	  295	   Chamorro,	  A.,	  Urra,	  X.	  &	  Planas,	  A.	  M.	  Infection	  after	  acute	  ischemic	  stroke:	  a	  manifestation	  of	  brain-­‐induced	  immunodepression.	  Stroke	  38,	  1097-­‐1103,	  doi:10.1161/01.STR.0000258346.68966.9d	  (2007).	  296	   Meisel,	  C.	  et	  al.	  Preventive	  antibacterial	  treatment	  improves	  the	  general	  medical	  and	  neurological	  outcome	  in	  a	  mouse	  model	  of	  stroke.	  Stroke	  35,	  2-­‐6,	  doi:10.1161/01.STR.0000109041.89959.4C	  (2004).	  297	   Offner,	  H.,	  Vandenbark,	  A.	  A.	  &	  Hurn,	  P.	  D.	  Effect	  of	  experimental	  stroke	  on	  peripheral	  immunity:	  CNS	  ischemia	  induces	  profound	  immunosuppression.	  
Neuroscience	  158,	  1098-­‐1111,	  doi:10.1016/j.neuroscience.2008.05.033	  (2009).	  298	   Prass,	  K.	  et	  al.	  Stroke-­‐induced	  immunodeficiency	  promotes	  spontaneous	  bacterial	  infections	  and	  is	  mediated	  by	  sympathetic	  activation	  reversal	  by	  poststroke	  T	  helper	  cell	  type	  1-­‐like	  immunostimulation.	  J	  Exp	  Med	  198,	  725-­‐736,	  doi:10.1084/jem.20021098	  (2003).	  299	   Klehmet,	  J.	  et	  al.	  Stroke-­‐induced	  immunodepression	  and	  post-­‐stroke	  infections:	  lessons	  from	  the	  preventive	  antibacterial	  therapy	  in	  stroke	  trial.	  Neuroscience	  158,	  1184-­‐1193,	  doi:10.1016/j.neuroscience.2008.07.044	  (2009).	  300	   Meisel,	  A.,	  Meisel,	  C.,	  Harms,	  H.,	  Hartmann,	  O.	  &	  Ulm,	  L.	  Predicting	  post-­‐stroke	  infections	  and	  outcome	  with	  blood-­‐based	  immune	  and	  stress	  markers.	  Cerebrovasc	  
Dis	  33,	  580-­‐588,	  doi:10.1159/000338080	  (2012).	  301	   Westendorp,	  W.	  F.,	  Nederkoorn,	  P.	  J.,	  Vermeij,	  J.	  D.,	  Dijkgraaf,	  M.	  G.	  &	  van	  de	  Beek,	  D.	  Post-­‐stroke	  infection:	  a	  systematic	  review	  and	  meta-­‐analysis.	  BMC	  Neurol	  11,	  110,	  doi:10.1186/1471-­‐2377-­‐11-­‐110	  (2011).	  302	   Kwan,	  J.	  et	  al.	  IL-­‐6	  is	  a	  predictive	  biomarker	  for	  stroke	  associated	  infection	  and	  future	  mortality	  in	  the	  elderly	  after	  an	  ischemic	  stroke.	  Exp	  Gerontol	  48,	  960-­‐965,	  doi:10.1016/j.exger.2013.07.003	  (2013).	  
	   	   	  220	  
303	   Sandau,	  M.	  M.,	  Winstead,	  C.	  J.	  &	  Jameson,	  S.	  C.	  IL-­‐15	  is	  required	  for	  sustained	  lymphopenia-­‐driven	  proliferation	  and	  accumulation	  of	  CD8	  T	  cells.	  J	  Immunol	  179,	  120-­‐125	  (2007).	  304	   Hug,	  A.	  et	  al.	  Infarct	  volume	  is	  a	  major	  determiner	  of	  post-­‐stroke	  immune	  cell	  function	  and	  susceptibility	  to	  infection.	  Stroke	  40,	  3226-­‐3232,	  doi:10.1161/STROKEAHA.109.557967	  (2009).	  305	   Gorczynski,	  R.	  M.	  Evidence	  for	  an	  immunoregulatory	  role	  of	  OX2	  with	  its	  counter	  ligand	  (OX2L)	  in	  the	  regulation	  of	  transplant	  rejection,	  fetal	  loss,	  autoimmunity	  and	  tumor	  growth.	  Arch	  Immunol	  Ther	  Exp	  (Warsz)	  49,	  303-­‐309	  (2001).	  306	   Rygiel,	  T.	  P.	  &	  Meyaard,	  L.	  CD200R	  signaling	  in	  tumor	  tolerance	  and	  inflammation:	  A	  tricky	  balance.	  Curr	  Opin	  Immunol	  24,	  233-­‐238,	  doi:10.1016/j.coi.2012.01.002	  (2012).	  307	   Frank,	  M.	  G.,	  Baratta,	  M.	  V.,	  Sprunger,	  D.	  B.,	  Watkins,	  L.	  R.	  &	  Maier,	  S.	  F.	  Microglia	  serve	  as	  a	  neuroimmune	  substrate	  for	  stress-­‐induced	  potentiation	  of	  CNS	  pro-­‐inflammatory	  cytokine	  responses.	  Brain	  Behav	  Immun	  21,	  47-­‐59,	  doi:10.1016/j.bbi.2006.03.005	  (2007).	  308	   Lyons,	  A.	  et	  al.	  CD200	  ligand	  receptor	  interaction	  modulates	  microglial	  activation	  in	  vivo	  and	  in	  vitro:	  a	  role	  for	  IL-­‐4.	  J	  Neurosci	  27,	  8309-­‐8313,	  doi:10.1523/JNEUROSCI.1781-­‐07.2007	  (2007).	  309	   Taki,	  Y.	  et	  al.	  A	  longitudinal	  study	  of	  gray	  matter	  volume	  decline	  with	  age	  and	  modifying	  factors.	  Neurobiol	  Aging	  32,	  907-­‐915,	  doi:10.1016/j.neurobiolaging.2009.05.003	  (2011).	  310	   Taki,	  Y.	  et	  al.	  Correlations	  among	  brain	  gray	  matter	  volumes,	  age,	  gender,	  and	  hemisphere	  in	  healthy	  individuals.	  PLoS	  One	  6,	  e22734,	  doi:10.1371/journal.pone.0022734	  (2011).	  311	   Howcroft,	  T.	  K.	  et	  al.	  The	  role	  of	  inflammation	  in	  age-­‐related	  disease.	  Aging	  (Albany	  
NY)	  5,	  84-­‐93	  (2013).	  312	   Kovacs,	  E.	  J.,	  Duffner,	  L.	  A.	  &	  Plackett,	  T.	  P.	  Immunosuppression	  after	  injury	  in	  aged	  mice	  is	  associated	  with	  a	  TH1-­‐TH2	  shift,	  which	  can	  be	  restored	  by	  estrogen	  treatment.	  Mech	  Ageing	  Dev	  125,	  121-­‐123,	  doi:10.1016/j.mad.2003.11.007	  (2004).	  313	   Gorczynski,	  R.,	  Chen,	  Z.,	  Khatri,	  I.	  &	  Yu,	  K.	  sCD200	  present	  in	  mice	  receiving	  cardiac	  and	  skin	  allografts	  causes	  immunosuppression	  in	  vitro	  and	  induces	  Tregs.	  
Transplantation	  95,	  442-­‐447,	  doi:10.1097/TP.0b013e3182754c30	  (2013).	  314	   Gorczynski,	  R.	  M.	  et	  al.	  Structural	  and	  functional	  heterogeneity	  in	  the	  CD200R	  family	  of	  immunoregulatory	  molecules	  and	  their	  expression	  at	  the	  feto-­‐maternal	  interface.	  
Am	  J	  Reprod	  Immunol	  52,	  147-­‐163,	  doi:10.1111/j.1600-­‐0897.2004.00192.x	  (2004).	  315	   Kojima,	  T.	  et	  al.	  Mast	  cells	  and	  basophils	  are	  selectively	  activated	  in	  vitro	  and	  in	  vivo	  through	  CD200R3	  in	  an	  IgE-­‐independent	  manner.	  J	  Immunol	  179,	  7093-­‐7100	  (2007).	  316	   Arase,	  H.	  &	  Lanier,	  L.	  L.	  Virus-­‐driven	  evolution	  of	  natural	  killer	  cell	  receptors.	  
Microbes	  Infect	  4,	  1505-­‐1512	  (2002).	  317	   Zhang,	  B.	  &	  Gensel,	  J.	  C.	  Is	  neuroinflammation	  in	  the	  injured	  spinal	  cord	  different	  than	  in	  the	  brain?	  Examining	  intrinsic	  differences	  between	  the	  brain	  and	  spinal	  cord.	  Experimental	  neurology	  258,	  112-­‐120,	  doi:10.1016/j.expneurol.2014.04.007	  (2014).	  
	   	   	  221	  
318	   Nayak,	  D.,	  Roth,	  T.	  L.	  &	  McGavern,	  D.	  B.	  Microglia	  development	  and	  function.	  Annual	  
review	  of	  immunology	  32,	  367-­‐402,	  doi:10.1146/annurev-­‐immunol-­‐032713-­‐120240	  (2014).	  319	   Wong,	  W.	  T.	  Microglial	  aging	  in	  the	  healthy	  CNS:	  phenotypes,	  drivers,	  and	  rejuvenation.	  Frontiers	  in	  cellular	  neuroscience	  7,	  22,	  doi:10.3389/fncel.2013.00022	  (2013).	  320	   Ransohoff,	  R.	  M.	  &	  Perry,	  V.	  H.	  Microglial	  physiology:	  unique	  stimuli,	  specialized	  responses.	  Annual	  review	  of	  immunology	  27,	  119-­‐145,	  doi:10.1146/annurev.immunol.021908.132528	  (2009).	  321	   Baskar	  Jesudasan,	  S.	  J.,	  Todd,	  K.	  G.	  &	  Winship,	  I.	  R.	  Reduced	  inflammatory	  phenotype	  in	  microglia	  derived	  from	  neonatal	  rat	  spinal	  cord	  versus	  brain.	  PloS	  one	  9,	  e99443,	  doi:10.1371/journal.pone.0099443	  (2014).	  322	   Hanisch,	  U.	  K.	  Functional	  diversity	  of	  microglia	  -­‐	  how	  heterogeneous	  are	  they	  to	  begin	  with?	  Frontiers	  in	  cellular	  neuroscience	  7,	  65,	  doi:10.3389/fncel.2013.00065	  (2013).	  323	   Schnell,	  L.,	  Fearn,	  S.,	  Schwab,	  M.	  E.,	  Perry,	  V.	  H.	  &	  Anthony,	  D.	  C.	  Cytokine-­‐induced	  acute	  inflammation	  in	  the	  brain	  and	  spinal	  cord.	  Journal	  of	  neuropathology	  and	  
experimental	  neurology	  58,	  245-­‐254	  (1999).	  324	   Batchelor,	  P.	  E.,	  Tan,	  S.,	  Wills,	  T.	  E.,	  Porritt,	  M.	  J.	  &	  Howells,	  D.	  W.	  Comparison	  of	  inflammation	  in	  the	  brain	  and	  spinal	  cord	  following	  mechanical	  injury.	  Journal	  of	  
neurotrauma	  25,	  1217-­‐1225,	  doi:10.1089/neu.2007.0308	  (2008).	  325	   Schnell,	  L.,	  Fearn,	  S.,	  Klassen,	  H.,	  Schwab,	  M.	  E.	  &	  Perry,	  V.	  H.	  Acute	  inflammatory	  responses	  to	  mechanical	  lesions	  in	  the	  CNS:	  differences	  between	  brain	  and	  spinal	  cord.	  The	  European	  journal	  of	  neuroscience	  11,	  3648-­‐3658	  (1999).	  326	   Bartanusz,	  V.,	  Jezova,	  D.,	  Alajajian,	  B.	  &	  Digicaylioglu,	  M.	  The	  blood-­‐spinal	  cord	  barrier:	  morphology	  and	  clinical	  implications.	  Annals	  of	  neurology	  70,	  194-­‐206,	  doi:10.1002/ana.22421	  (2011).	  327	   Phillips,	  L.	  M.,	  Simon,	  P.	  J.	  &	  Lampson,	  L.	  A.	  Site-­‐specific	  immune	  regulation	  in	  the	  brain:	  differential	  modulation	  of	  major	  histocompatibility	  complex	  (MHC)	  proteins	  in	  brainstem	  vs.	  hippocampus.	  The	  Journal	  of	  comparative	  neurology	  405,	  322-­‐333	  (1999).	  328	   Phillips,	  L.	  M.	  &	  Lampson,	  L.	  A.	  Site-­‐specific	  control	  of	  T	  cell	  traffic	  in	  the	  brain:	  T	  cell	  entry	  to	  brainstem	  vs.	  hippocampus	  after	  local	  injection	  of	  IFN-­‐gamma.	  Journal	  of	  
neuroimmunology	  96,	  218-­‐227	  (1999).	  329	   Vaughan,	  D.	  W.	  &	  Peters,	  A.	  Neuroglial	  cells	  in	  the	  cerebral	  cortex	  of	  rats	  from	  young	  adulthood	  to	  old	  age:	  an	  electron	  microscope	  study.	  Journal	  of	  neurocytology	  3,	  405-­‐429	  (1974).	  330	   Samorajski,	  T.	  How	  the	  human	  brain	  responds	  to	  aging.	  Journal	  of	  the	  American	  
Geriatrics	  Society	  24,	  4-­‐11	  (1976).	  331	   Perry,	  V.	  H.,	  Matyszak,	  M.	  K.	  &	  Fearn,	  S.	  Altered	  antigen	  expression	  of	  microglia	  in	  the	  aged	  rodent	  CNS.	  Glia	  7,	  60-­‐67,	  doi:10.1002/glia.440070111	  (1993).	  332	   Hart,	  A.	  D.,	  Wyttenbach,	  A.,	  Perry,	  V.	  H.	  &	  Teeling,	  J.	  L.	  Age	  related	  changes	  in	  microglial	  phenotype	  vary	  between	  CNS	  regions:	  grey	  versus	  white	  matter	  differences.	  Brain,	  behavior,	  and	  immunity	  26,	  754-­‐765,	  doi:10.1016/j.bbi.2011.11.006	  (2012).	  
	   	   	  222	  
333	   von	  Bernhardi,	  R.,	  Tichauer,	  J.	  E.	  &	  Eugenin,	  J.	  Aging-­‐dependent	  changes	  of	  microglial	  cells	  and	  their	  relevance	  for	  neurodegenerative	  disorders.	  Journal	  of	  neurochemistry	  
112,	  1099-­‐1114,	  doi:10.1111/j.1471-­‐4159.2009.06537.x	  (2010).	  334	   Chen,	  J.	  et	  al.	  Neuroinflammation	  and	  disruption	  in	  working	  memory	  in	  aged	  mice	  after	  acute	  stimulation	  of	  the	  peripheral	  innate	  immune	  system.	  Brain,	  behavior,	  and	  
immunity	  22,	  301-­‐311,	  doi:10.1016/j.bbi.2007.08.014	  (2008).	  335	   Tanic,	  N.,	  Perovic,	  M.,	  Mladenovic,	  A.,	  Ruzdijic,	  S.	  &	  Kanazir,	  S.	  Effects	  of	  aging,	  dietary	  restriction	  and	  glucocorticoid	  treatment	  on	  housekeeping	  gene	  expression	  in	  rat	  cortex	  and	  hippocampus-­‐evaluation	  by	  real	  time	  RT-­‐PCR.	  Journal	  of	  molecular	  
neuroscience	  :	  MN	  32,	  38-­‐46	  (2007).	  336	   Chan,	  D.	  C.	  Mitochondria:	  dynamic	  organelles	  in	  disease,	  aging,	  and	  development.	  
Cell	  125,	  1241-­‐1252,	  doi:10.1016/j.cell.2006.06.010	  (2006).	  337	   Balaban,	  R.	  S.,	  Nemoto,	  S.	  &	  Finkel,	  T.	  Mitochondria,	  oxidants,	  and	  aging.	  Cell	  120,	  483-­‐495,	  doi:10.1016/j.cell.2005.02.001	  (2005).	  338	   Chung,	  H.	  Y.,	  Sung,	  B.,	  Jung,	  K.	  J.,	  Zou,	  Y.	  &	  Yu,	  B.	  P.	  The	  molecular	  inflammatory	  process	  in	  aging.	  Antioxidants	  &	  redox	  signaling	  8,	  572-­‐581,	  doi:10.1089/ars.2006.8.572	  (2006).	  339	   de	  Gonzalo-­‐Calvo,	  D.	  et	  al.	  Differential	  inflammatory	  responses	  in	  aging	  and	  disease:	  TNF-­‐alpha	  and	  IL-­‐6	  as	  possible	  biomarkers.	  Free	  radical	  biology	  &	  medicine	  49,	  733-­‐737,	  doi:10.1016/j.freeradbiomed.2010.05.019	  (2010).	  340	   Scheffel,	  J.	  et	  al.	  Toll-­‐like	  receptor	  activation	  reveals	  developmental	  reorganization	  and	  unmasks	  responder	  subsets	  of	  microglia.	  Glia	  60,	  1930-­‐1943,	  doi:10.1002/glia.22409	  (2012).	  341	   de	  Haas,	  A.	  H.,	  Boddeke,	  H.	  W.	  &	  Biber,	  K.	  Region-­‐specific	  expression	  of	  immunoregulatory	  proteins	  on	  microglia	  in	  the	  healthy	  CNS.	  Glia	  56,	  888-­‐894,	  doi:10.1002/glia.20663	  (2008).	  342	   Carson,	  M.	  J.,	  Reilly,	  C.	  R.,	  Sutcliffe,	  J.	  G.	  &	  Lo,	  D.	  Mature	  microglia	  resemble	  immature	  antigen-­‐presenting	  cells.	  Glia	  22,	  72-­‐85	  (1998).	  343	   Ensinger,	  E.	  M.	  et	  al.	  Regional	  topographical	  differences	  of	  canine	  microglial	  immunophenotype	  and	  function	  in	  the	  healthy	  spinal	  cord.	  Journal	  of	  
neuroimmunology	  227,	  144-­‐152,	  doi:10.1016/j.jneuroim.2010.07.017	  (2010).	  344	   Pan,	  W.,	  Banks,	  W.	  A.	  &	  Kastin,	  A.	  J.	  Permeability	  of	  the	  blood-­‐brain	  and	  blood-­‐spinal	  cord	  barriers	  to	  interferons.	  Journal	  of	  neuroimmunology	  76,	  105-­‐111	  (1997).	  345	   Pan,	  W.,	  Banks,	  W.	  A.	  &	  Kastin,	  A.	  J.	  Blood-­‐brain	  barrier	  permeability	  to	  ebiratide	  and	  TNF	  in	  acute	  spinal	  cord	  injury.	  Experimental	  neurology	  146,	  367-­‐373,	  doi:10.1006/exnr.1997.6533	  (1997).	  346	   Gaudet,	  A.	  D.	  &	  Popovich,	  P.	  G.	  Extracellular	  matrix	  regulation	  of	  inflammation	  in	  the	  healthy	  and	  injured	  spinal	  cord.	  Experimental	  neurology	  258,	  24-­‐34,	  doi:10.1016/j.expneurol.2013.11.020	  (2014).	  347	   Manwani,	  B.	  et	  al.	  Perfusion	  of	  ischemic	  brain	  in	  young	  and	  aged	  animals:	  a	  laser	  speckle	  flowmetry	  study.	  Stroke	  45,	  571-­‐578,	  doi:10.1161/STROKEAHA.113.002944	  (2014).	  348	   Ogura,	  K.,	  Ogawa,	  M.	  &	  Yoshida,	  M.	  Effects	  of	  ageing	  on	  microglia	  in	  the	  normal	  rat	  brain:	  immunohistochemical	  observations.	  Neuroreport	  5,	  1224-­‐1226	  (1994).	  349	   Godbout,	  J.	  P.	  et	  al.	  Exaggerated	  neuroinflammation	  and	  sickness	  behavior	  in	  aged	  mice	  following	  activation	  of	  the	  peripheral	  innate	  immune	  system.	  FASEB	  journal	  :	  
	   	   	  223	  
official	  publication	  of	  the	  Federation	  of	  American	  Societies	  for	  Experimental	  Biology	  
19,	  1329-­‐1331,	  doi:10.1096/fj.05-­‐3776fje	  (2005).	  350	   Stadtman,	  E.	  R.	  Protein	  oxidation	  and	  aging.	  Free	  radical	  research	  40,	  1250-­‐1258,	  doi:10.1080/10715760600918142	  (2006).	  351	   Clausen,	  A.,	  Doctrow,	  S.	  &	  Baudry,	  M.	  Prevention	  of	  cognitive	  deficits	  and	  brain	  oxidative	  stress	  with	  superoxide	  dismutase/catalase	  mimetics	  in	  aged	  mice.	  
Neurobiology	  of	  aging	  31,	  425-­‐433,	  doi:10.1016/j.neurobiolaging.2008.05.009	  (2010).	  352	   Terman,	  A.,	  Gustafsson,	  B.	  &	  Brunk,	  U.	  T.	  The	  lysosomal-­‐mitochondrial	  axis	  theory	  of	  postmitotic	  aging	  and	  cell	  death.	  Chemico-­‐biological	  interactions	  163,	  29-­‐37,	  doi:10.1016/j.cbi.2006.04.013	  (2006).	  353	   Youm,	  Y.	  H.	  et	  al.	  Canonical	  Nlrp3	  inflammasome	  links	  systemic	  low-­‐grade	  inflammation	  to	  functional	  decline	  in	  aging.	  Cell	  metabolism	  18,	  519-­‐532,	  doi:10.1016/j.cmet.2013.09.010	  (2013).	  354	   Orre,	  M.	  et	  al.	  Isolation	  of	  glia	  from	  Alzheimer's	  mice	  reveals	  inflammation	  and	  dysfunction.	  Neurobiology	  of	  aging,	  doi:10.1016/j.neurobiolaging.2014.06.004	  (2014).	  355	   Lucin,	  K.	  M.	  et	  al.	  Microglial	  beclin	  1	  regulates	  retromer	  trafficking	  and	  phagocytosis	  and	  is	  impaired	  in	  Alzheimer's	  disease.	  Neuron	  79,	  873-­‐886,	  doi:10.1016/j.neuron.2013.06.046	  (2013).	  356	   Sokolowski,	  J.	  D.	  &	  Mandell,	  J.	  W.	  Phagocytic	  clearance	  in	  neurodegeneration.	  The	  
American	  journal	  of	  pathology	  178,	  1416-­‐1428,	  doi:10.1016/j.ajpath.2010.12.051	  (2011).	  357	   Selkoe,	  D.	  J.	  Toward	  a	  comprehensive	  theory	  for	  Alzheimer's	  disease.	  Hypothesis:	  Alzheimer's	  disease	  is	  caused	  by	  the	  cerebral	  accumulation	  and	  cytotoxicity	  of	  amyloid	  beta-­‐protein.	  Annals	  of	  the	  New	  York	  Academy	  of	  Sciences	  924,	  17-­‐25	  (2000).	  358	   Li,	  W.	  Phagocyte	  dysfunction,	  tissue	  aging	  and	  degeneration.	  Ageing	  research	  reviews	  
12,	  1005-­‐1012,	  doi:10.1016/j.arr.2013.05.006	  (2013).	  359	   Pyo,	  H.,	  Jou,	  I.,	  Jung,	  S.,	  Hong,	  S.	  &	  Joe,	  E.	  H.	  Mitogen-­‐activated	  protein	  kinases	  activated	  by	  lipopolysaccharide	  and	  beta-­‐amyloid	  in	  cultured	  rat	  microglia.	  
Neuroreport	  9,	  871-­‐874	  (1998).	  360	   Halle,	  A.	  et	  al.	  The	  NALP3	  inflammasome	  is	  involved	  in	  the	  innate	  immune	  response	  to	  amyloid-­‐beta.	  Nature	  immunology	  9,	  857-­‐865,	  doi:10.1038/ni.1636	  (2008).	  361	   Napoli,	  I.	  &	  Neumann,	  H.	  Microglial	  clearance	  function	  in	  health	  and	  disease.	  
Neuroscience	  158,	  1030-­‐1038,	  doi:10.1016/j.neuroscience.2008.06.046	  (2009).	  362	   Floden,	  A.	  M.	  &	  Combs,	  C.	  K.	  Beta-­‐amyloid	  stimulates	  murine	  postnatal	  and	  adult	  microglia	  cultures	  in	  a	  unique	  manner.	  The	  Journal	  of	  neuroscience	  :	  the	  official	  
journal	  of	  the	  Society	  for	  Neuroscience	  26,	  4644-­‐4648,	  doi:10.1523/JNEUROSCI.4822-­‐05.2006	  (2006).	  363	   Salminen,	  A.	  et	  al.	  Impaired	  autophagy	  and	  APP	  processing	  in	  Alzheimer's	  disease:	  The	  potential	  role	  of	  Beclin	  1	  interactome.	  Progress	  in	  neurobiology	  106-­‐107,	  33-­‐54,	  doi:10.1016/j.pneurobio.2013.06.002	  (2013).	  364	   Norden,	  D.	  M.	  &	  Godbout,	  J.	  P.	  Review:	  microglia	  of	  the	  aged	  brain:	  primed	  to	  be	  activated	  and	  resistant	  to	  regulation.	  Neuropathology	  and	  applied	  neurobiology	  39,	  19-­‐34,	  doi:10.1111/j.1365-­‐2990.2012.01306.x	  (2013).	  
	   	   	  224	  
365	   Han,	  M.	  H.	  et	  al.	  Janus-­‐like	  opposing	  roles	  of	  CD47	  in	  autoimmune	  brain	  inflammation	  in	  humans	  and	  mice.	  The	  Journal	  of	  experimental	  medicine	  209,	  1325-­‐1334,	  doi:10.1084/jem.20101974	  (2012).	  366	   Gitik,	  M.,	  Liraz-­‐Zaltsman,	  S.,	  Oldenborg,	  P.	  A.,	  Reichert,	  F.	  &	  Rotshenker,	  S.	  Myelin	  down-­‐regulates	  myelin	  phagocytosis	  by	  microglia	  and	  macrophages	  through	  interactions	  between	  CD47	  on	  myelin	  and	  SIRPalpha	  (signal	  regulatory	  protein-­‐alpha)	  on	  phagocytes.	  Journal	  of	  neuroinflammation	  8,	  24,	  doi:10.1186/1742-­‐2094-­‐8-­‐24	  (2011).	  367	   Ortman,	  J.	  M.,	  Velkoff,	  V.	  A.	  &	  Hogan,	  H.	  An	  aging	  nation:	  the	  older	  population	  in	  the	  United	  States.	  Washington,	  DC:	  US	  Census	  Bureau,	  25-­‐1140	  (2014).	  368	   Cribbs,	  D.	  H.	  et	  al.	  Extensive	  innate	  immune	  gene	  activation	  accompanies	  brain	  aging,	  increasing	  vulnerability	  to	  cognitive	  decline	  and	  neurodegeneration:	  a	  microarray	  study.	  J	  Neuroinflammation	  9,	  179,	  doi:10.1186/1742-­‐2094-­‐9-­‐179	  (2012).	  369	   Schwartz,	  M.,	  Kipnis,	  J.,	  Rivest,	  S.	  &	  Prat,	  A.	  How	  do	  immune	  cells	  support	  and	  shape	  the	  brain	  in	  health,	  disease,	  and	  aging?	  J	  Neurosci	  33,	  17587-­‐17596,	  doi:10.1523/JNEUROSCI.3241-­‐13.2013	  (2013).	  370	   Wrona,	  D.	  Neural-­‐immune	  interactions:	  an	  integrative	  view	  of	  the	  bidirectional	  relationship	  between	  the	  brain	  and	  immune	  systems.	  J	  Neuroimmunol	  172,	  38-­‐58,	  doi:10.1016/j.jneuroim.2005.10.017	  (2006).	  371	   Banks,	  W.	  A.	  The	  blood-­‐brain	  barrier	  in	  neuroimmunology:	  Tales	  of	  separation	  and	  assimilation.	  Brain	  Behav	  Immun	  44,	  1-­‐8,	  doi:10.1016/j.bbi.2014.08.007	  (2015).	  372	   Baruch,	  K.	  et	  al.	  CNS-­‐specific	  immunity	  at	  the	  choroid	  plexus	  shifts	  toward	  destructive	  Th2	  inflammation	  in	  brain	  aging.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  110,	  2264-­‐2269,	  doi:10.1073/pnas.1211270110	  (2013).	  373	   Louveau,	  A.	  et	  al.	  Structural	  and	  functional	  features	  of	  central	  nervous	  system	  lymphatic	  vessels.	  Nature,	  doi:10.1038/nature14432	  (2015).	  374	   Sierra,	  A.	  et	  al.	  Surveillance,	  phagocytosis,	  and	  inflammation:	  how	  never-­‐resting	  microglia	  influence	  adult	  hippocampal	  neurogenesis.	  Neural	  Plast	  2014,	  610343,	  doi:10.1155/2014/610343	  (2014).	  375	   Gemechu,	  J.	  M.	  &	  Bentivoglio,	  M.	  T	  Cell	  Recruitment	  in	  the	  Brain	  during	  Normal	  Aging.	  Front	  Cell	  Neurosci	  6,	  38,	  doi:10.3389/fncel.2012.00038	  (2012).	  376	   de	  Graaf,	  M.	  T.	  et	  al.	  Flow	  cytometric	  characterization	  of	  cerebrospinal	  fluid	  cells.	  
Cytometry	  B	  Clin	  Cytom	  80,	  271-­‐281,	  doi:10.1002/cyto.b.20603	  (2011).	  377	   de	  Graaf,	  M.	  T.	  et	  al.	  Central	  memory	  CD4+	  T	  cells	  dominate	  the	  normal	  cerebrospinal	  fluid.	  Cytometry	  B	  Clin	  Cytom	  80,	  43-­‐50,	  doi:10.1002/cyto.b.20542	  (2011).	  378	   Kivisakk,	  P.	  et	  al.	  Human	  cerebrospinal	  fluid	  central	  memory	  CD4+	  T	  cells:	  evidence	  for	  trafficking	  through	  choroid	  plexus	  and	  meninges	  via	  P-­‐selectin.	  Proc	  Natl	  Acad	  
Sci	  U	  S	  A	  100,	  8389-­‐8394,	  doi:10.1073/pnas.1433000100	  (2003).	  379	   Kipnis,	  J.,	  Gadani,	  S.	  &	  Derecki,	  N.	  C.	  Pro-­‐cognitive	  properties	  of	  T	  cells.	  Nat	  Rev	  
Immunol	  12,	  663-­‐669,	  doi:10.1038/nri3280	  (2012).	  380	   Radjavi,	  A.,	  Smirnov,	  I.,	  Derecki,	  N.	  &	  Kipnis,	  J.	  Dynamics	  of	  the	  meningeal	  CD4(+)	  T-­‐cell	  repertoire	  are	  defined	  by	  the	  cervical	  lymph	  nodes	  and	  facilitate	  cognitive	  task	  performance	  in	  mice.	  Mol	  Psychiatry	  19,	  531-­‐533,	  doi:10.1038/mp.2013.79	  (2014).	  
	   	   	  225	  
381	   Radjavi,	  A.,	  Smirnov,	  I.	  &	  Kipnis,	  J.	  Brain	  antigen-­‐reactive	  CD4+	  T	  cells	  are	  sufficient	  to	  support	  learning	  behavior	  in	  mice	  with	  limited	  T	  cell	  repertoire.	  Brain	  Behav	  
Immun	  35,	  58-­‐63,	  doi:10.1016/j.bbi.2013.08.013	  (2014).	  382	   Swann,	  J.	  B.	  &	  Smyth,	  M.	  J.	  Immune	  surveillance	  of	  tumors.	  J	  Clin	  Invest	  117,	  1137-­‐1146,	  doi:10.1172/JCI31405	  (2007).	  383	   Stichel,	  C.	  C.	  &	  Luebbert,	  H.	  Inflammatory	  processes	  in	  the	  aging	  mouse	  brain:	  participation	  of	  dendritic	  cells	  and	  T-­‐cells.	  Neurobiol	  Aging	  28,	  1507-­‐1521,	  doi:10.1016/j.neurobiolaging.2006.07.022	  (2007).	  384	   Smolders,	  J.	  et	  al.	  Characteristics	  of	  differentiated	  CD8(+)	  and	  CD4	  (+)	  T	  cells	  present	  in	  the	  human	  brain.	  Acta	  Neuropathol	  126,	  525-­‐535,	  doi:10.1007/s00401-­‐013-­‐1155-­‐0	  (2013).	  385	   Ritzel,	  R.	  M.	  et	  al.	  Age-­‐	  and	  location-­‐related	  changes	  in	  microglial	  function.	  Neurobiol	  
Aging	  36,	  2153-­‐2163,	  doi:10.1016/j.neurobiolaging.2015.02.016	  (2015).	  386	   Miguel-­‐Hidalgo,	  J.	  J.,	  Nithuairisg,	  S.,	  Stockmeier,	  C.	  &	  Rajkowska,	  G.	  Distribution	  of	  ICAM-­‐1	  immunoreactivity	  during	  aging	  in	  the	  human	  orbitofrontal	  cortex.	  Brain	  
Behav	  Immun	  21,	  100-­‐111,	  doi:10.1016/j.bbi.2006.05.001	  (2007).	  387	   Xu,	  Y.	  Z.,	  Nygard,	  M.,	  Kristensson,	  K.	  &	  Bentivoglio,	  M.	  Regulation	  of	  cytokine	  signaling	  and	  T-­‐cell	  recruitment	  in	  the	  aging	  mouse	  brain	  in	  response	  to	  central	  inflammatory	  challenge.	  Brain	  Behav	  Immun	  24,	  138-­‐152,	  doi:10.1016/j.bbi.2009.09.006	  (2010).	  388	   Anderson,	  K.	  G.	  et	  al.	  Intravascular	  staining	  for	  discrimination	  of	  vascular	  and	  tissue	  leukocytes.	  Nat	  Protoc	  9,	  209-­‐222,	  doi:10.1038/nprot.2014.005	  (2014).	  389	   Anderson,	  K.	  G.	  et	  al.	  Cutting	  edge:	  intravascular	  staining	  redefines	  lung	  CD8	  T	  cell	  responses.	  J	  Immunol	  189,	  2702-­‐2706,	  doi:10.4049/jimmunol.1201682	  (2012).	  390	   Liu,	  F.	  &	  Whitton,	  J.	  L.	  Cutting	  edge:	  re-­‐evaluating	  the	  in	  vivo	  cytokine	  responses	  of	  CD8+	  T	  cells	  during	  primary	  and	  secondary	  viral	  infections.	  J	  Immunol	  174,	  5936-­‐5940	  (2005).	  391	   Biber,	  K.,	  Zuurman,	  M.	  W.,	  Dijkstra,	  I.	  M.	  &	  Boddeke,	  H.	  W.	  Chemokines	  in	  the	  brain:	  neuroimmunology	  and	  beyond.	  Curr	  Opin	  Pharmacol	  2,	  63-­‐68	  (2002).	  392	   Chen,	  J.	  et	  al.	  Aging	  is	  associated	  with	  increased	  T-­‐cell	  chemokine	  expression	  in	  C57BL/6	  mice.	  J	  Gerontol	  A	  Biol	  Sci	  Med	  Sci	  58,	  975-­‐983	  (2003).	  393	   Felzien,	  L.	  K.,	  McDonald,	  J.	  T.,	  Gleason,	  S.	  M.,	  Berman,	  N.	  E.	  &	  Klein,	  R.	  M.	  Increased	  chemokine	  gene	  expression	  during	  aging	  in	  the	  murine	  brain.	  Brain	  Res	  890,	  137-­‐146	  (2001).	  394	   Mo,	  R.	  et	  al.	  T	  cell	  chemokine	  receptor	  expression	  in	  aging.	  J	  Immunol	  170,	  895-­‐904	  (2003).	  395	   Mo,	  F.	  M.,	  Proia,	  A.	  D.,	  Johnson,	  W.	  H.,	  Cyr,	  D.	  &	  Lashkari,	  K.	  Interferon	  gamma-­‐inducible	  protein-­‐10	  (IP-­‐10)	  and	  eotaxin	  as	  biomarkers	  in	  age-­‐related	  macular	  degeneration.	  Invest	  Ophthalmol	  Vis	  Sci	  51,	  4226-­‐4236,	  doi:10.1167/iovs.09-­‐3910	  (2010).	  396	   Shurin,	  G.	  V.	  et	  al.	  Dynamic	  alteration	  of	  soluble	  serum	  biomarkers	  in	  healthy	  aging.	  
Cytokine	  39,	  123-­‐129,	  doi:10.1016/j.cyto.2007.06.006	  (2007).	  397	   Villeda,	  S.	  A.	  et	  al.	  The	  ageing	  systemic	  milieu	  negatively	  regulates	  neurogenesis	  and	  cognitive	  function.	  Nature	  477,	  90-­‐94,	  doi:10.1038/nature10357	  (2011).	  398	   Jaerve,	  A.	  &	  Muller,	  H.	  W.	  Chemokines	  in	  CNS	  injury	  and	  repair.	  Cell	  Tissue	  Res	  349,	  229-­‐248,	  doi:10.1007/s00441-­‐012-­‐1427-­‐3	  (2012).	  
	   	   	  226	  
399	   Elahy,	  M.	  et	  al.	  Blood-­‐brain	  barrier	  dysfunction	  developed	  during	  normal	  aging	  is	  associated	  with	  inflammation	  and	  loss	  of	  tight	  junctions	  but	  not	  with	  leukocyte	  recruitment.	  Immun	  Ageing	  12,	  2,	  doi:10.1186/s12979-­‐015-­‐0029-­‐9	  (2015).	  400	   Floris,	  S.	  et	  al.	  Blood-­‐brain	  barrier	  permeability	  and	  monocyte	  infiltration	  in	  experimental	  allergic	  encephalomyelitis:	  a	  quantitative	  MRI	  study.	  Brain	  127,	  616-­‐627,	  doi:10.1093/brain/awh068	  (2004).	  401	   Greenwood,	  J.	  et	  al.	  Review:	  leucocyte-­‐endothelial	  cell	  crosstalk	  at	  the	  blood-­‐brain	  barrier:	  a	  prerequisite	  for	  successful	  immune	  cell	  entry	  to	  the	  brain.	  Neuropathol	  
Appl	  Neurobiol	  37,	  24-­‐39,	  doi:10.1111/j.1365-­‐2990.2010.01140.x	  (2011).	  402	   Vrethem,	  M.	  et	  al.	  CD4	  and	  CD8	  lymphocyte	  subsets	  in	  cerebrospinal	  fluid	  and	  peripheral	  blood	  from	  patients	  with	  multiple	  sclerosis,	  meningitis	  and	  normal	  controls.	  Acta	  Neurol	  Scand	  97,	  215-­‐220	  (1998).	  403	   Baruch,	  K.	  et	  al.	  Aging.	  Aging-­‐induced	  type	  I	  interferon	  response	  at	  the	  choroid	  plexus	  negatively	  affects	  brain	  function.	  Science	  346,	  89-­‐93,	  doi:10.1126/science.1252945	  (2014).	  404	   Barcia,	  C.	  et	  al.	  T	  cells'	  immunological	  synapses	  induce	  polarization	  of	  brain	  astrocytes	  in	  vivo	  and	  in	  vitro:	  a	  novel	  astrocyte	  response	  mechanism	  to	  cellular	  injury.	  PLoS	  One	  3,	  e2977,	  doi:10.1371/journal.pone.0002977	  (2008).	  405	   Sasaki,	  K.	  et	  al.	  Relapsing-­‐remitting	  central	  nervous	  system	  autoimmunity	  mediated	  by	  GFAP-­‐specific	  CD8	  T	  cells.	  J	  Immunol	  192,	  3029-­‐3042,	  doi:10.4049/jimmunol.1302911	  (2014).	  406	   Cabarrocas,	  J.,	  Bauer,	  J.,	  Piaggio,	  E.,	  Liblau,	  R.	  &	  Lassmann,	  H.	  Effective	  and	  selective	  immune	  surveillance	  of	  the	  brain	  by	  MHC	  class	  I-­‐restricted	  cytotoxic	  T	  lymphocytes.	  
Eur	  J	  Immunol	  33,	  1174-­‐1182,	  doi:10.1002/eji.200323492	  (2003).	  407	   Sun,	  D.	  et	  al.	  Myelin	  antigen-­‐specific	  CD8+	  T	  cells	  are	  encephalitogenic	  and	  produce	  severe	  disease	  in	  C57BL/6	  mice.	  J	  Immunol	  166,	  7579-­‐7587	  (2001).	  408	   Ariotti,	  S.	  et	  al.	  Tissue-­‐resident	  memory	  CD8+	  T	  cells	  continuously	  patrol	  skin	  epithelia	  to	  quickly	  recognize	  local	  antigen.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  109,	  19739-­‐19744,	  doi:10.1073/pnas.1208927109	  (2012).	  409	   Ariotti,	  S.,	  Haanen,	  J.	  B.	  &	  Schumacher,	  T.	  N.	  Behavior	  and	  function	  of	  tissue-­‐resident	  memory	  T	  cells.	  Adv	  Immunol	  114,	  203-­‐216,	  doi:10.1016/B978-­‐0-­‐12-­‐396548-­‐6.00008-­‐1	  (2012).	  410	   Jameson,	  S.	  C.	  Maintaining	  the	  norm:	  T-­‐cell	  homeostasis.	  Nat	  Rev	  Immunol	  2,	  547-­‐556,	  doi:10.1038/nri853	  (2002).	  411	   Lau,	  L.	  L.,	  Jamieson,	  B.	  D.,	  Somasundaram,	  T.	  &	  Ahmed,	  R.	  Cytotoxic	  T-­‐cell	  memory	  without	  antigen.	  Nature	  369,	  648-­‐652,	  doi:10.1038/369648a0	  (1994).	  412	   Tan,	  J.	  T.	  et	  al.	  Interleukin	  (IL)-­‐15	  and	  IL-­‐7	  jointly	  regulate	  homeostatic	  proliferation	  of	  memory	  phenotype	  CD8+	  cells	  but	  are	  not	  required	  for	  memory	  phenotype	  CD4+	  cells.	  J	  Exp	  Med	  195,	  1523-­‐1532	  (2002).	  413	   Wakim,	  L.	  M.,	  Woodward-­‐Davis,	  A.	  &	  Bevan,	  M.	  J.	  Memory	  T	  cells	  persisting	  within	  the	  brain	  after	  local	  infection	  show	  functional	  adaptations	  to	  their	  tissue	  of	  residence.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  107,	  17872-­‐17879,	  doi:10.1073/pnas.1010201107	  (2010).	  414	   Wolint,	  P.,	  Betts,	  M.	  R.,	  Koup,	  R.	  A.	  &	  Oxenius,	  A.	  Immediate	  cytotoxicity	  but	  not	  degranulation	  distinguishes	  effector	  and	  memory	  subsets	  of	  CD8+	  T	  cells.	  J	  Exp	  Med	  
199,	  925-­‐936,	  doi:10.1084/jem.20031799	  (2004).	  
	   	   	  227	  
415	   Baruch,	  K.	  &	  Schwartz,	  M.	  CNS-­‐specific	  T	  cells	  shape	  brain	  function	  via	  the	  choroid	  plexus.	  Brain	  Behav	  Immun	  34,	  11-­‐16,	  doi:10.1016/j.bbi.2013.04.002	  (2013).	  416	   Kondo,	  T.,	  Takata,	  H.,	  Matsuki,	  F.	  &	  Takiguchi,	  M.	  Cutting	  edge:	  Phenotypic	  characterization	  and	  differentiation	  of	  human	  CD8+	  T	  cells	  producing	  IL-­‐17.	  J	  
Immunol	  182,	  1794-­‐1798,	  doi:10.4049/jimmunol.0801347	  (2009).	  417	   Huber,	  M.	  et	  al.	  IL-­‐17A	  secretion	  by	  CD8+	  T	  cells	  supports	  Th17-­‐mediated	  autoimmune	  encephalomyelitis.	  J	  Clin	  Invest	  123,	  247-­‐260,	  doi:10.1172/JCI63681	  (2013).	  418	   Peelen,	  E.	  et	  al.	  Fraction	  of	  IL-­‐10+	  and	  IL-­‐17+	  CD8	  T	  cells	  is	  increased	  in	  MS	  patients	  in	  remission	  and	  during	  a	  relapse,	  but	  is	  not	  influenced	  by	  immune	  modulators.	  J	  
Neuroimmunol	  258,	  77-­‐84,	  doi:10.1016/j.jneuroim.2013.02.014	  (2013).	  419	   Tzartos,	  J.	  S.	  et	  al.	  Interleukin-­‐17	  production	  in	  central	  nervous	  system-­‐infiltrating	  T	  cells	  and	  glial	  cells	  is	  associated	  with	  active	  disease	  in	  multiple	  sclerosis.	  Am	  J	  Pathol	  
172,	  146-­‐155,	  doi:10.2353/ajpath.2008.070690	  (2008).	  420	   Huber,	  M.	  et	  al.	  A	  Th17-­‐like	  developmental	  process	  leads	  to	  CD8(+)	  Tc17	  cells	  with	  reduced	  cytotoxic	  activity.	  Eur	  J	  Immunol	  39,	  1716-­‐1725,	  doi:10.1002/eji.200939412	  (2009).	  421	   Melzer,	  N.,	  Meuth,	  S.	  G.	  &	  Wiendl,	  H.	  CD8+	  T	  cells	  and	  neuronal	  damage:	  direct	  and	  collateral	  mechanisms	  of	  cytotoxicity	  and	  impaired	  electrical	  excitability.	  FASEB	  J	  
23,	  3659-­‐3673,	  doi:10.1096/fj.09-­‐136200	  (2009).	  422	   Doyle,	  K.	  P.,	  Cekanaviciute,	  E.,	  Mamer,	  L.	  E.	  &	  Buckwalter,	  M.	  S.	  TGFbeta	  signaling	  in	  the	  brain	  increases	  with	  aging	  and	  signals	  to	  astrocytes	  and	  innate	  immune	  cells	  in	  the	  weeks	  after	  stroke.	  J	  Neuroinflammation	  7,	  62,	  doi:10.1186/1742-­‐2094-­‐7-­‐62	  (2010).	  423	   Liu,	  F.	  &	  McCullough,	  L.	  D.	  Interactions	  between	  age,	  sex,	  and	  hormones	  in	  experimental	  ischemic	  stroke.	  Neurochem	  Int	  61,	  1255-­‐1265,	  doi:10.1016/j.neuint.2012.10.003	  (2012).	  424	   Popa-­‐Wagner,	  A.	  et	  al.	  Accelerated	  infarct	  development,	  cytogenesis	  and	  apoptosis	  following	  transient	  cerebral	  ischemia	  in	  aged	  rats.	  Acta	  Neuropathol	  113,	  277-­‐293,	  doi:10.1007/s00401-­‐006-­‐0164-­‐7	  (2007).	  425	   Sieber,	  M.	  W.,	  Claus,	  R.	  A.,	  Witte,	  O.	  W.	  &	  Frahm,	  C.	  Attenuated	  inflammatory	  response	  in	  aged	  mice	  brains	  following	  stroke.	  PLoS	  One	  6,	  e26288,	  doi:10.1371/journal.pone.0026288	  (2011).	  426	   Sieber,	  M.	  W.	  et	  al.	  Age-­‐specific	  transcriptional	  response	  to	  stroke.	  Neurobiol	  Aging	  
35,	  1744-­‐1754,	  doi:10.1016/j.neurobiolaging.2014.01.012	  (2014).	  427	   Manwani,	  B.	  et	  al.	  Differential	  effects	  of	  aging	  and	  sex	  on	  stroke	  induced	  inflammation	  across	  the	  lifespan.	  Exp	  Neurol	  249,	  120-­‐131,	  doi:10.1016/j.expneurol.2013.08.011	  (2013).	  428	   Shapira,	  S.,	  Sapir,	  M.,	  Wengier,	  A.,	  Grauer,	  E.	  &	  Kadar,	  T.	  Aging	  has	  a	  complex	  effect	  on	  a	  rat	  model	  of	  ischemic	  stroke.	  Brain	  Res	  925,	  148-­‐158	  (2002).	  429	   Famakin,	  B.	  M.	  The	  Immune	  Response	  to	  Acute	  Focal	  Cerebral	  Ischemia	  and	  Associated	  Post-­‐stroke	  Immunodepression:	  A	  Focused	  Review.	  Aging	  Dis	  5,	  307-­‐326,	  doi:10.14336/AD.2014.0500307	  (2014).	  430	   Jickling,	  G.	  C.	  &	  Sharp,	  F.	  R.	  Improving	  the	  translation	  of	  animal	  ischemic	  stroke	  studies	  to	  humans.	  Metab	  Brain	  Dis	  30,	  461-­‐467,	  doi:10.1007/s11011-­‐014-­‐9499-­‐2	  (2015).	  
	   	   	  228	  
 
